U.S. patent application number 16/449123 was filed with the patent office on 2022-09-29 for fused heteroaromatic pyrrolidinones.
The applicant listed for this patent is Calithera Biosciences, Inc.. Invention is credited to Yasuyoshi Arikawa, Qing Dong, Victoria Feher, Benjamin Jones, Betty Lam, Zhe Nie, Christopher Smith, Masashi Takahashi.
Application Number | 20220306634 16/449123 |
Document ID | / |
Family ID | 1000006374185 |
Filed Date | 2022-09-29 |
United States Patent
Application |
20220306634 |
Kind Code |
A1 |
Arikawa; Yasuyoshi ; et
al. |
September 29, 2022 |
FUSED HETEROAROMATIC PYRROLIDINONES
Abstract
Disclosed are compounds of Formula 1, ##STR00001## and
pharmaceutically acceptable salts thereof, wherein G, L.sup.1,
L.sup.2, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are defined in the
specification. This disclosure also relates to materials and
methods for preparing compounds of Formula 1, pharmaceutical
compositions containing them, and their use for treating disorders,
diseases, and conditions involving the immune system and
inflammation, including rheumatoid arthritis, hematological
malignancies, epithelial cancers (i.e., carcinomas), and other
disorders, diseases, and conditions for which inhibition of SYK is
indicated.
Inventors: |
Arikawa; Yasuyoshi;
(Kawasaki, JP) ; Jones; Benjamin;
(Cardiff-by-the-Sea, CA) ; Lam; Betty; (San Diego,
CA) ; Takahashi; Masashi; (Chigasaki, JP) ;
Smith; Christopher; (San Diego, CA) ; Dong; Qing;
(San Diego, CA) ; Feher; Victoria; (San Diego,
CA) ; Nie; Zhe; (San Diego, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Calithera Biosciences, Inc. |
South San Francisco |
CA |
US |
|
|
Family ID: |
1000006374185 |
Appl. No.: |
16/449123 |
Filed: |
June 21, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15681953 |
Aug 21, 2017 |
|
|
|
16449123 |
|
|
|
|
14814878 |
Jul 31, 2015 |
|
|
|
15681953 |
|
|
|
|
13886032 |
May 2, 2013 |
9108970 |
|
|
14814878 |
|
|
|
|
12972333 |
Dec 17, 2010 |
8440689 |
|
|
13886032 |
|
|
|
|
61386964 |
Sep 27, 2010 |
|
|
|
61289969 |
Dec 23, 2009 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D 487/04 20130101;
A61K 45/06 20130101; A61K 31/527 20130101; A61K 31/519 20130101;
C07D 519/00 20130101; A61K 31/437 20130101; C07D 471/04 20130101;
C07D 487/10 20130101 |
International
Class: |
C07D 487/04 20060101
C07D487/04; C07D 471/04 20060101 C07D471/04; A61K 31/519 20060101
A61K031/519; A61K 31/527 20060101 A61K031/527; A61K 45/06 20060101
A61K045/06; C07D 487/10 20060101 C07D487/10; A61K 31/437 20060101
A61K031/437; C07D 519/00 20060101 C07D519/00 |
Claims
1. A compound of Formula 1, ##STR00348## or a pharmaceutically
acceptable salt thereof, wherein: G is selected from N and
C(R.sup.5); L.sup.1 and L.sup.2 are each independently selected
from --NH-- and a bond; R.sup.1 and R.sup.2 are each independently
selected from hydrogen, halo, C.sub.1-3 alkyl, and C.sub.1-3
haloalkyl, or R.sup.1 and R.sup.2, together with the atom to which
they are attached, form a C.sub.3-6 cycloalkyl; R.sup.3 is selected
from C.sub.2-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.2-5 heterocyclyl,
and C.sub.1-9 heteroaryl, each optionally substituted with from one
to five substituents independently selected from halo, oxo,
--NO.sub.2, --CN, R.sup.6, and R.sup.7; R.sup.4 is selected from
C.sub.3-8 cycloalkyl, C.sub.2-5 heterocyclyl, C.sub.6-14 aryl, and
C.sub.1-9 heteroaryl, each optionally substituted with from one to
five substituents independently selected from halo, oxo, --CN,
R.sup.6, and R.sup.7; R.sup.5 is selected from hydrogen, halo,
--CN, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl,
C.sub.2-5 heterocyclyl, C.sub.1-5 heteroaryl, and R.sup.10, wherein
the alkyl, alkenyl, alkynyl moieties are each optionally
substituted with from one to five substituents independently
selected from halo, --CN, oxo, and R.sup.10, and wherein the
heterocyclyl moiety has 3 to 6 ring atoms and the heteroaryl moiety
has 5 or 6 ring atoms, and the heterocyclyl and heteroaryl moieties
are each optionally substituted with from one to four substituents
independently selected from halo, --NO.sub.2, --CN, C.sub.1-4
alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, C.sub.1-4 haloalkyl,
and R.sup.10; each R.sup.6 is independently selected from --OW,
--N(R.sup.8)R.sup.9, --NR.sup.8C(O)R.sup.9, --C(O)R.sup.8,
--C(O)OR.sup.8, --C(O)N(R.sup.8)R.sup.9, --C(O)N(R.sup.8) OR.sup.9,
--C(O)N(R.sup.8)S(O).sub.2R.sup.9, --N(R.sup.8)S(O).sub.2R.sup.9,
--S(O).sub.nR.sup.8, and --S(O).sub.2N(R.sup.8)R.sup.9; each
R.sup.7 is independently selected from C.sub.1-6 alkyl, C.sub.2-6
alkenyl, C.sub.2-6 alkynyl, C.sub.3-6
cycloalkyl-(CH.sub.2).sub.m--, C.sub.6-14 aryl-(CH.sub.2).sub.m--,
C.sub.2-5 heterocyclyl-(CH.sub.2).sub.m--, and C.sub.1-9
heteroaryl-(CH.sub.2).sub.m--, each optionally substituted with
from one to five substituents independently selected from halo,
oxo, --NO.sub.2, --CN, C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, and
R.sup.10; each R.sup.8 and R.sup.9 is independently selected from
hydrogen or from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.3-6 cycloalkyl-(CH.sub.2).sub.m--, C.sub.6-14
aryl-(CH.sub.2).sub.m--, C.sub.2-5 heterocyclyl-(CH.sub.2).sub.m--,
and C.sub.1-9 heteroaryl-(CH.sub.2).sub.m--, each optionally
substituted with from one to five substituents independently
selected from halo, oxo, --NO.sub.2, --CN, C.sub.1-6 alkyl,
C.sub.1-6 haloalkyl, and R.sup.10; each R.sup.10 is independently
selected from --OR.sup.11, --N(R.sup.11)R.sup.12,
--N(R.sup.11)C(O)R.sup.12, --C(O)OR.sup.11,
--C(O)N(R.sup.11)R.sup.12, --C(O)N(R.sup.11)OR.sup.12,
--C(O)N(R.sup.11)S(O).sub.2R.sup.12, --NR.sup.11S(O).sub.2R.sup.12,
--S(O).sub.nR.sup.11, and --S(O).sub.2N(R.sup.11)R.sup.12; each
R.sup.11 and R.sup.12 is independently selected from hydrogen and
C.sub.1-6 alkyl; each n is independently selected from 0, 1 and 2;
and each m is independently selected from 0, 1, 2, 3, and 4;
wherein each of the aforementioned heteroaryl moieties has one to
four heteroatoms independently selected from N, O, and S, and each
of the aforementioned heterocyclyl moieties is saturated or
partially unsaturated and has one or two heteroatoms independently
selected from N, O, and S.
2. The compound or pharmaceutically acceptable salt according to
claim 1, wherein L.sup.1 is --NH--.
3-4. (canceled)
5. The compound or pharmaceutically acceptable salt according to
claim 1, wherein L.sup.2 is a bond.
6. (canceled)
7. The compound or pharmaceutically acceptable salt according to
claim 1, wherein G is C(R.sup.5).
8. The compound or pharmaceutically acceptable salt according to
claim 1, wherein R.sup.1 and R.sup.2 are both hydrogen.
9. The compound or pharmaceutically acceptable salt according to
claim 1, wherein R.sup.3 is C.sub.3-8 cycloalkyl, optionally
substituted with from one to five substituents independently
selected from halo, oxo, --NO.sub.2, --CN, R.sup.6, and
R.sup.7.
10. (canceled)
11. The compound or pharmaceutically acceptable salt according to
claim 9, wherein R.sup.3 is 2-amino-cyclohex-1-yl optionally
substituted with from one to four substituents independently
selected from halo, oxo, --NO.sub.2, --CN, R.sup.6, and
R.sup.7.
12-15. (canceled)
16. The compound or pharmaceutically acceptable salt according to
claim 1, wherein R.sup.3 is C.sub.2-5 heterocyclyl optionally
substituted with from one to five substituents independently
selected from halo, oxo, --NO.sub.2, --CN, R.sup.6, and
R.sup.7.
17. (canceled)
18. The compound or pharmaceutically acceptable salt according to
claim 1, wherein R.sup.3 is 3-aminotetrahydro-2H-pyran-4-yl
optionally substituted with from one to four substituents
independently selected from halo, oxo, --NO.sub.2, --CN, R.sup.6,
and R.sup.7.
19-24. (canceled)
25. The compound or pharmaceutically acceptable salt according to
claim 1, wherein R.sup.4 is selected from thiopheneyl, pyrazolyl,
isothiazolyl, and thiazolyl, each optionally substituted with from
one to three substituents independently selected from halo, --CN,
R.sup.6, and R.sup.7.
26. The compound or pharmaceutically acceptable salt according to
claim 25, wherein R.sup.4 is pyrazolyl optionally substituted with
from one to three substituents independently selected from halo,
--CN, R.sup.6, and R.sup.7.
27. (canceled)
28. The compound or pharmaceutically acceptable salt according to
claim 26, wherein R.sup.4 is substituted with methyl, ethyl,
cyclopropyl or C.sub.1-2 haloalkyl.
29. (canceled)
30. The compound or pharmaceutically acceptable salt according to
claim 1, wherein R.sup.5 is selected from hydrogen and halo.
31. (canceled)
32. The compound according to claim 1, which is selected from the
following compounds:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrol-
o[3,4-d]pyrimidin-5-one;
2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-fluorophenylamino)-6,7-dihydro-5H-
-pyrrolo[3,4-d]pyrimidin-5-one;
2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-chlorophenylamino)-6,7-dihydro-5H-
-pyrrolo[3,4-d]pyrimidin-5-one;
4-(1H-Indazol-6-ylamino)-2-((1R,2S)-2-aminocyclohexylamino)-6,7-dihydro-5-
H-pyrrolo[3,4-d]pyrimidin-5-one;
2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-
-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;
cis-2-(2-aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-dih-
ydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;
2-(1-Methyl-1H-pyrazol-4-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4--
d]pyrimidin-5-one;
2-(4-Ethylpiperazin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]p-
yrimidin-5-one;
2-(Cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimid-
in-5-one;
cis-2-(2-Hydroxycyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-
-pyrrolo[3,4-d]pyrimidin-5-one;
2-(3-Aminopiperidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]p-
yrimidin-5-one;
6-((1R,2S)-2-Aminocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyri-
din-3(2H)-one;
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-methyl-1H-pyrazol-4-yl)-6,7-dihyd-
ro-5H-pyrrolo[3,4-d]pyrimidin-5-one;
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-isobutyl-1H-pyrazol-4-yl)-6,7-dih-
ydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;
2-((1R,2S)-2-Aminocyclohexylamino)-4-phenyl-6,7-dihydro-5H-pyrrolo[3,4-d]-
pyrimidin-5-one;
2-((1R,2S)-2-Aminocyclohexylamino)-4-(benzo[b]thiophen-3-yl)-6,7-dihydro--
5H-pyrrolo[3,4-d]pyrimidin-5-one;
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-6,7-dihydr-
o-5H-pyrrolo[3,4-d]pyrimidin-5-one;
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-benzyl-1H-pyrazol-4-yl)-6,7-dihyd-
ro-5H-pyrrolo[3,4-d]pyrimidin-5-one;
2-((1R,2S)-2-Aminocyclohexylamino)-4-(imidazo[1,2-a]pyridin-3-yl)-6,7-dih-
ydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-propyl-1H-pyrazol-4-yl)-6,7-dihyd-
ro-5H-pyrrolo[3,4-d]pyrimidin-5-one;
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-
-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;
4-(1H-Indazol-6-ylamino)-6-((1R,2S)-2-aminocyclohexylamino)-1H-pyrrolo[3,-
4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-4-(4-fluoro-3-methylphenylamino)-1H-py-
rrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3-
,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrol-
o[3,4-c]pyridin-3(2H)-one;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-methyl-1H-pyrazol-4-
-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-7-chloro-4-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(pyrazolo[1,5-a]pyridin-3-y-
l)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
2-(2-(Aminomethyl)piperidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo-
[3,4-d]pyrimidin-5-one;
6-((1R,2S)-2-Aminocyclohexylamino)-4-(3-(methylsulfonyl)phenylamino)-1H-p-
yrrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclopentylamino)-4-(3-(methylsulfonyl)phenylamino)-1H--
pyrrolo[3,4-c]pyridin-3(2H)-one;
(R)-4-Methyl-2-(4-(3-(methylsulfonyl)phenylamino)-3-oxo-2,3-dihydro-1H-py-
rrolo[3,4-c]pyridin-6-ylamino)pentanamide;
(R)-4-Methyl-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-ylamino)pentanamide;
2-((1R,2S)-2-(Dimethylamino)cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-
-5H-pyrrolo[3,4-d]pyrimidin-5-one;
2-((1R,2S)-2-(Methylamino)cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5-
H-pyrrolo[3,4-d]pyrimidin-5-one;
2'-((1R,2S)-2-Aminocyclohexylamino)-4'-(m-tolylamino)spiro[cyclopropane-1-
,7'-pyrrolo[3,4-d]pyrimidin]-5'(6'H)-one;
2-(2-Aminoethylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrim-
idin-5-one;
2-(2-Amino-2-methylpropylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3-
,4-d]pyrimidin-5-one;
2-(5-Oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamin-
o)acetamide;
2-((2-Aminoethyl)(methyl)amino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3-
,4-d]pyrimidin-5-one;
2-(Pyrrolidin-2-ylmethylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,-
4-d]pyrimidin-5-one;
2-(3-Aminopyrrolidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]-
pyrimidin-5-one;
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1,5-dimethyl-1H-pyrazol-4-yl)-6,7-d-
ihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1H-indol-2-yl)-6,7-dihydro-5H-pyrro-
lo[3,4-d]pyrimidin-5-one;
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1H-pyrazol-5-yl)-6,7-dihydro-5H-pyr-
rolo[3,4-d]pyrimidin-5-one;
2-(3-Aminopropyl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-
-5-one;
6-((1R,2S)-2-Aminocyclohexylamino)-4-(benzofuran-3-yl)-7-fluoro-1H-
-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(imidazo[1,2-a]pyridin-3-yl-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-aminocyclohexylamino)-4-(benzo[b]thiophen-3-yl)-7-fluoro-1H--
pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((1S,2R)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
(R)-6-(2-Amino-3-ethoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyr-
idin-3(2H)-one;
(R)-6-(2-Amino-3-ethoxypropylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[-
3,4-c]pyridin-3(2H)-one;
6-(2-Amino-3,3,3-trifluoropropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]-
pyridin-3(2H)-one;
(R)-4-Methyl-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyrid-
in-6-ylamino)pentanamide;
6-(cis-4-Aminotetrahydrofuran-3-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4--
c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-1H-pyrrolo-
[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-7-fluoro-1-
H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-1H-p-
yrrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-
-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-7-fl-
uoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
cis-6-(2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-p-
yrrolo[3,4-c]pyridin-3(2H)-one;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(1-methyl-1H--
pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-(cis-2-Amino-4,4-difluorocyclopentylamino)-7-fluoro-4-(1-methyl-1H-pyra-
zol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-(cis-2-Amino-3,3-difluorocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyraz-
ol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-(1-(difluoromethyl)-1H-pyra-
zol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-(cis-2-amino-3,3-difluorocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-
-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
(R)-2-(7-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;
(R)-2-(4-(1-(Difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro--
1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;
(R)-2-(4-(1-Cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-py-
rrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;
(R)-2-(4-(Benzofuran-3-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]py-
ridin-6-ylamino)-4-methylpentanamide;
(R)-2-(7-Fluoro-3-oxo-4-(pyrazolo[1,5-a]pyridin-3-yl)-2,3-dihydro-1H-pyrr-
olo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide;
6-((1R,2S)-2-Aminocyclohexylamino)-7-chloro-4-(m-tolylamino)-1H-pyrrolo[3-
,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H--
pyrrolo[3,4-c]pyridine-7-carbonitrile;
(R)-6-(2-Amino-3-methoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]py-
ridin-3(2H)-one;
(R)-6-(2-Amino-3-methoxypropylamino)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1-
H-pyrrolo[3,4-c]pyridine-7-carbonitrile;
(R)-6-(2-Amino-3-methoxypropylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo-
[3,4-c]pyridin-3(2H)-one;
7-Acryloyl-6-((1R,2S)-2-aminocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo-
[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-7-iodo-4-(m-tolylamino)-1H-pyrrolo[3,4-
-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-7-(1H-pyrazol-4-yl)-4-(m-tolylamino)-1-
H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3-
,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-7-(1-methyl-1H-pyrazol-5-yl)-4-(m-toly-
lamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(m-tolylamino)-1H-pyrr-
olo[3,4-c]pyridin-3(2H)-one;
6-((3R,4R)-4-Aminotetrahydro-2H-pyran-3-ylamino)-4-(m-tolylamino)-1H-pyrr-
olo[3,4-c]pyridin-3(2H)-one; tert-Butyl
(1S,2R)-2-(3-oxo-7-phenyl-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate;
6-((1R,2S)-2-Aminocyclohexylamino)-7-methyl-4-(m-tolylamino)-1H-pyrrolo[3-
,4-c]pyridin-3(2H)-one;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(m-tolylamino-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-7-methyl-4-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
(R)-6-(2-Amino-3-methoxypropylamino)-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrr-
olo[3,4-c]pyridin-3(2H)-one;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(pyrazolo[1,5-
-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-(difluoromethyl)-1H-
-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(benzofuran-3-yl)-7-fl-
uoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
(S)-6-(3-Aminopyrrolidin-1-yl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-p-
yrrolo[3,4-c]pyridin-3(2H)-one;
(S)-6-(3-Aminopiperidin-1-yl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-py-
rrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-isopropyl-1H-pyrazol-4-y-
l)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
7-Fluoro-4,6-bis(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-
-one;
6-((1R,2S)-2-Aminocyclohexylamino)-7-bromo-4-(1-methyl-1H-pyrazol-4--
yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)-
-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one;
(R)-6-(2-Amino-3-methoxypropylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiophen-3-y-
l)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(4-methylthio-
phen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(4-methylthiophen-2-yl)-1H--
pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(thiophen-3-yl)-1H-pyrrolo[-
3,4-c]pyridin-3(2H)-one;
(R)-2-(7-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-ylamino)-N,4-dimethylpentanamide;
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(5-methylthiophen-2-yl)-1H--
pyrrolo[3,4-c]pyridin-3(2H)-one;
(R)-2-(7-Fluoro-4-(4-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,-
4-c]pyridin-6-ylamino)-4-methylpentanamide;
(R)-2-(7-Fluoro-3-oxo-4-(thiophen-3-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyri-
din-6-ylamino)-4-methylpentanamide;
(R)-2-(7-Fluoro-4-(5-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,-
4-c]pyridin-6-ylamino)-4-methylpentanamide;
6-((1R,2S)-2-Aminocyclohexylamino)-4-(2-aminothiazol-5-yl)-7-fluoro-1H-py-
rrolo[3,4-c]pyridin-3(2H)-one;
(R)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-
-6-ylamino)-4-methylpentanamide;
(R)-2-(7-Fluoro-4-(furan-3-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-
-6-ylamino)-4-methylpentanamide;
(R)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-
-6-ylamino)-4-methylpentanamide;
(R)-2-(4-(5-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-
-c]pyridin-6-ylamino)-4-methylpentanamide;
(R)-2-(4-(4-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-
-c]pyridin-6-ylamino)-4-methylpentanamide;
(R)-2-(7-Fluoro-3-oxo-4-(thiazol-5-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyrid-
in-6-ylamino)-4-methylpentanamide;
(R)-2-(7-Fluoro-4-(isothiazol-5-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]py-
ridin-6-ylamino)-4-methylpentanamide;
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-1,1-dimethyl-4-(1-methyl-1H-p-
yrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-3-yl)-1H-
-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1H-p-
yrrolo[3,4-c]pyridin-3(2H)-one;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(5-methylthio-
phen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-1-methyl-4-(1-methyl-1H-pyraz-
ol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
(R)-2-(7-Fluoro-3-oxo-4-(thiophen-2-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyri-
din-6-ylamino)-4-methylpentanamide;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiophen-2-y-
l)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiazol-5-yl-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(thiophen-2-yl)-1H-pyrrolo[-
3,4-c]pyridin-3(2H)-one;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(4-(trifluoro-
methyl)-1H-imidazol-1-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(4-methyl-1H-imidazol-1-yl)-
-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(3-methylisot-
hiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(2-methylthia-
zol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
(R)-2-(7-Fluoro-4-(2-methylthiazol-5-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-
-c]pyridin-6-ylamino)-4-methylpentanamide;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(5-chlorothiophen-2-yl-
)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-cyclopropyl-1H-pyra-
zol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; a
stereoisomer of any of the aforementioned compounds; and a
pharmaceutically acceptable salt of any of the aforementioned
compounds or stereoisomers.
33. A pharmaceutical composition comprising: a compound or
pharmaceutically acceptable salt as defined in claim 1; and a
pharmaceutically acceptable excipient.
34-35. (canceled)
36. A method of treating a disease or condition in a subject for
which a SYK inhibitor is indicated, the method comprising
administering to the subject an effective amount of a compound or
pharmaceutically acceptable salt as defined in claim 1.
37. The method according to claim 36, wherein the disease or
condition is selected from allergic rhinitis, allergic asthma,
atopic dermatitis, rheumatoid arthritis, multiple sclerosis,
systemic lupus erythematosus, psoriasis, immune thrombocytopenic
purpura, inflammatory bowel disease, chronic obstructive pulmonary
disease, and thrombosis.
38. The method according to claim 36, wherein the disease or
condition is selected from a hematological malignancy and an
epithelial cancer.
39. The method according to claim 38, wherein the hematological
malignancy is selected from acute myeloid leukemia, B-cell chronic
lymphocytic leukemia, B-cell lymphoma, and T-cell lymphoma.
40. The method according to claim 38, wherein the epithelial cancer
is selected from lung cancer, pancreatic cancer, and colon
cancer.
41-43. (canceled)
Description
FIELD OF THE INVENTION
[0001] This invention relates to fused heteroaromatic pyrrolidinone
compounds, to pharmaceutical compositions containing them, and to
the use of the compounds for treating disorders and conditions
involving the immune system and inflammation, including rheumatoid
arthritis. The heteroaromatic pyrrolidinones are inhibitors of
spleen tyrosine kinase.
BACKGROUND OF THE INVENTION
[0002] Spleen tyrosine kinase (SYK) is a 72 kDa non-receptor
cytoplasmic tyrosine kinase. SYK has a primary amino acid sequence
similar to that of zeta-associated protein-70 (ZAP-70) and is
involved in receptor-mediated signal transduction. The N-terminal
domain of SYK contains two Src-homology 2 (SH2) domains, which bind
to diphosphorylated immunoreceptor tyrosine-based activation motifs
(ITAMs) found in the cytoplasmic signaling domains of many
immunoreceptor complexes. The C-terminus contains the catalytic
domain, and includes several catalytic loop autophosphorylation
sites that are responsible for receptor-induced SYK activation and
subsequent downstream signal propagation. SYK is expressed in many
cell types involved in adaptive and innate immunity, including
lymphocytes (B cells, T cells, and NK cells), granulocytes
(basophils, neutrophils, and eosinophils), monocytes, macrophages,
dendritic cells, and mast cells. SYK is expressed in other cell
types, including airway epithelium and fibroblasts in the upper
respiratory system. See, e.g., Martin Turner et al., Immunology
Today (2000) 21(3):148-54; and Michael P. Sanderson et al.,
Inflammation & Allergy--Drug Targets (2009) 8:87-95.
[0003] SYK's role in ITAM-dependent signaling and its expression in
many cell types suggest that compounds which inhibit SYK activity
may be useful for treating disorders involving the immune system
and inflammation. Such disorders include Type I hypersensitivity
reactions (allergic rhinitis, allergic asthma, and atopic
dermatitis); autoimmune diseases (rheumatoid arthritis, multiple
sclerosis, systemic lupus erythematosus, psoriasis, and immune
thrombocytopenic purpura); and inflammation of the lung (chronic
obstructive pulmonary disease). See, e.g., Brian R. Wong et al.,
Expert Opin. Investig. Drugs (2004) 13(7):743-62; Sanderson et al.
(2009); Jane Denyer & Vipul Patel, Drug News Perspective (2009)
22(3):146-50; Esteban S. Masuda & Jochen Schmitz, Pulmonary
Pharmacology & Therapeutics (2008) 21:461-67; Malini Bajpai et
al., Expert Opin. Investig. Drugs (2008) 17(5):641-59; and Anna
Podolanczuk et al., Blood (2009) 113:3154-60. Other disorders
include hematological malignancies, such as acute myeloid leukemia,
B-cell chronic lymphocytic leukemia, B-cell lymphoma (e.g., mantle
cell lymphoma), and T-cell lymphoma (e.g., peripheral T-cell
lymphoma); as well as epithelial cancers, such as lung cancer,
pancreatic cancer, and colon cancer. See, e.g., Cynthia K. Hahn et
al., Cancer Cell (2009) 16:281-294; D. H. Chu et al., Immnol. Rev.
(1998) 165:167-180; A. L. Feldman et al., Leukemia (2008)
22:1139-43; A. Rinaldi et al., Br. J. Haematol. (2006) 132:303-316;
B. Streubel et al., Leukemia (2006) 20:313-18; Maike Buchner et
al., Cancer Research (2009) 69(13):5424-32; A. D. Baudot et al.,
Oncogene (2009) 28:3261-73; and Anurag Singh et al., Cancer Cell
(2009) 15:489-500.
[0004] Various SYK inhibitors have been described in published
patent applications. See, e.g., EP 1184376 A1; WO 01/83485 A1; WO
03/057695 A1; WO 2006/129100 A1; WO 01/09134 A1; WO 03/063794 A1;
WO 2005/012294 A1; WO 2004/087699 A2; WO 2009/026107 A1;
WO2009136995 A2; and WO2009/145856 A1.
SUMMARY OF THE INVENTION
[0005] This invention provides fused heteroaromatic pyrrolidinone
derivatives, including
6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-ones,
1H-pyrrolo[3,4-c]pyridin-3(2H)-ones, and pharmaceutically
acceptable complexes, salts, solvates, and hydrates thereof. This
invention also provides pharmaceutical compositions containing the
heteroaromatic pyrrolidinone derivatives, and uses of the
heteroaromatic pyrrolidinone derivatives to treat disorders and
conditions involving the immune system and inflammation, including
rheumatoid arthritis.
[0006] One aspect of the invention provides compounds of Formula
1:
##STR00002## [0007] or pharmaceutically acceptable salts thereof,
wherein: [0008] G is selected from N and C(R.sup.5); [0009] L.sup.1
and L.sup.2 are each independently selected from --NH-- and a bond;
[0010] R.sup.1 and R.sup.2 are each independently selected from
hydrogen, halo, C.sub.1-3 alkyl, and C.sub.1-3 haloalkyl, or
R.sup.1 and R.sup.2, together with the atom to which they are
attached, form a C.sub.3-6 cycloalkyl; [0011] R.sup.3 is selected
from C.sub.2-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.2-5 heterocyclyl,
and C.sub.1-9 heteroaryl, each optionally substituted with from one
to five substituents independently selected from halo, oxo,
--NO.sub.2, --CN, R.sup.6, and R.sup.7; [0012] R.sup.4 is selected
from C.sub.3-8 cycloalkyl, C.sub.2-5 heterocyclyl, C.sub.6-14 aryl,
and C.sub.1-9 heteroaryl, each optionally substituted with from one
to five substituents independently selected from halo, oxo, --CN,
R.sup.6, and R.sup.7; [0013] R.sup.5 is selected from hydrogen,
halo, --CN, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl,
C.sub.2-5 heterocyclyl, C.sub.1-5 heteroaryl, and R.sup.10, wherein
the alkyl, alkenyl, alkynyl moieties are each optionally
substituted with from one to five substituents independently
selected from halo, --CN, oxo, and R.sup.10, and wherein the
heterocyclyl moiety has 3 to 6 ring atoms and the heteroaryl moiety
has 5 or 6 ring atoms, and the heterocyclyl and heteroaryl moieties
are each optionally substituted with from one to four substituents
independently selected from halo, --NO.sub.2, --CN, C.sub.1-4
alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, C.sub.1-4 haloalkyl,
and R.sup.10; [0014] each R.sup.6 is independently selected from
--OR.sup.8, --N(R.sup.8)R.sup.9, --NR.sup.8C(O)R.sup.9,
--C(O)R.sup.8, --C(O)OR.sup.8, --C(O)N(R.sup.8)R.sup.9,
--C(O)N(R.sup.8)OR.sup.9, --C(O)N(R.sup.8)S(O).sub.2R.sup.9,
--N(R.sup.8)S(O).sub.2R.sup.9, --S(O).sub.nR, and
--S(O).sub.2N(R.sup.8)R.sup.9; [0015] each R.sup.7 is independently
selected from C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6
alkynyl, C.sub.3-4 cycloalkyl-(CH.sub.2).sub.m--, C.sub.6-14
aryl-(CH.sub.2).sub.m--, C.sub.2-5 heterocyclyl-(CH.sub.2).sub.m--,
and C.sub.1-9 heteroaryl-(CH.sub.2).sub.m--, each optionally
substituted with from one to five substituents independently
selected from halo, oxo, --NO.sub.2, --CN, C.sub.1-6 alkyl,
C.sub.1-6 haloalkyl, and R.sup.10; [0016] each R.sup.8 and R.sup.9
is independently selected from hydrogen or from C.sub.1-4 alkyl,
C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, C.sub.3-4
cycloalkyl-(CH.sub.2).sub.m--, C.sub.6-14 aryl-(CH.sub.2).sub.m--,
C.sub.2-5 heterocyclyl-(CH.sub.2).sub.m--, and C.sub.1-9
heteroaryl-(CH.sub.2).sub.m--, each optionally substituted with
from one to five substituents independently selected from halo,
oxo, --NO.sub.2, --CN, C.sub.1-6 alkyl, C.sub.1-6 haloalkyl, and
R.sup.10; [0017] each R.sup.10 is independently selected from
--OR.sup.11, --N(R.sup.11)R.sup.12, --N(R.sup.11)C(O)R.sup.12,
--C(O)R.sup.11, --C(O)OR.sup.11, --C(O)N(R.sup.11)R.sup.12,
--C(O)N(R.sup.11)OR.sup.12, --C(O)N(R.sup.11)S(O).sub.2R.sup.12,
--NR.sup.11S(O).sub.2R.sup.12, --S(O).sub.nR.sup.11, and
--S(O).sub.2N(R.sup.11)R.sup.12; [0018] each R.sup.11 and R.sup.12
is independently selected from hydrogen and C.sub.1-6 alkyl; [0019]
each n is independently selected from 0, 1 and 2; and [0020] each m
is independently selected from 0, 1, 2, 3, and 4; [0021] wherein
each of the aforementioned heteroaryl moieties has one to four
heteroatoms independently selected from N, O, and S, and each of
the aforementioned heterocyclyl moieties is saturated or partially
unsaturated and has one or two heteroatoms independently selected
from N, O, and S.
[0022] Another aspect of the invention provides a compound which is
selected from the following group of compounds and their
pharmaceutically acceptable salts: [0023]
2-((1R,2S)-2-Aminocyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrol-
o[3,4-d]pyrimidin-5-one; [0024]
2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-fluorophenylamino)-6,7-dihydro-5H-
-pyrrolo[3,4-d]pyrimidin-5-one; [0025]
2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-chlorophenylamino)-6,7-dihydro-5H-
-pyrrolo[3,4-d]pyrimidin-5-one; [0026]
4-(1H-Indazol-6-ylamino)-2-((1R,2S)-2-aminocyclohexylamino)-6,7-dihydro-5-
H-pyrrolo[3,4-d]pyrimidin-5-one; [0027]
2-((1R,2S)-2-aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-
-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one; [0028]
cis-2-(2-aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6,7-dih-
ydro-5H-pyrrolo[3,4-d]pyrimidin-5-one; [0029]
2-(1-Methyl-1H-pyrazol-4-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4--
d]pyrimidin-5-one; [0030]
2-(4-Ethylpiperazin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]p-
yrimidin-5-one; [0031]
2-(Cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimid-
in-5-one; [0032]
cis-2-(2-Hydroxycyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[-
3,4-d]pyrimidin-5-one; [0033]
2-(3-Aminopiperidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]p-
yrimidin-5-one; [0034]
6-((1R,2S)-2-Aminocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyri-
din-3(2H)-one; [0035]
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-methyl-1H-pyrazol-4-yl)-6,7-dihyd-
ro-5H-pyrrolo[3,4-d]pyrimidin-5-one; [0036]
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-isobutyl-1H-pyrazol-4-yl)-6,7-dih-
ydro-5H-pyrrolo[3,4-d]pyrimidin-5-one; [0037]
2-((1R,2S)-2-Aminocyclohexylamino)-4-phenyl-6,7-dihydro-5H-pyrrolo[3,4-d]-
pyrimidin-5-one; [0038]
2-((1R,2S)-2-Aminocyclohexylamino)-4-(benzo[b]thiophen-3-yl)-6,7-dihydro--
5H-pyrrolo[3,4-d]pyrimidin-5-one; [0039]
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-6,7-dihydr-
o-5H-pyrrolo[3,4-d]pyrimidin-5-one; [0040]
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-benzyl-1H-pyrazol-4-yl)-6,7-dihyd-
ro-5H-pyrrolo[3,4-d]pyrimidin-5-one; [0041]
2-((1R,2S)-2-Aminocyclohexylamino)-4-(imidazo[1,2-a]pyridin-3-yl)-6,7-dih-
ydro-5H-pyrrolo[3,4-d]pyrimidin-5-one; [0042]
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-propyl-1H-pyrazol-4-yl)-6,7-dihyd-
ro-5H-pyrrolo[3,4-d]pyrimidin-5-one; [0043]
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-
-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one; [0044]
4-(1H-Indazol-6-ylamino)-6-((1R,2S)-2-aminocyclohexylamino)-1H-pyrrolo[3,-
4-c]pyridin-3(2H)-one; [0045]
6-((1R,2S)-2-Aminocyclohexylamino)-4-(4-fluoro-3-methylphenylamino)-1H-py-
rrolo[3,4-c]pyridin-3(2H)-one; [0046]
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3-
,4-c]pyridin-3(2H)-one; [0047]
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrol-
o[3,4-c]pyridin-3(2H)-one; [0048]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-methyl-1H-pyrazol-4-
-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0049]
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0050]
6-((1R,2S)-2-Aminocyclohexylamino)-7-chloro-4-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0051]
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(pyrazolo[1,5-a]pyridin-3-y-
l)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0052]
2-(2-(Aminomethyl)piperidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo-
[3,4-d]pyrimidin-5-one; [0053]
6-((1R,2S)-2-Aminocyclohexylamino)-4-(3-(methylsulfonyl)phenylamino)-1H-p-
yrrolo[3,4-c]pyridin-3(2H)-one; [0054]
6-((1R,2S)-2-Aminocyclopentylamino)-4-(3-(methylsulfonyl)phenylamino)-1H--
pyrrolo[3,4-c]pyridin-3(2H)-one; [0055]
(R)-4-Methyl-2-(4-(3-(methylsulfonyl)phenylamino)-3-oxo-2,3-dihydro-1H-py-
rrolo[3,4-c]pyridin-6-ylamino)pentanamide; [0056]
(R)-4-Methyl-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-ylamino)pentanamide; [0057]
2-((1R,2S)-2-(Dimethylamino)cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-
-5H-pyrrolo[3,4-d]pyrimidin-5-one; [0058]
2-((1R,2S)-2-(Methylamino)cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5-
H-pyrrolo[3,4-d]pyrimidin-5-one; [0059]
2'-((1R,2S)-2-Aminocyclohexylamino)-4'-(m-tolylamino)spiro[cyclopropane-1-
,7'-pyrrolo[3,4-d]pyrimidin]-5'(6'H)-one; [0060]
2-(2-Aminoethylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrim-
idin-5-one; [0061]
2-(2-Amino-2-methylpropylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3-
,4-d]pyrimidin-5-one; [0062]
2-(5-Oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamin-
o)acetamide; [0063]
2-((2-Aminoethyl)(methyl)amino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3-
,4-d]pyrimidin-5-one; [0064]
2-(Pyrrolidin-2-ylmethylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,-
4-d]pyrimidin-5-one; [0065]
2-(3-Aminopyrrolidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]-
pyrimidin-5-one; [0066]
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1,5-dimethyl-1H-pyrazol-4-yl)-6,7-d-
ihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one; [0067]
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1H-indol-2-yl)-6,7-dihydro-5H-pyrro-
lo[3,4-d]pyrimidin-5-one; [0068]
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1H-pyrazol-5-yl)-6,7-dihydro-5H-pyr-
rolo[3,4-d]pyrimidin-5-one; [0069]
2-(3-Aminopropyl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-
-5-one; [0070]
6-((1R,2S)-2-Aminocyclohexylamino)-4-(benzofuran-3-yl)-7-fluoro-1H-pyrrol-
o[3,4-c]pyridin-3(2H)-one; [0071]
6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(imidazo[1,2-a]pyridin-3-yl-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0072]
6-((1R,2S)-2-aminocyclohexylamino)-4-(benzo[b]thiophen-3-yl)-7-fluoro-1H--
pyrrolo[3,4-c]pyridin-3(2H)-one; [0073]
6-((1S,2R)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0074]
(R)-6-(2-Amino-3-ethoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyr-
idin-3(2H)-one; [0075]
(R)-6-(2-Amino-3-ethoxypropylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[-
3,4-c]pyridin-3(2H)-one; [0076]
6-(2-Amino-3,3,3-trifluoropropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]-
pyridin-3(2H)-one; [0077]
(R)-4-Methyl-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyrid-
in-6-ylamino)pentanamide; [0078]
6-(cis-4-Aminotetrahydrofuran-3-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4--
c]pyridin-3(2H)-one; [0079]
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-1H-pyrrolo-
[3,4-c]pyridin-3(2H)-one; [0080]
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-7-fluoro-1-
H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0081]
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-1H-p-
yrrolo[3,4-c]pyridin-3(2H)-one; [0082]
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-
-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0083]
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-7-fl-
uoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0084]
cis-6-(2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-p-
yrrolo[3,4-c]pyridin-3(2H)-one; [0085]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(1-methyl-1H--
pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0086]
6-(cis-2-Amino-4,4-difluorocyclopentylamino)-7-fluoro-4-(1-methyl-1H-pyra-
zol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0087]
6-(cis-2-Amino-3,3-difluorocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyraz-
ol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0088]
6-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-(1-(difluoromethyl)-1H-pyra-
zol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0089]
6-(cis-2-amino-3,3-difluorocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-
-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0090]
(R)-2-(7-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-ylamino)-4-methylpentanamide; [0091]
(R)-2-(4-(1-(Difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro--
1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide; [0092]
(R)-2-(4-(1-Cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-py-
rrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide; [0093]
(R)-2-(4-(Benzofuran-3-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]py-
ridin-6-ylamino)-4-methylpentanamide; [0094]
(R)-2-(7-Fluoro-3-oxo-4-(pyrazolo[1,5-a]pyridin-3-yl)-2,3-dihydro-1H-pyrr-
olo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide; [0095]
6-((1R,2S)-2-Aminocyclohexylamino)-7-chloro-4-(m-tolylamino)-1H-pyrrolo[3-
,4-c]pyridin-3(2H)-one; [0096]
6-((1R,2S)-2-Aminocyclohexylamino)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H--
pyrrolo[3,4-c]pyridine-7-carbonitrile; [0097]
(R)-6-(2-Amino-3-methoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]py-
ridin-3(2H)-one; [0098]
(R)-6-(2-Amino-3-methoxypropylamino)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1-
H-pyrrolo[3,4-c]pyridine-7-carbonitrile; [0099]
(R)-6-(2-Amino-3-methoxypropylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo-
[3,4-c]pyridin-3(2H)-one; [0100]
7-Acryloyl-6-((1R,2S)-2-aminocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo-
[3,4-c]pyridin-3(2H)-one; [0101]
6-((1R,2S)-2-Aminocyclohexylamino)-7-iodo-4-(m-tolylamino)-1H-pyrrolo[3,4-
-c]pyridin-3(2H)-one; [0102]
6-((1R,2S)-2-Aminocyclohexylamino)-7-(1H-pyrazol-4-yl)-4-(m-tolylamino)-1-
H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0103]
6-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3-
,4-c]pyridin-3(2H)-one; [0104]
6-((1R,2S)-2-Aminocyclohexylamino)-7-(1-methyl-1H-pyrazol-5-yl)-4-(m-toly-
lamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0105]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(m-tolylamino)-1H-pyrr-
olo[3,4-c]pyridin-3(2H)-one; [0106]
6-((3R,4R)-4-Aminotetrahydro-2H-pyran-3-ylamino)-4-(m-tolylamino)-1H-pyrr-
olo[3,4-c]pyridin-3(2H)-one; [0107] tert-Butyl
(1S,2R)-2-(3-oxo-7-phenyl-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate; [0108]
6-((1R,2S)-2-Aminocyclohexylamino)-7-methyl-4-(m-tolylamino)-1H-pyrrolo[3-
,4-c]pyridin-3(2H)-one; [0109]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(m-tolylamino-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0110]
6-((1R,2S)-2-Aminocyclohexylamino)-7-methyl-4-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0111]
(R)-6-(2-Amino-3-methoxypropylamino)-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrr-
olo[3,4-c]pyridin-3(2H)-one; [0112]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(pyrazolo[1,5-
-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0113]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-(difluoromethyl)-1H-
-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0114]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(benzofuran-3-yl)-7-fl-
uoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0115]
(S)-6-(3-Aminopyrrolidin-1-yl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-p-
yrrolo[3,4-c]pyridin-3(2H)-one; [0116]
(S)-6-(3-Aminopiperidin-1-yl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-py-
rrolo[3,4-c]pyridin-3(2H)-one; [0117]
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-isopropyl-1H-pyrazol-4-y-
l)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0118]
7-Fluoro-4,6-bis(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-
-one; [0119]
6-((1R,2S)-2-Aminocyclohexylamino)-7-bromo-4-(1-methyl-1H-pyrazol-4-yl)-1-
H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0120]
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)-
-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one; [0121]
(R)-6-(2-Amino-3-methoxypropylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0122]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiophen-3-y-
l)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0123]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(4-methylthio-
phen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0124]
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(4-methylthiophen-2-yl)-1H--
pyrrolo[3,4-c]pyridin-3(2H)-one; [0125]
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(thiophen-3-yl)-1H-pyrrolo[-
3,4-c]pyridin-3(2H)-one; [0126]
(R)-2-(7-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-ylamino)-N,4-dimethylpentanamide; [0127]
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(5-methylthiophen-2-yl)-1H--
pyrrolo[3,4-c]pyridin-3(2H)-one; [0128]
(R)-2-(7-Fluoro-4-(4-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,-
4-c]pyridin-6-ylamino)-4-methylpentanamide; [0129]
(R)-2-(7-Fluoro-3-oxo-4-(thiophen-3-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyri-
din-6-ylamino)-4-methylpentanamide; [0130]
(R)-2-(7-Fluoro-4-(5-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,-
4-c]pyridin-6-ylamino)-4-methylpentanamide; [0131]
6-((1R,2S)-2-Aminocyclohexylamino)-4-(2-aminothiazol-5-yl)-7-fluoro-1H-py-
rrolo[3,4-c]pyridin-3(2H)-one; [0132]
(R)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-
-6-ylamino)-4-methylpentanamide; [0133]
(R)-2-(7-Fluoro-4-(furan-3-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-
-6-ylamino)-4-methylpentanamide; [0134]
(R)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-
-6-ylamino)-4-methylpentanamide; [0135]
(R)-2-(4-(5-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-
-c]pyridin-6-ylamino)-4-methylpentanamide; [0136]
(R)-2-(4-(4-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-
-c]pyridin-6-ylamino)-4-methylpentanamide; [0137]
(R)-2-(7-Fluoro-3-oxo-4-(thiazol-5-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyrid-
in-6-ylamino)-4-methylpentanamide; [0138]
(R)-2-(7-Fluoro-4-(isothiazol-5-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]py-
ridin-6-ylamino)-4-methylpentanamide; [0139]
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-1,1-dimethyl-4-(1-methyl-1H-p-
yrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0140]
((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-3-yl)-1H-
-pyrrolo[3,4-c]pyridin-3(2H)-one; [0141]
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1H-p-
yrrolo[3,4-c]pyridin-3(2H)-one; [0142]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(5-methylthio-
phen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0143]
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-1-methyl-4-(1-methyl-1H-pyraz-
ol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0144]
(R)-2-(7-Fluoro-3-oxo-4-(thiophen-2-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyri-
din-6-ylamino)-4-methylpentanamide; [0145]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiophen-2-y-
l)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0146]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiazol-5-yl-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0147]
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(thiophen-2-yl)-1H-pyrrolo[-
3,4-c]pyridin-3(2H)-one; [0148]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(4-(trifluoro-
methyl)-1H-imidazol-1-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one;
[0149]
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(4-methyl-1H-imidazol-1-yl)-
-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0150]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(3-methylisot-
hiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0151]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(2-methylthia-
zol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0152]
(R)-2-(7-Fluoro-4-(2-methylthiazol-5-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-
-c]pyridin-6-ylamino)-4-methylpentanamide;
[0153]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(5-chlorothioph-
en-2-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; [0154]
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-cyclopropyl-1H-pyra-
zol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one; and [0155] a
stereoisomer of any of the aforementioned compounds and their
pharmaceutically acceptable salts.
[0156] A further aspect of the invention provides a pharmaceutical
composition which includes: a compound of Formula 1, as defined
above, or a pharmaceutically acceptable salt thereof, or a compound
selected from the group of compounds defined in the preceding
paragraph, or a pharmaceutically acceptable salt thereof; and a
pharmaceutically acceptable excipient.
[0157] An additional aspect of the invention provides a use as a
medicament of a compound of Formula 1, as defined above, or a
pharmaceutically acceptable salt thereof, or a compound selected
from the group of compounds defined above, or a pharmaceutically
acceptable salt thereof.
[0158] Another aspect of the invention provides a use of a compound
of Formula 1, as defined above, or pharmaceutically acceptable salt
thereof, or a compound selected from the group of compounds defined
above, or a pharmaceutically acceptable salt thereof, for the
manufacture of a medicament for the treatment of a disease or
condition for which a SYK inhibitor is indicated.
[0159] A further aspect of the invention provides a method of
treating a disease or condition in a subject for which a SYK
inhibitor is indicated, the method comprising administering to the
subject an effective amount of a compound of Formula 1, as defined
above, or a compound selected from the group of compounds defined
above, or a pharmaceutically acceptable salt thereof.
[0160] An additional aspect of the invention provides a method of
treating a disease or condition in a subject, the method comprising
administering to the subject an effective amount of a compound of
Formula 1, as defined above, or a pharmaceutically acceptable salt
thereof, or a compound selected from the group of compounds defined
above, or a pharmaceutically acceptable salt thereof, wherein the
disease or condition is selected from allergic rhinitis, allergic
asthma, atopic dermatitis, rheumatoid arthritis, multiple
sclerosis, systemic lupus erythematosus, psoriasis, immune
thrombocytopenic purpura, inflammatory bowel disease, chronic
obstructive pulmonary disease, and thrombosis.
[0161] Another aspect of the invention provides a method of
treating a disease or condition in a subject, the method comprising
administering to the subject an effective amount of a compound of
Formula 1, as defined above, or pharmaceutically acceptable salt
thereof, or a compound selected from the group of compounds defined
above, or a pharmaceutically acceptable salt thereof, wherein the
disease or condition is selected from a hematological malignancy
and an epithelial cancer.
[0162] A further aspect of the invention provides a combination of
an effective amount of a compound of Formula 1, as defined above,
or pharmaceutically acceptable salt thereof, or a compound selected
from the group of compounds defined above, or a pharmaceutically
acceptable salt thereof, and at least one additional
pharmacologically active agent.
DETAILED DESCRIPTION OF THE INVENTION
[0163] Unless indicated otherwise, this disclosure uses definitions
given below.
[0164] "Substituted," when used in connection with a chemical
substituent or moiety (e.g., an alkyl group), means that one or
more hydrogen atoms of the substituent or moiety have been replaced
with one or more non-hydrogen atoms or groups, provided that
valence requirements are met and that a chemically stable compound
results from the substitution.
[0165] "About" or "approximately," when used in connection with a
measurable numerical variable, refers to the indicated value of the
variable and to all values of the variable that are within the
experimental error of the indicated value or within .+-.10 percent
of the indicated value, whichever is greater.
[0166] "Alkyl" refers to straight chain and branched saturated
hydrocarbon groups, generally having a specified number of carbon
atoms (e.g., C.sub.1-3 alkyl refers to an alkyl group having 1 to 3
carbon atoms, C.sub.1-6 alkyl refers to an alkyl group having 1 to
6 carbon atoms, and so on). Examples of alkyl groups include
methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, i-butyl,
t-butyl, pent-1-yl, pent-2-yl, pent-3-yl, 3-methylbut-1-yl,
3-methylbut-2-yl, 2-methylbut-2-yl, 2,2,2-trimethyleth-1-yl,
n-hexyl, and the like.
[0167] "Alk-1-yl" refers to an alkyl group, as defined above, which
is attached to a parent group or substrate through a carbon atom
located at the 1 position of the alkyl group.
[0168] "Alkenyl" refers to straight chain and branched hydrocarbon
groups having one or more carbon-carbon double bonds, and generally
having a specified number of carbon atoms. Examples of alkenyl
groups include ethenyl, 1-propen-1-yl, 1-propen-2-yl,
2-propen-1-yl, 1-buten-1-yl, 1-buten-2-yl, 3-buten-1-yl,
3-buten-2-yl, 2-buten-1-yl, 2-buten-2-yl, 2-methyl-1-propen-1-yl,
2-methyl-2-propen-1-yl, 1,3-butadien-1-yl, 1,3-butadien-2-yl, and
the like.
[0169] "Alkynyl" refers to straight chain or branched hydrocarbon
groups having one or more triple carbon-carbon bonds, and generally
having a specified number of carbon atoms. Examples of alkynyl
groups include ethynyl, 1-propyn-1-yl, 2-propyn-1-yl, 1-butyn-1-yl,
3-butyn-1-yl, 3-butyn-2-yl, 2-butyn-1-yl, and the like.
[0170] "Halo," "halogen" and "halogeno" may be used interchangeably
and refer to fluoro, chloro, bromo, and iodo.
[0171] "Haloalkyl," "haloalkenyl," and "haloalkynyl," refer,
respectively, to alkyl, alkenyl, and alkynyl groups substituted
with one or more halogen atoms, where alkyl, alkenyl, and alkynyl
are defined above, and generally having a specified number of
carbon atoms. Examples of haloalkyl groups include fluoromethyl,
difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl,
trichloromethyl, and the like.
[0172] "Cycloalkyl" refers to saturated monocyclic and bicyclic
hydrocarbon groups, generally having a specified number of carbon
atoms that comprise the ring or rings (e.g., C.sub.3-8 cycloalkyl
refers to a cycloalkyl group having 3 to 8 carbon atoms as ring
members). Bicyclic hydrocarbon groups may include isolated rings
(two rings sharing no carbon atoms), spiro rings (two rings sharing
one carbon atom), fused rings (two rings sharing two carbon atoms
and the bond between the two common carbon atoms), and bridged
rings (two rings sharing two carbon atoms, but not a common bond).
The cycloalkyl group may be attached to a parent group or to a
substrate at any ring atom unless such attachment would violate
valence requirements. In addition, the cycloalkyl group may include
one or more non-hydrogen substituents unless such substitution
would violate valence requirements.
[0173] Examples of monocyclic cycloalkyl groups include
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.
Examples of fused bicyclic cycloalkyl groups include
bicyclo[2.1.0]pentanyl (i.e., bicyclo[2.1.0]pentan-1-yl,
bicyclo[2.1.0]pentan-2-yl, and bicyclo[2.1.0]pentan-5-yl),
bicyclo[3.1.0]hexanyl, bicyclo[3.2.0]heptanyl,
bicyclo[4.1.0]heptanyl, bicyclo[3.3.0]octanyl,
bicyclo[4.2.0]octanyl, bicyclo[4.3.0]nonanyl,
bicyclo[4.4.0]decanyl, and the like. Examples of bridged cycloalkyl
groups include bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl,
bicyclo[3.1.1]heptanyl, bicyclo[2.2.2]octanyl,
bicyclo[3.2.1]octanyl, bicyclo[4.1.1]octanyl,
bicyclo[3.3.1]nonanyl, bicyclo[4.2.1]nonanyl,
bicyclo[3.3.2]decanyl, bicyclo[4.2.2]decanyl,
bicyclo[4.3.1]decanyl, bicyclo[3.3.3]undecanyl,
bicyclo[4.3.2]undecanyl, bicyclo[4.3.3]dodecanyl, and the like.
Examples of spiro cycloalkyl groups include spiro[3.3]heptanyl,
spiro[2.4]heptanyl, spiro[3.4]octanyl, spiro[2.5]octanyl,
spiro[3.5]nonanyl, and the like. Examples of isolated bicyclic
cycloalkyl groups include those derived from bi(cyclobutane),
cyclobutanecyclopentane, bi(cyclopentane), cyclobutanecyclohexane,
cyclopentanecyclohexane, bi(cyclohexane), etc.
[0174] "Cycloalk-1-yl" refers to a cycloalkyl group, as defined
above, which is attached to a parent group or substrate through a
carbon atom located at the 1 position of the cycloalkyl group.
[0175] "Cycloalkenyl" refers to partially unsaturated monocyclic
and bicyclic hydrocarbon groups, generally having a specified
number of carbon atoms that comprise the ring or rings. As with
cycloalkyl groups, the bicyclic cycloalkenyl groups may include
isolated, spiro, fused, or bridged rings. Similarly, the
cycloalkenyl group may be attached to a parent group or to a
substrate at any ring atom and may include one or more non-hydrogen
substituents unless such attachment or substitution would violate
valence requirements. Examples of cycloalkenyl groups include the
partially unsaturated analogs of the cycloalkyl groups described
above, such as cyclobutenyl (i.e., cyclobuten-1-yl and
cyclobuten-3-yl), cyclopentenyl, cyclohexenyl,
bicyclo[2.2.1]hept-2-enyl, and the like.
[0176] "Aryl" refers to fully unsaturated monocyclic aromatic
hydrocarbons and to polycyclic hydrocarbons having at least one
aromatic ring, both monocyclic and polycyclic aryl groups generally
having a specified number of carbon atoms that comprise their ring
members (e.g., C.sub.6-14 aryl refers to an aryl group having 6 to
14 carbon atoms as ring members). The aryl group may be attached to
a parent group or to a substrate at any ring atom and may include
one or more non-hydrogen substituents unless such attachment or
substitution would violate valence requirements. Examples of aryl
groups include phenyl, biphenyl, cyclobutabenzenyl, indenyl,
naphthalenyl, benzocycloheptanyl, biphenylenyl, fluorenyl, groups
derived from cycloheptatriene cation, and the like.
[0177] "Heterocycle" and "heterocyclyl" may be used interchangeably
and refer to saturated or partially unsaturated monocyclic or
bicyclic groups having ring atoms composed of carbon atoms and 1 to
4 heteroatoms independently selected from nitrogen, oxygen, and
sulfur. Both the monocyclic and bicyclic groups generally have a
specified number of carbon atoms in their ring or rings (e.g.,
C.sub.2-5 heterocyclyl refers to a heterocyclyl group having 2 to 5
carbon atoms and 1 to 4 heteroatoms as ring members). As with
bicyclic cycloalkyl groups, bicyclic heterocyclyl groups may
include isolated rings, spiro rings, fused rings, and bridged
rings. The heterocyclyl group may be attached to a parent group or
to a substrate at any ring atom and may include one or more
non-hydrogen substituents unless such attachment or substitution
would violate valence requirements or result in a chemically
unstable compound. Examples of monocyclic heterocyclyl groups
include oxiranyl, thiaranyl, aziridinyl (e.g., aziridin-1-yl and
aziridin-2-yl), oxetanyl, thiatanyl, azetidinyl, tetrahydrofuranyl,
tetrahydrothiopheneyl, pyrrolidinyl, tetrahydropyranyl,
tetrahydrothiopyranyl, piperidinyl, 1,4-dioxanyl, 1,4-oxathianyl,
morpholinyl, 1,4-dithianyl, piperazinyl, 1,4-azathianyl, oxepanyl,
thiepanyl, azepanyl, 1,4-dioxepanyl, 1,4-oxathiepanyl,
1,4-oxaazepanyl, 1,4-dithiepanyl, 1,4-thiazepanyl, 1,4-diazepanyl,
3,4-dihydro-2H-pyranyl, 5,6-dihydro-2H-pyranyl, 2H-pyranyl,
1,2,3,4-tetrahydropyridinyl, and 1,2,5,6-tetrahydropyridinyl.
[0178] "Heteroaryl" refers to unsaturated monocyclic aromatic
groups and to polycyclic groups having at least one aromatic ring,
each of the groups having ring atoms composed of carbon atoms and 1
to 4 heteroatoms independently selected from nitrogen, oxygen, and
sulfur. Both the monocyclic and polycyclic groups generally have a
specified number of carbon atoms as ring members (e.g., C.sub.1-9
heteroaryl refers to a heteroaryl group having 1 to 9 carbon atoms
and 1 to 4 heteroatoms as ring members) and may include any
bicyclic group in which any of the above-listed monocyclic
heterocycles are fused to a benzene ring. The heteroaryl group may
be attached to a parent group or to a substrate at any ring atom
and may include one or more non-hydrogen substituents unless such
attachment or substitution would violate valence requirements or
result in a chemically unstable compound. Examples of heteroaryl
groups include monocyclic groups such as pyrrolyl (e.g.,
pyrrol-1-yl, pyrrol-2-yl, and pyrrol-3-yl), furanyl, thiopheneyl,
pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazolyl,
thiazolyl, 1,2,3-triazolyl, 1,3,4-triazolyl, 1-oxa-2,3-diazolyl,
1-oxa-2,4-diazolyl, 1-oxa-2,5-diazolyl, 1-oxa-3,4-diazolyl,
1-thia-2,3-diazolyl, 1-thia-2,4-diazolyl, 1-thia-2,5-diazolyl,
1-thia-3,4-diazolyl, tetrazolyl, pyridinyl, pyridazinyl,
pyrimidinyl, and pyrazinyl.
[0179] Examples of heteroaryl groups also include bicyclic groups
such as benzofuranyl, isobenzofuranyl, benzothiopheneyl,
benzo[c]thiopheneyl, indolyl, 3H-indolyl, isoindolyl,
1H-isoindolyl, indolinyl, isoindolinyl, benzimidazolyl, indazolyl,
benzotriazolyl, 1H-pyrrolo[2,3-b]pyridinyl,
1H-pyrrolo[2,3-c]pyridinyl, 1H-pyrrolo[3,2-c]pyridinyl,
1H-pyrrolo[3,2-b]pyridinyl, 3H-imidazo[4,5-b]pyridinyl,
3H-imidazo[4,5-c]pyridinyl, 1H-pyrazolo[4,3-b]pyridinyl,
1H-pyrazolo[4,3-c]pyridinyl, 1H-pyrazolo[3,4-c]pyridinyl,
1H-pyrazolo[3,4-b]pyridinyl, 7H-purinyl, indolizinyl,
imidazo[1,2-a]pyridinyl, imidazo[1,5-a]pyridinyl,
pyrazolo[1,5-a]pyridinyl, pyrrolo[1,2-b]pyridazinyl,
imidazo[1,2-c]pyrimidinyl, quinolinyl, isoquinolinyl, cinnolinyl,
quinazolinyl, quinoxalinyl, phthalazinyl, 1,6-naphthyridinyl,
1,7-naphthyridinyl, 1,8-naphthyridinyl, 1,5-naphthyridinyl,
2,6-naphthyridinyl, 2,7-naphthyridinyl, pyrido[3,2-d]pyrimidinyl,
pyrido[4,3-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl,
pyrido[2,3-d]pyrimidinyl, pyrido[2,3-b]pyrazinyl,
pyrido[3,4-b]pyrazinyl, pyrimido[5,4-d]pyrimidinyl,
pyrazino[2,3-b]pyrazinyl, and pyrimido[4,5-d]pyrimidinyl.
[0180] "Oxo" refers to a double bonded oxygen (.dbd.O).
[0181] "Leaving group" refers to any group that leaves a molecule
during a fragmentation process, including substitution reactions,
elimination reactions, and addition-elimination reactions. Leaving
groups may be nucleofugal, in which the group leaves with a pair of
electrons that formerly served as the bond between the leaving
group and the molecule, or may be electrofugal, in which the group
leaves without the pair of electrons. The ability of a nucleofugal
leaving group to leave depends on its base strength, with the
strongest bases being the poorest leaving groups. Common
nucleofugal leaving groups include nitrogen (e.g., from diazonium
salts); sulfonates, including alkylsulfonates (e.g., mesylate),
fluoroalkylsulfonates (e.g., triflate, hexaflate, nonaflate, and
tresylate), and arylsulfonates (e.g., tosylate, brosylate,
closylate, and nosylate). Others include carbonates, halide ions,
carboxylate anions, phenolate ions, and alkoxides. Some stronger
bases, such as NH.sub.2.sup.- and OH.sup.- can be made better
leaving groups by treatment with an acid. Common electrofugal
leaving groups include the proton, CO.sub.2, and metals.
[0182] "Opposite enantiomer" refers to a molecule that is a
non-superimposable mirror image of a reference molecule, which may
be obtained by inverting all of the stereogenic centers of the
reference molecule. For example, if the reference molecule has S
absolute stereochemical configuration, then the opposite enantiomer
has R absolute stereochemical configuration. Likewise, if the
reference molecule has S,S absolute stereochemical configuration,
then the opposite enantiomer has R,R stereochemical configuration,
and so on.
[0183] "Stereoisomer" and "stereoisomers" of a compound with given
stereochemical configuration refer to the opposite enantiomer of
the compound and to any diastereoisomers, including geometrical
isomers (Z/E) of the compound. For example, if a compound has S,R,Z
stereochemical configuration, its stereoisomers would include its
opposite enantiomer having R,S,Z configuration, and its
diastereomers having S,S,Z configuration, R,R,Z configuration,
S,R,E configuration, R,S,E configuration, S,S,E configuration, and
R,R,E configuration. If the stereochemical configuration of a
compound is not specified, then "stereoisomer" refers to any one of
the possible stereochemical configurations of the compound.
[0184] "Substantially pure stereoisomer" and variants thereof refer
to a sample containing a compound having a specific stereochemical
configuration and which comprises at least about 95% of the
sample.
[0185] "Pure stereoisomer" and variants thereof refer to a sample
containing a compound having a specific stereochemical
configuration and which comprises at least about 99.5% of the
sample.
[0186] "Subject" refers to a mammal, including a human.
[0187] "Pharmaceutically acceptable" substances refers to those
substances which are within the scope of sound medical judgment
suitable for use in contact with the tissues of subjects without
undue toxicity, irritation, allergic response, and the like,
commensurate with a reasonable benefit-to-risk ratio, and effective
for their intended use.
[0188] "Treating" refers to reversing, alleviating, inhibiting the
progress of, or preventing a disorder, disease or condition to
which such term applies, or to reversing, alleviating, inhibiting
the progress of, or preventing one or more symptoms of such
disorder, disease or condition.
[0189] "Treatment" refers to the act of "treating," as defined
immediately above.
[0190] "Drug," "drug substance," "active pharmaceutical
ingredient," and the like, refer to a compound (e.g., compounds of
Formula 1 and compounds specifically named above) that may be used
for treating a subject in need of treatment.
[0191] "Therapeutically effective amount" of a drug refers to the
quantity of the drug that may be used for treating a subject and
may depend on the weight and age of the subject and the route of
administration, among other things.
[0192] "Excipient" refers to any substance that may influence the
bioavailability of a drug, but is otherwise pharmacologically
inactive.
[0193] "Pharmaceutical composition" refers to the combination of
one or more drug substances and one or more excipients.
[0194] "Drug product," "pharmaceutical dosage form," "dosage form,"
"final dosage form" and the like, refer to a pharmaceutical
composition that is administered to a subject in need of treatment
and generally may be in the form of tablets, capsules, sachets
containing powder or granules, liquid solutions or suspensions,
patches, films, and the like.
[0195] The following abbreviations are used throughout the
specification: Ac (acetyl); ACN (acetonitrile); AIBN
(azo-bis-isobutyronitrile); API (active pharmaceutical ingredient);
aq (aqueous); Boc (tert-butoxycarbonyl); BSA (bovine serum
albumin); Cbz (carbobenzyloxy); dba (dibenzylideneacetone); DCC
(1,3-dicyclohexylcarbodiimide); DCM (dichloromethane); DIPEA
(N,N-diisopropylethyl-amine, Hunig's Base); DMA
(N,N-dimethylacetamide); DMAP (4-dimethylaminopyridine); DMARD
(disease modifying antirheumatic drug); DME (1,2-dimethoxyethane);
DMF (N,N-dimethylformamide); DMSO (dimethylsulfoxide); dppf
(1,1'-bis(diphenylphosphino)ferrocene); DTT (dithiothreitol); EDA
ethoxylated dodecyl alcohol, Brj.RTM.35); EDCI
(N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide); EDTA
(ethylenediaminetetraacetic acid); ee (enantiomeric excess); eq
(equivalents); Et (ethyl); Et.sub.3N (triethyl-amine); EtOAc (ethyl
acetate); EtOH (ethanol); FAM (5-carboxyfluorescein); HATU
(2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate(V)); HEPES
(4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid); HOAc (acetic
acid); HOBt (1H-benzo[d][1,2,3]triazol-1-ol); IC.sub.50
(concentration at 50% inhibition); IPA (isopropanol); IPAc
(isopropyl acetate); IPE (isopropylether); LDA (lithium
diisopropylamide); LiHMDS (lithium bis(trimethylsilyl)amide); mCPBA
(m-chloroperoxybenzoic acid); Me (methyl); MeOH (methanol); MTBE
(methyl tert-butyl ether); MOI (multiplicity of infection); mp
(melting point); NaOt-Bu (sodium tertiary butoxide); NBS
(N-bromosuccinimide); NCS (N-chlorosuccinimide); NIS
(N-iodosuccinimide); PE (petroleum ether); Ph (phenyl); pIC.sub.50
(-log.sub.10 (IC.sub.50), where ICs is given in molar (M) units);
Pr (propyl); i-Pr (isopropyl); PTFE (polytetrafluoroethylene); RT
(room temperature, approximately 20.degree. C. to 25.degree. C.);
SYK (spleen tyrosine kinase); TCEP (tris(2-carboxyethyl)phosphine);
TFA (trifluoroacetic acid); TFAA (2,2,2-trifluoroacetic anhydride);
THF (tetrahydrofuran); and Tris buffer
(2-amino-2-hydroxymethyl-propane-1,3-diol buffer).
[0196] This disclosure concerns compounds of Formula 1, which
includes compounds specifically named above, and their
pharmaceutically acceptable complexes, salts, solvates and
hydrates. This disclosure also concerns materials and methods for
preparing compounds of Formula 1, pharmaceutical compositions
containing them, and their use for treating disorders, diseases,
and conditions involving the immune system and inflammation,
including rheumatoid arthritis, hematological malignancies,
epithelial cancers (i.e., carcinomas), and other disorders,
diseases, and conditions for which inhibition of SYK is
indicated.
[0197] Compounds of Formula 1 include those in which L.sup.1 is a
bond and L.sup.2 is --NH--; L.sup.1 is --NH-- and L.sup.2 is a
bond; L.sup.1 and L.sup.2 are both bonds; or L.sup.1 and L.sup.2
are both --NH--.
[0198] Compounds of Formula 1 also include those in which R.sup.1
is hydrogen and R.sup.2 is C.sub.1-3 alkyl, in particular, methyl
or ethyl; R.sup.1 and R.sup.2 are both C.sub.1-3 alkyl groups, in
particular methyl; R.sup.1 and R.sup.2, together with the carbon
atom to which they are attached, form a cyclopropyl group; or
R.sup.1 and R.sup.2 are both hydrogen atoms.
[0199] Compounds of Formula 1 include those in which L.sup.1 is
--NH-- and L.sup.2 is --NH-- or a bond; G is N; R.sup.1 and R.sup.2
are both hydrogen; and R.sup.3 is a 2-amino-C.sub.3-8
cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl,
optionally substituted with from one to four substituents
independently selected from halo, oxo, --NO.sub.2, --CN, R.sup.6,
and R.sup.7.
[0200] Compounds of Formula 1 also include those in which L.sup.1
is --NH-- and L.sup.2 is --NH-- or a bond; G is N; R.sup.1 and
R.sup.2 are both hydrogen; and R.sup.3 is a 2-amino-C.sub.2-6
alk-1-yl, or more particularly 2-aminoethan-1-yl or
2-amino-2-oxoethan-1-yl, optionally substituted with from one to
five, from one to four or from one to two substituents,
respectively, independently selected from halo, oxo, --NO.sub.2,
--CN, R.sup.6, and R.sup.7.
[0201] Compounds of Formula 1 further include those in which
L.sup.1 is --NH-- and L.sup.2 is --NH-- or a bond; G is N; R.sup.1
and R.sup.2 are both hydrogen; and R.sup.3 is a C.sub.2-5
heterocyclyl, or more particularly an amino-C.sub.2-5 heterocyclyl
such as 3-aminotetrahydro-2H-pyran-4-yl, optionally substituted
with from one to five or from one to four substituents,
respectively, independently selected from halo, oxo, --NO.sub.2,
--CN, R.sup.6, and R.sup.7, wherein the heterocyclyl moiety has 5
or 6 ring atoms.
[0202] Compounds of Formula 1 include those in which L.sup.1 is
--NH-- and L.sup.2 is --NH-- or a bond; G is N; R.sup.1 and R.sup.2
are both hydrogen; and R.sup.4 is a C.sub.6-14 aryl, or more
particularly phenyl, optionally substituted with from one to five
substituents independently selected from halo, oxo, --CN, R.sup.6,
and R.sup.7.
[0203] Compounds of Formula 1 also include those in which L.sup.1
is --NH-- and L.sup.2 is --NH-- or a bond; G is N; R.sup.1 and
R.sup.2 are both hydrogen; and R.sup.4 is a C.sub.1-9 heteroaryl,
or more particularly a monocyclic C.sub.2-4 heteroaryl, optionally
substituted with from one to five or from one to four substituents,
respectively, independently selected from halo, oxo, --CN, R.sup.6,
and R.sup.7.
[0204] Compounds of Formula 1 also include those in which L.sup.1
is --NH-- and L.sup.2 is --NH-- or a bond; G is N; R.sup.1 and
R.sup.2 are both hydrogen; and R.sup.4 is a monocyclic C.sub.2-4
heteroaryl selected from pyrrolyl, furanyl, thiopheneyl, pyrazolyl,
imidazolyl, isoxazolyl, oxazolyl, isothiazoly, and thiazolyl, or
more particularly from thiopheneyl, pyrazolyl, isothiazoly, and
thiazolyl, each optionally substituted with from one to three
substituents independently selected from halo, --CN, R.sup.6, and
R.sup.7.
[0205] Compounds of Formula 1 further include those in which
L.sup.1 is --NH-- and L.sup.2 is --NH-- or a bond; G is N; R.sup.1
and R.sup.2 are both hydrogen; and R.sup.4 is a pyrazole moiety
(e.g., pyrazol-4-yl) optionally substituted with from one to three
substituents independently selected from halo, --CN, R.sup.6, and
R.sup.7.
[0206] Compounds of Formula 1 include those in which L.sup.1 is
--NH-- and L.sup.2 is --NH-- or a bond; G is C(R.sup.5); R.sup.1
and R.sup.2 are both hydrogen; and R.sup.5 is a C.sub.1-5
heteroaryl optionally substituted with from one to four
substituents independently selected from halo, --NO.sub.2, --CN,
C.sub.14 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, C.sub.14
haloalkyl, and R.sup.10.
[0207] Compounds of Formula 1 also include those in which L.sup.1
is --NH-- and L.sup.2 is --NH-- or a bond; G is C(R.sup.5); R.sup.1
and R.sup.2 are both hydrogen; and R.sup.5 is hydrogen or halo, or
more particularly, chloro or fluoro.
[0208] Compounds of Formula 1 include those in which L.sup.1 is
--NH-- and L.sup.2 is --NH-- or a bond; G is C(R.sup.5); R.sup.1
and R.sup.2 are both hydrogen; and R.sup.3 is a 2-amino-C.sub.3-8
cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl,
optionally substituted with from one to four substituents
independently selected from halo, oxo, --NO.sub.2, --CN, R.sup.6,
and R.sup.7.
[0209] Compounds of Formula 1 also include those in which L.sup.1
is --NH-- and L.sup.2 is --NH-- or a bond; G is C(R.sup.5); R.sup.1
and R.sup.2 are both hydrogen; and R.sup.3 is a 2-amino-C.sub.2-6
alk-1-yl, or more particularly 2-aminoethan-1-yl or
2-amino-2-oxoethan-1-yl, optionally substituted with from one to
five, from one to four or from one to two substituents,
respectively, independently selected from halo, oxo, --NO.sub.2,
--CN, R.sup.6, and R.sup.7.
[0210] Compounds of Formula 1 further include those in which
L.sup.1 is --NH-- and L.sup.2 is --NH-- or a bond; G is C(R.sup.5);
R.sup.1 and R.sup.2 are both hydrogen; and R.sup.3 is a C.sub.2-5
heterocyclyl, or more particularly an amino-C.sub.2-5 heterocyclyl
such as 3-aminotetrahydro-2H-pyran-4-yl, optionally substituted
with from one to five or from one to four substituents,
respectively, independently selected from halo, oxo, --NO.sub.2,
--CN, R.sup.6, and R.sup.7, wherein the heterocyclyl moiety has 5
or 6 ring atoms.
[0211] Compounds of Formula 1 include those in which L.sup.1 is
--NH-- and L.sup.2 is --NH-- or a bond; G is C(R.sup.5); R.sup.1
and R.sup.2 are both hydrogen; and R.sup.4 is a C.sub.6-14 aryl, or
more particularly phenyl, optionally substituted with from one to
five substituents independently selected from halo, oxo, --CN,
R.sup.6, and R.sup.7.
[0212] Compounds of Formula 1 also include those in which L.sup.1
is --NH-- and L.sup.2 is --NH-- or a bond; G is C(R.sup.5); R.sup.1
and R.sup.2 are both hydrogen, and R.sup.4 is a C.sub.1-9
heteroaryl, or more particularly a monocyclic C.sub.2-4 heteroaryl,
optionally substituted with from one to five or from one to four
substituents, respectively, independently selected from halo, oxo,
--CN, R.sup.6, and R.sup.7.
[0213] Compounds of Formula 1 also include those in which L.sup.1
is --NH-- and L.sup.2 is --NH-- or a bond; G is C(R.sup.5); R.sup.1
and R.sup.2 are both hydrogen; and R.sup.4 is a monocyclic
C.sub.2-4 heteroaryl selected from pyrrolyl, furanyl, thiopheneyl,
pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isothiazoly, and
thiazolyl, or more particularly from thiopheneyl, pyrazolyl,
isothiazoly, and thiazolyl, each optionally substituted with from
one to three substituents independently selected from halo, --CN,
R.sup.6, and R.sup.7.
[0214] Compounds of Formula 1 further include those in which
L.sup.1 is --NH-- and L.sup.2 is --NH-- or a bond; G is C(R.sup.5);
R.sup.1 and R.sup.2 are both hydrogen; and R.sup.4 is pyrazole
moiety (e.g., pyrazol-4-yl) optionally substituted with from one to
three substituents independently selected from halo, --CN, R.sup.6,
and R.sup.7.
[0215] Compounds of Formula 1 include those in which L.sup.1 is
--NH-- and L.sup.2 is --NH-- or a bond; G is N; R.sup.1 and R.sup.2
are both hydrogen; R.sup.3 is a 2-amino-C.sub.3-4 cycloalk-1-yl, or
more particularly 2-amino-cyclohex-1-yl, optionally substituted
with from one to four substituents independently selected from
halo, oxo, --NO.sub.2, --CN, R.sup.6, and R.sup.7; and R.sup.4 is a
C.sub.6-14 aryl, or more particularly phenyl, optionally
substituted with from one to five substituents independently
selected from halo, oxo, --CN, R.sup.6, and R.sup.7.
[0216] Compounds of Formula 1 also include those in which L.sup.1
is --NH-- and L.sup.2 is --NH-- or a bond; G is N; R.sup.1 and
R.sup.2 are both hydrogen; R.sup.3 is a 2-amino-C.sub.3-8
cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl,
optionally substituted with from one to four substituents
independently selected from halo, oxo, --NO.sub.2, --CN, R.sup.6,
and R.sup.7; and R.sup.4 is a C.sub.1-9 heteroaryl, or more
particularly a monocyclic C.sub.2-4 heteroaryl, optionally
substituted with from one to five or from one to four substituents,
respectively, independently selected from halo, oxo, --CN, R.sup.6,
and R.sup.7.
[0217] Compounds of Formula 1 include those in which L.sup.1 is
--NH-- and L.sup.2 is --NH-- or a bond; G is N; R.sup.1 and R.sup.2
are both hydrogen; R.sup.3 is a 2-amino-C.sub.3-4 cycloalk-1-yl, or
more particularly 2-amino-cyclohex-1-yl, optionally substituted
with from one to four substituents independently selected from
halo, oxo, --NO.sub.2, --CN, R.sup.6, and R.sup.7; and R.sup.4 is a
monocyclic C.sub.2-4 heteroaryl selected from pyrrolyl, furanyl,
thiopheneyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl,
isothiazoly, and thiazolyl, or more particularly from thiopheneyl,
pyrazolyl, isothiazoly, and thiazolyl, each optionally substituted
with from one to three substituents independently selected from
halo, --CN, R.sup.6, and R.sup.7.
[0218] Compounds of Formula 1 further include those in which
L.sup.1 is --NH-- and L.sup.2 is --NH-- or a bond; G is N; R.sup.1
and R.sup.2 are both hydrogen; R.sup.3 is a 2-amino-C.sub.3-8
cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl,
optionally substituted with from one to four substituents
independently selected from halo, oxo, --NO.sub.2, --CN, R.sup.6,
and R.sup.7; and R.sup.4 is a pyrazole moiety (e.g., pyrazol-4-yl)
optionally substituted with from one to three substituents
independently selected from halo, --CN, R.sup.6, and R.sup.7.
[0219] Compounds of Formula 1 include those in which L.sup.1 is
--NH-- and L.sup.2 is --NH-- or a bond; G is C(R.sup.5); R.sup.1
and R.sup.2 are both hydrogen; R.sup.3 is a 2-amino-C.sub.3-8
cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl,
optionally substituted with from one to four substituents
independently selected from halo, oxo, --NO.sub.2, --CN, R.sup.6,
and R.sup.7; and R.sup.4 is a C.sub.6-14 aryl, or more particularly
phenyl, optionally substituted with from one to five substituents
independently selected from halo, oxo, --CN, R.sup.6, and
R.sup.7.
[0220] Compounds of Formula 1 also include those in which L.sup.1
is --NH-- and L.sup.2 is --NH-- or a bond; G is C(R.sup.5); R.sup.1
and R.sup.2 are both hydrogen; R.sup.3 is a 2-amino-C.sub.3-8
cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl,
optionally substituted with from one to four substituents
independently selected from halo, oxo, --NO.sub.2, --CN, R.sup.6,
and R.sup.7; and R.sup.4 is a C.sub.1-9 heteroaryl, or more
particularly a monocyclic C.sub.2-4 heteroaryl, optionally
substituted with from one to five or from one to four substituents,
respectively, independently selected from halo, oxo, --CN, R.sup.6,
and R.sup.7.
[0221] Compounds of Formula 1 include those in which L.sup.1 is
--NH-- and L.sup.2 is --NH-- or a bond; G is C(R.sup.5); R.sup.1
and R.sup.2 are both hydrogen; R.sup.3 is a 2-amino-C.sub.3-8
cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl,
optionally substituted with from one to four substituents
independently selected from halo, oxo, --NO.sub.2, --CN, R.sup.6,
and R.sup.7; and R.sup.4 is a monocyclic C.sub.2-4 heteroaryl
selected from pyrrolyl, furanyl, thiopheneyl, pyrazolyl,
imidazolyl, isoxazolyl, oxazolyl, isothiazoly, and thiazolyl, or
more particularly from thiopheneyl, pyrazolyl, isothiazoly, and
thiazolyl, each optionally substituted with from one to three
substituents independently selected from halo, --CN, R.sup.6, and
R.sup.7.
[0222] Compounds of Formula 1 further include those in which
L.sup.1 is --NH-- and L.sup.2 is --NH-- or a bond; G is C(R.sup.5);
R.sup.1 and R.sup.2 are both hydrogen; R.sup.3 is a
2-amino-C.sub.3-8 cycloalk-1-yl, or more particularly
2-amino-cyclohex-1-yl, optionally substituted with from one to four
substituents independently selected from halo, oxo, --NO.sub.2,
--CN, R.sup.6, and R.sup.7; and R.sup.4 is a pyrazole moiety (e.g.,
pyrazol-4-yl) optionally substituted with from one to three
substituents independently selected from halo, --CN, R.sup.6, and
R.sup.7.
[0223] Compounds of Formula 1 include any of the aforementioned
embodiments in which L.sup.1 is --NH-- and L.sup.2 is a bond.
[0224] Thus, compounds of Formula 1 include those in which L.sup.1
is --NH--; L.sup.2 is a bond; G is C(R.sup.5); R.sup.1 and R.sup.2
are both hydrogen; R.sup.5 is hydrogen or halo, or more
particularly, chloro or fluoro; and R.sup.3 is a 2-amino-C.sub.3-8
cycloalk-1-yl, or more particularly 2-amino-cyclohex-1-yl,
optionally substituted with from one to four substituents
independently selected from halo, oxo, --NO.sub.2, --CN, R.sup.6,
and R.sup.7.
[0225] Compounds of Formula 1 include those in which L.sup.1 is
--NH--; L.sup.2 is a bond; G is C(R.sup.5); R.sup.1 and R.sup.2 are
both hydrogen; R.sup.5 is hydrogen or halo, or more particularly,
chloro or fluoro; and R.sup.3 is a 2-amino-C.sub.2-6 alk-1-yl, or
more particularly 2-aminoethan-1-yl or 2-amino-2-oxoethan-1-yl,
optionally substituted with from one to five, from one to four or
from two to two substituents, respectively, independently selected
from halo, oxo, --NO.sub.2, --CN, R.sup.6, and R.sup.7.
[0226] Compounds of Formula 1 include those in which L.sup.1 is
--NH--; L.sup.2 is a bond; G is C(R.sup.5); R.sup.1 and R.sup.2 are
both hydrogen; R.sup.5 is hydrogen or halo, or more particularly,
chloro or fluoro; and R.sup.3 is a C.sub.2-5 heterocyclyl, or more
particularly an amino-C.sub.2-5 heterocyclyl such as
3-aminotetrahydro-2H-pyran-4-yl, optionally substituted with from
one to five or from one to four substituents, respectively,
independently selected from halo, oxo, --NO.sub.2, --CN, R.sup.6,
and R.sup.7, wherein the heterocyclyl moiety has 5 or 6 ring
atoms.
[0227] Compounds of Formula 1 include those in which L.sup.1 is
--NH--; L.sup.2 is a bond; G is C(R.sup.5); R.sup.1 and R.sup.2 are
both hydrogen; R.sup.5 is hydrogen or halo, or more particularly,
chloro or fluoro; and R.sup.4 is a C.sub.6-14 aryl, or more
particularly phenyl, optionally substituted with from one to five
substituents independently selected from halo, oxo, --CN, R.sup.6,
and R.sup.7.
[0228] Compounds of Formula 1 also include those in which L.sup.1
is --NH--; L.sup.2 is a bond; G is C(R.sup.5); R.sup.1 and R.sup.2
are both hydrogen; R.sup.5 is hydrogen or halo, or more
particularly, chloro or fluoro; and R.sup.4 is a C.sub.1-9
heteroaryl, or more particularly a monocyclic C.sub.2-4 heteroaryl,
optionally substituted with from one to five or from one to four
substituents, respectively, independently selected from halo, oxo,
--CN, R.sup.6, and R.sup.7.
[0229] Compounds of Formula 1 include those in which L.sup.1 is
--NH--; L.sup.2 is a bond; G is C(R.sup.5); R.sup.1 and R.sup.2 are
both hydrogen; R.sup.5 is hydrogen or halo, or more particularly,
chloro or fluoro; and R.sup.4 is a monocyclic C.sub.2-4 heteroaryl
selected from pyrrolyl, furanyl, thiopheneyl, pyrazolyl,
imidazolyl, isoxazolyl, oxazolyl, isothiazoly, and thiazolyl, or
more particularly from thiopheneyl, pyrazolyl, isothiazoly, and
thiazolyl, each optionally substituted with from one to three
substituents independently selected from halo, --CN, R.sup.6, and
R.sup.7.
[0230] Compounds of Formula 1 include those in which L.sup.1 is
--NH--; L.sup.2 is a bond; G is C(R.sup.5); R.sup.1 and R.sup.2 are
both hydrogen; R.sup.5 is hydrogen or halo, or more particularly,
chloro or fluoro; and R.sup.4 is a pyrazole moiety (e.g.,
pyrazol-4-yl) optionally substituted with from one to three
substituents independently selected from halo, --CN, R.sup.6, and
R.sup.7.
[0231] Compounds of Formula 1 include those in which L.sup.1 is
--NH--; L.sup.2 is a bond; G is C(R.sup.5); R.sup.1 and R.sup.2 are
both hydrogen; R.sup.5 is hydrogen or halo, or more particularly,
chloro or fluoro; R.sup.3 is a 2-amino-C.sub.3-8 cycloalk-1-yl, or
more particularly 2-amino-cyclohex-1-yl, optionally substituted
with from one to four substituents independently selected from
halo, oxo, --NO.sub.2, --CN, R.sup.6, and R.sup.7; and R.sup.4 is a
C.sub.6-14 aryl, or more particularly phenyl, optionally
substituted with from one to five substituents independently
selected from halo, oxo, --CN, R.sup.6, and R.sup.7.
[0232] Compounds of Formula 1 include those in which L.sup.1 is
--NH--; L.sup.2 is a bond; G is C(R.sup.5); R.sup.1 and R.sup.2 are
both hydrogen; R.sup.5 is hydrogen or halo, or more particularly,
chloro or fluoro; R.sup.3 is a 2-amino-C.sub.3-8 cycloalk-1-yl, or
more particularly 2-amino-cyclohex-1-yl, optionally substituted
with from one to four substituents independently selected from
halo, oxo, --NO.sub.2, --CN, R.sup.6, and R.sup.7; and R.sup.4 is a
C.sub.1-9 heteroaryl, or more particularly a monocyclic C.sub.2-4
heteroaryl, optionally substituted with from one to five or from
one to four substituents, respectively, independently selected from
halo, oxo, --CN, R.sup.6, and R.sup.7.
[0233] Compounds of Formula 1 include those in which L.sup.1 is
--NH--; L.sup.2 is a bond; G is C(R.sup.5); R.sup.1 and R.sup.2 are
both hydrogen; R.sup.5 is hydrogen or halo, or more particularly,
chloro or fluoro; R.sup.3 is a 2-amino-C.sub.3-8 cycloalk-1-yl, or
more particularly 2-amino-cyclohex-1-yl, optionally substituted
with from one to four substituents independently selected from
halo, oxo, --NO.sub.2, --CN, R.sup.6, and R.sup.7; and R.sup.4 is a
monocyclic C.sub.2-4 heteroaryl selected from pyrrolyl, furanyl,
thiopheneyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl,
isothiazoly, and thiazolyl, or more particularly from thiopheneyl,
pyrazolyl, isothiazoly, and thiazolyl, each optionally substituted
with from one to three substituents independently selected from
halo, --CN, R.sup.6, and R.sup.7.
[0234] Compounds of Formula 1 include those in which L.sup.1 is
--NH--; L.sup.2 is a bond; G is C(R.sup.5); R.sup.1 and R.sup.2 are
both hydrogen; R.sup.5 is hydrogen or halo, or more particularly,
chloro or fluoro; R.sup.3 is a 2-amino-C.sub.3-8 cycloalk-1-yl, or
more particularly 2-amino-cyclohex-1-yl, optionally substituted
with from one to four substituents independently selected from
halo, oxo, --NO.sub.2, --CN, R.sup.6, and R.sup.7; and R.sup.4 is a
pyrazole moiety (e.g., pyrazol-4-yl) optionally substituted with
from one to three substituents independently selected from halo,
--CN, R.sup.6, and R.sup.7.
[0235] Compounds of Formula 1 also include any of the above
embodiments in which one or more of the R.sup.3, R.sup.4, R.sup.5,
R.sup.7, R.sup.8, and R.sup.9 substituents have no optional
substituents.
[0236] All references to compounds, including compounds of Formula
1 and compounds named in the specification, generally include all
complexes, salts, solvates, hydrates, and liquid crystals of the
compounds. Likewise, all references to compounds include all
complexes, solvates, hydrates, and liquid crystals of the salts of
the compounds.
[0237] Compounds of Formula 1, which include compounds specifically
named above, may form pharmaceutically acceptable complexes, salts,
solvates and hydrates. These salts include acid addition salts
(including di-acids) and base salts. Pharmaceutically acceptable
acid addition salts include nontoxic salts derived from inorganic
acids such as hydrochloric acid, nitric acid, phosphoric acid,
sulfuric acid, hydrobromic acid, hydroiodic acid, hydrofluoric
acid, and phosphorous acids, as well nontoxic salts derived from
organic acids, such as aliphatic mono- and dicarboxylic acids,
phenyl-substituted alkanoic acids, hydroxy alkanoic acids,
alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic
acids, etc. Such salts include acetate, adipate, aspartate,
benzoate, besylate, bicarbonate, carbonate, bisulfate, sulfate,
borate, camsylate, citrate, cyclamate, edisylate, esylate, formate,
fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate,
hibenzate, hydrochloride/chloride, hydrobromide/bromide,
hydroiodide/iodide, isethionate, lactate, malate, maleate,
malonate, mesylate, methylsulfate, naphthylate, 2-napsylate,
nicotinate, nitrate, orotate, oxalate, palmitate, pamoate,
phosphate, hydrogen phosphate, dihydrogen phosphate, pyroglutamate,
saccharate, stearate, succinate, tannate, tartrate, tosylate,
trifluoroacetate and xinofoate salts.
[0238] Pharmaceutically acceptable base salts include nontoxic
salts derived from bases, including metal cations, such as an
alkali or alkaline earth metal cation, as well as amines. Examples
of suitable metal cations include sodium (Na.sup.+), potassium
(K.sup.+), magnesium (Mg.sup.2+), calcium (Ca.sup.2+), zinc
(Zn.sup.2+), and aluminum (Al.sup.3+). Examples of suitable amines
include arginine, N,N'-dibenzylethylenediamine, chloroprocaine,
choline, diethylamine, diethanolamine, dicyclohexylamine,
ethylenediamine, glycine, lysine, N-methylglucamine, olamine,
2-amino-2-hydroxymethyl-propane-1,3-diol, and procaine. For a
discussion of useful acid addition and base salts, see S. M. Berge
et al., J. Pharm. Sci. (1977) 66:1-19; see also Stahl and Wermuth,
Handbook of Pharmaceutical Salts: Properties, Selection, and Use
(2002).
[0239] Pharmaceutically acceptable salts may be prepared using
various methods. For example, one may react a compound of Formula 1
with an appropriate acid or base to give the desired salt. One may
also react a precursor of the compound of Formula 1 with an acid or
base to remove an acid- or base-labile protecting group or to open
a lactone or lactam group of the precursor. Additionally, one may
convert a salt of the compound of Formula 1 to another salt through
treatment with an appropriate acid or base or through contact with
an ion exchange resin. Following reaction, one may then isolate the
salt by filtration if it precipitates from solution, or by
evaporation to recover the salt. The degree of ionization of the
salt may vary from completely ionized to almost non-ionized.
[0240] Compounds of Formula 1 may exist in a continuum of solid
states ranging from fully amorphous to fully crystalline. The term
"amorphous" refers to a state in which the material lacks long
range order at the molecular level and, depending upon temperature,
may exhibit the physical properties of a solid or a liquid.
Typically such materials do not give distinctive X-ray diffraction
patterns and, while exhibiting the properties of a solid, are more
formally described as a liquid. Upon heating, a change from solid
to liquid properties occurs which is characterized by a change of
state, typically second order ("glass transition"). The term
"crystalline" refers to a solid phase in which the material has a
regular ordered internal structure at the molecular level and gives
a distinctive X-ray diffraction pattern with defined peaks. Such
materials when heated sufficiently will also exhibit the properties
of a liquid, but the change from solid to liquid is characterized
by a phase change, typically first order ("melting point").
[0241] Compounds of Formula 1 may also exist in unsolvated and
solvated forms. The term "solvate" describes a molecular complex
comprising the compound and one or more pharmaceutically acceptable
solvent molecules (e.g., EtOH). The term "hydrate" is a solvate in
which the solvent is water. Pharmaceutically acceptable solvates
include those in which the solvent may be isotopically substituted
(e.g., D.sub.2O, acetone-d.sub.6, DMSO-d.sub.6).
[0242] A currently accepted classification system for solvates and
hydrates of organic compounds is one that distinguishes between
isolated site, channel, and metal-ion coordinated solvates and
hydrates. See, e.g., K. R. Morris (H. G. Brittain ed.) Polymorphism
in Pharmaceutical Solids (1995). Isolated site solvates and
hydrates are ones in which the solvent (e.g., water) molecules are
isolated from direct contact with each other by intervening
molecules of the organic compound. In channel solvates, the solvent
molecules lie in lattice channels where they are next to other
solvent molecules. In metal-ion coordinated solvates, the solvent
molecules are bonded to the metal ion.
[0243] When the solvent or water is tightly bound, the complex will
have a well-defined stoichiometry independent of humidity. When,
however, the solvent or water is weakly bound, as in channel
solvates and in hygroscopic compounds, the water or solvent content
will depend on humidity and drying conditions. In such cases,
non-stoichiometry will typically be observed.
[0244] Compounds of Formula 1 may also exist as multi-component
complexes (other than salts and solvates) in which the compound
(drug) and at least one other component are present in
stoichiometric or non-stoichiometric amounts. Complexes of this
type include clathrates (drug-host inclusion complexes) and
co-crystals. The latter are typically defined as crystalline
complexes of neutral molecular constituents which are bound
together through non-covalent interactions, but could also be a
complex of a neutral molecule with a salt. Co-crystals may be
prepared by melt crystallization, by recrystallization from
solvents, or by physically grinding the components together. See,
e.g., O. Almarsson and M. J. Zaworotko, Chem. Commun. (2004)
17:1889-1896. For a general review of multi-component complexes,
see J. K. Haleblian, J. Pharm. Sci. (1975) 64(8):1269-88.
[0245] When subjected to suitable conditions, compounds of Formula
1 may exist in a mesomorphic state (mesophase or liquid crystal).
The mesomorphic state lies between the true crystalline state and
the true liquid state (either melt or solution). Mesomorphism
arising as the result of a change in temperature is described as
"thermotropic" and mesomorphism resulting from the addition of a
second component, such as water or another solvent, is described as
"lyotropic." Compounds that have the potential to form lyotropic
mesophases are described as "amphiphilic" and include molecules
which possess a polar ionic moiety (e.g., --COO.sup.-Na.sup.+,
--COO.sup.-K.sup.+, --SO.sub.3.sup.-Na.sup.+) or polar non-ionic
moiety (such as --N.sup.-N.sup.+(CH.sub.3).sub.3). See, e.g., N. H.
Hartshorne and A. Stuart, Crystals and the Polarizing Microscope
(4th ed, 1970).
[0246] All references to compounds, including compounds of Formula
1 and compounds named in the specification, generally include all
polymorphs and crystal habits, prodrugs, metabolites,
stereoisomers, and tautomers thereof, as well as all
isotopically-labeled compounds thereof.
[0247] "Prodrugs" refer to compounds having little or no
pharmacological activity that can, when metabolized in vivo,
undergo conversion to compounds having desired pharmacological
activity. Prodrugs may be prepared by replacing appropriate
functionalities present in pharmacologically active compounds with
"pro-moieties" as described, for example, in H. Bundgaar, Design of
Prodrugs (1985). Examples of prodrugs include ester, ether or amide
derivatives of compounds of Formula 1 having carboxylic acid,
hydroxy, or amino functional groups, respectively. For further
discussions of prodrugs, see e.g., T. Higuchi and V. Stella
"Pro-drugs as Novel Delivery Systems," ACS Symposium Series 14
(1975) and E. B. Roche ed., Bioreversible Carriers in Drug Design
(1987).
[0248] "Metabolites" refer to compounds formed in vivo upon
administration of pharmacologically active compounds. Examples
include hydroxymethyl, hydroxy, secondary amino, primary amino,
phenol, and carboxylic acid derivatives of compounds of Formula 1
having methyl, alkoxy, tertiary amino, secondary amino, phenyl, and
amide groups, respectively.
[0249] Certain compounds described herein may have stereoisomers.
These compounds may exist as single enantiomers (enantiopure
compounds) or mixtures of enantiomers (enriched and racemic
samples), which depending on the relative excess of one enantiomer
over another in a sample, may exhibit optical activity. Such
stereoisomers, which are non-superimposable mirror images, possess
a stereogenic axis or one or more stereogenic centers (i.e.,
chirality). Other compounds may be stereoisomers that are not
mirror images. Such stereoisomers, which are known as
diastereoisomers, may be chiral or achiral (contain no stereogenic
centers). They include molecules containing an alkenyl or cyclic
group, so that cis/trans (or ZIE) stereoisomers are possible, or
molecules containing two or more stereogenic centers, in which
inversion of a single stereogenic center generates a corresponding
diastereoisomer. Unless stated or otherwise clear (e.g., through
use of stereobonds, stereocenter descriptors, etc.) the scope of
the invention and disclosure generally includes the reference
compound and its stereoisomers, whether they are each pure (e.g.,
enantiopure) or mixtures (e.g., enantiomerically enriched or
racemic).
[0250] Geometrical (cis/trans) isomers may be separated by
conventional techniques such as chromatography and fractional
crystallization.
[0251] Individual enantiomers of compounds may be prepared via
chiral synthesis from a suitable optically pure precursor or
isolated via resolution of the racemate (or the racemate of a salt
or derivative) using, for example, chiral HPLC. Alternatively, the
racemate (or a racemic precursor) may be reacted with a suitable
enantiomerically pure compound (e.g., acid or base) to yield a pair
of diastereoisomers, each composed of a single enantiomer, which
are separated via, say, fractional recrystallization or
chromatography. The desired enantiomer is subsequently regenerated
from the appropriate diastereoisomer. Often, the desired enantiomer
may be further enriched by recrystallization in a suitable solvent
(e.g., ACN) when it is it available in sufficient quantity (e.g.,
typically not much less than about 85% ee, and in some cases, not
much less than about 90% ee). For a further discussion of
techniques for separating stereoisomers, see E. L. Eliel and S. H.
Wilen, Stereochemistry of Organic Compounds (1994).
[0252] "Tautomers" refer to structural isomers that are
interconvertible via a low energy barrier. Tautomeric isomerism
(tautomerism) may take the form of proton tautomerism in which the
compound contains, for example, an imino, keto, or oxime group, or
valence tautomerism in which the compound contains an aromatic
moiety.
[0253] Compounds described herein also include all pharmaceutically
acceptable isotopic variations, in which at least one atom is
replaced by an atom having the same atomic number, but an atomic
mass different from the atomic mass usually found in nature.
Isotopes suitable for inclusion in compounds of Formula 1 include,
for example, isotopes of hydrogen, such as .sup.2H and .sup.3H;
isotopes of carbon, such as .sup.11C, .sup.13C and .sup.14C;
isotopes of nitrogen, such as .sup.13N and .sup.15N; isotopes of
oxygen, such as .sup.15O, .sup.17O and .sup.18O; isotopes of
sulfur, such as .sup.35S; isotopes of fluorine, such as .sup.18F;
isotopes of chlorine, such as .sup.36Cl, and isotopes of iodine,
such as .sup.123I and .sup.125I. Use of isotopic variations (e.g.,
deuterium, .sup.2H) may afford certain therapeutic advantages
resulting from greater metabolic stability, for example, increased
in vivo half-life or reduced dosage requirements. Additionally,
certain isotopic variations of the disclosed compounds may
incorporate a radioactive isotope (e.g., tritium, .sup.3H, or
.sup.14C), which may be useful in drug and/or substrate tissue
distribution studies. Substitution with positron emitting isotopes,
such as .sup.11C, .sup.18F, .sup.15O and .sup.13N, may be useful in
Positron Emission Topography (PET) studies for examining substrate
receptor occupancy. Isotopically-labeled compounds may be prepared
by processes analogous to those described elsewhere in the
disclosure using an appropriate isotopically-labeled reagent in
place of a non-labeled reagent.
[0254] The compounds of Formula 1 may be prepared using the
techniques described below. Some of the schemes and examples may
omit details of common reactions, including oxidations, reductions,
and so on, separation techniques (extraction, evaporation,
precipitation, chromatography, filtration, trituration,
crystallization, and the like), and analytical procedures, which
are known to persons of ordinary skill in the art of organic
chemistry. The details of such reactions and techniques can be
found in a number of treatises, including Richard Larock,
Comprehensive Organic Transformations (1999), and the multi-volume
series edited by Michael B. Smith and others, Compendium of Organic
Synthetic Methods (1974 et seq.). Starting materials and reagents
may be obtained from commercial sources or may be prepared using
literature methods. Some of the reaction schemes may omit minor
products resulting from chemical transformations (e.g., an alcohol
from the hydrolysis of an ester, CO.sub.2 from the decarboxylation
of a diacid, etc.). In addition, in some instances, reaction
intermediates may be used in subsequent steps without isolation or
purification (i.e., in situ).
[0255] In some of the reaction schemes and examples below, certain
compounds can be prepared using protecting groups, which prevent
undesirable chemical reaction at otherwise reactive sites.
Protecting groups may also be used to enhance solubility or
otherwise modify physical properties of a compound. For a
discussion of protecting group strategies, a description of
materials and methods for installing and removing protecting
groups, and a compilation of useful protecting groups for common
functional groups, including amines, carboxylic acids, alcohols,
ketones, aldehydes, and so on, see T. W. Greene and P. G. Wuts,
Protecting Groups in Organic Chemistry (1999) and P. Kocienski,
Protective Groups (2000).
[0256] Generally, the chemical transformations described throughout
the specification may be carried out using substantially
stoichiometric amounts of reactants, though certain reactions may
benefit from using an excess of one or more of the reactants.
Additionally, many of the reactions disclosed throughout the
specification may be carried out at about room temperature (RT) and
ambient pressure, but depending on reaction kinetics, yields, and
so on, some reactions may be run at elevated pressures or employ
higher temperatures (e.g., reflux conditions) or lower temperatures
(e.g., -78.degree. C. to 0.degree. C.). Any reference in the
disclosure to a stoichiometric range, a temperature range, a pH
range, etc., whether or not expressly using the word "range," also
includes the indicated endpoints.
[0257] Many of the chemical transformations may also employ one or
more compatible solvents, which may influence the reaction rate and
yield. Depending on the nature of the reactants, the one or more
solvents may be polar protic solvents (including water), polar
aprotic solvents, non-polar solvents, or some combination.
Representative solvents include saturated aliphatic hydrocarbons
(e.g., n-pentane, n-hexane, n-heptane, n-octane); aromatic
hydrocarbons (e.g., benzene, toluene, xylenes); halogenated
hydrocarbons (e.g., methylene chloride, chloroform, carbon
tetrachloride); aliphatic alcohols (e.g., methanol, ethanol,
propan-1-ol, propan-2-ol, butan-1-ol, 2-methyl-propan-1-ol,
butan-2-ol, 2-methyl-propan-2-ol, pentan-1-ol, 3-methyl-butan-1-ol,
hexan-1-ol, 2-methoxy-ethanol, 2-ethoxy-ethanol, 2-butoxy-ethanol,
2-(2-methoxy-ethoxy)-ethanol, 2-(2-ethoxy-ethoxy)-ethanol,
2-(2-butoxy-ethoxy)-ethanol); ethers (e.g., diethyl ether,
di-isopropyl ether, dibutyl ether, 1,2-dimethoxy-ethane,
1,2-diethoxy-ethane, 1-methoxy-2-(2-methoxy-ethoxy)-ethane,
1-ethoxy-2-(2-ethoxy-ethoxy)-ethane, tetrahydrofuran, 1,4-dioxane);
ketones (e.g., acetone, methyl ethyl ketone); esters (methyl
acetate, ethyl acetate); nitrogen-containing solvents (e.g.,
formamide, N,N-dimethylformamide, acetonitrile,
N-methyl-pyrrolidone, pyridine, quinoline, nitrobenzene);
sulfur-containing solvents (e.g., carbon disulfide, dimethyl
sulfoxide, tetrahydro-thiophene-1,1,-dioxide); and
phosphorus-containing solvents (e.g., hexamethylphosphoric
triamide).
[0258] In the schemes, below, substituent identifiers (e.g.,
R.sup.1, R.sup.3, R.sup.4, R.sup.5, R.sup.7, R.sup.8, R.sup.9,
L.sup.1 and L.sup.2) are as defined above for Formula 1. As
mentioned earlier, however, some of the starting materials and
intermediates may include protecting groups, which are removed
prior to the final product. In such cases, the substituent
identifier refers to moieties defined in Formula 1 and to those
moieties with appropriate protecting groups. For example, a
starting material or intermediate in the schemes may include an
R.sup.3 that is a moiety having a potentially reactive amine. In
such cases, R.sup.3 would include the moiety with or without, say,
a Boc or Cbz group attached to the amine.
[0259] Scheme 1 illustrates a method for preparing compound 1-5.
Starting material 1-0 (e.g., methyl
6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate) is
chlorinated at elevated temperature (e.g., 95-105.degree. C.) using
phosphoryl trichloride as a reactive solvent, in the presence of a
catalytic amount of N,N-dimethyl aniline to give a methyl
pyrimidine carboxylate 1-1. The 2-chloro and 4-chloro groups of
intermediate 1-1 are subsequently displaced via treatment with an
appropriately-substituted amine. As depicted in Scheme 1, the
2-chloro group is reacted with R.sup.4--NH.sub.2 (e.g. substituted
aniline) in a polar aprotic organic solvent (e.g., ACN or THF) and
in the presence of a hindered base such as Et.sub.3N or DIPEA (2
eq) to give intermediate 1-2. The reaction may be carried out at
elevated temperatures (e.g. 90.degree. C. or reflux conditions). In
a similar manner, the 4-chloro group is displaced with
R.sup.3--NH.sub.2 to give intermediate 1-3. The second displacement
is carried out at elevated temperatures (e.g., 90.degree. C. or
reflux conditions) in a polar aprotic organic solvent (e.g., DMA or
DMF) in the presence of a hindered base (e.g., Et.sub.3N or
DIPEA).
##STR00003##
[0260] Scheme 1 shows two methods for cyclizing intermediate 1-3.
In one method, intermediate 1-3 is oxidized with SeO.sub.2 (2-4 eq)
in an organic solvent, such as 1,4-dioxane, under reflux conditions
(e.g., about 100.degree. C.) to give a ketone (or aldehyde)
intermediate (not shown). Subsequent reaction with
2,4-dimethoxybenzylamine in the presence of a mild reducing agent,
such as sodium cyanoborohydride (1.5 eq) or sodium
triacetoxy-borohydride in MeOH, gives via reductive amination, an
amino intermediate which cyclizes to 1-4, either immediately or
upon heating to about 50.degree. C. The dimethoxybenzyl group can
be removed by treating intermediate 1-4 with an acid (e.g., TFA) at
about 60.degree. C., which gives the desired compound 1-5. In a
second method, intermediate 1-3 is treated with a bromination
reagent such as NBS in the presence of an initiator (e.g.,
dibenzoyl peroxide or AINBN) in CCl.sub.4. Refluxing the reaction
mixture gives intermediate 1-6, which is treated with a source of
ammonia (e.g., ammonium hydroxide) in THF to give 1-5.
##STR00004##
[0261] Scheme 2 provides a method for preparing compound 2-8.
Starting material 2-0 (2-(1,3-dioxoisoindolin-2-yl)acetic acid) is
reacted with 2,2-dimethyl-1,3-dioxane-4,6-dione (1-1.5 eq) and
4-dimethylaminopyridine (1-1.5 eq) in the presence of DCC (1-1.5
eq) and an organic solvent such as dichloromethane to give
intermediate 2-1. Subsequent treatment of 2-1 with
2,4-dimethoxybenzylamine (1 eq) in EtOH at about 50.degree. C.
gives an imine 2-2, which is isolated, re-dissolved in an organic
solvent (e.g., THF) and treated with an activated
carbonylisocyanate (e.g., carbonisocyanatidic chloride, 1 eq) at
about 80.degree. C. to give intermediate 2-3. Treating 2-3 with an
acid (e.g., TFA at RT to 60.degree. C.) removes the dimethoxybenzyl
group to give intermediate 2-4, which is subsequently reacted with
a chlorinating agent (e.g., POCl.sub.3) under refluxing conditions
(e.g., about 100.degree. C.) to give intermediate 2-5. Stepwise
displacement of the two chloro groups with
appropriately-substituted amines (R.sup.4--NH.sub.2 and
R.sup.3--NH.sub.2) gives intermediates 2-6 and 2-7. Treatment of
intermediate 2-7 with hydrazine hydrate (4-5 eq) in EtOH with
heating (e.g., at about 65.degree. C.) gives compound 2-8.
##STR00005##
[0262] Scheme 3 provides another method for preparing compound 2-8.
Starting material 3-0 (2,4,6-trichloropyrimidine) is treated with a
strong base such as LDA (made freshly from diisopropyl amine and
n-BuLi or purchased) at -78.degree. C. in dry THF, followed by
quenching with dry ice. Warming the mixture to RT and stirring
gives intermediate 3-1. Displacement of a chloro group via
treatment with an appropriately-substituted amine
(R.sup.4--NH.sub.2, 1 eq) in the presence of a hindered base (e.g.,
Et.sub.3N or DIPEA, 2 eq) and a polar aprotic organic solvent
(e.g., DMF) gives intermediate 3-2. Subsequent treatment of 3-2
with MeI (1-1.5 eq) and a base (e.g. sodium bicarbonate, 1.5-3 eq)
yields an ester 3-3, which may proceed to compound 2-8 through two
different routes. In one route, intermediate 3-3 undergoes
treatment with an appropriately-substituted amine
(R.sup.3--NH.sub.2, 1-1.1 eq) in the presence of a hindered base
(e.g., DIPEA) and a polar aprotic organic solvent (e.g., THF) to
give intermediate 3-4 and an isomer. Following isolation,
intermediate 3-4 is reacted with zinc cyanide (0.5-1 eq) and a
catalytic amount (10%) of tetrakis (triphenylphosphine)
palladium(0) in DMF at about 90.degree. C. to give nitrile 3-5.
Reduction of the nitrile group to an amine via hydrogenation using
Pd on carbon (5-10%) in EtOH and a catalytic amount of HCl gives,
upon treatment with sodium bicarbonate, 2-8.
[0263] In an alternative route, intermediate 3-3 is first converted
to nitrile 3-6 via palladium-catalyzed cyanation by heating a
mixture of 3-3, zinc cyanide (0.5-1 eq), tetrakis(triphenyl
phosphine)palladium(0) (0.1 eq), and a polar aprotic solvent (e.g.,
DMF) in a microwave oven at about 120.degree. C. for about 1 hour.
Following isolation, intermediate 3-6 is converted at RT to 3-5 via
reaction with an appropriately-substituted amine
(R.sup.3--NH.sub.2, 1-1.5 eq) in a polar aprotic solvent (e.g.,
DMF) and in the presence of a hindered base (e.g., DIPEA). As
described above, reduction of the nitrile group of 3-5 and
subsequent cyclization gives compound 2-8.
[0264] Scheme 4 shows a method for preparing compound 4-6.
Lithiation of starting material 4-0 (2,6-di-halo-3-iodopyridine)
via directed ortho-lithiation by LDA in THF at -78.degree. C.,
followed by quenching with dry ice, gives 4-1, which is
subsequently esterified at RT using MeI and a base (e.g., potassium
carbonate). As in Scheme 3, the iodo group of intermediate 4-2 is
converted to a nitrile group via palladium-catalyzed cyanation to
give 4-3. Stepwise displacement of the two chloro groups with
appropriately-substituted amines (R.sup.4--NH.sub.2 and
R.sup.3--NH.sub.2) gives intermediates 4-4 and 4-5. As in the
ring-closure step depicted in Scheme 3, hydrogenation followed by
cyclization gives compound 4-6.
##STR00006##
[0265] Scheme 5 depicts a method for preparing compound 5-4.
Starting material 1-1 (methyl
2,4-dichloro-6-methylpyrimidine-5-carboxylate) is reacted with an
aromatic boronic acid or borate (e.g., R.sup.4--B(OR.sup.13).sub.2,
where R.sup.4 is C.sub.6-14 aryl or C.sub.1-9 heteroaryl, and e.g.,
each R.sup.3 is H or C.sub.1-4 alkyl) in the presence of a
palladium catalyst (e.g., Pd(PPh.sub.3).sub.4,
(PPh.sub.3).sub.2PdCl.sub.2, etc.), a base (e.g., KF or
Na.sub.2CO.sub.3), and an organic solvent (e.g., dioxane, DMF,
etc.). The Suzuki-type coupling is carried out at elevated
temperature (e.g., about 90.degree. C.) and gives intermediate 5-1.
Displacement of the chloro group with an appropriately-substituted
amine (R.sup.3--NH.sub.2) gives intermediate 5-2. As in Scheme 1,
the methyl group on pyrimidine is oxidized with SeO.sub.2 (2-4 eq)
in an organic solvent (e.g., 1,4-dioxane) under reflux conditions
to give an aldehyde intermediate, which is subsequently reacted
with 2,4-dimethoxybenzylamine in the presence of a mild reducing
agent (e.g., about 1.5 eq of NaCNBH.sub.3 or NaBH(OAc).sub.3) in
MeOH, to give, via reductive amination, an amino intermediate which
cyclizes to 5-3, either immediately or upon heating to about
50.degree. C. Treating intermediate 5-3 with an acid (e.g., TFA) at
about 60.degree. C. gives compound 5-4.
##STR00007##
[0266] Scheme 6 depicts a method for preparing compound 6-3.
Starting material 6-0, which may be prepared from methyl
2,4-dichloro-6-methylpyrimidine-5-carboxylate using the methods
described above, is reacted with an aromatic boronic acid or borate
(e.g., R.sup.3--B(OR.sup.3).sub.2, where R.sup.3 is C.sub.6-14 aryl
or C.sub.1-9 heteroaryl and e.g., R.sup.3 is H or C.sub.14 alkyl)
in the presence of a palladium catalyst (e.g., Pd(PPh.sub.3).sub.4,
(PPh.sub.3).sub.2PdCl.sub.2, etc.), a base (e.g., KF or
Na.sub.2CO.sub.3), and an organic solvent (e.g., dioxane, DMF, DME,
etc.). The Suzuki-type coupling is carried out at elevated
temperature (e.g., about 90.degree. C.) and gives intermediate 6-1.
The methyl group on pyrimidine is oxidized with SeO.sub.2 (2-4 eq)
in an organic solvent (e.g., 1,4-dioxane) under reflux conditions
to give an aldehyde intermediate, which is subsequently reacted
with 2,4-dimethoxybenzylamine in the presence of a mild reducing
agent (e.g., about 1.5 eq of NaCNBH.sub.3 or NaBH(OAc).sub.3) in
MeOH, to give intermediate 6-2. Treating 6-2 with an acid (e.g.,
TFA) at about 60.degree. C. yields compound 6-3.
##STR00008##
[0267] Scheme 7 illustrates methods for preparing compounds 7-2,
7-3, 7-4, 7-5, and 7-6. Starting material 7-0, which may be
prepared using the methods described above, may be reacted with NBS
or NIS to give halo-pyridine intermediate 7-1 (Y.sup.1 is Br or I).
As in Scheme 3, the halo group of 7-1 may be converted to a nitrile
group via palladium-catalyzed cyanation to give 7-2. Compound 7-2
is subsequently reacted with a Grignard reagent (R.sup.7--MgBr) to
give an imine intermediate (not shown), which upon acid hydrolysis,
yields compound 7-3. Alternatively, halo-pyridine intermediate 7-1
may be reacted with NHR.sup.8R.sup.9 in the presence of a palladium
(II) catalyst (e.g., PdCl.sub.2(dppf)), a stoichiometric amount of
base (e.g., NaOt-Bu), and an organic solvent (e.g., dioxane,
toluene, etc.), at elevated temperature (e.g., about 100.degree.
C.). The Buchwald-Hartwig coupling gives heteroaryl amine 7-4. In
addition, 7-1 may be reacted with a terminal alkyne
(HC.ident.R.sup.13, e.g., R.sup.13 is H or C.sub.1-4 alkyl) in the
presence of a palladium(II) catalyst (e.g.,
(PPh.sub.3).sub.2PdCl.sub.2), a copper(I) co-catalyst (e.g., CuI),
and an amine base (e.g. Et.sub.3N), at RT. Following the
Sonogashira coupling, reduction of the alkyne moiety yields
compound 7-5 with R.sup.5 being, e.g., C.sub.1-5 alkyl. Compound
7-1 may be reacted with an aromatic boronic acid or borate (e.g.,
R.sup.5--B(OR.sup.13).sub.2, where R.sup.5 is C.sub.1-9 heteroaryl
and e.g., R.sup.13 is H or C.sub.1-4 alkyl) in the presence of a
palladium catalyst (e.g., Pd(PPh.sub.3).sub.4,
(PPh.sub.3).sub.2PdCl.sub.2, etc.), a base (e.g., KF or
Na.sub.2CO.sub.3), and an organic solvent (e.g., dioxane, DMF,
etc.). The Suzuki-type coupling is carried out at elevated
temperature (e.g., about 90.degree. C.) and gives compound 7-5 with
R.sup.5 being C.sub.1-9 heteroaryl.
##STR00009##
[0268] As shown in Scheme 7, compound 7-0 may alternatively be
treated with a fluorinating agent, such as SELECTFLUOR.RTM.
(1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane
ditetrafluoroborate), in an organic solvent (e.g., DCM) or a
mixture of organic solvents (e.g., DCM and McOH), to give a
fluoro-pyridine derivative 7-6 (Y.sup.2 is F). Similarly, 7-0 may
be treated with a chlorinating agent, such as NCS, in an aprotic
solvent (e.g., DCM) to give a chloro-pyridine derivative 7-6
(Y.sup.2 is Cl).
[0269] Scheme 8 shows an alternative method for preparing compound
4-6. Starting material 8-0 (2-chloro-3-iodopyridine) undergoes
ortho-directed lithiation via treatment with LDA in THF at
-78.degree. C. Quenching with dry ice gives 8-1, which is
subsequently esterified at RT using iodomethane and a base (e.g.,
potassium carbonate). As in Scheme 4, the iodo group of
intermediate 8-2 is converted to a nitrile group via
palladium-catalyzed cyanation or through treatment with cyanocopper
or zinc cyanide in a suitable solvent (e.g., DMF, DMA, etc.) at
elevated temperature. The R.sup.4 substituent is installed on 8-3
using a Suzuki reaction, which gives intermediate 8-4. N-oxidation
of the pyridine moiety via treatment with hydrogen peroxide/urea
complex gives an activated intermediate 8-5, which is chlorinated
through reaction with phosphorus oxychloride at an elevated
temperature (e.g., 90-100.degree. C.). Displacement of the chloro
group on 8-6 via reaction with an appropriately-substituted amine
(R.sup.3--NH.sub.2) gives intermediate 8-7. Subsequent reduction
through palladium-catalyzed hydrogenation and cyclization gives
compound 4-6.
##STR00010##
##STR00011##
[0270] Scheme 9 depicts the synthesis of compound 9-5. Starting
material 9-0 (2,6-dichloro-5-fluoronicotinic acid) is lithiated via
treatment with LDA in THF at -78.degree. C. Quenching with DMF
gives an aldehyde intermediate 9-1, which undergoes reductive
amination through reaction with an amine (e.g.,
2,4-dimethoxyphenyl)methanamine) and reducing agent (e.g.,
NaBH(OAc).sub.3). The resulting amino acid (not shown) is cyclized
via amide coupling, which employs a suitable coupling agent (e.g.,
EDCI, DCC, etc.), catalyst (HOBt, DMAP, etc.), and solvent (e.g.,
DMF, DMSO, ACN, THF, DCM, etc.). As in previous schemes,
displacement of the chloro group of compound 9-2 with an
appropriate amine (R.sup.3--NH.sub.2) gives intermediate 9-3, which
is subsequently reacted with an aromatic boronic acid or borate
(e.g., R.sup.4--B(OR.sup.3).sub.2 in the presence of a palladium
catalyst (e.g., Pd(PPh.sub.3).sub.4, (PPh.sub.3).sub.2PdCl.sub.2,
etc.), base (e.g., KF or Na.sub.2CO.sub.3), and organic solvent
(e.g., dioxane, DMF, etc.) at elevated temperature (e.g., about
90.degree. C.) to give 9-4. Following the Suzuki coupling,
treatment of 9-4 with TFA at elevated temperature (e.g.,
40-60.degree. C.) generates 9-5.
##STR00012##
[0271] Scheme 10 shows another method for preparing compound 1-5.
The chloro group of compound 1-2 is first displaced with sodium
methanethiolate to give 10-1. As in Scheme 1, intermediate 10-1 is
oxidized with SeO.sub.2 to give a ketone (or aldehyde) intermediate
(not shown), which is reacted with 2,4-dimethoxybenzylamine in the
presence of a reducing agent to give, via reductive amination, an
amino acid intermediate which cyclizes to 10-2. The methylthio
group is converted to methylsulfonyl using mCPBA
(m-chloroperoxybenzoic acid), which is displaced with an
appropriate amine (R.sup.3--NH.sub.2) to give intermediate 10-4.
Treatment of 10-4 with an acid (e.g., TFA) at elevated temperature
(e.g., 40-60.degree. C.) gives compound 1-5.
##STR00013##
[0272] Scheme 11 depicts an alternate synthesis of compound 9-5.
Starting material 11-0 (2,6-dichloro-5-fluoronicotinonitrile) is
hydrolyzed by treatment with concentrated sulfuric acid at elevated
temperature (e.g., about 65.degree. C.) to give amide 11-1, which
is lithiated via treatment with LiHMDS at about 0.degree. C. or
reaction with LDA in THF at -78.degree. C. Quenching with DMF gives
aldehyde intermediate 11-2, which is reduced to lactam 11-3 by
treatment with a reducing agent (e.g., triethyl silane) and an acid
(e.g., TFA) in an organic solvent (e.g., DCM). Following
installation of a Boc protecting group on lactam 11-3, displacement
of a chloro group on compound 11-4 via reaction with an appropriate
amine (R.sup.3--NH.sub.2) gives intermediate 11-5. The intermediate
is subsequently reacted with an aromatic boronic acid or borate
(e.g., R.sup.4--B(OR.sup.13).sub.2 in the presence of a palladium
catalyst (e.g., Pd(PPh.sub.3).sub.4, (PPh.sub.3).sub.2PdCl.sub.2,
Pd.sub.2(dba).sub.3, etc.), an optional ligand (e.g.,
2-(dicyclohexylphosphino)biphenyl), a base (e.g., KF or
Na.sub.2CO.sub.3), and an organic solvent (e.g., dioxane, DMF,
etc.) to give compound 11-6. The Suzuki reaction is carried out at
elevated temperature (e.g., 90-160.degree. C.), either by
conventional heating or via microwave irradiation. Alternatively,
compound 11-5 may be reacted with an aromatic tin reagent (e.g.,
R.sup.4--Sn(n-Bu).sub.3) in the presence of a palladium catalyst
(e.g., Pd(PPh.sub.3).sub.4) and an organic solvent (e.g., toluene)
at elevated temperature (e.g., about 100.degree. C.). Following the
Suzuki or Stille coupling, treatment of 11-6 with an acid (e.g.,
TFA or HCl) at RT or above (e.g., about 20-60.degree. C.) generates
9-5.
[0273] Compounds of Formula 1, which include compounds named above,
and their pharmaceutically acceptable complexes, salts, solvates
and hydrates, should be assessed for their biopharmaceutical
properties, such as solubility and solution stability across pH,
permeability, and the like, to select an appropriate dosage form
and route of administration. Compounds that are intended for
pharmaceutical use may be administered as crystalline or amorphous
products, and may be obtained, for example, as solid plugs,
powders, or films by methods such as precipitation,
crystallization, freeze drying, spray drying, evaporative drying,
microwave drying, or radio frequency drying.
[0274] Compounds of Formula 1 may be administered alone or in
combination with one another or with one or more pharmacologically
active compounds which are different than the compounds of Formula
1. Generally, one or more these compounds are administered as a
pharmaceutical composition (a formulation) in association with one
or more pharmaceutically acceptable excipients. The choice of
excipients depends on the particular mode of administration, the
effect of the excipient on solubility and stability, and the nature
of the dosage form, among other things. Useful pharmaceutical
compositions and methods for their preparation may be found, for
example, in A. R. Gennaro (ed.), Remington: The Science and
Practice of Pharmacy (20th ed., 2000).
[0275] Compounds of Formula 1 may be administered orally. Oral
administration may involve swallowing in which case the compound
enters the bloodstream via the gastrointestinal tract.
Alternatively or additionally, oral administration may involve
mucosal administration (e.g., buccal, sublingual, supralingual
administration) such that the compound enters the bloodstream
through the oral mucosa.
[0276] Formulations suitable for oral administration include solid,
semi-solid and liquid systems such as tablets; soft or hard
capsules containing multi- or nano-particulates, liquids, or
powders; lozenges which may be liquid-filled; chews; gels; fast
dispersing dosage forms; films; ovules; sprays; and buccal or
mucoadhesive patches. Liquid formulations include suspensions,
solutions, syrups and elixirs. Such formulations may be employed as
fillers in soft or hard capsules (made, e.g., from gelatin or
hydroxypropylmethylcellulose) and typically comprise a carrier
(e.g., water, ethanol, polyethylene glycol, propylene glycol,
methylcellulose, or a suitable oil) and one or more emulsifying
agents, suspending agents or both. Liquid formulations may also be
prepared by the reconstitution of a solid (e.g., from a
sachet).
[0277] Compounds of Formula 1 may also be used in fast-dissolving,
fast-disintegrating dosage forms such as those described in Liang
and Chen, Expert Opinion in Therapeutic Patents (2001)
11(6):981-986.
[0278] For tablet dosage forms, depending on dose, the active
pharmaceutical ingredient (API) may comprise from about 1 wt % to
about 80 wt % of the dosage form or more typically from about 5 wt
% to about 60 wt % of the dosage form. In addition to the API,
tablets may include one or more disintegrants, binders, diluents,
surfactants, glidants, lubricants, anti-oxidants, colorants,
flavoring agents, preservatives, and taste-masking agents. Examples
of disintegrants include sodium starch glycolate, sodium
carboxymethyl cellulose, calcium carboxymethyl cellulose,
croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl
cellulose, microcrystalline cellulose, C.sub.1-6 alkyl-substituted
hydroxypropylcellulose, starch, pregelatinized starch, and sodium
alginate. Generally, the disintegrant will comprise from about 1 wt
% to about 25 wt % or from about 5 wt % to about 20 wt % of the
dosage form.
[0279] Binders are generally used to impart cohesive qualities to a
tablet formulation. Suitable binders include microcrystalline
cellulose, gelatin, sugars, polyethylene glycol, natural and
synthetic gums, polyvinylpyrrolidone, pregelatinized starch,
hydroxypropylcellulose and hydroxypropylmethylcellulose. Tablets
may also contain diluents, such as lactose (monohydrate,
spray-dried monohydrate, anhydrous), mannitol, xylitol, dextrose,
sucrose, sorbitol, microcrystalline cellulose, starch and dibasic
calcium phosphate dihydrate.
[0280] Tablets may also include surface active agents, such as
sodium lauryl sulfate and polysorbate 80, and glidants such as
silicon dioxide and talc. When present, surface active agents may
comprise from about 0.2 wt % to about 5 wt % of the tablet, and
glidants may comprise from about 0.2 wt % to about 1 wt % of the
tablet.
[0281] Tablets may also contain lubricants such as magnesium
stearate, calcium stearate, zinc stearate, sodium stearyl fumarate,
and mixtures of magnesium stearate with sodium lauryl sulfate.
Lubricants may comprise from about 0.25 wt % to about 10 wt % or
from about 0.5 wt % to about 3 wt % of the tablet.
[0282] Tablet blends may be compressed directly or by roller
compaction to form tablets. Tablet blends or portions of blends may
alternatively be wet-, dry-, or melt-granulated, melt congealed, or
extruded before tableting. If desired, prior to blending one or
more of the components may be sized by screening or milling or
both. The final dosage form may comprise one or more layers and may
be coated, uncoated, or encapsulated. Exemplary tablets may contain
up to about 80 wt % of API, from about 10 wt % to about 90 wt % of
binder, from about 0 wt % to about 85 wt % of diluent, from about 2
wt % to about 10 wt % of disintegrant, and from about 0.25 wt % to
about 10 wt % of lubricant. For a discussion of blending,
granulation, milling, screening, tableting, coating, as well as a
description of alternative techniques for preparing drug products,
see A. R. Gennaro (ed.), Remington: The Science and Practice of
Pharmacy (20th ed., 2000); H. A. Lieberman et al. (ed.),
Pharmaceutical Dosage Forms: Tablets, Vol. 1-3 (2d ed., 1990); and
D. K. Parikh & C. K. Parikh, Handbook of Pharmaceutical
Granulation Technology, Vol. 81 (1997).
[0283] Consumable oral films for human or veterinary use are
pliable water-soluble or water-swellable thin film dosage forms
which may be rapidly dissolving or mucoadhesive. In addition to the
API, a typical film includes one or more film-forming polymers,
binders, solvents, humectants, plasticizers, stabilizers or
emulsifiers, viscosity-modifying agents, and solvents. Other film
ingredients may include anti-oxidants, colorants, flavorants and
flavor enhancers, preservatives, salivary stimulating agents,
cooling agents, co-solvents (including oils), emollients, bulking
agents, anti-foaming agents, surfactants, and taste-masking agents.
Some components of the formulation may perform more than one
function.
[0284] In addition to dosing requirements, the amount of API in the
film may depend on its solubility. If water soluble, the API would
typically comprise from about 1 wt % to about 80 wt % of the
non-solvent components (solutes) in the film or from about 20 wt %
to about 50 wt % of the solutes in the film. A less soluble API may
comprise a greater proportion of the composition, typically up to
about 88 wt % of the non-solvent components in the film.
[0285] The film-forming polymer may be selected from natural
polysaccharides, proteins, or synthetic hydrocolloids and typically
comprises from about 0.01 wt % to about 99 wt % or from about 30 wt
% to about 80 wt/of the film.
[0286] Film dosage forms are typically prepared by evaporative
drying of thin aqueous films coated onto a peelable backing support
or paper, which may carried out in a drying oven or tunnel (e.g.,
in a combined coating-drying apparatus), in lyophilization
equipment, or in a vacuum oven.
[0287] Useful solid formulations for oral administration may
include immediate release formulations and modified release
formulations. Modified release formulations include delayed-,
sustained-, pulsed-, controlled-, targeted-, and
programmed-release. For a general description of suitable modified
release formulations, see U.S. Pat. No. 6,106,864. For details of
other useful release technologies, such as high energy dispersions
and osmotic and coated particles, see Verma et al, Pharmaceutical
Technology On-line (2001) 25(2):1-14.
[0288] Compounds of Formula 1 may also be administered directly
into the blood stream, muscle, or an internal organ of the subject.
Suitable techniques for parenteral administration include
intravenous, intraarterial, intraperitoneal, intrathecal,
intraventricular, intraurethral, intrasternal, intracranial,
intramuscular, intrasynovial, and subcutaneous administration.
Suitable devices for parenteral administration include needle
injectors, including microneedle injectors, needle-free injectors,
and infusion devices.
[0289] Parenteral formulations are typically aqueous solutions
which may contain excipients such as salts, carbohydrates and
buffering agents (e.g., pH of from about 3 to about 9). For some
applications, however, compounds of Formula 1 may be more suitably
formulated as a sterile non-aqueous solution or as a dried form to
be used in conjunction with a suitable vehicle such as sterile,
pyrogen-free water. The preparation of parenteral formulations
under sterile conditions (e.g., by lyophilization) may be readily
accomplished using standard pharmaceutical techniques.
[0290] The solubility of compounds which are used in the
preparation of parenteral solutions may be increased through
appropriate formulation techniques, such as the incorporation of
solubility-enhancing agents. Formulations for parenteral
administration may be formulated to be immediate or modified
release. Modified release formulations include delayed, sustained,
pulsed, controlled, targeted, and programmed release. Thus,
compounds of Formula 1 may be formulated as a suspension, a solid,
a semi-solid, or a thixotropic liquid for administration as an
implanted depot providing modified release of the active compound.
Examples of such formulations include drug-coated stents and
semi-solids and suspensions comprising drug-loaded
poly(DL-lactic-coglycolic)acid (PGLA) microspheres.
[0291] Compounds of Formula 1 may also be administered topically,
intradermally, or transdermally to the skin or mucosa. Typical
formulations for this purpose include gels, hydrogels, lotions,
solutions, creams, ointments, dusting powders, dressings, foams,
films, skin patches, wafers, implants, sponges, fibers, bandages
and microemulsions. Liposomes may also be used. Typical carriers
may include alcohol, water, mineral oil, liquid petrolatum, white
petrolatum, glycerin, polyethylene glycol and propylene glycol.
Topical formulations may also include penetration enhancers. See,
e.g., Finnin and Morgan, J. Pharm. Sci. 88(10):955-958 (1999).
[0292] Other means of topical administration include delivery by
electroporation, iontophoresis, phonophoresis, sonophoresis and
microneedle or needle-free (e.g. Powderject.TM. and Bioject.TM.)
injection. Formulations for topical administration may be
formulated to be immediate or modified release as described
above.
[0293] Compounds of Formula 1 may also be administered intranasally
or by inhalation, typically in the form of a dry powder, an aerosol
spray, or nasal drops. An inhaler may be used to administer the dry
powder, which comprises the API alone, a powder blend of the API
and a diluent, such as lactose, or a mixed component particle that
includes the API and a phospholipid, such as phosphatidylcholine.
For intranasal use, the powder may include a bioadhesive agent,
e.g., chitosan or cyclodextrin. A pressurized container, pump,
sprayer, atomizer, or nebulizer, may be used to generate the
aerosol spray from a solution or suspension comprising the API, one
or more agents for dispersing, solubilizing, or extending the
release of the API (e.g., EtOH with or without water), one or more
solvents (e.g., 1,1,1,2-tetrafluoroethane or
1,1,1,2,3,3,3-heptafluoropropane) which serve as a propellant, and
an optional surfactant, such as sorbitan trioleate, oleic acid, or
an oligolactic acid. An atomizer using electrohydrodynamics may be
used to produce a fine mist.
[0294] Prior to use in a dry powder or suspension formulation, the
drug product is usually comminuted to a particle size suitable for
delivery by inhalation (typically 90% of the particles, based on
volume, having a largest dimension less than 5 microns). This may
be achieved by any appropriate size reduction method, such as
spiral jet milling, fluid bed jet milling, supercritical fluid
processing, high pressure homogenization, or spray drying.
[0295] Capsules, blisters and cartridges (made, for example, from
gelatin or hydroxypropylmethyl cellulose) for use in an inhaler or
insufflator may be formulated to contain a powder mixture of the
active compound, a suitable powder base such as lactose or starch,
and a performance modifier such as L-leucine, mannitol, or
magnesium stearate. The lactose may be anhydrous or monohydrated.
Other suitable excipients include dextran, glucose, maltose,
sorbitol, xylitol, fructose, sucrose, and trehalose.
[0296] A suitable solution formulation for use in an atomizer using
electrohydrodynamics to produce a fine mist may contain from about
1 .mu.g to about 20 mg of the API per actuation and the actuation
volume may vary from about 1 .mu.L to about 100 .mu.L. A typical
formulation may comprise one or more compounds of Formula 1,
propylene glycol, sterile water, EtOH, and NaCl. Alternative
solvents, which may be used instead of propylene glycol, include
glycerol and polyethylene glycol.
[0297] Formulations for inhaled administration, intranasal
administration, or both, may be formulated to be immediate or
modified release using, for example, PGLA. Suitable flavors, such
as menthol and levomenthol, or sweeteners, such as saccharin or
sodium saccharin, may be added to formulations intended for
inhaled/tranasal administration.
[0298] In the case of dry powder inhalers and aerosols, the dosage
unit is determined by means of a valve that delivers a metered
amount. Units are typically arranged to administer a metered dose
or "puff" containing from about 10 .mu.g to about 1000 .mu.g of the
API. The overall daily dose will typically range from about 100
.mu.g to about 10 mg which may be administered in a single dose or,
more usually, as divided doses throughout the day.
[0299] The active compounds may be administered rectally or
vaginally, e.g., in the form of a suppository, pessary, or enema.
Cocoa butter is a traditional suppository base, but various
alternatives may be used as appropriate. Formulations for rectal or
vaginal administration may be formulated to be immediate or
modified release as described above.
[0300] Compounds of Formula 1 may also be administered directly to
the eye or ear, typically in the form of drops of a micronized
suspension or solution in isotonic, pH-adjusted, sterile saline.
Other formulations suitable for ocular and aural administration
include ointments, gels, biodegradable implants (e.g. absorbable
gel sponges, collagen), non-biodegradable implants (e.g. silicone),
wafers, lenses, and particulate or vesicular systems, such as
niosomes or liposomes. The formulation may include one or more
polymers and a preservative, such as benzalkonium chloride. Typical
polymers include crossed-linked polyacrylic acid, polyvinylalcohol,
hyaluronic acid, cellulosic polymers (e.g.,
hydroxypropylmethylcellulose, hydroxyethylcellulose, methyl
cellulose), and heteropolysaccharide polymers (e.g., gelan gum).
Such formulations may also be delivered by iontophoresis.
Formulations for ocular or aural administration may be formulated
to be immediate or modified release as described above.
[0301] To improve their solubility, dissolution rate,
taste-masking, bioavailability, or stability, compounds of Formula
1 may be combined with soluble macromolecular entities, including
cyclodextrin and its derivatives and polyethylene glycol-containing
polymers. For example, API-cyclodextrin complexes are generally
useful for most dosage forms and routes of administration. Both
inclusion and non-inclusion complexes may be used. As an
alternative to direct complexation with the API, the cyclodextrin
may be used as an auxiliary additive, i.e. as a carrier, diluent,
or solubilizer. Alpha-, beta- and gamma-cyclodextrins are commonly
used for these purposes. See, e.g., WO 91/11172, WO 94/02518, and
WO 98/55148.
[0302] As noted above, one or more compounds of Formula 1,
including compounds specifically named above, and their
pharmaceutically active complexes, salts, solvates and hydrates,
may be combined with each other or with one or more other active
pharmaceutically active compounds to treat various diseases,
conditions and disorders. In such cases, the active compounds may
be combined in a single dosage form as described above or may be
provided in the form of a kit which is suitable for
coadministration of the compositions. The kit comprises (1) two or
more different pharmaceutical compositions, at least one of which
contains a compound of Formula 1; and (2) a device for separately
retaining the two pharmaceutical compositions, such as a divided
bottle or a divided foil packet. An example of such a kit is the
familiar blister pack used for the packaging of tablets or
capsules. The kit is suitable for administering different types of
dosage forms (e.g., oral and parenteral) or for administering
different pharmaceutical compositions at separate dosing intervals,
or for titrating the different pharmaceutical compositions against
one another. To assist with patient compliance, the kit typically
comprises directions for administration and may be provided with a
memory aid.
[0303] For administration to human patients, the total daily dose
of the claimed and disclosed compounds is typically in the range of
about 0.1 mg to about 3000 mg depending on the route of
administration. For example, oral administration may require a
total daily dose of from about 1 mg to about 3000 mg, while an
intravenous dose may only require a total daily dose of from about
0.1 mg to about 300 mg. The total daily dose may be administered in
single or divided doses and, at the physician's discretion, may
fall outside of the typical ranges given above. Although these
dosages are based on an average human subject having a mass of
about 60 kg to about 70 kg, the physician will be able to determine
the appropriate dose for a patient (e.g., an infant) whose mass
falls outside of this weight range.
[0304] As noted above, the compounds of Formula 1 may be used to
treat disorders, diseases, and conditions for which inhibition of
SYK is indicated. Such disorders, diseases, and conditions
generally relate to any unhealthy or abnormal state in a subject
for which the inhibition of SYK provides a therapeutic benefit.
More particularly, such disorders, diseases, and conditions may
involve the immune system and inflammation, including Type I
hypersensitivity (allergic) reactions (allergic rhinitis, allergic
asthma, and atopic dermatitis); autoimmune diseases (rheumatoid
arthritis, multiple sclerosis, systemic lupus erythematosus,
psoriasis, and immune thrombocytopenic purpura); inflammation of
the lung (chronic obstructive pulmonary disease) and thrombosis.
The compounds of Formula 1 may also be used to treat disorders,
diseases, and conditions related to abnormal cell growth, including
hematological malignancies, such as acute myeloid leukemia, B-cell
chronic lymphocytic leukemia, B-cell lymphoma (e.g., mantle cell
lymphoma), and T-cell lymphoma (e.g., peripheral T-cell lymphoma),
as well as epithelial cancers (i.e., carcinomas), such as lung
cancer (small cell lung cancer and non-small cell lung cancer),
pancreatic cancer, and colon cancer.
[0305] In addition to the hematological malignancies and epithelial
cancers noted above, the compounds of Formula 1 may also be used to
treat other types of cancer, including leukemia (chronic
myelogenous leukemia and chronic lymphocytic leukemia); breast
cancer, genitourinary cancer, skin cancer, bone cancer, prostate
cancer, and liver cancer; brain cancer; cancer of the larynx, gall
bladder, rectum, parathyroid, thyroid, adrenal, neural tissue,
bladder, head, neck, stomach, bronchi, and kidneys; basal cell
carcinoma, squamous cell carcinoma, metastatic skin carcinoma,
osteosarcoma, Ewing's sarcoma, veticulum cell sarcoma, and Kaposi's
sarcoma; myeloma, giant cell tumor, islet cell tumor, acute and
chronic lymphocytic and granulocytic tumors, hairy-cell tumor,
adenoma, medullary carcinoma, pheochromocytoma, mucosal neuromas,
intestinal ganglioneuromas, hyperplastic corneal nerve tumor,
marfanoid habitus tumor, Wilms' tumor, seminoma, ovarian tumor,
leiomyomater tumor, cervical dysplasia, neuroblastoma,
retinoblastoma, myelodysplastic syndrome, rhabdomyosarcoma,
astrocytoma, non-Hodgkin's lymphoma, malignant hypercalcemia,
polycythermia vera, adenocarcinoma, glioblastoma multiforma,
glioma, lymphomas, and malignant melanomas, among others.
[0306] In addition to cancer, the compounds of Formula 1 may also
be used to treat other diseases related to abnormal cell growth,
including non-malignant proliferative diseases such as benign
prostatic hypertrophy, restinosis, hyperplasia, synovial
proliferation disorder, retinopathy or other neovascular disorders
of the eye, among others.
[0307] The compounds of Formula 1 may also be used to treat
autoimmune disorders in addition to those listed above. Such
disorders, diseases, and conditions include Crohns disease,
dermatomyositis, diabetes mellitus type 1, Goodpasture's syndrome,
Graves' disease, Guillain-Barre syndrome, Hashimoto's disease,
mixed connective tissue damage, myasthenia gravis, narcolepsy,
pemphigus vulgaris, pernicious anemia, polymyositis, primary
biliary cirrhosis, Sjogren's syndrome, temporal arteritis,
ulcerative colitis, vasculitis, and Wegener's granulomatosis, among
others.
[0308] Furthermore, compounds of Formula 1 may be used to treat
inflammatory disorders including asthma, chronic inflammation,
chronic prostatitis, glomerulonephritis, hypersensitivities,
inflammatory bowel diseases (ulcerative colitis in addition to
Crohn's disease), pelvic inflammatory disease, reperfusion injury,
transplant rejection, vasculitis, and systemtic inflammatory
response syndrome.
[0309] The compounds of Formula 1 may also be used to treat
specific diseases that may fall within one or more general
disorders described above, including arthritis. In addition to
rheumatoid arthritis, Sjogren's syndrome, systemic lupus
erythematosus, SLE in children and adolescents, compounds of
Formula 1 may also be used to treat other arthritis diseases,
including ankylosing spondylitis, avascular necrosis, Bechet's
disease, bursitis, calcium pyrophosphate dihyrate crystal
deposition disease (pseudo gout), carpal tunnel syndrome,
Ehlers-Danlos syndrome, fibromyalgia, Fifth disease, giant cell
arteritis, gout, juvenile dermatomyositis, juvenile rheumatoid
arthritis, juvenile spondyloarthopathy, Lyme disease, Marfan
syndrome, myositis, osteoarthritis, osteogenesis imperfect,
osteoporosis, Paget's disease, psoriatic arthritis, Raynaud's
phenomenon, reactive arthritis, reflex sympathetic dystrophy
syndrome, scleroderma, spinal stenosis, Still's disease, and
tendinitis, among others.
[0310] The claimed and disclosed compounds may be combined with one
or more other pharmacologically active compounds or therapies for
the treatment of one or more disorders, diseases or conditions for
which SYK is indicated, including disorders, diseases, and
conditions involving the immune system, inflammation, and abnormal
cell growth. For example, compounds of Formula 1, which include
compounds specifically named above, and their pharmaceutically
acceptable complexes, salts, solvates and hydrates, may be
administered simultaneously, sequentially or separately in
combination with one or more compounds or therapies for treating
arthritis, including rheumatoid arthritis and osteoarthritis, or
for treating cancer, including hematological malignancies, such as
acute myeloid leukemia, B-cell chronic lymphocytic leukemia, B-cell
lymphoma, and T-cell lymphoma, and carcinomas, such as lung cancer,
pancreatic cancer, and colon cancer. Such combinations may offer
significant therapeutic advantages, including fewer side effects,
improved ability to treat underserved patient populations, or
synergistic activity.
[0311] For example, when used to treat arthritis, the compounds of
Formula 1 may be combined with one or more nonsteroidal
anti-inflamatory drugs (NSAIDs), analgesics, corticosteroids,
biological response modifiers, and protein-A immunoadsorption
therapy. Alternatively or additionally, when treating rheumatoid
arthritis, the compounds of Formula 1 may be combined with one or
more disease modifying antirheumatic drugs (DMARDs), and when
treating osteoarthritis, the compounds of Formula 1 may be combined
with one or more osteoporosis agents.
[0312] Representative NSAIDs include apazone, aspirin, celecoxib,
diclofenac (with and without misoprostol), diflunisal, etodolac,
fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen,
meclofenamate sodium, mefenamic acid, meloxicam, nabumetone,
naproxen, oxaprozin, phenylbutazone, piroxicam, choline and
magnesium salicylates, salsalate, and sulindac. Representative
analgesics include acetaminophen and morphine sulfate, as well as
codeine, hydrocodone, oxycodone, propoxyphene, and tramadol, all
with or without acetaminophen. Representative corticosteroids
include betamethasone, cortisone acetate, dexamethasone,
hydrocortisone, methylprednisolone, prednisolone, and prednisone.
Representative biological response modifiers include TNF-.alpha.
inhibitors, such as adalimumab, etanercept, and infliximab;
selective B-cell inhibitors, such as rituximab; IL-1 inhibitors,
such as anakinra, and selective costimulation modulators, such as
abatacept.
[0313] Representative DMARDs include auranofin (oral gold),
azathioprine, chlorambucil, cyclophosamide, cyclosporine, gold
sodium thiomalate (injectable gold), hydroxychloroquine,
leflunomide, methotrexate, minocycline, myophenolate mofetil,
penicillamine, and sulfasalazine. Representative osteoporosis
agents include bisphosphonates, such as alendronate, ibandronate,
risedronate, and zoledronic acid; selective estrogen receptor
modulators, such as droloxifene, lasofoxifene, and raloxifene;
hormones, such as calcitonin, estrogens, and parathyroid hormone;
and immunosuppressant agents such as azathioprine, cyclosporine,
and rapamycin.
[0314] Particularly useful combinations for treating rheumatoid
arthritis include a compound of Formula 1 and methotrexate; a
compound of Formula 1 and one or more biological response
modifiers, such as lefluonomide, etanercept, adalimumab, and
infliximab; or a compound of Formula 1, methotrexate, and one or
more biological response modifiers, such as lefluonomide,
etanercept, adalimumab, and infliximab.
[0315] For the treatment of thrombis and restensosis, the compounds
of Formula 1 may be combined with one or more cardiovascular agents
such as calcium channel blockers, statins, fibrates, beta-blockers,
ACE inhibitors, and platelet aggregation inhibitors.
[0316] The compounds of Formula 1 may also be combined with one or
more compounds or therapies for treating cancer. These include
chemotherapeutic agents (i.e., cytotoxic or antineoplastic agents)
such as alkylating agents, antibiotics, antimetabolic agents,
plant-derived agents, and topoisomerase inhibitors, as well as
molecularly targeted drugs which block the growth and spread of
cancer by interfering with specific molecules involved in tumor
growth and progression. Molecularly targeted drugs include both
small molecules and biologics.
[0317] Representative alkylating agents include
bischloroethylamines (nitrogen mustards, e.g., chlorambucil,
cyclophosphamide, ifosfamide, mechlorethamine, melphalan, and
uracil mustard); aziridines (e.g., thiotepa); alkyl alkone
sulfonates (e.g., busulfan); nitrosoureas (e.g., carmustine,
lomustine, and streptozocin); nonclassical alkylating agents (e.g.,
altretamine, dacarbazine, and procarbazine); and platinum compounds
(e.g., carboplatin, cisplatin, nedaplatin, oxaliplatin,
satraplatin, and triplatin tetranitrate).
[0318] Representative antibiotic agents include anthracyclines
(e.g., aclarubicin, amrubicin, daunorubicin, doxorubicin,
epirubicin, idarubicin, pirarubicin, valrubicin, and zorubicin);
anthracenediones (e.g., mitoxantrone and pixantrone); and
streptomyces (e.g., actinomycin, bleomycin, dactinomycin, mitomycin
C, and plicamycin).
[0319] Representative antimetabolic agents include dihydrofolate
reductase inhibitors (e.g., aminopterin, methotrexate, and
pemetrexed); hymidylate synthase inhibitors (e.g., raltitrexed and
pemetrexed); folinic acid (e.g., leucovorin); adenosine deaminase
inhibitors (e.g., pentostatin); halogenated/ribonucleotide
reductase inhibitors (e.g., cladribine, clofarabine, and
fludarabine); thiopurines (e.g, thioguanine and mercaptopurine);
thymidylate synthase inhibitors (e.g., fluorouracil, capecitabine,
tegafur, carmofur, and floxuridine); DNA polymerase inhibitors
(e.g., cytarabine); ribonucleotide reductase inhibitors (e.g.,
gemcitabine); hypomethylating agent (e.g., azacitidine and
decitabine); and ribonucleotide reductase inhibitor (e.g.,
hydroxyurea); and an asparagine depleter (e.g., asparaginase)
[0320] Representative plant-derived agents include vinca alkaloids
(e.g., vincristine, vinblastine, vindesine, vinzolidine, and
vinorelbine), podophyllotoxins (e.g., etoposide and teniposide),
and taxanes (e.g., docetaxel, larotaxel, ortataxel, paclitaxel, and
tesetaxel).
[0321] Representative type I topoisomerase inhibitors include
camptothecins, such as belotecan, irinotecan, rubitecan, and
topotecan. Representative type II topoisomerase inhibitors include
amsacrine, etoposide, etoposide phosphate, and teniposide, which
are derivatives of epipodophyllotoxins.
[0322] Molecularly targeted therapies include biologic agents such
as cytokines and other immune-regulating agents. Useful cytokines
include interleukin-2 (IL-2, aldesleukin), interleukin 4 (IL-4),
interleukin 12 (IL-12), and interferon, which includes more than 23
related subtypes. Other cytokines include granulocyte colony
stimulating factor (CSF) (filgrastim) and granulocyte macrophage
CSF (sargramostim). Other immuno-modulating agents include bacillus
Calmette-Guerin, levamisole, and octreotide; monoclonal antibodies
against tumor antigens, such as trastruzumab and rituximab; and
cancer vaccines, which induce an immune response to tumors.
[0323] In addition, molecularly targeted drugs that interfere with
specific molecules involved in tumor growth and progression include
inhibitors of epidermal growth factor (EGF), transforming growth
factor-alpha (TGF.sub..alpha.), TGF.sub..beta., heregulin,
insulin-like growth factor (IGF), fibroblast growth factor (FGF),
keratinocyte growth factor (KGF), colony stimulating factor (CSF),
erythropoietin (EPO), interleukin-2 (IL-2), nerve growth factor
(NGF), platelet-derived growth factor (PDGF), hetaptocyte growth
factor (HGF), vascular endothelial growth factor (VEGF),
angiopoietin, epidermal growth factor receptor (EGFR), human
epidermal growth factor receptor 2 (HER2), HER4, insulin-like
growth factor 1 receptor (IGFIR), IGF2R, fibroblast growth factor 1
receptor (FGFIR), FGF2R, FGF3R, FGF4R, vascular endothelial growth
factor receptor (VEGFR), tyrosine kinase with immunoglobulin-like
and epidermal growth factor-like domains 2 (Tie-2),
platelet-derived growth factor receptor (PDGFR), Abl, Bcr-Abl, Raf,
FMS-like tyrosine kinase 3 (FLT3), c-Kit, Src, protein kinase c
(PKC), tropomyosin receptor kinase (Trk), Ret, mammalian target of
rapamycin (mTOR), Aurora kinase, polo-like kinase (PLK), mitogen
activated protein kinase (MAPK), mesenchymal-epithelial transition
factor (c-MET), cyclin-dependant kinase (CDK), Akt, extracellular
signal-regulated kinases (ERK), poly(ADP) ribose polymerase (PARP),
and the like.
[0324] Specific molecularly targeted drugs include selective
estrogen receptor modulators, such as tamoxifen, toremifene,
fulvestrant, and raloxifene; antiandrogens, such as bicalutamide,
nilutamide, megestrol, and flutamide; and aromatase inhibitors,
such as exemestane, anastrozole, and letrozole. Other specific
molecularly targeted drugs include agents which inhibit signal
transduction, such as imatinib, dasatinib, nilotinib, trastuzumab,
gefitinib, erlotinib, cetuximab, lapatinib, panitumumab, and
temsirolimus; agents that induce apoptosis, such as bortezomib;
agents that block angiogensis, such as bevacizumab, sorafenib, and
sunitinib; agents that help the immune system destroy cancel cells,
such as rituximab and alemtuzumab; and monoclonal antibodies which
deliver toxic molecules to cancer cells, such as gemtuzumab
ozogamicin, tositumomab, 131I-tositumoab, and ibritumomab
tiuxetan.
[0325] Biological Activity: SYK Inhibition
[0326] The ability of compounds to inhibit SYK activity may be
assessed using a variety of methods, including in vitro and in vivo
assays. The following in vitro assay measures a test compound's
ability to inhibit SYK-mediated phosphorylation of a FAM-labeled
SYK-specific substrate (5FAM-KKKKEEIYFFFG-NH.sub.2).
[0327] SYK protein is prepared from cDNA encoding human spleen
tyrosine kinase and is expressed in insect cells using a
baculovirus expression vector. The cDNA (IMAGE: 3542895) is
purchased from Open Biosystems. The SYK kinase domain (residues
356-635) is amplified via PCR and cloned into plasmid pFastBac1
(Invitrogen) at BamHI/XbaI sites. Recombinant plasmid encoding
Met-Ala-Lys-SYK(356-635)-HHHHHH is sequenced and transformed into
E. coli DH10Bac strain. The recombinant bacmid DNA is isolated and
transfected into Sf9 insect cells. Recombinant virus is harvested
72 h after transfection. High titer viral stock is prepared by
infecting Sf9 cells at a multiplicity of infection (MOI) of
approximately 0.01. A suspension of Sf9 cells (10 L) is infected
with recombinant virus (MOI=5) and is incubated in a Wave
Bioreactor (GE-Healthcare) for 48 h. The cells are harvested and
stored at -80.degree. C.
[0328] To purify the expressed protein, the frozen Sf9 cells (10 L)
are broken into small (<1 cm) particles and suspended in a lysis
buffer (300 mL) containing 20 mM Tris (pH 7.6), 0.25 mM TCEP, 100
mM NaCl, 5% glycerol and a protease inhibitor. The suspension is
stirred at RT until completely thawed, lysed an additional 2-4 min
on a rotary blade homogenizer, and then centrifuged at 4200 g for 1
h. Following centrifugation, the supernatant is poured through
cheese cloth and combined with a nickel chelating resin (Probond
Resin.TM., Invitrogen) which is pre-equilibrated in a wash buffer
containing 10 mM Tris (pH 7.6), 0.25 mM TCEP, 300 mM NaCl, 5%
glycerol, and 20 mM imidazole. The mixture is agitated for 3 h in a
cold room and then centrifuged at 900 g for 10 min. The resin is
dispersed in wash buffer (50 mL), centrifuged for 10 min at 900 g,
re-dispersed in a small amount of wash buffer (5 mL), and then pour
into a disposable Poly-Prep chromatography column, through which
wash buffer is passed by gravity until no protein is observed in
coomassie buffer (about 120 mL of wash buffer). An elution buffer
(30 mL) containing 10 mM HEPES (pH 7.4), 150 mM NaCl, 10% glycerol,
5 mM DTT, and 400 mM imidazole is used to elute the SYK protein
from the resin. The eluate is concentrated (5 mL) and further
purified on a Superdex 200 column (1.2 mL/min for 160 min, 10 mM
HEPES (pH 7.4), 10 mM NaCl, 10 mM MgCl, 0.1 mM EDTA, and 0.25 mM
TCEP). The chromatographed fractions are run on SDS-PAGE and the
requisite fractions are pooled and concentrated. Final delivery
buffer is 10 mM HEPES (pH 7.4), 10 mM Methione, 150 mM NaCl, 10%
glycerol, 5 mM DTT.
[0329] SYK inhibition is determined using a black 384 well plate
format in buffer containing 50 mM HEPES, 10 mM NaCl, 10 mM
MgCl.sub.2, 0.2 mM EDTA, 0.01% EDA (Brij.RTM.35), 1 mM DTT, and 0.1
mg/ml BSA at pH 7.3. Each test compound is prepared in DMSO using
2-fold serial dilutions for 11 data points, which are added to the
buffer so that each dilution contains 3% DMSO. To each well is
added 2 .mu.L of 3 .mu.M 5FAM-KKKKEEIYFFFG-NH.sub.2 (in buffer), 2
.mu.L of diluted test compound (3% DMSO in buffer), and 2 .mu.L of
2.4 nM SYK and 45 .mu.M ATP (in buffer). The reaction mixture is
incubated at RT for 60 min, and quenched by adding 50 mM Hepes, 30
mM EDTA, 0.1% Triton X-100 (pH 7.3). To quantify the
fluorescent-labeled substrate and product following reaction, the
test plate is loaded on a Caliper LC-3000, which measures percent
of conversion by microfluidic-based separation. Corresponding
IC.sub.50 values are calculated by non-linear curve fitting of the
compound concentrations and percent of inhibition to the standard
IC.sub.50 equation and reported as pIC.sub.50, i.e.,
-log(IC.sub.50), where IC.sub.50 is molar concentration.
EXAMPLES
[0330] The following examples are intended to be illustrative and
non-limiting, and represent specific embodiments of the present
invention.
[0331] .sup.1H Nuclear magnetic resonance (NMR) spectra were
obtained for many of the compounds in the following examples.
Characteristic chemical shifts (S) are given in parts-per-million
downfield from tetramethylsilane using conventional abbreviations
for designation of major peaks, including s (singlet), d (doublet),
t (triplet), q (quartet), m (multiplet), spt (septet) and br
(broad). The mass spectra (m/z) were recorded using either
electrospray ionization (ESI) or atmospheric pressure chemical
ionization (APCI). The following abbreviations are used for common
solvents: CDCl.sub.3 (deuterochloroform), DMSO-d.sub.6
(deuterodimethylsulfoxide), CD.sub.3OD (deuteromethanol), and
THF-d.sub.8 (deuterotetrahydrofuran). "Ammonia" refers to a
concentrated solution of ammonia in water possessing a specific
gravity of 0.88.
[0332] Where indicated, products of certain preparations and
examples are purified by mass-triggered HPLC (e.g., Pump:
Waters.TM. 2525; MS: ZQ.TM.; Software: MassLynx.TM.), flash
chromatography or preparative thin layer chromatography (TLC).
Preparative HPLC is carried out using either acidic or basic
conditions. Acid conditions are typically gradients in Solvent A
(water with 0.05% TFA) and Solvent B (acetonitrile with 0.035%
TFA); basic conditions are typically gradients in Solvent A (10 mM
NH.sub.4HCO.sub.3 in water) and Solvent B (10 mM NH.sub.4HCO.sub.3
in 20/80 (v/v) water/acetonitrile). The mentioned preparative HPLC
conditions use acidic conditions unless indicated as basic.
Preparative TLC is typically carried out on silica gel 60 F.sub.254
plates. After isolation by chromatography, the solvent is removed
and the product is obtained by drying in a centrifugal evaporator
(e.g., GeneVac.TM.), rotary evaporator, evacuated flask,
lyophilizer, etc. Reactions in an inert (e.g., nitrogen) or
reactive (e.g., H.sub.2) atmosphere are typically carried out at a
pressure of about 1 atmosphere (14.7 psi) or greater.
Preparation 1: Methyl
2,4-dichloro-6-methylpyrimidine-5-carboxylate
##STR00014##
[0334] To a suspension of methyl
6-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1 g,
5.43 mmol) in POCl.sub.3 (10 mL) was added 10 drops of
N,N-dimethylaniline. The reaction mixture was heated at 105.degree.
C. for 6 h until it became a clear solution. It was then cooled,
concentrated under reduced pressure, poured over ice, and extracted
with EtOAc. The organic extract was washed with water and brine,
dried and concentrated under reduced pressure to give the title
compound as greenish-yellow solid (940 mg, 78%). [M+H] calc'd for
C.sub.7H.sub.6Cl.sub.2N.sub.2O.sub.2, 222; found, 221, 223.
Preparation 2: Methyl
2-chloro-4-methyl-6-(m-tolylamino)pyrimidine-5-carboxylate
##STR00015##
[0336] A mixture of methyl
2,4-dichloro-6-methylpyrimidine-5-carboxylate (940 mg, 4.25 mmol),
m-toluidine (0.461 mL, 4.25 mmol) and N-ethyldiisopropylamine
(1.481 mL, 8.51 mmol) in CH.sub.3CN (30 mL) was heated under reflux
for 3 h. The mixture was diluted with EtOAc, and was washed with
brine and water. The organic extract was dried and concentrated
under reduced pressure to give the title compound as a light yellow
solid (1.2 g, 97%). [M+H] calc'd for
C.sub.14H.sub.14N.sub.3ClO.sub.2, 292; found, 292.
Example 1:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-
-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00016##
[0337] A. Methyl
2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-methyl-6-(m-tol-
ylamino)pyrimidine-5-carboxylate
##STR00017##
[0339] A solution of methyl
2-chloro-4-methyl-6-(m-tolylamino)pyrimidine-5-carboxylate (1.2 g,
4.11 mmol), tert-butyl (1S,2R)-2-aminocyclohexylcarbamate (0.882 g,
4.11 mmol) and triethylamine (1.720 mL, 12.34 mmol) in DMA (10 mL)
was heated at 90.degree. C. for 4 h. The solution was then diluted
with EtOAc, washed with brine and water. The organic extract was
dried and concentrated under reduced pressure to give a light
yellow residue; white crystals were formed upon triturating with
ACN (5 mL). The resultant solid was filtered, washed with ACN, and
dried to give the title compound as white solid (1.2 g, 62%). [M+H]
calc'd for C.sub.25H.sub.35N.sub.5O.sub.4, 470; found, 470.
B. tert-Butyl
(1S,2R)-2-(6-(2,4-dimethoxybenzyl)-5-oxo-4-(m-tolylamino)-6,7-dihydro-5H--
pyrrolo[3,4-d]pyrimidin-2-ylamino)cyclohexylcarbamate
##STR00018##
[0341] A mixture of methyl
2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-methyl-6-(m-tol-
ylamino)pyrimidine-5-carboxylate (500 mg, 1.065 mmol) and selenium
dioxide (236 mg, 2.130 mmol) in dioxane (10 mL) was heated at
100.degree. C. for 24 h. The solution was subsequently cooled and
filtered. The filtrate was concentrated under reduced pressure and
dried to give a brown foam (534 mg; dihydroxyl form was observed
via mass spectroscopy), which was used directly in the next step
without further purification. A mixture of the unpurified
intermediate (534 mg, 1.065 mmol) and
(2,4-dimethoxyphenyl)methanamine (0.160 mL, 1.065 mmol) in MeOH (10
mL) was stirred at RT for 10 min, after which sodium
cyanoborohydride (100 mg, 1.597 mmol) was added, and the reaction
mixture was stirred at RT for 20 h. The reaction mixture was warmed
to 50.degree. C. and stirred for an additional 2 h to complete the
reaction. The mixture was cooled to RT and the solid filtered and
washed with MeOH to give the title compound as a pinkish solid (237
mg, 37%). [M+H] calc'd for C.sub.33H.sub.42N.sub.6O.sub.5, 603;
found, 603.
C.
2-((1R,2S)-2-Aminocyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrr-
olo[3,4-d]pyrimidin-5-one
[0342] A mixture of crude tert-butyl
(1S,2R)-2-(6-(2,4-dimethoxybenzyl)-5-oxo-4-(m-tolylamino)-6,7-dihydro-5H--
pyrrolo[3,4-d]pyrimidin-2-ylamino)cyclohexylcarbamate (235 mg,
0.390 mmol) in TFA (5 mL) was stirred at 60.degree. C. for 2 h and
was then purified by reverse phase preparative HPLC. The fractions
were collected, concentrated under reduced pressure, diluted in
EtOAc, and basified with an aqueous saturated solution of
NaHCO.sub.3. The organic extract was dried and concentrated under
reduced pressure to give the title compound as a white solid (60
mg, 44%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.33-1.60
(m, 10H), 2.32 (s, 3H), 3.16 (m, 2H), 3.92 (br s, 1H), 4.14 (s,
2H), 6.88 (d, J=7.07 Hz, 1H), 7.13 (br s, 1H), 7.22 (t, J=7.45 Hz,
1H), 7.34-7.55 (m, 1H), 7.70 (br s, 1H), 8.01 (br s, 1H), 8.58 (br
s, 1H). [M+H] calc'd for C.sub.19H.sub.24N.sub.6O, 353; found,
353.
Example 2:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-fluorophenylamino)-6,7--
dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00019##
[0344] The title compound was prepared in a manner similar to
EXAMPLE 1 by reacting methyl
2,4-dichloro-6-methylpyrimidine-5-carboxylate with 3-fluoroaniline
instead of m-toluidine. The final product was purified via reverse
phase preparative HPLC. Lyophilization gave a TFA salt of the title
compound as a white solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.29-1.56 (m, 2H), 1.56-1.73 (m, 4H), 1.77-1.85 (br s,
2H), 4.22 (br s, 4H), 6.90 (br s, 1H), 7.25-7.44 (m, 2H), 7.48 (br
s, 1H), 7.77 (br s, 3H), 8.20 (d, J=13.64 Hz, 1H), 8.83 (d, J=14.40
Hz, 1H). [M+H] calc'd for C.sub.18H.sub.21FN.sub.6O, 357; found,
357.
Example 3:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-chlorophenylamino)-6,7--
dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00020##
[0346] The title compound was prepared in a manner similar to
EXAMPLE 1 by reacting methyl
2,4-dichloro-6-methylpyrimidine-5-carboxylate with 3-chloroaniline
instead of m-toluidine. The final product was purified via reverse
phase preparative HPLC. Lyophilization gave a TFA salt of the title
compound as a white solid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.43 (br s, 2H), 1.67-1.96 (m, 6H), 4.20 (br s, 3H),
7.13 (d, J=7.33 Hz, 1H), 7.36 (t, J=8.08 Hz, 1H), 7.48 (br s, 1H),
7.75 (br s, 2H), 8.16 (br s, 1H), 8.82 (br s, 1H). [M+H] calc'd for
C.sub.18H.sub.21ClN.sub.6O, 373; found, 373.
Example 4:
4-(1H-Indazol-6-ylamino)-2-((1R,2S)-2-aminocyclohexylamino)-6,7-
-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00021##
[0348] The title compound was prepared in a manner similar to
EXAMPLE 1 by reacting methyl
2,4-dichloro-6-methylpyrimidine-5-carboxylate with
1H-indazol-6-amine instead of m-toluidine. The final product was
purified via reverse phase preparative HPLC. Lyophilization gave a
TFA salt of the title compound as a white solid. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 1.43-1.92 (br s, 8H), 2.33 (s, 1H),
3.57 (m, 1H), 4.21 (br s, 2H), 6.94 (s, 1H), 7.07 (s, 1H),
7.14-7.31 (m, 1H), 7.43 (m, 1H), 7.71 (d, J=8.59 Hz, 2H), 8.01 (s,
1H), 8.14 (br s, 1H), 8.84 (s, 1H), 12.99 (br s, 1H). [M+H] calc'd
for C.sub.19H.sub.22N.sub.8O, 379; found, 379.
Example 5:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-(trifluoromethyl)phenyl-
amino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00022##
[0349] A. Methyl
4-(bromomethyl)-2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-6-
-(3-(trifluoromethyl)phenylamino)pyrimidine-5-carboxylate
##STR00023##
[0351] Methyl
2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-methyl-6-(3-(tr-
ifluoromethyl)phenylamino)pyrimidine-5-carboxylate (104 mg, 0.199
mmol), which was prepared in a manner similar to methyl
2-((1R,2S)-2-(tert-butoxycarbonyl-amino)cyclohexylamino)-4-methyl-6-(m-to-
lylamino)pyrimidine-5-carboxylate in step B of EXAMPLE 1 using
3-(trifluoromethyl)aniline in place of m-toluidine in step A of the
example, was combined with 1-bromopyrrolidine-2,5-dione (53.0 mg,
0.298 mmol) and benzoic peroxyanhydride (48.1 mg, 0.199 mmol) in
CCl.sub.4 (10 mL), and the resulting mixture was stirred at
70.degree. C. for 18 h. The reaction was stopped. The mixture was
concentrated under reduced pressure, separated between water and
EtOAc. The organic extract was dried and concentrated under reduced
pressure to give the title compound, which was used in the next
step without further purification. [M+H] calc'd for
C.sub.25H.sub.31BrN.sub.5O.sub.4, 603; found, 604.
B.
2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6-
,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00024##
[0353] A mixture of methyl
4-(bromomethyl)-2-((1R,2S)-2-(tert-butoxycarbonyl-amino)cyclohexylamino)--
6-(3-(trifluoromethyl)phenylamino)pyrimidine-5-carboxylate (120 mg,
0.199 mmol) in THF was treated with ammonium hydroxide. The
reaction mixture was stirred at RT overnight, and subsequently
worked up and purified by reverse phase preparative HPLC. The
fractions were collected and concentrated under reduced pressure to
give a residue, which was treated with TFA/DCM. The final product
was purified again by preparative HPLC. Lyophilization gave a TFA
salt of the title compound as a white solid (2.6 mg, 3%). [M+H]
calc'd for C.sub.19H.sub.21F.sub.3N.sub.6O, 407; found, 407.
Example 6:
cis-2-(2-Aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamin-
o)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00025##
[0355] The title compound was prepared in a manner similar to
EXAMPLE 5 using methyl
cis-2-(2-(tert-butoxycarbonylamino)cyclohexylamino)-4-methyl-6-(3-(triflu-
oromethyl)phenylamino)pyrimidine-5-carboxylate in place of methyl
2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-methyl-6-(3-(tr-
ifluoromethyl)phenyl-amino)pyrimidine-5-carboxylate. The final
product was purified via reverse phase preparative HPLC.
Lyophilization gave a TFA salt of the title compound as a white
solid. [M+H] calc'd for C.sub.19H.sub.21F.sub.3N.sub.6O, 407;
found, 407.
Example 7:
2-(1-Methyl-1H-pyrazol-4-yl)-4-(m-tolylamino)-6,7-dihydro-5H-py-
rrolo[3,4-d]pyrimidin-5-one
##STR00026##
[0357] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 1 using
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
in place of tert-butyl (1S,2R)-2-aminocyclohexylcarbamate. .sup.1H
NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 2.37 (s, 3H), 3.93 (s, 3H),
4.39 (s, 2H), 6.95 (d, J=7.32 Hz, 1H), 7.32 (t, J=7.81 Hz, 1H),
7.62 (s, 1H), 7.77 (d, J=8.30 Hz, 1H), 8.03 (s, 1H), 8.37 (s, 1H),
8.65 (s, 1H), 8.82 (s, 1H). [M+H] calc'd for
C.sub.7H.sub.16N.sub.6O, 321; found, 321.
Preparation 3: Ethyl
2,4-dichloro-6-((1,3-dioxoisoindolin-2-yl)methyl)pyrimidine-5-carboxylate
##STR00027##
[0358] A. Ethyl
4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-oxobutanoate
##STR00028##
[0360] To a solution of 2-(1,3-dioxoisoindolin-2-yl)acetic acid
(3.01 g, 14.67 mmol), 2,2-dimethyl-1,3-dioxane-4,6-dione (2.23 g,
15.47 mmol) and 4-dimethylaminopyridine (2.73 g, 22.35 mmol) in
dichloromethane (150 mL) was added a solution of DCC (3.36 g, 16.28
mmol) in DCM (50 mL) at 0.degree. C. The mixture was stirred at RT
for 16 h. The insoluble materials were filtered off, and the
filtrate was washed with 5% NaHSO.sub.4 aqueous solution. The
organic phase was dried over anhydrous Na.sub.2SO.sub.4, filtered
and the filtrate was concentrated under reduced pressure. The
residue was treated with EtOH (200 mL) and the resulting mixture
was stirred at 70.degree. C. for 4 h and then concentrated under
reduced pressure. Water was added to the residue and the mixture
was extracted with EtOAc. The organic layers were washed with water
and brine, dried over anhydrous MgSO.sub.4, and filtered. The
filtrate was concentrated under reduced pressure and the residue
was washed with IPE to give the title compound as a colorless solid
(3.43 g, 85%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.31
(t, J=6.8 Hz, 3H), 3.58 (s, 2H), 4.24 (q, J=6.8 Hz, 2H), 4.67 (s,
2H), 7.73-7.78 (m, 2H), 7.86-7.91 (m, 2H).
B. Ethyl
1-(2,4-dimethoxybenzyl)-6-((1,3-dioxoisoindolin-2-yl)methyl)-2,4--
dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
##STR00029##
[0362] A mixture of ethyl
4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-oxobutanoate (249.8
mg, 0.908 mmol) and (2,4-dimethoxyphenyl)methanamine (152 mg, 0.908
mmol) in EtOH (4 mL) was stirred at 50.degree. C. for 16 h. The
obtained solid was isolated by filtration to give a colorless solid
(51.7 mg). To a suspension of the solid in THF (4 mL) was added
carbonisocyanatidic chloride (96 mg, 0.908 mmol) and the mixture
was stirred at 80.degree. C. for 1 h. After cooling to RT, water
(10 mL) was added and the mixture was extracted with EtOAc. The
organic layers were washed with brine, dried over anhydrous
Na.sub.2SO.sub.4, and filtered. The filtrate was concentrated under
reduced pressure and the residue was purified by column
chromatography (SiO.sub.2, hexane/EtOAc=1/1) to give the title
compound (56.2 mg, 13%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
ppm 1.28 (t, J=7.2 Hz, 3H), 3.63 (s, 3H), 3.81 (s, 3H), 4.22 (q,
J=7.2 Hz, 2H), 4.95 (s, 2H), 5.12 (s, 2H), 6.18 (dd, J=8.4, 6.4 Hz,
1H), 6.23 (d, J=6.4 Hz, 1H), 6.75 (d, J=8.4 Hz, 1H), 7.63-7.72 (m,
4H), 8.23 (br s, 1H).
C. Ethyl
6-((1,3-dioxoisoindolin-2-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydro-
pyrimidine-5-carboxylate
##STR00030##
[0364] To trifluoroacetic acid (2 mL, 26.0 mmol) was added ethyl
1-(2,4-dimethoxybenzyl)-6-((1,3-dioxoisoindolin-2-yl)methyl)-2,4-dioxo-1,-
2,3,4-tetrahydropyrimidine-5-carboxylate (198.9 mg, 0.403 mmol) at
0.degree. C. The mixture was stirred at 0.degree. C. for 1 h, then
at RT for 6 h. The mixture was concentrated under reduced pressure,
and the residue was washed with IPE (5 mL) to give the title
compound (183.3 mg). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
1.42 (t, J=7.2 Hz, 3H), 4.45 (q, J=7.2 Hz, 2H), 4.98 (s, 2H),
7.78-7.81 (m, 2H), 7.91-7.93 (m, 2H), 8.19 (br s, 1H), 8.96 (br s,
1H).
D. Ethyl
2,4-dichloro-6-((1,3-dioxoisoindolin-2-yl)methyl)pyrimidine-5-car-
boxylate
[0365] A mixture of ethyl
6-((1,3-dioxoisoindolin-2-yl)methyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidi-
ne-5-carboxylate (96.1 mg, 0.280 mmol) and phosphorus oxychloride
(1 mL, 10.92 mmol) was stirred at 100.degree. C. for 12 h and
allowed to cool. The mixture was concentrated under reduced
pressure to remove excess POCl.sub.3. The residue was treated with
saturated aq NaHCO.sub.3 and extracted with EtOAc. The organic
phase was washed with saturated aqueous NaHCO.sub.3, water, and
brine, was dried over anhydrous Na.sub.2SO.sub.4, and then filtered
through SiO.sub.2. The filtrate was concentrated under reduced
pressure and the residue was purified by column chromatography
(SiO.sub.2, hexanes/EtOAc=4/1) to give the title compound (46.0 mg,
43%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.42 (t, J=7.2
Hz, 3H), 4.45 (q, J=7.2 Hz, 2H), 5.05 (s, 2H), 7.76-7.80 (m, 2H),
7.89-7.93 (m, 2H).
Example 8:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-(trifluoromethyl)phenyl-
amino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one (Free Base)
##STR00031##
[0366] A. Ethyl
2-chloro-4-((1,3-dioxoisoindolin-2-yl)methyl)-6-(m-tolylamino)pyrimidine--
5-carboxylate
##STR00032##
[0368] To a solution of ethyl
2,4-dichloro-6-((1,3-dioxoisoindolin-2-yl)methyl)pyrimidine-5-carboxylate
(45.3 mg, 0.119 mmol) in MeCN (1 mL) was added m-toluidine (0.020
mL, 0.187 mmol) and N,N-diisopropylethylamine (0.037 mL, 0.212
mmol). The mixture was stirred at RT for 12 h. Saturated aq
NaHCO.sub.3 was added to the mixture, which was subsequently
extracted with EtOAc. The organic layers were washed again with
saturated aq NaHCO.sub.3, water, and brine, were dried over
anhydrous Na.sub.2SO.sub.4, and then filtered through SiO.sub.2.
The filtrate was concentrated under reduced pressure and the
residue was washed with IPE to give the title compound as a pale
brown solid (37.1 mg, 69%). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.50 (t, J=7.2 Hz, 3H), 2.36 (s, 3H), 4.52 (q, J=7.2
Hz, 2H), 5.20 (s, 2H), 6.97-6.98 (m, 1H), 7.23-7.27 (m, 1H), 7.33
(br s, 1H), 7.45-7.47 (m, 1H), 7.73-7.78 (m, 2H), 7.89-7.94 (m,
2H), 10.67 (br s, 1H).
B. Ethyl
2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-((1,3-d-
ioxoisoindolin-2-yl)methyl)-6-(m-tolylamino)pyrimidine-5-carboxylate
##STR00033##
[0370] A mixture of ethyl
2-chloro-4-((1,3-dioxoisoindolin-2-yl)methyl)-6-(m-tolylamino)pyrimidine--
5-carboxylate (96.3 mg, 0.214 mmol), tert-butyl
(1S,2R)-2-aminocyclohexylcarbamate (58.14 mg, 0.271 mmol) and
Et.sub.3N (0.030 mL, 0.214 mmol) in DMA (2 mL) was stirred at
80.degree. C. for 3 h. Saturated aq NaHCO.sub.3 was added to the
mixture, which was extracted with EtOAc. The combined organic
layers were washed with aqueous NaHCO.sub.3, water, and brine, were
dried over anhydrous Na.sub.2SO.sub.4, and then filtered through
SiO.sub.2. The filtrate was concentrated under reduced pressure and
the residue was purified by column chromatography (SiO.sub.2,
hexanes/EtOAc=3/1) to give the title compound as a yellow oil
(123.8 mg, 92%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
1.12-1.71 (m, 20H), 2.33 (s, 3H), 3.39-3.57 (m, 1H), 3.84-3.99 (m,
1H), 4.42 (q, J=7.2 Hz, 2H), 4.55-4.79 (m, 1H), 5.16 (s, 2H), 5.41
(br s, 1H), 6.87-6.89 (m, 1H), 7.16-7.49 (m, 3H), 7.74-7.75 (m,
2H), 7.90-7.91 (m, 2H), 10.68-10.81 (m, 1H). [M+H] calc'd for
C.sub.34H.sub.41N.sub.6O.sub.6, 629; found, 629.
C. tert-Butyl
(1S,2R)-2-(5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin--
2-ylamino)cyclohexylcarbamate
##STR00034##
[0372] A mixture of ethyl
2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-((1,3-dioxoisoi-
ndolin-2-yl)methyl)-6-(m-tolylamino)pyrimidine-5-carboxylate (109
mg, 0.174 mmol) and hydrazine hydrate (36.5 mg, 0.729 mmol) in EtOH
(2 mL) was stirred at 65.degree. C. for 12 h. After cooling, the
mixture was concentrated under reduced pressure and the residue was
treated with water and extracted with EtOAc. The combined organic
layers were washed with aqueous NaHCO.sub.3, water, and brine, were
filtered through SiO.sub.2, and the filtrate was concentrated under
reduced pressure. The residue was recrystallized from EtOAc/hexanes
and filtered to give the title compound (34.8 mg). The filtrate was
concentrated and triturated with IPE to give a second batch (20.3
mg) of the title compound (total 65.1 mg, 83%). .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 1.24-1.79 (m, 17H), 2.32 (s, 3H),
3.84 (br s, 1H), 4.06 (br s, 1H), 4.14 (s, 2H), 6.55-6.70 (m, 1H),
6.87-7.04 (m, 2H), 7.20-7.24 (m, 1H), 7.40-7.48 (m, 1H), 7.68-7.80
(m, 1H), 8.01-8.06 (m, 1H), 8.56-8.59 (m, 1H). [M+H] calc'd for
C.sub.24H.sub.33N.sub.6O.sub.3, 453; found, 453.
D.
2-((1R,2S)-2-Aminocyclohexylamino)-4-(3-(trifluoromethyl)phenylamino)-6-
,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one
[0373] To a solution of tert-butyl
(1S,2R)-2-(5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin--
2-ylamino)cyclohexylcarbamate (50.4 mg, 0.111 mmol) in HOAc (2 mL)
was added hydrochloric acid (0.5 mL, 16.46 mmol). The mixture was
stirred at RT for 30 min and then concentrated under reduced
pressure. The residue was treated with saturated aq NaHCO.sub.3 and
extracted with EtOAc. The organic layers were washed with saturated
aq NaHCO.sub.3, water, and brine, were dried over anhydrous
Na.sub.2SO.sub.4, and then filtered. The filtrate was concentrated
under reduced pressure and the residue was purified by column
chromatography (SiO.sub.2, EtOAc/MeOH=20/1) to give the title
compound as a white powder (11.3 mg, 29%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 1.48-1.80 (m, 10H), 2.37 (s, 3H), 3.24 (br
s, 1H), 4.07 (br s, 1H), 4.20 (s, 2H), 5.55 (br s, 1H), 5.89 (br s,
1H), 6.89-6.91 (m, 1H), 7.22-7.24 (m, 1H), 7.53-7.63 (m, 2H), 8.49
(br s, 1H). [M+H] calc'd for C.sub.19H.sub.25N.sub.6O, 353; found,
353.
Preparation 4: Methyl
2,4-dichloro-6-(m-tolylamino)pyrimidine-5-carboxylate
##STR00035##
[0374] A. 2,4,6-Trichloropyrimidine-5-carboxylic acid
##STR00036##
[0376] To a solution of diisopropylamine (23.42 mL, 164 mmol) in
THF (200 mL) was slowly added butyllithium (100 mL, 160 mmol) at
-78.degree. C. The mixture was stirred at -78.degree. C. for 15
min. To this mixture was slowly added a solution of
2,4,6-trichloropyrimidine (20.06 g, 109 mmol) in THF (50 mL) at
-78.degree. C. The mixture was stirred for 1 h. Dry ice was added
and the mixture was stirred at RT for 1 h. To the mixture was added
1N HCl, which was subsequently extracted with EtOAc. The organic
layers were basified with aqueous NaHCO.sub.3, and washed with
EtOAc. The aqueous layer was then acidified with 1N HCl, and
extracted with EtOAc. The organic layers were washed with 1N HCl,
water, and brine, were dried over anhydrous MgSO.sub.4, and then
filtered. The filtrate was concentrated under reduced pressure. The
residue was washed with hexane to give the desired product as a
pale brown solid (12.28 g, 49%). .sup.1H NMR (500 MHz, CDCl.sub.3)
.delta. ppm 7.65 (br s, 1H).
B. 2,4-Dichloro-6-(m-tolylamino)pyrimidine-5-carboxylic acid
##STR00037##
[0378] To a solution of 2,4,6-trichloropyrimidine-5-carboxylic acid
(5.69 g, 25.02 mmol) in DMF (60 mL) was added Et.sub.3N (8 mL, 57.4
mmol) and m-toluidine (3.2 mL, 29.5 mmol) at 0.degree. C. The
mixture was stirred at RT for 12 h. To the mixture was added 1N
HCl. The mixture was extracted with EtOAc. The organic layers were
basified with saturated aq NaHCO.sub.3 and the aqueous layers were
washed with EtOAc. The washed aqueous layer was acidified with 1N
HCl and extracted with EtOAc. The combined organic layers were
washed with 1N HCl, water, and brine, were dried over anhydrous
Na.sub.2SO.sub.4, and then filtered. The filtrate was concentrated
under reduced pressure, triturated with hexane, and filtered to
give a first batch of the title compound (4.36 g). The filtrate was
concentrated, triturated with hexane, and filtered to give a second
batch (0.36 g) of the title compound (total 4.72 g, 63%). .sup.1H
NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 2.30 (s, 3H), 7.00-7.02 (m,
1H), 7.25-7.28 (m, 2H), 7.33-7.35 (m, 2H), 10.13 (s, 1H), 1H not
detected. [M+H] calc'd for C.sub.12H.sub.10Cl.sub.2N.sub.3O.sub.2,
298; found, 298.
C. Methyl 2,4-dichloro-6-(m-tolylamino)pyrimidine-5-carboxylate
[0379] To a solution of
2,4-dichloro-6-(m-tolylamino)pyrimidine-5-carboxylic acid (7.67 g,
25.7 mmol) in DMF (80 mL) was added NaHCO.sub.3 (3.30 g, 39.3 mmol)
and iodomethane (1.605 mL, 25.7 mmol) at 0.degree. C. The mixture
was stirred at RT for 14 h, after which saturated aq NaHCO.sub.3
was added. The mixture was extracted with EtOAc. The organic layers
were washed with aqueous NaHOC.sub.3, water, and brine, were dried
over anhydrous Na.sub.2SO.sub.4, and then filtered through
SiO.sub.2. The filtrate was concentrated under reduced pressure.
The residue was triturated with isopropyl ether and filtered to
give a first batch (5.28 g) of the title compound. The filtrate was
concentrated, triturated with IPE, and filtered to give a second
batch (0.66 g) of the title compound as a yellow solid (total 5.94
g, 74%). .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. ppm 2.38 (s,
3H), 4.00 (s, 3H), 7.02-7.03 (m, 1H), 7.27-7.33 (m, 2H), 7.44-7.46
(m, 1H), 10.30 (br s, 1H). [M+H] calc'd for
C.sub.13H.sub.12Cl.sub.2N.sub.3O.sub.2, 312; found, 312.
Example 9:
2-(4-Ethylpiperazin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrro-
lo[3,4-d]pyrimidin-5-one
##STR00038##
[0380] A. Methyl
4-chloro-2-(4-ethylpiperazin-1-yl)-6-(m-tolylamino)pyrimidine-5-carboxyla-
te
##STR00039##
[0382] A mixture of methyl
2,4-dichloro-6-(m-tolylamino)pyrimidine-5-carboxylate (502.6 mg,
1.610 mmol), N-ethyldiisopropylamine (0.3 mL, 1.718 mmol) and
N-ethylpiperazine (0.21 mL, 1.653 mmol) in THF (8 mL) was stirred
at RT for 12 h. Saturated aq NaHCO.sub.3 was added and the
resulting mixture was extracted with EtOAc. The organic layers were
washed with saturated aq NaHCO.sub.3, water, and brine, were dried
over anhydrous Na.sub.2SO.sub.4, and then filtered through
SiO.sub.2. The filtrate was concentrated under reduced pressure and
the residue was purified by column chromatography (SiO.sub.2,
hexanes/EtOAc=4/1) to give the title compound (152.6 mg, 24%).
.sup.1H NMR (500 MHz, CDCl.sub.3) .delta. ppm 1.12 (t, J=6.5 Hz,
3H), 2.35 (s, 3H), 2.48 (br s, 6H), 3.82-3.97 (m, 7H), 6.92-6.93
(m, 1H), 7.21-7.22 (m, 1H), 7.37-7.42 (m, 2H), 10.45 (s, 1H). [M+H]
calc'd for C.sub.19H.sub.25ClN.sub.5O.sub.2, 390; found, 390.
B. Methyl
4-cyano-2-(4-ethylpiperazin-1-yl)-6-(m-tolylamino)pyrimidine-5-c-
arboxylate
##STR00040##
[0384] A mixture of methyl
4-chloro-2-(4-ethylpiperazin-1-yl)-6-(m-tolylamino)pyrimidine-5-carboxyla-
te (152.6 mg, 0.391 mmol), tetrakis(triphenylphosphine)palladium
(40.8 mg, 0.035 mmol) and zinc(II) cyanide (25.2 mg, 0.215 mmol) in
DMF (3 mL) was stirred at 90.degree. C. for 3 h. Water was added
and the resulting mixture was extracted with EtOAc. The organic
layers were washed with aq NaHCO.sub.3, water, and brine, were
dried over anhydrous Na.sub.2SO.sub.4, and then filtered through
SiO.sub.2. The filtrate was concentrated under reduced pressure and
the residue was purified by column chromatography (SiO.sub.2
hexanes/EtOAc=5/1) to give the title compound as a yellow oil (51.1
mg, 34%). .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. ppm 1.12 (t,
J=7.5 Hz, 3H), 2.35 (s, 3H), 2.44-2.49 (m, 6H), 3.81-3.98 (m, 7H),
6.95-6.96 (m, 1H), 7.23-7.26 (m, 1H), 7.37-7.47 (m, 2H), 10.46 (s,
1H). [M+H] calc'd for CH.sub.25N.sub.6O.sub.2, 381; found, 381.
C.
2-(4-Ethylpiperazin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d-
]pyrimidin-5-one
[0385] A mixture of methyl
4-cyano-2-(4-ethylpiperazin-1-yl)-6-(m-tolylamino)pyrimidine-5-carboxylat-
e (49.8 mg, 0.131 mmol) and palladium on carbon (10.1 mg) in EtOH
(3 mL) and 1N HCl (3 mL) was stirred at RT for 2 h under a hydrogen
atmosphere. The insoluble materials were filtered off, and the
filtrate was concentrated under reduced pressure. The residue was
treated with saturated aq NaHCO.sub.3 and EtOAc for 3 h. The
mixture was extracted with EtOAc. The organic layers were washed
with aq NaHCO.sub.3, water, and brine, were dried over anhydrous
Na.sub.2SO.sub.4, and then filtered. The filtrate was concentrated
under reduced pressure and the residue was purified by column
chromatography twice (SiO.sub.2, EtOAc then DM1020 EtOAc/MeOH=20/1)
to give the title compound as a white solid (19.8 mg, 43%). .sup.1H
NMR (500 MHz, CDCl.sub.3) .delta. ppm 1.19 (br s, 3H), 2.36 (s,
3H), 2.5 (br s, 6H), 4.08 (br s, 4H), 4.23 (s, 2H), 5.50 (s, 1H),
6.91-6.92 (m, 1H), 7.22-7.26 (m, 1H), 7.49-7.54 (m, 2H), 8.44 (s,
1H). [M+H] calc'd for C.sub.19H.sub.25N.sub.6O, 353; found,
353.
Example 10:
2-(Cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimid-
in-5-one
##STR00041##
[0386] A. Methyl
2,4-dicyano-6-(m-tolylamino)pyrimidine-5-carboxylate
##STR00042##
[0388] A mixture of methyl
2,4-dichloro-6-(m-tolylamino)pyrimidine-5-carboxylate (500.5 mg,
1.603 mmol), zinc(II) cyanide (100.7 mg, 0.857 mmol) and
tetrakis(triphenylphosphine)palladium (187.3 mg, 0.162 mmol) in DMF
(5 mL) was stirred at 120.degree. C. for 1 h in a microwave oven.
After cooling, saturated aq NaHCO.sub.3 was added and the mixture
was extracted with EtOAc. The organic layers were washed with aq
NaHCO.sub.3, water, and brine, were dried over anhydrous
Na.sub.2SO.sub.4, and then filtered through SiO.sub.2. The filtrate
was concentrated under reduced pressure and the residue was
purified by column chromatography (SiO.sub.2, hexanes/EtOAc=4/1) to
afford a yellow solid (182.5 mg), which was washed with IPE to give
the title compound (117.5 mg). .sup.1H NMR (500 MHz, CDCl.sub.3)
.delta. ppm 2.41 (s, 3H), 4.12 (s, 3H), 7.10-7.12 (m, 1H),
7.31-7.35 (m, 2H), 7.42-7.43 (m, 1H), 10.65 (br s, 1H). [M+H]
calc'd for C.sub.15H.sub.2N.sub.5O.sub.2, 294; found, 294.
B. Methyl
4-cyano-2-(cyclohexylamino)-6-(m-tolylamino)pyrimidine-5-carboxy-
late
##STR00043##
[0390] A mixture of methyl
2,4-dicyano-6-(m-tolylamino)pyrimidine-5-carboxylate (102.3 mg,
0.349 mmol), N,N-diisopropylethylamine (0.075 mL, 0.429 mmol) and
cyclohexylamine (0.05 mL, 0.437 mmol) in DMF (2 mL) was stirred at
RT for 14 h. Saturated aq NaHCO.sub.3 was added and the mixture was
extracted with EtOAc. The organic layers were washed with aq
NaHCO.sub.3, water, and brine, and were filtered through SiO.sub.2.
The filtrate was concentrated under reduced pressure and the
residue was purified by column chromatography (SiO.sub.2,
hexanes/EtOAc=4/1) to give the title compound as a yellow oil
(114.7 mg, 90%). .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. ppm
1.19-1.45 (m, 5H), 1.64-1.67 (m, 1H), 1.73-1.80 (m, 2H), 2.00-2.05
(m, 2H), 2.38 (s, 3H), 3.75-3.82 (m, 1H), 3.98 (s, 3H), 5.57-5.58
(br d, J=7.9 Hz, 1H), 6.97-6.98 (m, 1H), 7.27-7.29 (m, 1H),
7.46-7.51 (m, 2H), 10.62 (br s, 1H). [M+H] calc'd for
C.sub.20H.sub.24N.sub.5O.sub.2, 366; found, 366.
C.
2-(Cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrim-
idin-5-one
[0391] A mixture of methyl
4-cyano-2-(cyclohexylamino)-6-(m-tolylamino)pyrimidine-5-carboxylate
(112.6 mg, 0.308 mmol) and palladium on carbon (26.4 mg, 0.248
mmol) in MeOH (2 mL) and HCl (1N, 2 mL) was stirred at RT for 4 h
under a hydrogen atmosphere. Saturated aq NaHCO.sub.3 was added and
the mixture was stirred for 12 h. The mixture was filtered and the
filtrate was concentrated under reduced pressure. The residue was
extracted with EtOAc. The organic layers were washed with aq
NaHCO.sub.3, water, and brine, were dried over anhydrous
Na.sub.2SO.sub.4, and then filtered through SiO.sub.2. The filtrate
was concentrated under reduced pressure and the residue was
purified by column chromatography (SiO.sub.2, EtOAc) to give a
white solid (72.2 mg, 69%). The white solid was recrystallized from
EtOH gave the title compound (35.2 mg). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 1.14-1.17 (m, 1H), 1.24-1.34 (m, 4H),
1.62-1.63 (m, 1H), 1.73-1.78 (m, 2H), 1.89-1.97 (m, 2H), 2.33 (s,
3H), 3.74-3.83 (m, 1H), 4.12-4.17 (m, 2H), 6.86-6.88 (m, 1H),
7.20-7.23 (m, 1H), 7.42-7.52 (m, 2H), 7.76 (s, 1H), 8.00-8.05 (m,
1H), 8.53-8.57 (m, 1H). [M+H] calc'd for C.sub.19H.sub.24N.sub.5O,
338; found, 338.
Example 11:
cis-2-(2-Hydroxycyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[-
3,4-d]pyrimidin-5-one
##STR00044##
[0393] The above compound was prepared in a manner similar to
EXAMPLE 10 using cis-2-aminocyclohexanol in place of
cyclohexylamine. .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm
1.31-1.37 (m, 2H), 1.46-1.78 (m, 6H), 2.32 (s, 3H), 3.82-3.96 (m,
2H), 4.13-4.17 (m, 2H), 4.66-4.71 (m, 1H), 6.86-6.92 (m, 2H),
7.20-7.23 (m, 1H), 7.46-7.50 (m, 1H), 7.71-7.77 (m, 1H), 8.03-8.08
(m, 1H), 8.58-8.59 (m, 1H). [M+H] calc'd for
C.sub.19H.sub.24N.sub.5O.sub.2, 354; found, 354.
Example 12:
2-(3-Aminopiperidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]p-
yrimidin-5-one
##STR00045##
[0395] The above compound was prepared in a manner similar to
EXAMPLE 10 using tert-butyl piperidin-3-ylcarbamate in place of
cyclohexylamine. Following cyclization, tert-butyl
1-(5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)pip-
eridin-3-ylcarbamate (20.00 mg, 0.046 mmol) was treated with 4M HCl
in dioxane (2 mL, 8.00 mmol) at RT for 5 h to deprotect the Boc
group. The mixture was subsequently basified with 2N NaOH,
extracted with EtOAc, washed with brine, dried over MgSO.sub.4, and
evaporated. The residue was purified by recrystallization
(EtOH-Hexane) to give the title compound as white solid (10 mg,
64.8% yield). .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm
0.99-2.03 (m, 4H), 2.30 (s, 3H), 2.57-3.07 (m, 3H), 4.16 (s, 2H),
4.26-4.86 (m, 2H), 6.88 (d, J=5.6 Hz, 1H), 7.23 (s, 1H), 7.42-7.55
(m, 1H), 7.59 (s, 1H), 8.08 (s, 1H), 8.55 (s, 1H). [M+H] calc'd for
C.sub.18H.sub.22N.sub.6O, 339; found, 339.
Preparation 5: Methyl 2,6-dichloro-4-cyanonicotinate
##STR00046##
[0396] A. Methyl 2,6-dichloro-4-iodonicotinate
##STR00047##
[0398] A solution of n-butyllithium in hexane (1.6M, 120 mL, 192
mmol) was added dropwise to a solution of diisopropylamine (31.2
mL, 219 mmol) in THF (200 mL) at -78.degree. C. and the mixture was
stirred for 30 min. A solution of 2,6-dichloro-3-iodopyridine (50.0
g, 183 mmol) in THF (100 mL) was added dropwise to the reaction
mixture at -78.degree. C. and the resulting mixture was stirred at
-78.degree. C. for 2 h. After adding dry ice to the reaction
mixture, the mixture was warmed to RT and stirred overnight. The
resulting mixture was quenched with H.sub.2O and the organic phase
was washed with H.sub.2O. The combined aqueous phase was acidified
with HCl and extracted with CHCl.sub.3 (3.times.). The organic
phases were combined, washed with brine, dried over MgSO.sub.4, and
evaporated. After the residue was dissolved into DMF (500 mL),
K.sub.2CO.sub.3 (39.2 g, 284 mmol) and CH.sub.3I (17.73 mL, 284
mmol) were added. The reaction mixture was stirred at RT for 3 h.
To the resulting mixture was added 1N HCl and Et.sub.2O. The
aqueous phase was extracted with Et.sub.2O and the combined organic
layers were washed with H.sub.2O and brine, dried over MgSO.sub.4
and evaporated. The residue was purified by chromatography on
SiO.sub.2 to give the title compound as a white solid (7.24 g,
11%). .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. ppm 3.99 (s, 3H),
7.77 (s, 1H). [M+H] calc'd for C.sub.7H.sub.4ClINO.sub.2, 332;
found, 332.
B. Methyl 2,6-dichloro-4-cyanonicotinate
[0399] A mixture of tetrakis(triphenylphosphine)palladium (34.8 mg,
0.03 mmol), methyl 2,6-dichloro-4-iodonicotinate (100 mg, 0.301
mmol) and dicyanozinc (38.9 mg, 0.331 mmol) in DMF (2 mL) was
stirred at 100.degree. C. overnight under N.sub.2 atmosphere. To
the resulting mixture were added H.sub.2O and EtOAc. The aqueous
phase was extracted with EtOAc, and the combined organic layers
were washed with H.sub.2O and brine, dried over MgSO.sub.4 and
evaporated. The residue was purified by chromatography on SiO.sub.2
to give the title compound as a white solid (28 mg, 40%). H NMR
(500 MHz, DMSO-d.sub.6) .delta. ppm 3.99 (s, 3H), 8.44 (s, 1H).
Preparation 6: Methyl
6-chloro-4-cyano-2-(m-tolylamino)nicotinate
##STR00048##
[0401] A solution of methyl 2,6-dichloro-4-cyanonicotinate (455 mg,
1.97 mmol), triethylamine (0.549 mL, 3.94 mmol) and m-toluidine
(0.32 mL, 2.95 mmol) in THF (10 mL) was stirred at RT for 3 days.
Water was added to the resulting mixture, and the aqueous phase was
extracted with EtOAc. The organic phases were combined, washed with
H.sub.2O and brine, dried over MgSO.sub.4, and evaporated. The
residue was purified by chromatography on SiO.sub.2 to give the
title compound as a yellow solid (198 mg, 33.3%). .sup.1H NMR (500
MHz, CDCl.sub.3) .delta. ppm 2.40 (s, 3H), 3.99 (s, 3H), 6.92 (s,
1H), 7.05-7.14 (m, 4H), 7.33 (t, J=7.81 Hz, 1H).
Preparation 7: tert-Butyl
(1S,2R)-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6--
ylamino)cyclohexylcarbamate
##STR00049##
[0402] A. Methyl
6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(m-toly-
lamino)nicotinate
##STR00050##
[0404] A solution of methyl
6-chloro-4-cyano-2-(m-tolylamino)nicotinate (198 mg, 0.656 mmol),
tert-butyl (1S,2R)-2-aminocyclohexylcarbamate (562 mg, 2.62 mmol)
and Et.sub.3N (0.402 mL, 2.89 mmol) was stirred at reflux
overnight. To the resulting mixture were added H.sub.2O and EtOAc.
The aqueous phase was extracted with EtOAc. The organic layers were
combined, washed with brine, dried over MgSO.sub.4, and evaporated.
The residue was triturated with EtOAc. The resulting solid was
filtered, rinsed with EtOAc, and dried to give the title compound
as a yellow solid (250 mg, 79%). .sup.1H NMR (500 MHz, CDCl.sub.3)
.delta. ppm 1.23-1.77 (m, 17H), 2.34 (s, 3H), 3.94 (br s, 3H), 3.98
(br s, 1H), 4.80 (s, 1H), 6.15 (s, 1H), 6.91 (d, J=5.37 Hz, 1H),
7.21 (t, J=7.81 Hz, 1H), 7.29 (s, 1H), 7.47-7.55 (m, 1H), 10.64 (br
s, 1H).
B. tert-Butyl
(1S,2R)-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6--
ylamino)cyclohexylcarbamate
[0405] Methyl
6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(m-toly-
lamino)nicotinate (100 mg, 0.209 mmol) was dissolved into DMF (5
mL). To the solution was added palladium on carbon (22.19 mg, 0.209
mmol) and the resulting mixture was stirred at 80.degree. C.
overnight under H.sub.2 atmosphere. The mixture was filtered, the
filtrate was evaporated, and the residue was diluted with H.sub.2O
and EtOAc. The aqueous phase was extracted with EtOAc. The organic
phases were combined, washed with H.sub.2O and brine, dried over
MgSO.sub.4, and evaporated. The residue was purified by
recrystallization (EtOH-Hexane) to give the title compound as a
white solid (70 mg, 74.3%). .sup.1H NMR (500 MHz, CDCl.sub.3)
.delta. ppm 1.03-2.10 (m, 17H), 2.34 (s, 3H), 3.81-4.29 (m, 4H),
5.03 (s, 1H), 5.32 (s, 1H), 5.81 (s, 1H), 6.20 (s, 1H), 6.81 (s,
1H), 7.18 (s, 1H), 7.49 (s, 1H), 7.64 (s, 1H), 8.77 (s, 1H). [M+H]
calc'd for C.sub.25H.sub.33N.sub.5O.sub.3, 452; found, 452.
Example 13:
6-((1R,2S)-2-Aminocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyri-
din-3(2H)-one
##STR00051##
[0407] A mixture of tert-butyl
(1S,2R)-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6--
ylamino)cyclohexylcarbamate (50.0 mg, 0.111 mmol) and 4N HCl in
dioxane (2 mL, 8.00 mmol) was stirred at RT for 2 h. The reaction
mixture was concentrated under reduced pressure, the residue was
purified by reverse phase preparative HPLC. The fractions were
collected, concentrated, diluted with EtOAc, and basified with
saturated aq NaHCO.sub.3 solution. The organic extract was dried
and evaporated to give the title compound as a white solid (10 mg,
25.7%). .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. ppm 1.19-1.77 (m,
8H), 2.29 (s, 3H), 3.20 (br s, 1H), 3.99 (br s, 1H), 4.19 (s, 2H),
6.06 (s, 1H), 6.75 (d, J=7.32 Hz, 2H), 7.14 (t, J=7.81 Hz, 1H),
7.48 (d, J=7.32 Hz, 1H), 7.60 (s, 1H), 7.90 (s, 1H), 8.87 (s, 1H).
[M+H] calc'd for C.sub.20H.sub.25N.sub.5O, 352; found, 352.
Example 14:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-methyl-1H-pyrazol-4-yl)-6,7-dihyd-
ro-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00052##
[0408] A. Methyl
2-chloro-4-methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-5-carboxylate
##STR00053##
[0410] A mixture of methyl
2,4-dichloro-6-methylpyrimidine-5-carboxylate (0.79 g, 3.57 mmol),
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(0.595 g, 2.86 mmol) and bis(triphenylphosphine)palladium chloride
(0.050 g, 0.071 mmol) in dioxane (5 mL) was stirred at RT for 10
min, after which potassium fluoride (1.038 g, 17.87 mmol) was
added. The mixture was stirred under a nitrogen atmosphere and
heated at 90.degree. C. for 12 h. The reaction mixture was filtered
through a bed of Celite 545, rinsed with DCM and a small amount of
MeOH. Following solvent removal, the residue was dispersed in
DMSO/MeOH (1/1) and purified via reverse phase preparative HPLC to
give the title compound (237 mg, 25%). [M+H] calc'd for
C.sub.11H.sub.11ClN.sub.4O.sub.2, 267; found, 267.
B. Methyl
2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-methyl-
-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-5-carboxylate
##STR00054##
[0412] To a mixture of methyl
2-chloro-4-methyl-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-5-carboxylate
(0.227 g, 0.851 mmol) and tert-butyl
(1S,2R)-2-aminocyclohexylcarbamate (0.182 g, 0.851 mmol) in DMA (3
mL) was added Et.sub.3N (0.356 mL, 2.55 mmol). The reaction mixture
was heated at 90.degree. C. for 4 h. The reaction mixture was
cooled to RT and poured onto ice. The solid was filtered and dried
under high vacuum to yield the title compound as an off-white foam
(170 mg). [M+H] calc'd for C.sub.22H.sub.32N.sub.6O.sub.4, 445;
found, 445.
C. Methyl
2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-formyl-
-6-(1-methyl-1H-pyrazol-4-yl)pyrimidine-5-carboxylate
##STR00055##
[0414] To a 25 mL round bottom flask was added methyl
2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-methyl-6-(1-met-
hyl-1H-pyrazol-4-yl)pyrimidine-5-carboxylate (0.17 g, 0.382 mmol),
selenium dioxide (0.085 g, 0.765 mmol) and dioxane. The reaction
mixture was heated at 100.degree. C. overnight, cooled to RT, and
filtered through a bed of Celite 545, which was rinsed with MeOH.
The solvent was removed to give the title compound as
yellowish-brown foam, which was used in the next step without
further purification (245 mg).
D. tert-Butyl
(1S,2R)-2-(6-(2,4-dimethoxybenzyl)-4-(1-methyl-1H-pyrazol-4-yl)-5-oxo-6,7-
-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)cyclohexylcarbamate
##STR00056##
[0416] Methyl
2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-formyl-6-(1-met-
hyl-1H-pyrazol-4-yl)pyrimidine-5-carboxylate (0.175 g, 0.382 mmol)
was dissolved in DCM (2 mL) and MeOH (1 mL). To this mixture was
added (2,4-dimethoxyphenyl)methanamine (0.057 mL, 0.382 mmol) and
sodium acetate (0.094 g, 1.145 mmol). The mixture was stirred in a
capped 20 mL vial for 1 h, after which sodium cyanoborohydride
(0.060 g, 0.954 mmol) was added. The reaction mixture was stirred
at RT overnight. After the solvent was removed under reduced
pressure, the residue was dissolved in DMSO/MeOH (1/1) solution. An
off-white solid precipitate was initially formed, which was
isolated by vacuum filtration, rinsed with MeOH, and air dried to
give a first batch of the title compound (6.7 mg). The mother
liquor was purified via preparative HPLC. The fractions were
concentrated under reduced pressure until an off-white solid
precipitate was formed, which was collected by vacuum filtration
and air dried to give a second batch (46 mg) of the title compound
(total 62.5 mg, 28%). [M+H] calc'd for
C.sub.30H.sub.39N.sub.7O.sub.5, 578; found, 578.
E.
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-methyl-1H-pyrazol-4-yl)-6,7-dih-
ydro-5H-pyrrolo[3,4-d]pyrimidin-5-one
[0417] tert-Butyl
(1S,2R)-2-(6-(2,4-dimethoxybenzyl)-4-(1-methyl-1H-pyrazol-4-yl)-5-oxo-6,7-
-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)cyclohexylcarbamate
(0.0625 g, 0.108 mmol) was dissolved in TFA (2 mL) and heated at
70.degree. C. for 1 h. The solvent was removed under reduced
pressure and the resulting residue was dispersed in DMSO/MeOH (1/1)
solution. A pale purple precipitate was formed and was separated by
filtration. The filtrate, which contained the product, was purified
via reverse phase preparative HPLC. Lyophilized fractions gave a
TFA salt of the title compound as a white solid (21 mg, 59%).
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 1.28-1.52 (m, 2H)
1.51-1.94 (m, 6H) 3.93 (s, 3H) 4.14-4.30 (m, 2H) 4.29-4.58 (m, 1H)
7.51 (d, J=6.83 Hz, 1H) 7.71 (br s, 2H) 8.29 (s, 1H) 8.34-8.69 (m,
1H) 9.11 (d, J=17.09 Hz, 1H). [M+H] calc'd for
C.sub.16H.sub.21N.sub.7O, 328; found, 328.
Example 15:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-isobutyl-1H-pyrazol-4-yl)-6,7-dih-
ydro-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00057##
[0419] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 14 using
1-isobutyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
in place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyra-
zole. .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 0.92 (d, J=1.00
Hz, 6H), 0.87-1.00 (m, 6H), 1.45-1.70 (m, 2H), 1.46-1.70 (m, 2H),
1.70-2.00 (m, 6H), 2.22 (spt, J=13.70 Hz, 1H), 3.64 (br s, 1H),
4.02 (d, J=6.83 Hz, 2H), 4.30 (s, 2H), 4.63 (d, J=3.91 Hz, 1H),
8.54 (s, 1H), 9.12 (br s, 1H). [M+H] calc'd for
C.sub.19H.sub.27N.sub.7O, 370; found, 370.
Example 16:
2-((1R,2S)-2-Aminocyclohexylamino)-4-phenyl-6,7-dihydro-5H-pyrrolo[3,4-d]-
pyrimidin-5-one
##STR00058##
[0421] The title compound was prepared in a manner similar to
EXAMPLE 14 using phenylboronic acid in place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
The final product was purified via reverse phase preparative HPLC.
The fractions were collected, concentrated, neutralized with
saturated aq NaHCO.sub.3, and extracted into EtOAc. The organic
phase was dried over anhydrous Na.sub.2SO.sub.4 and the solvent
removed in vacuo to give the title compound as an off-white film.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 1.40-1.95 (m, 8H),
3.27 (br s, 1H), 4.18-4.54 (m, 3H), 7.35-7.59 (m, 3H), 8.12 (br s,
2H). [M+H] calc'd for C.sub.18H.sub.21N.sub.5O, 324; found,
324.
Example 17:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(benzo[b]thiophen-3-yl)-6,7-dihydro--
5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00059##
[0423] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 14 using benzo[b]thiophen-3-ylboronic acid in
place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 1.44-2.02 (m, 8H),
3.53-3.84 (m, 1H), 4.25-4.43 (m, 2H), 4.54-4.72 (m, 1H), 7.32-7.55
(m, 2H), 7.84-8.03 (m, 1H), 8.40-8.88 (m, 1H), 8.86-9.10 (m, 1H).
[M+H] calc'd for C.sub.20H.sub.21N.sub.5OS, 380; found, 380.
Example 18:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-6,7-dihydr-
o-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00060##
[0425] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 14 using
1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
in place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyra-
zole. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 1.47-1.55 (m,
3H), 1.54-1.99 (m, 8H), 3.64 (br s, 1H), 4.26 (q, J=7.32 Hz, 2H),
4.30 (s, 2H), 4.63 (br s, 1H), 8.54 (br s, 1H), 9.14 (s, 1H). [M+H]
calc'd for C.sub.17H.sub.23N.sub.7O, 342; found, 342.
Example 19:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-benzyl-1H-pyrazol-4-yl)-6,7-dihyd-
ro-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00061##
[0427] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 14 using
1-benzyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
in place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyra-
zole. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 1.45-1.69 (m,
2H), 1.69-2.00 (m, 6H), 3.63 (br s, 1H), 4.29 (s, 2H), 4.61 (br s,
1H), 5.40 (s, 2H), 7.22-7.41 (m, 5H), 8.58 (s, 1H), 9.16 (br s,
1H). [M+H] calc'd for C.sub.22H.sub.25N.sub.7O, 404; found,
404.
Example 20:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(imidazo[1,2-a]pyridin-3-yl)-6,7-dih-
ydro-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00062##
[0429] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 14 using imidazo[1,2-a]pyridin-3-ylboronic acid
in place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
.sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 1.47-1.73 (m, 2H),
1.74-2.03 (m, 6H), 3.68 (br s, 1H), 4.27-4.54 (m, 2H), 4.58-4.75
(m, 1H), 7.52-7.79 (m, 1H), 8.00-8.12 (m, 1H), 8.14 (t, J=7.57 Hz,
1H), 10.23 (br s, 1H), 10.81 (d, J=5.86 Hz, 1H). [M+H] calc'd for
C.sub.19H.sub.21N.sub.7O, 364; found, 364.
Example 21:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-propyl-1H-pyrazol-4-yl)-6,7-dihyd-
ro-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00063##
[0431] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 14 using
1-propyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
in place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyra-
zole. .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 0.92 (t, J=1.00
Hz, 3H), 1.43-1.70 (m, 2H), 1.69-2.14 (m, 8H), 3.62 (br s, 1H),
4.18 (t, J=6.83 Hz, 2H), 4.24-4.41 (m, 2H), 4.63 (br s, 1H), 8.56
(br s, 1H), 9.13 (br s, 1H). [M+H] calc'd for
C.sub.18H.sub.25N.sub.7O, 356; found, 356.
Example 22:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(2-methoxyethyl)-1H-pyrazol-4-yl)-
-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00064##
[0433] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 14 using
1-(2-methoxyethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyr-
azole in place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
.sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 1.45-1.70 (m, 2H),
1.70-2.05 (m, 6H), 3.33-3.35 (m, 3H), 3.63 (br s, 1H), 3.73-3.90
(m, 2H), 4.30 (s, 2H), 4.33-4.47 (m, 2H), 4.63 (br s, 1H), 8.58 (br
s, 1H), 9.13 (br s, 1H). [M+H] calc'd for
C.sub.18H.sub.25N.sub.7O.sub.2, 372; found, 372.
Example 23:
4-(1H-Indazol-6-ylamino)-6-((1R,2S)-2-aminocyclohexylamino)-1H-pyrrolo[3,-
4-c]pyridin-3(2H)-one
##STR00065##
[0434] A. Methyl
2-(1H-indazol-6-ylamino)-6-chloro-4-cyanonicotinate
##STR00066##
[0436] A mixture of methyl 2,6-dichloro-4-cyanonicotinate (250 mg,
1.082 mmol), 1H-indazol-6-amine (173 mg, 1.299 mmol) and Et.sub.3N
(0.226 mL, 1.623 mmol) in THF (10 mL) was stirred at 80.degree. C.
overnight. Water and EtOAc were added to the mixture. The organic
phase was washed with H.sub.2O and brine, dried over MgSO.sub.4,
and evaporated. The residue was purified by chromatography on
SiO.sub.2(Hexane/EtOAc=5/1) to give the title compound as a yellow
solid (120 mg, 38.5%).
B. Methyl
2-(1H-indazol-6-ylamino)-6-((1R,2S)-2-(tert-butoxycarbonylamino)-
cyclohexylamino)-4-cyanonicotinate
##STR00067##
[0438] A solution of methyl
2-(1H-indazol-6-ylamino)-6-chloro-4-cyanonicotinate (115 mg, 0.351
mmol), tert-butyl (1S,2R)-2-aminocyclohexylcarbamate (90 mg, 0.421
mmol) and Et.sub.3N (0.073 mL, 0.526 mmol) in THF (1 mL) was
stirred at reflux overnight. Water and EtOAc were added to the
mixture. The aqueous phase was extracted with EtOAc. The organic
phases were combined, washed with H.sub.2O and brine, dried over
MgSO.sub.4, and evaporated. The residue was rinsed with EtOAc to
give the title compound as yellow solid (110 mg, 62.0%). .sup.1H
NMR (500 MHz, CDCl.sub.3) .delta. ppm 1.00-1.86 (m, 17H), 3.84 (s,
3H), 3.91 (br s, 1H), 4.12 (br s, 1H), 6.51 (s, 1H), 6.63 (d,
J=8.79 Hz, 1H), 7.13 (d, J=8.30 Hz, 1H), 7.97 (s, 1H), 8.03 (br s,
1H), 10.71 (br s, 1H), 12.87 (br s, 1H).
C. Methyl
2-(1H-indazol-6-ylamino)-6-((1R,2S)-2-aminocyclohexylamino)-4-cy-
anonicotinate
##STR00068##
[0440] A solution of methyl
2-(1H-indazol-6-ylamino)-6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexy-
lamino)-4-cyanonicotinate (110 mg, 0.218 mmol) and TFA (2 mL, 26.9
mmol) in DCM (1 mL) was stirred at room temperature for 3 h.
Following reaction, the mixture was concentrated in vacuo to give
the title compound, which was used in the next step without further
purification.
D.
4-(1H-Indazol-6-ylamino)-6-((1R,2S)-2-aminocyclohexylamino)-1H-pyrrolo[-
3,4-c]pyridin-3(2H)-one
[0441] To a solution of methyl
2-(1H-indazol-6-ylamino)-6-((1R,2S)-2-aminocyclohexylamino)-4-cyanonicoti-
nate (88 mg, 218 mmol) in MeOH (2 mL) was added palladium on
carbon, and the resulting mixture was stirred at room temperature
overnight under H.sub.2 atmosphere. The mixture was subsequently
filtered to remove the catalyst and the filtrate was evaporated.
The residue was diluted with saturated aq NaHCO.sub.3 and MeOH, and
the mixture was stirred at RT for 30 min. The resulting suspension
was filtered and the precipitate was washed with EtOAc and dried to
give the title compound as a white solid (15 mg, 18.2%). .sup.1H
NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 1.22-1.74 (m, 8H), 3.13 (br
s, 1H), 3.94-4.07 (m, 1H), 4.21 (s, 2H), 6.02-6.14 (m, 1H), 6.70
(br s, 1H), 7.13 (d, J=8.30 Hz, 1H), 7.63 (d, J=8.30 Hz, 1H), 7.94
(d, J=2.93 Hz, 2H), 8.23 (s, 1H), 9.08 (s, 1H), 12.84 (br s, 1H).
[M+H] calc'd for C.sub.20H.sub.23N.sub.7O, 378; found, 378.
Example 24:
6-((1R,2S)-2-Aminocyclohexylamino)-4-(4-fluoro-3-methylphenylamino)-1H-py-
rrolo[3,4-c]pyridin-3(2H)-one
##STR00069##
[0442] A. Methyl
6-chloro-4-cyano-2-(4-fluoro-3-ethylphenylamino)nicotinate
##STR00070##
[0444] A solution of methyl 2,6-dichloro-4-cyanonicotinate (500 mg,
2.164 mmol), 4-fluoro-3-methylaniline (325 mg, 2.60 mmol) and
Et.sub.3N (0.452 mL, 3.25 mmol) in ACN (5 mL) was stirred at
50.degree. C. for 24 h. Water and EtOAc were added to the mixture
and the aqueous phase was extracted with EtOAc. The organic phases
were combined, washed with H.sub.2O and brine, dried over
MgSO.sub.4, and evaporated. The residue was purified by
chromatography on SiO.sub.2 to give the title compound, which
contains some starting material and was used without further
purification (390 mg). [M+H] calc'd for
C.sub.1H.sub.11ClFN.sub.3O.sub.2, 320; found, 320.
B. Methyl
6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano--
2-(4-fluoro-3-methylphenylamino)nicotinate
##STR00071##
[0446] A mixture of methyl
6-chloro-4-cyano-2-(4-fluoro-3-methylphenylamino)nicotinate (390
mg, 1.220 mmol), Et.sub.3N (0.204 mL, 1.464 mmol) and tert-butyl
(1S,2R)-2-aminocyclohexylcarbamate (392 mg, 1.830 mmol) in THF (5
mL) was stirred at 80.degree. C. overnight. Water and EtOAc were
subsequently added to the mixture and the aqueous phase was
extracted with EtOAc. The organic phases were combined, washed with
H.sub.2O and brine, dried over MgSO.sub.4, and evaporated. The
residue was diluted with EtOAc and filtered to give the title
compound as a yellow solid (75 mg, 12.36%). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 1.03-1.71 (m, 17H), 2.22 (d, J=0.98 Hz,
3H), 3.80-3.82 (m, 3H), 3.83 (br s, 1H), 4.01-4.09 (m, 1H), 6.48
(s, 1H), 6.62 (d, J=7.81 Hz, 1H), 7.06 (t, J=9.03, 1H), 7.39 (d,
J=4.39 Hz, 1H), 7.50-7.68 (m, 1H), 10.41 (br s, 1H).
C. tert-Butyl
(1S,2R)-2-(4-(4-fluoro-3-methylphenylamino)-3-oxo-2,3-dihydro-1H-pyrrolo[-
3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
##STR00072##
[0448] A mixture of methyl
6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(4-fluo-
ro-3-methylphenylamino)nicotinate (75 mg, 0.151 mmol) and platinum
oxide (34.2 mg, 0.151 mmol) in DCM (2 mL) and HOAc (0.5 mL) was
stirred at RT under H.sub.2 atmosphere. The mixture was
subsequently filtered through Celite. The filtrate was concentrated
and the residue was purified by preparative HPLC to give the title
compound (50 mg, 70.6%). [M+H] calc'd for
C.sub.25H.sub.32FN.sub.5O.sub.3, 470; found, 470.
D.
6-((1R,2S)-2-Aminocyclohexylamino)-4-(4-fluoro-3-methylphenylamino)-1H--
pyrrolo[3,4-c]pyridin-3(2H)-one
[0449] A solution of tert-butyl
(1S,2R)-2-(4-(4-fluoro-3-methylphenylamino)-3-oxo-2,3-dihydro-1H-pyrrolo[-
3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (50.0 mg, 0.106 mmol)
and TFA (1 mL, 12.98 mmol) in DCM (0.5 mL) was stirred at RT for 1
hr. The resulting mixture was concentrated and the residue was
purified by preparative HPLC to give the title compound as a white
solid (1 mg, 2.54%). .sup.1H NMR (500 MHz, CD.sub.3OD) S ppm
1.14-1.95 (m, 8H), 2.28 (s, 3H), 3.73 (br s, 1H), 4.30 (s, 2H),
4.38 (s, 1H), 6.17 (s, 1H), 7.00 (t, J=9.03 Hz, 1H), 7.41-7.54 (m,
2H).
Example 25:
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[3-
,4-c]pyridin-3(2H)-one
##STR00073##
[0450] A. tert-Butyl
(1S,2R)-2-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate
##STR00074##
[0452] A solution of tert-butyl
(1S,2R)-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6--
ylamino)cyclohexylcarbamate (94 mg, 0.208 mmol) and
SELECTFLUOR.RTM. (73.7 mg, 0.208 mmol) was stirred at 0.degree. C.
for 5 h and at RT for 1 h. The mixture was filtered and the
filtrate was purified by preparative HPLC. The fractions were
collected and concentrated. The residue was washed with saturated
aq NaHCO.sub.3 solution, extracted with EtOAc, washed with brine,
dried over MgSO.sub.4, and evaporated to give the title compound as
yellow solid (45 mg, 46.0%). [M+H] calc'd for
C.sub.25H.sub.32FN.sub.5O.sub.3, 470; found, 470.
B.
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo-
[3,4-c]pyridin-3(2H)-one
[0453] A solution of tert-butyl
(1S,2R)-2-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate (40.0 mg, 0.085 mmol) and TFA
(2 mL, 26.0 mmol) in DCM (1 mL) was stirred at RT for 1 h. The
mixture was concentrated and the resulting residue was purified by
preparative HPLC to give the title compound as a white solid (20
mg, 63.5%). .sup.1H NMR (500 MHz, DMSO-d) .delta. ppm 1.36-1.97 (m,
8H), 2.30 (s, 3H), 3.70 (br s, 1H), 4.27 (br s, 1H), 4.33-4.46 (m,
2H), 6.73 (d, J=6.35 Hz, 1H), 6.79 (d, J=7.32 Hz, 1H), 7.17 (t,
J=7.57 Hz, 1H), 7.43 (d, J=7.81 Hz, 1 H), 7.46 (s, 1H), 7.76 (br s,
2H), 8.29 (s, 1H), 8.79 (s, 1H). [M+H] calc'd for
C.sub.20H.sub.24FN.sub.5O, 370; found, 370.
Preparation 8: Methyl 2-chloro-4-cyanonicotinate
##STR00075##
[0454] A. Methyl 2-chloro-4-iodonicotinate
##STR00076##
[0456] Butyllithium in hexane solution (1.6 M, 13.70 mL, 21.93
mmol) was added drop wise to a solution of diisopropylamine (3.57
mL, 25.06 mmol) in THF (100 mL) at -78.degree. C. and the mixture
was stirred for 30 min. A solution of 2-chloro-3-iodopyridine (5.00
g, 20.88 mmol) in THF (50 mL) was added drop wise to the reaction
mixture at -78.degree. C. and the resulting mixture was stirred at
-78.degree. C. for 2 h. Dry ice was added to the reaction mixture,
which was warmed to room temperature and stirred overnight. The
resulting mixture was quenched with H.sub.2O and the organic phase
was washed with H.sub.2O. The combined aqueous phase was acidified
with concentrated HCl and extracted with EtOAc. The organic phases
were combined, washed with brine, dried over MgSO.sub.4, and
evaporated to yield crude 2-chloro-4-iodonicotinic acid, which was
combined with potassium carbonate (5.77 g, 41.8 mmol) and
iodomethane (1.567 mL, 25.06 mmol) in DMF (70 mL). The mixture was
stirred at room temperature for 1 h, which was followed by the
addition of Et.sub.2O and H.sub.2O. The organic phase was washed
with H.sub.2O and brine, dried over MgSO.sub.4, and evaporated. The
residue was purified by chromatography on SiO.sub.2 to give the
title compound as a white solid (3.23 g, 52.0%). .sup.1H NMR (500
MHz, CDCl.sub.3) .delta. ppm 4.01 (s, 3H), 7.68-7.76 (m, 1H),
7.97-8.11 (m, 1H). [M+H] calc'd for C.sub.7H.sub.5ClINO.sub.2, 298;
found, 298.
B. Methyl 2-chloro-4-cyanonicotinate
##STR00077##
[0458] A solution of methyl 2-chloro-4-iodonicotinate (3.20 g,
10.76 mmol) and cyanocopper (0.963 g, 10.76 mmol) in DMA (40 mL)
was stirred at 140.degree. C. overnight. Following reaction, the
mixture was filtered through Celite and the filtrate was diluted
with H.sub.2O and EtOAc. The aqueous phase was extracted with
EtOAc. The organic phases were combined, washed with H.sub.2O and
brine, dried over MgSO.sub.4, and evaporated. The residue was
purified by chromatography on SiO.sub.2 (Hexane/EtOAc=10/1) to give
the title compound as a white solid (730 mg, 34.5%). .sup.1H NMR
(500 MHz, CDCl.sub.3) .delta. ppm 4.07 (s, 3H), 7.57 (d, J=5.37 Hz,
1H), 8.66 (d, J=4.88 Hz, 1H).
Preparation 9: Methyl
6-chloro-4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate
##STR00078##
[0459] A. Methyl 4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate
##STR00079##
[0461] A mixture of methyl 2-chloro-4-cyanonicotinate (730 mg, 3.71
mmol),
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(927 mg, 4.46 mmol), trans-dichlorobis(triphenylphosphine)palladium
(261 mg, 0.371 mmol) and potassium fluoride (2697 mg, 14.85 mmol)
in DME (15 mL) was stirred at 120.degree. C. for 1 h under
microwave irradiation. The mixture was filtered through Celite, and
the filtrate was diluted with H.sub.2O and EtOAc. The organic phase
was washed with H.sub.2O and brine, dried over MgSO.sub.4, and
evaporated. The residue was purified by chromatography on SiO.sub.2
to give the title compound as a pale yellow solid (470 mg, 52.3%).
.sup.1H NMR (500 MHz, CDCl.sub.3) .delta. ppm 3.97 (s, 3H), 4.03
(s, 3H), 7.41 (d, J=4.88 Hz, 1H), 7.82 (s, 1H), 7.91 (s, 1H), 8.79
(d, J=4.88 Hz, 1H). [M+H] calc'd for
C.sub.12H.sub.10N.sub.4O.sub.2, 243; found, 243.
B. Methyl
6-chloro-4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate
[0462] To a mixture of methyl
4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate (470 mg, 1.940 mmol)
in DCM (10 mL) was added urea-hydrogen peroxide compound (1/1, 913
mg, 9.70 mmol), and 2,2,2-trifluoroacetic anhydride (1.370 mL, 9.70
mmol) at 0.degree. C. The mixture was stirred at room temperature
for 4 h. More urea-hydrogen peroxide compound (1/1, 400 mg) was
added and the mixture was stirred at RT for an additional 3 h after
which was added saturated aq NaHCO.sub.3 solution and CHCl.sub.3.
The aqueous phase was extracted with CHCl.sub.3 (3.times.), and the
combined organic layers were washed with brine, dried over
MgSO.sub.4, and evaporated to obtain crude
4-cyano-3-(methoxycarbonyl)-2-(1-methyl-1H-pyrazol-4-yl)pyridine
1-oxide, which was combined with phosphorus oxychloride (2 mL,
21.46 mmol). The resulting mixture was stirred at 80.degree. C. for
5 h and then concentrated to a residue, which was neutralized with
2N NaOH. The organic phase was washed with brine, dried over
MgSO.sub.4, and evaporated. The residue was purified by
chromatography on SiO.sub.2(Hexane/EtOAc=1/1) to give the title
compound as a white solid (155 mg, 41.3%). .sup.1H NMR (500 MHz,
CDCl.sub.3) .delta. ppm 3.96 (s, 3H), 4.03 (s, 3H), 7.41 (s, 1H),
7.81 (s, 1H), 7.94 (s, 1H). [M+H] calc'd for
C.sub.12H.sub.9ClN.sub.4O.sub.2, 277; found, 277.
Preparation 10: tert-Butyl
(1S,2R)-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4--
c]pyridin-6-ylamino)cyclohexylcarbamate
##STR00080##
[0463] A. Methyl
6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(1-meth-
yl-1H-pyrazol-4-yl)nicotinate
##STR00081##
[0465] A mixture of methyl
6-chloro-4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate (155 mg,
0.560 mmol) and tert-butyl (1S,2R)-2-aminocyclohexylcarbamate (144
mg, 0.672 mmol) in DMA (2 mL) was stirred at 150.degree. C. for 1 h
under microwave irradiation. To the resulting mixture were added
H.sub.2O and EtOAc. The organic phase was washed with H.sub.2O
(3.times.) and brine, dried over MgSO.sub.4, and evaporated. The
residue was purified by chromatography on SiO.sub.2 to give the
title compound as a yellow oil (100 mg, 39.3%). .sup.1H NMR (500
MHz, CDCl.sub.3) .delta. ppm 1.34-1.95 (m, 17H), 3.92 (s, 3H), 3.93
(s, 3H), 4.87 (br s, 1H), 5.66 (br s, 1H), 6.52 (s, 1H), 7.78-7.83
(m, 2H). [M+H] calc'd for C.sub.23H.sub.30N.sub.6O.sub.4, 455;
found, 455.
B. tert-Butyl
(1S,2R)-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4--
c]pyridin-6-ylamino)cyclohexylcarbamate
[0466] A solution of methyl
6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(1-meth-
yl-1H-pyrazol-4-yl)nicotinate (110 mg, 0.242 mmol) and palladium on
carbon (2.58 mg, 0.024 mmol) in MeOH (5 mL) and HOAc (1 mL) was
stirred at RT overnight under H.sub.2 atmosphere. After reaction,
the mixture was filtered through Celite, the filtrate was
evaporated, and the residue was diluted with MeOH and sat aq
NaHCO.sub.3. The mixture was stirred at RT for 30 min and extracted
with EtOAc. The organic phase was washed with brine, dried over
MgSO.sub.4, and evaporated. The residue was purified by
chromatography on SiO.sub.2 and preparative HPLC to give the title
compound (60 mg, 58.1%). .sup.1H NMR (500 MHz, CDCl.sub.3) .delta.
ppm 1.26-1.87 (m, 17H), 3.91 (s, 3H), 4.25 (br s, 2H), 5.16-5.49 (m
2H), 6.23 (br s, 1H), 6.75 (br s, 1H), 8.18-8.44 (m, 1H), 8.76-9.05
(m, 1H).
Example 26:
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrol-
o[3,4-c]pyridin-3(2H)-one
##STR00082##
[0468] A mixture of tert-butyl
(1S,2R)-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4--
c]pyridin-6-ylamino)cyclohexylcarbamate (94 mg, 0.22 mmol) and TFA
(1 mL, 12.98 mmol) in DCM (1 mL) was stirred at RT for 2 h. The
mixture was subsequently concentrated. The residue was purified by
preparative HPLC (01-25; 5.45 min) and basified to give the title
compound as a yellow solid (10 mg, 14%). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 122-1.61 (m, 8H), 3.63 (s, 3H), 4.19 (s,
2H), 6.46 (br s, 1H), 7.98 (s, 1H), 8.29 (s, 1H), 8.85 (s, 1H).
[M+H] calc'd for C.sub.17H.sub.22N.sub.6O, 327; found, 327.
Preparation 11: (3R,4R)-Tetrahydro-2H-pyran-3,4-diamine
##STR00083##
[0469] A. (3R,4S)-Tetrahydro-2H-pyran-3,4-diyl diacetate
##STR00084##
[0471] A mixture of (3R,4S)-3,4-dihydro-2H-pyran-3,4-diyl diacetate
(8 g, 40 mmol) and Pd/C (10%, 5.0 g) in MeOH was stirred at RT for
12 h under H.sub.2 atmosphere (50 psi). After filtration, the
residue was concentrated to give the title compound, which was used
without further purification (7.5 g). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 2.06 (s, 6H), 3.95-4.03 (m, 2H), 4.84 (t,
J=4.0 Hz, 1H), 5.15-5.20 (m, 1H), 5.43 (t, J=4.0 Hz, 1H), 6.49 (d,
J=4.0 Hz, 1H).
B. (3R,4S)-Tetrahydro-2H-pyran-3,4-diol
##STR00085##
[0473] (3R,4S)-Tetrahydro-2H-pyran-3,4-diyl diacetate (7.5 g, 0.4
mmol) and sodium methylate (8.64 g, 0.16 mol) in MeOH was stirred
overnight at RT. The reaction mixture was subsequently quenched
with 6 N HCl in an ice bath. The mixture was concentrated to
dryness. The residue was treated with EtOAc (500 mL) and vigorously
stirred at 45.degree. C. for 30 min. After filtration, the filtrate
was concentrated to give the title compound, which was used without
further purification (4.4 g). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.79-1.84 (m, 1H), 2.00 (s, 6H), 3.56-3.67 (m, 2H),
3.88-3.97 (m, 2H), 5.09-5.14 (m, 2H).
C. (3R,4R)-3,4-Diazidotetrahydro-2H-pyran
##STR00086##
[0475] (3R,4S)-Tetrahydro-2H-pyran-3,4-diol (5.0 g, 42.4 mmol) was
dissolved in DCM (50 mL). To the mixture was added pyridine (2.5
eq), and in an ice bath, trifluoromethanesulfonic anhydride (21.5
g, 94.3 mmol). The reaction was complete in 15 min. To the mixture
was added DMF (50 mL) and hexamethylphosphoramide (1 mL), followed
by sodium azide (25.0 g, 385.0 mmol). The reaction mixture was
stirred at 50.degree. C. for 3 h. DCM was removed under reduced
pressure. Water was added and the mixture was extracted with EtOAc
(3.times.30 mL). The organic layer was washed with water, dried
over Na.sub.2SO.sub.4, and concentrated to give the title compound,
which was used without further purification (1.88 g). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. ppm 1.85-1.90 (m, 1H), 2.05-2.09 (m,
1H), 3.54-3.60 (m, 1H), 3.65-3.72 (m, 1H), 3.81-3.89 (m, 1H),
3.91-3.95 (m, 1H).
D. (3R,4R)-Tetrahydro-2H-pyran-3,4-diamine
[0476] A mixture of (3R,4R)-3,4-diazidotetrahydro-2H-pyran (1.0 g,
5.9 mmol), di-tert-butyl pyrocarbonate (2.8 g, 12.9 mmol) and Pd/C
(10%, 1.0 g) in MeOH was stirred at RT for 12 h under H.sub.2
atmosphere (50 psi). After filtration, the residue was concentrated
and purified by column chromatography eluting with EtOAc and
petroleum ether (EtOAc/PE=1/3) to give the intermediate
di-tert-butyl
N,N-((3R,4R)-tetrahydro-2H-pyran-3,4-diyl)-biscarbamate (1.2 g).
The intermediate was dissolved in 1 M HCl-EtOAc and stirred at RT
overnight to give the title compound (400 mg, 58%). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. ppm 1.93-1.97 (m, 1H), 2.12-2.22 (m,
1H), 3.60-3.66 (m, 1H), 3.76-3.79 (m, 2H), 3.86-3.92 (m, 1H),
4.04-4.15 (m, 1H). [M+H] calc'd for C.sub.5H.sub.12N.sub.2O, 117;
found, 117.
Example 27:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-methyl-1H-pyrazol-4-
-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00087##
[0478] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 26 using (3R,4R)-tetrahydro-2H-pyran-3,4-diamine
in place of tert-butyl (1S,2R)-2-aminocyclohexylcarbamate. The
desired stereoisomer was isolated using preparative HPLC. .sup.1H
NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 3.52 (m, 2H), 3.78-4.01 (m
& s, 10H), 4.21-4.42 (m & s, 3H), 6.50 (s, 1H), 7.91 (br s,
2H), 8.29-8.39 (m, 1H), 8.88-8.96 (m, 1H). [M+H] calc'd for
C.sub.16H.sub.20N.sub.6O.sub.2, 329; found, 329.
Example 28:
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00088##
[0479] A. tert-Butyl
(1S,2R)-2-(7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyr-
rolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
##STR00089##
[0481] A solution of tert-butyl
(1S,2R)-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4--
c]pyridin-6-ylamino)cyclohexylcarbamate (150 mg, 0.352 mmol) and
SELECTFLUOR.RTM. (150 mg, 0.422 mmol) in DCM (1 mL) and MeOH (1 mL)
was stirred at RT overnight. Water was subsequently added and the
mixture was extracted with CHCl.sub.3 (3.times.). The organic
phases were combined, washed with brine, dried over MgSO.sub.4, and
evaporated. The residue was purified by preparative HPLC to give
the title compound (15 mg, 9.60%). [M+H] calc'd for
C.sub.22H.sub.29FN.sub.6O.sub.3, 445; found, 445.
B.
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
[0482] A solution of tert-butyl
(1S,2R)-2-(7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyr-
rolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (15 mg, 0.034
mmol) and TFA (0.5 mL, 6.49 mmol) in DCM (0.5 mL) was stirred at RT
for 30 min. The reaction mixture was concentrated and the resulting
residue was purified by preparative HPLC to give a TFA salt of the
title compound (7 mg, 60.2%). .sup.1H NMR (500 MHz, DMSO-d.sub.6)
.delta. ppm 1.37-2.01 (m, 8H), 3.67 (br s, 1H), 3.89 (s, 3H),
4.32-4.43 (m, 2H), 4.45 (br s, 1H), 6.77 (d, J=6.35 Hz, 1H), 7.93
(br s, 3H), 8.30 (s, 1H), 8.36 (s, 1H), 8.84 (s, 1H). [M+H] calc'd
for C.sub.17H.sub.21FN.sub.6O, 345; found, 345.
Example 29:
6-((1R,2S)-2-Aminocyclohexylamino)-7-chloro-4-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00090##
[0483] A. tert-Butyl
(1S,2R)-2-(7-chloro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyr-
rolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
##STR00091##
[0485] A solution of tert-butyl
(1S,2R)-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4--
c]pyridin-6-ylamino)cyclohexylcarbamate (30 mg, 0.070 mmol) and
N-chlorosuccinimide (9.86 mg, 0.074 mmol) in DCM (1 mL) was stirred
at RT overnight. Additional N-chlorosuccinimide (1 eq) was added
and the mixture was stirred at RT for 3 h. Water and CHCl.sub.3
were added to the mixture and the organic phase was washed with
brine, dried over MgSO.sub.4, and evaporated. The residue was
purified by preparative HPLC to give the title compound (20 mg,
61.7%). .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. ppm 1.18-2.09 (m,
17H), 4.02 (s, 3H), 4.28-4.45 (m, 2H), 5.80 (br s, 1H), 8.39 (br s,
1H), 9.03 (br s, 1H). [M+H] calc'd for
C.sub.22H.sub.29ClN.sub.6O.sub.3, 461; found, 461.
B.
6-((1R,2S)-2-Aminocyclohexylamino)-7-chloro-4-(1-methyl-1H-pyrazol-4-yl-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
[0486] A solution of tert-butyl
(1S,2R)-2-(7-chloro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyr-
rolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (10.00 mg, 0.022
mmol) in HCl (0.5 mL, 16.46 mmol) and HOAc (1 mL) was stirred at RT
for 30 min. The reaction mixture was concentrated and the resulting
residue was washed with IPE to give the HCl salt of the title
compound (5 mg, 63.9%). .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta.
ppm 1.48-1.97 (m, 8H), 3.72-3.78 (m, 1H), 3.96 (br s, 3H), 4.35 (d,
J=4.88 Hz, 2H), 4.57 (br s, 1H), 6.29 (d, J=6.83 Hz, 1H), 7.93 (br
s, 2H), 8.40-8.45 (m, 1H), 8.49 (s, 1H), 8.98 (s, 1H). [M+H] calc'd
for C.sub.17H.sub.21ClN.sub.6O, 361; found, 361.
Preparation 12:
4,6-Dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(-
2H)-one
##STR00092##
[0487] A.
4,6-Dichloro-7-fluoro-1-hydroxyfuro[3,4-c]pyridin-3(1H)-one
##STR00093##
[0489] To a butyllithium-hexane solution (100 mL, 160 mmol) in THF
(200 mL) was slowly added diisopropylamine (27.4 mL, 192 mmol) in
THF (15 mL) at -78.degree. C. The mixture was stirred at the same
temperature for 15 min. A solution of
2,6-dichloro-5-fluoronicotinic acid (14.98 g, 71.4 mmol) in THF (15
mL) was added and the mixture was stirred for 2 h. Next, DMF (29.3
mL, 378 mmol) was added and the mixture was stirred for 1 h.
Hydrochloric acid (1N, 400 mL) was added and the mixture was
subsequently extracted with EtOAc (2.times.300 mL). The organic
phase was basified with saturated aq NaHCO.sub.3 solution and the
aqueous phase was separated. The aqueous phase was re-acidified
with 1N HCl (300 mL) and extracted with EtOAc (2.times.300 mL). The
organic phase was washed with H.sub.2O (200 mL) and brine (200 mL),
dried over MgSO.sub.4, and evaporated. The residue was washed with
Hexane/EtOAc (1/8) to give the title compound as a white solid
(11.5 g, 67.7%). .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm
6.85 (br s, 1H), 8.82 (br s, 1H).
B.
4,6-Dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin--
3(2H)-one
[0490] A mixture of
4,6-dichloro-7-fluoro-1-hydroxyfuro[3,4-c]pyridin-3(1H)-one (25.8
g, 108 mmol) and (2,4-dimethoxyphenyl)methanamine (34.2 mL, 228
mmol) in MeOH (400 mL) was stirred at RT for 2 h. Sodium
triacetoxyhydroborate (22.98 g, 108 mmol) was added to the mixture,
which was stirred at RT for 2 h. Next, HCl (2N, 120 mL) was added
and the resulting solid (17.3 g) was isolated by filtration. A
mixture of the solid,
N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine
hydrochloride (10.35 g, 54 mmol) and 1H-benzo[d][1,2,3]triazol-1-ol
hydrate (8.27 g, 54 mmol) in DMF (200 mL) was stirred at room
temperature for 2 h. Next, water was added and the mixture was
extracted with EtOAc (2.times.300 mL). The organic phases were
combined, washed with saturated aq NaHCO.sub.3 solution (300 mL),
H.sub.2O (300 mL), and brine (300 mL), dried over anhydrous
Na.sub.2SO.sub.4, and filtered. The filtrate was concentrated under
reduced pressure and the residue was washed with EtOAc to give the
title compound as a pale yellow solid (6.7 g, 16.7%). [M+H] calc'd
for C.sub.16H.sub.13C.sub.12FN.sub.2O.sub.3, 371; found, 371.
Preparation 13: tert-Butyl
(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-
-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
##STR00094##
[0492] A mixture of
4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(-
2H)-one (4.8 g, 12.93 mmol) and tert-butyl
(1S,2R)-2-aminocyclohexylcarbamate (4.16 g, 19.40 mmol) and
diisopropylethylamine (3.39 mL, 19.40 mmol) in ACN (20 mL) was
stirred at 100.degree. C. for 3 days. Water and EtOAc were added
and the aqueous phase was extracted with EtOAc. The organic phases
were combined, washed with brine, dried over MgSO.sub.4, and
evaporated. The residue was purified by chromatography on SiO.sub.2
(Hexane/EtOAc=1/1) to give the title compound as a brown amorphous
solid (3.31 g, 46.6%). .sup.1H NMR (500 MHz, CDCl.sub.3) .delta.
ppm 1.35-2.02 (m, 17H), 3.80 (s, 3H), 3.84 (s, 3H), 4.01 (br s,
1H), 4.20 (s, 2H), 4.23 (br s, 1H), 4.66 (s, 2H), 4.91 (br s, 1H),
6.40-6.52 (m, 2H), 7.20-7.28 (m, 1H). [M+H] calc'd for
C.sub.27H.sub.34ClFN.sub.4O.sub.5, 549; found, 549.
Example 30:
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrolo[3,4-c]pyridin-3(2H)-one (HCl Salt)
##STR00095##
[0493] A. tert-Butyl
(1S,2R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)--
3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
##STR00096##
[0495] A mixture of tert-butyl
(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-
-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (200 mg, 0.364
mmol), sodium carbonate (77 mg, 0.729 mmol),
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(91 mg, 0.437 mmol) and bis(triphenylphosphine)palladium chloride
(25.6 mg, 0.036 mmol) in DME (2 mL) and H.sub.2O (0.667 mL) was
stirred at 85.degree. C. for 2 h. To the resulting mixture was
added EtOAc. The aqueous phase was extracted with EtOAc. The
organic phases were combined, washed with brine, dried over
MgSO.sub.4, and evaporated. The residue was purified by
chromatography on SiO.sub.2(Hexane/EtOAc=2/3) to give the title
compound as a yellow oil (88 mg, 40.6%). .sup.1H NMR (500 MHz,
CDCl.sub.3) .delta. ppm 1.28-2.01 (m, 17H), 3.80 (d, J=2.93 Hz,
3H), 3.85 (s, 3H), 3.91-4.01 (m, 4H), 4.23 (br s, 2H), 4.41 (br s,
1H), 4.68 (d, J=1.95 Hz, 2H), 5.36 (br s, 1H), 6.36-6.54 (m, 2H),
7.15-7.21 (m, 1H), 8.26 (br s, 1H), 9.02 (br s, 1H). [M+H] calc'd
for C.sub.31H.sub.39FN.sub.6O.sub.5, 595; found, 595.
B.
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
[0496] A solution of tert-butyl
(1S,2R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)--
3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
(2.4 g, 4.04 mmol) and TFA (5 mL, 64.9 mmol) was stirred at
80.degree. C. for 30 min. The resulting suspension was diluted with
EtOAc (5 mL) and filtered. The filtrate was evaporated in vacuo.
The residue was diluted with H.sub.2O (300 mL) and EtOAc (100 mL)
and filtered. The precipitate was washed with EtOAc and dried to
give the title compound as a TFA salt (900 mg). The filtrate was
extracted with EtOAc (200 mL). The aqueous phase was neutralized
with saturated aq NaHCO.sub.3 solution and extracted with EtOAc
(2.times.400 mL) and THF (2.times.200 mL). The organic phases were
combined, dried over MgSO.sub.4, and evaporated. The residue was
washed with EtOAc to give a first crop (400 mg) of the title
compound as the free base. The TFA salt obtained above was diluted
with saturated aq NaHCO.sub.3 solution (20 mL) and stirred at RT
overnight. The resulting suspension was filtered and the solids
were washed with EtOAc to give a second crop (700 mg) of the title
compound as the free base (1.1 g, 79%).
C.
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one (HCl Salt)
[0497] To a solution of
6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrolo[3,4-c]pyridin-3(2H)-one (2.300 g, 6.68 mmol) in THF (300
mL) was added 1N HCl in EtOAc (20 mL, 20.0 mmol) dropwise and the
mixture was stirred at room temperature for 30 min. The resulting
suspension was filtered and the precipitate was collected and
washed with EtOAc (10 mL) to afford crude HCl salt of the title
compound (2.55 g). The crude compound was recrystallized from EtOH
(60 mL) and H.sub.2O (16 mL) to give the HCl salt of the title
compound as a white solid (1.5 g, 59.0%). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 1.34-1.99 (m, 8H), 3.67 (br s, 3H), 3.89
(br s, 3H), 4.32-4.43 (m, 2H), 4.45 (br s, 1H), 6.76 (d, J=5.86 Hz,
1H), 7.88 (br s, 3H), 8.29 (d, J=4.88 Hz, 1H), 8.36 (s, 1H), 8.84
(s, 1H). [M+H] calc'd for C.sub.17H.sub.21FN.sub.6O, 345; found,
345.
Example 31:
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(pyrazolo[1,5-a]pyridin-3-y-
l)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00097##
[0498] A. tert-butyl
(1S,2R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-4-(pyrazolo[1,5-a]pyrid-
in-3-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamat-
e
##STR00098##
[0500] A mixture of tert-butyl
(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-
-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (100 mg, 0.182
mmol),
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyridine
(53.4 mg, 0.219 mmol), sodium carbonate (48.3 mg, 0.455 mmol) and
tetrakis(triphenylphosphine)palladium (21.05 mg, 0.018 mmol) in DME
(1 mL) and H.sub.2O (0.333 mL) was stirred at 85.degree. C. for 3
h. Following reaction, the mixture was filtered and the filtrate
was diluted with EtOAc and H.sub.2O. The aqueous phase was
extracted with EtOAc. The organic phases were combined, washed with
brine, dried over MgSO.sub.4, and evaporated. The residue was
purified by chromatography on SiO.sub.2 to give the title compound
(53 mg, 46.1%). .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. ppm
1.17-2.03 (m, 17H), 3.74-3.81 (m, 3H), 3.84-3.89 (m, 3H), 4.04 (br
s, 1H), 4.26 (br s, 2H), 4.46 (br s, 1H), 4.71 (br s, 2H),
6.36-6.55 (m, 2H), 6.83 (d, J=5.86 Hz, 1H), 7.18-7.31 (m, 2H), 8.42
(br s, 1H), 8.47-8.57 (m, 1H), 9.42 (br s, 1H).
B.
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(pyrazolo[1,5-a]pyridin-3-
-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
[0501] A mixture of tert-butyl
(1S,2R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-4-(pyrazolo[1,5-a]pyrid-
in-3-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamat-
e (52 mg, 0.082 mmol) and TFA (1 mL, 12.98 mmol) was stirred at
65.degree. C. for 30 min. The mixture was concentrated and the
residue was purified by preparative HPLC to give the title compound
as a white solid (15 mg, 47.8%). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 1.21-2.07 (m, 8H), 3.31 (br s, 1H),
4.18-4.26 (m, 1H), 4.46 (br s, 2H), 6.61 (br s, 1H), 7.09 (d,
J=6.35 Hz, 1H), 7.49 (d, J=7.32, 1H), 8.36 (br s, 1H), 8.59 (d,
J=7.81 Hz, 1H), 8.83 (d, J=6.83 Hz, 1H), 9.56 (br s, 1H). [M+H]
calc'd for C.sub.20H.sub.21FN.sub.6O, 381; found, 381.
Example 32:
2-(2-(Aminomethyl)piperidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo-
[3,4-d]pyrimidin-5-one
##STR00099##
[0502] A. Methyl
2-(2-((tert-butoxycarbonylamino)methyl)piperidin-1-yl)-4-chloro-6-(m-toly-
lamino)pyrimidine-5-carboxylate
##STR00100##
[0504] A mixture of methyl
2,4-dichloro-6-(m-tolylamino)pyrimidine-5-carboxylate (600.6 mg,
1.924 mmol), tert-butyl piperidin-2-ylmethylcarbamate (500.9 mg,
2.337 mmol) and N-ethyl-N-isopropylpropan-2-amine (0.4 mL, 2.296
mmol) in DMF (10 mL) was stirred at 0.degree. C. for 3 h. Water (50
mL) was added to the mixture, which was extracted with EtOAc
(2.times.40 mL). The organic layers were washed with saturated aq
NaHCO.sub.3 (20 mL), water (20 mL) and brine (20 mL), were dried
over anhydrous Na.sub.2SO.sub.4, and then filtered (DM1020). The
filtrate was concentrated under reduced pressure and the residue
was purified by column chromatography (SiO.sub.2,
hexanes/EtOAc=4/1) to give the title compound as a clear oil (310.5
mg). .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. ppm 1.34-1.74 (m,
15H), 2.35-2.37 (m, 3H), 3.03-3.21 (m, 2H), 3.60-3.71 (m, 1H), 3.90
(s, 3H), 4.43-5.04 (m, 3H), 6.94-6.98 (m, 1H), 7.23-7.46 (m, 3H),
10.13-10.43 (m, 1H). [M+H] calc'd for
C.sub.24H.sub.33ClN.sub.5O.sub.4, 490; found, 490.
B. Methyl
2-(2-((tert-butoxycarbonylamino)methyl)piperidin-1-yl)-4-cyano-6-
-(m-tolylamino)pyrimidine-5-carboxylate
##STR00101##
[0506] A mixture of methyl
2-(2-((tert-butoxycarbonylamino)methyl)piperidin-1-yl)-4-chloro-6-(m-toly-
lamino)pyrimidine-5-carboxylate (399.7 mg, 0.816 mmol),
tetrakis(triphenylphosphine)palladium(0) (96.3 mg, 0.083 mmol), and
zinc cyanide (53.2 mg, 0.453 mmol) in DMF (5 mL) was stirred at
120.degree. C. for 1 h under microwave irradiation. Water (50 mL)
was added and the mixture was extracted with EtOAc (2.times.100
mL). The organic layers were washed with saturated aq NaHCO.sub.3
(50 mL), water (50 mL), and brine (50 mL), were dried over
anhydrous Na.sub.2SO.sub.4, and then filtered (DM1020). The
filtrate was concentrated under reduced pressure and was purified
by column chromatography (SiO.sub.2, hexanes/EtOAc=4/1) to give the
title compound as a colorless oil (315.0 mg, 80%). .sup.1H NMR (500
MHz, CDCl.sub.3) .delta. ppm 1.34-1.77 (m, 15H), 2.36-2.39 (m, 3H),
3.00-3.21 (m, 2H), 3.49-3.69 (m, 1H), 3.97 (s, 3H), 4.49-5.10 (m,
3H), 6.96-7.02 (m, 1H), 7.24-7.41 (m, 3H), 10.14-10.45 (m, 1H).
[M+H] calc'd for C.sub.25H.sub.33N.sub.6O.sub.4, 481; found,
481.
C. tert-Butyl
(1-(5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)pi-
peridin-2-yl)methylcarbamate
##STR00102##
[0508] A mixture of methyl
2-(2-((tert-butoxycarbonylamino)methyl)piperidin-1-yl)-4-cyano-6-(m-tolyl-
amino)pyrimidine-5-carboxylate (310.1 mg, 0.645 mmol), palladium on
carbon (72.4 mg, 0.680 mmol) in EtOH (8 mL), and 1N HCl (4 mL) was
stirred at RT for 16 h. The mixture was filtered to remove the
catalyst. The filtrate was treated with saturated aq NaHCO.sub.3
(20 mL) for 3 h. The mixture was concentrated under reduced
pressure and the residue was extracted with EtOAc (2.times.40 mL).
The organic layers were washed with saturated aq NaHCO.sub.3 (20
mL), water (20 mL), and brine (20 mL), were dried over anhydrous
Na.sub.2SO.sub.4, and then filtered through SiO.sub.2. The filtrate
was concentrated under reduced pressure to give the title compound
as a colorless solid (213.4 mg, 73%). .sup.1H-NMR (DMSO-d.sub.6)
.delta. ppm 1.28 (s, 9H), 1.35 (br s, 1H), 1.49-1.56 (m, 2H),
1.67-1.69 (m, 3H), 2.31 (s, 3H), 3.06 (br s, 1H), 3.24 (br s, 2H),
4.16 (s, 2H), 4.67 (br s, 1H), 5.08 (br s, 1H), 6.77 (br s, 1H),
6.87 (d, 1H, J=7.0 Hz), 7.23-7.25 (m, 1H), 7.53 (br s, 2 h), 8.07
(s, 1H), 8.55 (s, 1H). [M+H] calc'd for
C.sub.24H.sub.33N.sub.6O.sub.3, 453; found, 453.5.
D.
2-(2-(Aminomethyl)piperidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrro-
lo[3,4-d]pyrimidin-5-one
[0509] To a solution of tert-butyl
(1-(5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-yl)pi-
peridin-2-yl)methylcarbamate (207.1 mg, 0.458 mmol) in HOAc (3 mL)
was added HCl (1 mL, 32.9 mmol). The mixture was stirred at RT for
1 h and then concentrated under reduced pressure. The residue was
treated with saturated aq NaHCO.sub.3 (50 mL) and was extracted
with EtOAc-THF(1/1, 2.times.40 mL). The organic layers were washed
with saturated aq NaHCO.sub.3 (20 mL), water (20 mL), and brine (20
mL), were dried over anhydrous Na.sub.2SO.sub.4, and then filtered.
The filtrate was concentrated under reduced pressure and the
residue was washed with EtOH to give the title compound as a pale
yellow solid (27.4 mg, 17%). .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm
1.32-1.70 (m, 7H), 1.89-1.92 (m, 1H), 2.31 (s, 3H), 2.74-2.87 (m,
1H), 2.81-2.85 (m, 1H), 2.94 (br s, 1H), 4.17 (s, 2H), 4.68-4.79
(m, 2H), 6.88 (d, 1H, J=7.5 Hz), 7.22-7.25 (m, 1H), 7.49-7.50 (m,
1H), 7.60 (s, 1H), 8.06 (s, 1H), 8.58 (s, 1H). [M+H] calc'd for
C.sub.19H.sub.25N6O, 353; found, 353.5.
Preparation 14: Methyl
6-chloro-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate
##STR00103##
[0510] A. Methyl
6-chloro-4-cyano-2-(3-(methylthio)phenylamino)nicotinate
##STR00104##
[0512] A mixture of methyl 2,6-dichloro-4-cyanonicotinate (340.8
mg, 1.475 mmol), DIPEA (0.3 mL, 1.718 mmol) and
3-(methylthio)aniline (234.8 mg, 1.687 mmol) in CH.sub.3CN (5 mL)
was stirred at 60.degree. C. for 2 days. After the mixture was
cooled, saturated aq NaHCO.sub.3 (30 mL) was added and the mixture
was extracted with EtOAc (2.times.30 mL). The organic layers were
washed with saturated aq NaHCO.sub.3 (20 mL), water (20 mL) and
brine (20 mL), were dried over anhydrous Na.sub.2SO.sub.4, and then
filtered through SiO.sub.2. The filtrate was concentrated under
reduced pressure and the residue was washed with IPE and filtered
to give the title compound as a yellow solid (157.8 mg). The
filtrate was purified by column chromatography (SiO.sub.2,
hexanes/EtOAc=8/1) to give another crop (135.5 mg) of the title
compound as a yellow oil of (total 293 mg, 60%). .sup.1H-NMR
(CDCl.sub.3) .delta. ppm 2.52 (s, 3H), 4.05 (s, 3H), 7.00 (s, 1H),
7.03-7.05 (m, 1H), 7.25-7.32 (m, 2H), 7.66-7.67 (m, 1H), 10.51 (br
s, 1H). [M+H] calc'd for C.sub.15H.sub.13ClN.sub.3O.sub.2S, 334;
found, 334.
B. Methyl
6-chloro-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate
[0513] To a solution of methyl
6-chloro-4-cyano-2-(3-(methylthio)phenylamino)nicotinate (291.1 mg,
0.872 mmol) in DMF (10 mL) was added m-chloroperoxybenzoic acid
(538.9 mg, 2.405 mmol) at 0.degree. C. The mixture was stirred at
RT for 16 h. Aqueous Na.sub.2S.sub.2O.sub.3 (30 mL) was added and
the mixture was extracted with EtOAc (2.times.30 mL). The organic
layers were washed with saturated aq NaHCO.sub.3 (20 mL), water (20
mL) and brine (20 mL), were dried over anhydrous Na.sub.2SO.sub.4,
and then filtered (DM1020). The filtrate was concentrated under
reduced pressure and the residue was washed with IPE to give the
title compound as a yellow solid (158.2 mg, 50%). .sup.1H-NMR
(CDCl.sub.3) .delta. ppm 3.11 (s, 3H), 4.07 (s, 3H), 7.10 (s, 1H),
7.57-7.60 (m, 1H), 7.70-7.72 (m, 1H), 7.91-7.93 (m, 1H), 8.25-8.26
(m, 1H), 10.73 (s, 1H).
Example 33:
6-((1R,2S)-2-Aminocyclohexylamino)-4-(3-(methylsulfonyl)phenylamino)-1H-p-
yrrolo[3,4-c]pyridin-3(2H)-one
##STR00105##
[0514] A. Methyl
6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(3-(met-
hylsulfonyl)phenylamino)nicotinate
##STR00106##
[0516] A mixture of methyl
6-chloro-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate (162.8
mg, 0.445 mmol), tert-butyl (1S,2R)-2-aminocyclohexylcarbamate
(111.6 mg, 0.521 mmol) and Et.sub.3N (0.1 mL, 0.717 mmol) in THF (6
mL) and DMF (6.00 mL) was stirred at 60.degree. C. for 12 h. After
the mixture was cooled, saturated aq NaHCO.sub.3 (30 mL) was added
and the mixture was extracted with EtOAc (2.times.30 mL). The
organic layers were washed with saturated aq NaHCO.sub.3 (15 mL),
water (15 mL) and brine (15 mL), were dried over anhydrous
Na.sub.2SO.sub.4, and filtered through SiO.sub.2. The filtrate was
concentrated under reduced pressure and the residue was washed with
IPE to give the title compound as a yellow solid (182.2 mg, 75%).
.sup.1H-NMR (CDCl.sub.3) .delta. ppm 1.42-1.67 (m, 15H), 1.84-1.91
(m, 2H), 3.07 (s, 3H), 3.95-3.97 (m, 4H), 4.16-4.17 (m, 1H), 4.77
(s, 1H), 6.24 (s, 1H), 7.48-7.51 (m, 1H), 7.58-7.61 (m, 1H),
7.77-7.78 (m, 1H), 8.41 (s, 1H), 10.99 (s, 1H), 1H not
detected.
B. Methyl
6-((1R,2S)-2-aminocyclohexylamino)-4-cyano-2-(3-(methylsulfonyl)-
phenylamino)nicotinate
##STR00107##
[0518] To a solution of methyl
6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(3-(met-
hylsulfonyl)phenylamino)nicotinate (178.3 mg, 0.328 mmol) in HOAc
(4 mL) was added HCl (4 mL, 132 mmol). The mixture was stirred at
RT for 4 h and then concentrated under reduced pressure. Water (15
mL) and 1M HCl (15 mL) were added to the concentrate and the
aqueous layer was washed with EtOAc (10 mL). The washed aqueous
layer was basified with saturated aqueous NaHCO.sub.3 (50 mL) and
extracted with EtOAc (2.times.30 mL). The organic layers were
combined, washed with saturated aq NaHCO.sub.3 (20 mL), water (20
mL) and brine (20 mL), dried over anhydrous Na.sub.2SO.sub.4, and
filtered. The filtrate was concentrated under reduced pressure to
give the title compound as a brown solid (123.2 mg, 85%).
.sup.1H-NMR (CDCl.sub.3) .delta. ppm 1.45-16.4 (m, 6H), 1.77-1.79
(m, 4H), 3.06 (s, 3H), 3.17-3.18 (m, 1H), 3.94 (s, 3H), 4.10-4.14
(m, 1H), 6.03-6.05 (m, 1H), 6.29 (s, 1H), 7.48-7.51 (m, 1H),
7.58-7.60 (m, 1H), 7.71-7.72 (m, 1H), 8.53 (s, 1H), 11.01 (s,
1H).
C.
6-((1R,2S)-2-Aminocyclohexylamino)-4-(3-(methylsulfonyl)phenylamino)-1H-
-pyrrolo[3,4-c]pyridin-3(2H)-one
[0519] A mixture of methyl
6-((1R,2S)-2-aminocyclohexylamino)-4-cyano-2-(3-(methylsulfonyl)phenylami-
no)nicotinate (117.3 mg, 0.264 mmol) and palladium on carbon (23.6
mg, 0.222 mmol) in MeOH (4 mL) and 1N HCl (4 mL) was stirred at RT
for 16 h under a hydrogen atmosphere. The mixture was filtered to
remove the catalyst and the filtrate was treated with saturated aq
NaHCO.sub.3 (20 mL) and stirred at RT for 20 h. The mixture was
concentrated under reduced pressure and the residue was extracted
with EtOAc/THF (2/1, 2.times.30 mL). The organic layers were washed
with saturated aq NaHCO.sub.3 (15 mL), water (15 mL) and brine (15
mL), were dried over anhydrous Na.sub.2SO.sub.4, and then filtered.
The filtrate was concentrated under reduced pressure and the
residue was purified by column chromatography (DM1020,
EtOAc/MeOH=20/1) to give the desired product (37.2 mg, 34%). The
product was recrystallized from EtOH to give the title compound as
a colorless solid (13.2 mg, 12%). .sup.1H-NMR (DMSO-d.sub.6)
.delta. ppm 1.31-1.41 (m, 4H), 1.55-1.68 (m, 6H), 3.05 (s, 1H),
3.21 (s, 3H), 4.08 (s, 1H), 4.23 (s, 2H), 6.17 (s, 1H), 6.78-6.79
(m, 1H), 7.46-7.47 (m, 1H), 7.53-7.56 (m, 1H), 7.96-7.99 (m, 2H),
8.49 (s, 1H), 9.18 (s, 1H).
Example 34:
6-((1R,2S)-2-Aminocyclopentylamino)-4-(3-(methylsulfonyl)phenylamino)-1H--
pyrrolo[3,4-c]pyridin-3(2H)-one (HCl Salt)
##STR00108##
[0520] A. Methyl
6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclopentylamino)-4-cyano-2-(3-(me-
thylsulfonyl)phenylamino)nicotinate
##STR00109##
[0522] A mixture of methyl
6-chloro-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate (165.0
mg, 0.451 mmol), Et.sub.3N (0.15 mL, 1.076 mmol), and tert-butyl
(1S,2R)-2-aminocyclopentylcarbamate (142.0 mg, 0.709 mmol) in DMF
(6 mL) was stirred at 60.degree. C. for 12 h. Saturated aq
NaHCO.sub.3 (20 mL) was added to the mixture, which was
subsequently extracted with EtOAc (2.times.30 mL). The organic
layers were washed with saturated aq NaHCO.sub.3 (20 mL), water (20
mL) and brine (20 mL), were dried over anhydrous Na.sub.2SO.sub.4,
and filtered (DM1020). The filtrate was concentrated under reduced
pressure. The residue was purified by column chromatography
(SiO.sub.2, hexanes/EtOAc=1/1) and then triturated with IPE to
provide the title compound (147 mg).
B. tert-Butyl
(1S,2R)-2-(4-(3-(methylsulfonyl)phenylamino)-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-ylamino)cyclopentylcarbamate
##STR00110##
[0524] A mixture of methyl
6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclopentylamino)-4-cyano-2-(3-(me-
thylsulfonyl)phenylamino)nicotinate (141.1 mg, 0.266 mmol) and
palladium hydroxide on carbon (43.2 mg, 0.308 mmol) in MeOH (10 mL)
and HOAc (10 mL) was stirred at RT for 12 h under a hydrogen
atmosphere. The mixture was filtered to remove the catalyst and the
filtrate was concentrated under reduced pressure. The residue was
treated with saturated aq NaHCO.sub.3 (20 mL) and MeOH (20 mL). The
mixture was stirred at RT for 6 h and then concentrated under
reduced pressure. The residue was treated with saturated aq
NaHCO.sub.3 (30 mL) and extracted with EtOAc (2.times.50 mL). The
organic layers were washed with saturated aq NaHCO.sub.3 (20 mL),
water (20 mL) and brine (20 mL), were dried over anhydrous
Na.sub.2SO.sub.4, and filtered. The filtrate was concentrated under
reduced pressure and the residue was purified by column
chromatography (DM1020, EtOAc) to give the desired product (46.5
mg). The product was washed with IPE/EtOAc to give the title
compound as a pale brown solid (34.7 mg, 26%).
C.
6-((1R,2S)-2-Aminocyclopentylamino)-4-(3-(methylsulfonyl)phenylamino)-1-
H-pyrrolo[3,4-c]pyridin-3(2H)-one (HCl Salt)
[0525] A mixture of tert-butyl
(1S,2R)-2-(4-(3-(methylsulfonyl)phenylamino)-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-ylamino)cyclopentylcarbamate (16.5 mg, 0.329 mmol)
and HCl (1 mL, 32.9 mmol) in HOAc (2 mL) was stirred at RT for 3 h.
The mixture was concentrated under reduced pressure and the residue
was recrystalized from EtOH--H.sub.2O to give the title compound
(9.6 mg, 67%). .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm 1.63-1.79 (m,
4H), 20.3-2.06 (m, 1H), 2.19-2.20 (m, 1H), 3.32 (s, 3H), 3.74 (br
s, 1H), 4.23-4.28 (m, 2H), 4.45 (br s, 1H), 6.22 (s, 1H), 7.34-7.35
(m, 1H), 7.51-7.58 (m, 3H), 7.73 (br s, 3H), 8.13 (s, 1H), 8.82 (s,
1H), 9.26 (s, 1H).
Example 35:
(R)-4-Methyl-2-(4-(3-(methylsulfonyl)phenylamino)-3-oxo-2,3-dihydro-1H-py-
rrolo[3,4-c]pyridin-6-ylamino)pentanamide
##STR00111##
[0526] A. (R)-Methyl
6-(1-amino-4-methyl-1-oxopentan-2-ylamino)-4-cyano-2-(3-(methylsulfonyl)p-
henylamino)nicotinate
##STR00112##
[0528] A mixture of methyl
6-chloro-4-cyano-2-(3-(methylsulfonyl)phenylamino)nicotinate (120.7
mg, 0.330 mmol), (R)-2-amino-4-methylpentanamide (67.1 mg, 0.515
mmol), and Et.sub.3N (0.1 mL, 0.717 mmol) in DMF (4 mL) was stirred
at 60.degree. C. for 14 h. Saturated aq NaHCO.sub.3 (20 mL) was
added to the mixture, which was subsequently extracted with EtOAc
(2.times.30 mL). The organic layers were washed with saturated aq
NaHCO.sub.3 (20 mL), water (20 mL) and brine (20 mL), were dried
over anhydrous Na.sub.2SO.sub.4, and filtered (DM1020). The
filtrate was concentrated under reduced pressure. The residue was
purified by column chromatography (SiO.sub.2, hexanes/EtOAc=1/2)
and then triturated with IPE to give the title compound (76 mg,
50%).
B.
(R)-4-Methyl-2-(4-(3-(methylsulfonyl)phenylamino)-3-oxo-2,3-dihydro-1H--
pyrrolo[3,4-c]pyridin-6-ylamino)pentanamide
[0529] A mixture of (R)-methyl
6-(1-amino-4-methyl-1-oxopentan-2-ylamino)-4-cyano-2-(3-(methylsulfonyl)p-
henylamino)nicotinate (73.2 mg, 0.159 mmol) and palladium hydroxide
on carbon (23.2 mg, 0.165 mmol) in MeOH (6 mL) and HOAc (3 mL) was
stirred at RT for 12 h under a hydrogen atmosphere. The mixture was
filtered to remove the catalyst and the filtrate was concentrated
under reduced pressure. The residue was treated with saturated aq
NaHCO.sub.3 (20 mL) and MeOH (20 mL). The resulting mixture was
stirred at RT for 16 h and then concentrated under reduced
pressure. The residue was treated with saturated aq NaHCO.sub.3 (30
mL) and extracted with EtOAc (2.times.50 mL). The organic layers
were washed with saturated aq NaHCO.sub.3 (20 mL), water (20 mL)
and brine (20 mL), were dried over anhydrous Na.sub.2SO.sub.4, and
filtered. The filtrate was concentrated under reduced pressure and
the residue was recrystallized from EtOH to give the title compound
as a white solid (18.8 mg, 27%). .sup.1H-NMR (DMSO-d.sub.6) .delta.
ppm 0.87-0.94 (m, 6H), 1.54-1.63 (m, 2H), 1.76 (br s, 1H), 3.32 (s,
3H), 4.24 (s, 2H), 4.50 (br s, 1H), 6.17 (s, 1H), 7.00-7.04 (m,
2H), 7.22 (br s, 1H), 7.47-7.57 (m, 2H), 8.01 (br s, 1H), 8.06 (s,
1H), 8.45 (br s, 1H), 9.23 (s, 1H). [M+H] calc'd for
C.sub.20H.sub.26N.sub.5O.sub.4S, 432; found, 432.5.
Example 36:
(R)-4-Methyl-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-ylamino)pentanamide
##STR00113##
[0530] A. (R)-Methyl
6-(1-amino-4-methyl-1-oxopentan-2-ylamino)-4-cyano-2-(1-methyl-1H-pyrazol-
-4-yl)nicotinate
##STR00114##
[0532] A mixture of methyl
6-chloro-4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate (82.9 mg,
0.300 mmol) and (R)-2-amino-4-methylpentanamide (39.0 mg, 0.300
mmol) in DMA (2 mL) was stirred at 150.degree. C. for 12 h. Water
was subsequently added and the mixture was extracted with EtOAc.
The organic layers were washed with saturated aq NaHCO.sub.3,
water, and brine, were dried over anhydrous Na.sub.2SO.sub.4, and
filtered. The filtrate was concentrated under reduced pressure. The
residue was purified by column chromatography (SiO.sub.2, EtOAc) to
give the title compound as a yellow oil (11.7 mg, 11%).
B.
(R)-4-Methyl-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrro-
lo[3,4-c]pyridin-6-ylamino)pentanamide
[0533] A mixture of (R)-methyl
6-(1-amino-4-methyl-1-oxopentan-2-ylamino)-4-cyano-2-(1-methyl-1H-pyrazol-
-4-yl)nicotinate (20.3 mg, 0.055 mmol) and palladium hydroxide (10
mg, 0.094 mmol) in MeOH (2 mL) and HOAc (2 mL) was stirred at RT
for 3 h under a hydrogen atmosphere. The mixture was filtered to
remove the catalyst and the filtrate was concentrated under reduced
pressure. The residue was treated with saturated aq NaHCO.sub.3 (20
mL) and EtOAc (20 mL) for 12 h. The mixture was extracted with
EtOAc (2.times.20 mL). The organic layers were washed with
saturated aq NaHCO.sub.3 (20 mL), water (20 mL) and brine (20 mL),
were dried over anhydrous Na.sub.2SO.sub.4, and filtered. The
filtrate was concentrated under reduced pressure and the residue
was purified by column chromatography (DM1020,
EtOAc/MeOH=15/1-10/1) to give the title compound as a white solid
(10.2 mg, 54%). .sup.1H-NMR (DMSO-d.sub.6) .delta. ppm 0.88-0.95
(m, 6H), 1.52-1.60 (m, 2H), 1.73-1.76 (m, 1H), 3.88 (s, 3H), 4.21
(s, 2H), 4.48 (br s, 1H), 6.43 (s, 1H), 6.90 (s, 1H), 7.03 (br s,
1H), 7.42 (s, 1H), 8.01 (s, 1H), 8.41 (s, 1H), 8.92 (s, 1H). [M+H]
calc'd for C.sub.17H.sub.23N.sub.6O.sub.2, 343; found, 343.
Example 37:
2-((1R,2S)-2-(Dimethylamino)cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-
-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00115##
[0535] A solution of
2-((1R,2S)-2-aminocyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrol-
o[3,4-d]pyrimidin-5-one (10 mg, 0.028 mmol), paraformaldehyde
(0.852 mg, 0.028 mmol) in MeOH (2 mL) was stirred at RT for 10 min.
Sodium cyanotrihydroborate (1.783 mg, 0.028 mmol) was added and the
reaction mixture was stirred at RT overnight. The mixture was
purified by reverse phase preparative HPLC to give the TFA salt of
the title compound (5 mg, 46%). .sup.1H NMR (400 MHz, DMSO-d) S ppm
1.44-1.57 (m, 4H), 1.85 (br s, 4H), 2.32 (s, 3H), 2.64-2.87 (2s,
6H), 4.20 (d, J=4.55 Hz, 2H), 6.91 (d, J=7.07 Hz, 1H), 7.00 (s,
1H), 7.13 (s, 1H), 7.17-7.34 (m, 2H), 8.19 (br s, 1H), 8.68 (br s,
1H). [M+H] calc'd for C.sub.21H.sub.28N.sub.6O, 381; found,
381.
Example 38:
2-((1R,2S)-2-(Methylamino)cyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5-
H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00116##
[0537] A solution of
2-((1R,2S)-2-Aminocyclohexylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrol-
o[3,4-d]pyrimidin-5-one (17.7 mg, 0.050 mmol), paraformaldehyde
(1.508 mg, 0.050 mmol) in MeOH (2 mL) was stirred at RT for 10 min.
Sodium cyanotrihydroborate (3.16 mg, 0.050 mmol) was added and the
reaction mixture was stirred at RT for 4 h. The reaction was
stopped and the mixture was purified by reverse phase preparative
HPLC to give the TFA salt of the title compound (5 mg, 27%).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.35-1.79 (m, 8H),
2.32 (s, 3H), 4.20 (br s, 2H), 6.52 (br s, 2H), 6.91 (d, J=7.33 Hz,
1H), 7.24 (t, J=7.71 Hz, 2H), 8.03 (br s, 1H), 8.16 (br s, 2H),
8.40 (br s, 1H), 8.66 (br s, 1H). [M+H] calc'd for
C.sub.20H.sub.26N.sub.6O, 367; found, 367.
Example 39:
2'-((1R,2S)-2-Aminocyclohexylamino)-4'-(m-tolylamino)spiro[cyclopropane-1-
,7'-pyrrolo[3,4-d]pyrimidin]-5'(6'H)-one
##STR00117##
[0538] A. tert-Butyl
(1S,2R)-2-(5'-oxo-4'-(m-tolylamino)-5',6'-dihydrospiro[cyclopropane-1,7'--
pyrrolo[3,4-d]pyrimidine]-2'-ylamino)cyclohexylcarbamate
##STR00118##
[0540] Ethylmagnesium bromide (0.069 mL, 0.208 mmol) was added at
RT to a solution of methyl
2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-6-(m-toly-
lamino)pyrimidine-5-carboxylate (50 mg, 0.104 mmol) and
tetraisopropylorthotitanate (0.091 mL, 0.312 mmol) in Et.sub.2O (5
mL). The reaction mixture was stirred at RT for 20 h and was
subsequently diluted with EtOAc. The organic phase was washed with
saturated aq NaHCO.sub.3, brine and water, was dried then
concentrated to give a pink residue, which was purified by reverse
phase preparative HPLC. The fractions were collected and
concentrated to a residue, which was used in next step. [M+H]
calc'd for C.sub.26H.sub.34N.sub.6O.sub.3, 479; found, 479.
B.
2'-((1R,2S)-2-Aminocyclohexylamino)-4'-(m-tolylamino)spiro[cyclopropane-
-1,7'-pyrrolo[3,4-d]pyrimidin]-5' (6'1)-one
[0541] A solution of tert-Butyl
(1S,2R)-2-(5'-oxo-4'-(m-tolylamino)-5',6'-dihydrospiro[cyclopropane-1,7'--
pyrrolo[3,4-d]pyrimidine]-2'-ylamino)cyclohexylcarbamate (50 mg,
0.104 mmol) in DCM (5 mL) was treated with TFA (2 mL) for 1 h and
was purified by reverse phase preparative HPLC. The collected
fractions were lyophilized to give the TFA salt of the title
compound (4 mg, 10% in two steps). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.12-1.31 (m, 1H), 1.42 (m, 6H), 1.63 (m,
3H), 1.86 (m, 2H), 2.33 (s, 3H), 3.62 (br s, 1H), 4.18 (br s, 1H),
6.91 (d, J=7.33 Hz, 1H), 7.24 (t, J=7.71 Hz, 1H), 7.36-7.56 (m,
1H), 7.60 (br s, 1H), 7.73 (br s, 2H), 8.33 (br s, 1H), 8.65 (br s,
1H). [M+H] calc'd for C.sub.21H.sub.26N.sub.6O, 379; found,
379.
Example 40:
2-(2-Aminoethylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrim-
idin-5-one
##STR00119##
[0542] A. Methyl
4-methyl-2-(methylthio)-6-(m-tolylamino)pyrimidine-5-carboxylate
##STR00120##
[0544] Methyl
2-chloro-4-methyl-6-(m-tolylamino)pyrimidine-5-carboxylate (0.078
g, 0.267 mmol) was dissolved in DMF (3 mL). Sodium thiomethoxide
(0.019 g, 0.267 mmol) was added and the reaction mixture was
allowed to stir at RT for 1 h. The reaction mixture was poured onto
ice. The pH was adjusted to 7 with 1 N HCl. The title compound was
isolated as a yellow solid by vacuum filtration (72.8 mg, 90%).
[M+H] calc'd for C.sub.15H.sub.17N.sub.3O.sub.2S, 304; found,
304.
B.
6-(2,4-Dimethoxybenzyl)-2-(methylthio)-4-(m-tolylamino)-6,7-dihydro-5H--
pyrrolo[3,4-d]pyrimidin-5-one
##STR00121##
[0546] A mixture methyl
4-methyl-2-(methylthio)-6-(m-tolylamino)pyrimidine-5-carboxylate
(0.44 g, 1.45 mmol) and selenium dioxide (0.32 g, 2.89 mmol) in
dioxane (12 mL) was heated at 100.degree. C. for 24 h. The reaction
mixture was subsequently cooled and filtered. The filtrate was
concentrated and dried to give a brown foam (0.459 g) which was
dispersed in (2,4-dimethoxyphenyl)methanamine (0.217 mL, 1.446
mmol) in DCM (6 mL) and MeOH (3 mL). The resulting mixture was
stirred at RT for 30 min. Sodium cyanoborohydride (0.227 g, 3.62
mmol) was added and the reaction mixture was stirred at RT for 20
h. The solid phase was filtered and washed with MeOH to give the
title compound as a yellow solid (0.537 g, 85%). [M+H] calc'd for
C.sub.23H.sub.24N.sub.4O.sub.3S, 437; found, 437.
C.
6-(2,4-dimethoxybenzyl)-2-(methylsulfonyl)-4-(m-tolylamino)-6,7-dihydro-
-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00122##
[0548]
6-(2,4-Dimethoxybenzyl)-2-(methylthio)-4-(m-tolylamino)-6,7-dihydro-
-5H-pyrrolo[3,4-d]pyrimidin-5-one (0.432 g, 0.990 mmol) was
dissolved in DCM (10 mL). The solution was chilled in an ice bath
and m-chloroperoxybenzoic acid (0.256 g, 1.484 mmol) was added. The
reaction was allowed to warm to RT with stirring for 3 h. A second
aliquot of m-chloroperoxybenzoic acid (0.170 g, 0.990 mmol) was
added to the reaction mixture, which was stirred for 1 h. A third
aliquot of m-chloroperoxybenzoic acid (0.100 g, 0.579 mmol) was
added. The reaction mixture was stirred for 30 min, diluted with
DCM (20 mL), and quenched with saturated aq NaHCO.sub.3 (20 mL).
The organic phase was washed with saturated aq NaHCO.sub.3 (20 mL)
and brine (20 mL), and was dried over anhydrous Na.sub.2SO.sub.4.
The solvent was removed in vacuo to give the title compound as a
light brown glassy solid (330 mg, 71%). [M+H] calc'd for
C.sub.23H.sub.24N.sub.4O.sub.5S, 469; found, 469.
D. tert-Butyl
2-(6-(2,4-dimethoxybenzyl)-5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[-
3,4-d]pyrimidin-2-ylamino)ethylcarbamate
##STR00123##
[0550] A mixture of
6-(2,4-dimethoxybenzyl)-2-(methylsulfonyl)-4-(m-tolylamino)-6,7-dihydro-5-
H-pyrrolo[3,4-d]pyrimidin-5-one (0.07 g, 0.149 mmol), tert-butyl
2-aminoethylcarbamate (0.024 g, 0.149 mmol), and Et.sub.3N (0.104
mL, 0.747 mmol) in DMA (2 mL) was heated in a sealed tube at
90.degree. C. for 4 h. The reaction mixture was poured slowly onto
ice and its pH adjusted to about 7 through addition of 1 N HCl,
resulting in precipitation of a tan solid. The solid was isolated
by vacuum filtration, washed with water, and dried under vacuum to
give the title compound as a tan brown solid (55 mg, 67%). [M+H]
calc'd for C.sub.29H.sub.36N.sub.6O.sub.5, 549; found, 549.
E.
2-(2-Aminoethylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyr-
imidin-5-one
[0551] A mixture of tert-butyl
2-(6-(2,4-dimethoxybenzyl)-5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[-
3,4-d]pyrimidin-2-ylamino)ethylcarbamate (0.055 g, 0.100 mmol) in
TFA (2 mL) was stirred at 70.degree. C. for 1.5 h. Following
reaction, the solvent was removed and the resulting residue was
dispersed into a solution of DMSO and MeOH (1/1). The mixture was
filtered and the filtrate was purified by preparative HPLC. The
fractions were collected and dried in vacuo to give a TFA salt of
the title compound as an off-white solid (28 mg, 93%). .sup.1H NMR
(500 MHz, DMSO-d.sub.6) .delta. ppm 2.21-2.40 (m, 3H) 2.90-3.21 (m,
2H) 3.57 (q, J=5.86 Hz, 2H) 4.19 (brs, 2H) 6.90 (brs, 1H) 7.13-7.34
(m, 1H) 7.54 (br s, 1H) 7.56-7.74 (m, 2H) 7.80 (br s, 2H) 8.18 (d,
J=13.67 Hz, 1H) 8.54-8.82 (m, 1H). [M+H] calc'd for
C.sub.15H.sub.18N.sub.6O, 299; found, 299.
Example 41:
2-(2-Amino-2-methylpropylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3-
,4-d]pyrimidin-5-one
##STR00124##
[0553] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 40 using tert-butyl
1-amino-2-methylpropan-2-ylcarbamate in place of tert-butyl
2-aminoethylcarbamate. .sup.1H NMR (500 MHz, CD.sub.3OD) .delta.
ppm 1.14-1.53 (m, 6H), 2.37 (br s, 3H), 3.62 (br s, 2H), 4.12-4.47
(m, 2H), 6.77-7.15 (m, 1H), 7.13-7.40 (m, 1H), 7.40-7.79 (m, 2H).
[M+H] calc'd for C.sub.17H.sub.22N.sub.6O, 327; found, 327.
Example 42:
2-(5-Oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamin-
o)acetamide
##STR00125##
[0555] The title compound was prepared in a manner similar to
EXAMPLE 40 using glycinamide hydrochloride in place of tert-butyl
2-aminoethylcarbamate. .sup.1H NMR (500 MHz, CD.sub.3OD) .delta.
ppm 2.38 (s, 3H), 4.11 (br s, 2H), 4.41 (br s, 2H), 7.02 (br s,
1H), 7.27 (br s, 1H), 7.51 (br s, 2H). [M+H] calc'd for
C.sub.15H.sub.16N.sub.6O.sub.2, 313; found, 313.
Example 43:
2-((2-Aminoethyl)(methyl)amino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3-
,4-d]pyrimidin-5-one
##STR00126##
[0557] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 40 using tert-butyl
2-(methylamino)ethylcarbamate hydrochloride in place of tert-butyl
2-aminoethylcarbamate. .sup.1H NMR (500 MHz, CD.sub.3OD) .delta.
ppm 2.35 (s, 3H), 3.26 (t, J=5.86 Hz, 2H), 3.30 (s, 3H), 3.89-4.04
(m, 2H), 4.24 (s, 2H), 6.94 (d, J=7.32 Hz, 1H), 7.23 (t, J=7.81 Hz,
1H), 7.55 (d, J=7.81 Hz, 2H). [M+H] calc'd for
C.sub.16H.sub.20N.sub.6O, 313; found, 313.
Example 44:
2-(Pyrrolidin-2-ylmethylamino)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,-
4-d]pyrimidin-5-one
##STR00127##
[0559] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 40 using tert-butyl
2-(aminomethyl)pyrrolidine-1-carboxylate in place of tert-butyl
2-aminoethylcarbamate. .sup.1H NMR (500 MHz, CD.sub.3OD) .delta.
ppm 1.80 (br s, 1H), 1.91-2.26 (m, 3H), 2.38 (br s, 3H), 3.19 (br
s, 1H), 3.63 (d, J=7.32 Hz, 1H), 3.71-4.03 (m, 2H), 4.15-4.51 (m,
2H), 6.74-7.16 (m, 1H), 7.13-7.76 (m, 3H). [M+H] calc'd for
C.sub.18H.sub.22N.sub.6O, 339; found, 339.
Example 45:
2-(3-Aminopyrrolidin-1-yl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]-
pyrimidin-5-one
##STR00128##
[0561] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 40 using tert-butyl pyrrolidin-3-ylcarbamate in
place of tert-butyl 2-aminoethylcarbamate. .sup.1H NMR (500 MHz,
CD.sub.3OD) .delta. ppm 2.13-2.28 (m, 1H), 2.35 (s, 3H), 2.51 (dd,
J=13.42, 6.10 Hz, 1H), 3.69-4.12 (m, 5H), 4.22 (d, J=18.06 Hz, 2H),
6.93 (d, J=7.32 Hz, 1H), 7.21 (t, J=7.81 Hz, 1H), 7.46-7.69 (m,
2H). [M+H] calc'd for C.sub.17H.sub.20N.sub.6O, 325; found,
325.
Preparation 15: Ethyl
4-chloro-6-methyl-2-(methylthio)pyrimidine-5-carboxylate
##STR00129##
[0563] Ethyl
4-hydroxy-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (0.2 g,
0.876 mmol), tetraethylammonium chloride (0.145 g, 0.876 mmol), and
N,N-dimethylaniline (0.112 mL, 0.876 mmol) were dispersed in
acetonitrile (10 mL). The reaction mixture was stirred briefly
followed by the addition of phosphorous oxychloride (0.204 mL,
2.190 mmol). The reaction was heated at 100.degree. C. for 4 h. The
solvent was subsequently removed in vacuo. The residue was poured
onto ice to give an off-white oil, which was extracted with DCM
(2.times.15 mL), and dried over anhydrous Na.sub.2SO.sub.4. The
solvent was removed in vacuo to give the title compound as a
yellowish-green oil (0.179 g, 83%). [M+H] calc'd for
C.sub.9H.sub.11ClN.sub.2O.sub.2S, 247; found, 247.
Example 46:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1,5-dimethyl-1H-pyrazol-4-yl)-6,7-d-
ihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00130##
[0564] A. Ethyl
4-(1,5-dimethyl-1H-pyrazol-4-yl)-6-methyl-2-(methylthio)pyrimidine-5-carb-
oxylate
##STR00131##
[0566] Ethyl
4-chloro-6-methyl-2-(methylthio)pyrimidine-5-carboxylate (0.179 g,
0.726 mmol),
1,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(0.242 g, 1.088 mmol), and PdCl.sub.2(dppf) (0.106 g, 0.145 mmol)
were dispersed in DMA (2 mL). After 10 min, 2 N sodium carbonate
(1.814 mL, 3.63 mmol) was added to the reaction mixture. The
reaction mixture was purged with nitrogen, sealed in a vial, and
then heated at 80.degree. C. for 5 h. The mixture was subsequently
filtered through a pad of Celite, rinsed with MeOH, and the
filtrate was purified via reverse phase preparative HPLC. The
fractions were concentrated in vacuo to give the title compound as
tan needles (0.159 g, 71%). [M+H] calc'd for
C.sub.14H.sub.18N.sub.4O.sub.2S, 307; found, 307.
B. Ethyl
4-(1,5-dimethyl-1H-pyrazol-4-yl)-6-methyl-2-(methylsulfonyl)pyrim-
idine-5-carboxylate
##STR00132##
[0568] Ethyl
4-(1,5-dimethyl-1H-pyrazol-4-yl)-6-methyl-2-(methylthio)pyrimidine-5-carb-
oxylate (0.159 g, 0.519 mmol) was dissolved in DCM (10 mL). The
solution was chilled in an ice bath and m-chloroperoxybenzoic acid
(0.134 g, 0.778 mmol) was added. The reaction was allowed to warm
to RT over a 30 min period with stirring. Another aliquot of
m-chloroperoxybenzoic acid (0.159 g, 0.519 mmol) was added to the
reaction mixture and it was stirred for an additional 45 min. The
reaction mixture was subsequently diluted with DCM (10 mL) and was
quenched with saturated aq NaHCO.sub.3 (10 mL). The organic phase
was washed with saturated aq NaHCO.sub.3 (5 mL) and brine (5 mL)
and was dried over anhydrous Na.sub.2SO.sub.4. The solvents were
removed in vacuo to give the title compound as a yellow oil (173
mg, 98%). [M+H] calc'd for C.sub.14H.sub.18N.sub.4O.sub.4S, 339;
found, 339.
C. Ethyl
2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-(1,5-di-
methyl-1H-pyrazol-4-yl)-6-methylpyrimidine-5-carboxylate
##STR00133##
[0570] A solution of ethyl
4-(1,5-dimethyl-1H-pyrazol-4-yl)-6-methyl-2-(methylsulfonyl)pyrimidine-5--
carboxylate (0.07 g, 0.207 mmol), tert-butyl
(1S,2R)-2-aminocyclohexylcarbamate (0.089 g, 0.414 mmol) and
Et.sub.3N (0.115 mL, 0.827 mmol) in DMA (3 mL) was heated in a
sealed tube at 90.degree. C. for 8 h. The reaction mixture was
poured slowly onto ice to yield a pale yellow precipitate, which
was isolated by vacuum filtration, washed with water, and dried
under vacuum to give the title compound. [M+H] calc'd for
C.sub.24H.sub.36N.sub.6O.sub.4, 473; found, 473.
D. tert-Butyl
(1S,2R)-2-(6-(2,4-dimethoxybenzyl)-4-(1,5-dimethyl-1H-pyrazol-4-yl)-5-oxo-
-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)cyclohexylcarbamate
##STR00134##
[0572] A mixture ethyl
2-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-(1,5-dimethyl-1-
H-pyrazol-4-yl)-6-methylpyrimidine-5-carboxylate (0.098 g, 0.207
mmol) and selenium dioxide (0.046 g, 0.415 mmol) in dioxane (2 mL)
was heated at 100.degree. C. for 24 h. The mixture was subsequently
cooled and filtered. The filtrate was concentrated and dried to
give a brown foam (0.1 g, 0.206 mmol) which was combined with
sodium acetate (0.051 g, 0.617 mmol) and
(2,4-dimethoxyphenyl)methanamine (0.031 mL, 0.206 mmol) in DCM (2
mL) and MeOH (1 mL). The mixture was stirred at RT for 30 min,
after which sodium cyanoborohydride (0.032 g, 0.514 mmol) was
added. The reaction mixture was stirred at RT for 20 h, and then
filtered through a pad of Celite, which was rinsed with MeOH. The
filtrate was purified by reverse phase preparative HPLC and the
fractions concentrated in vacuo to give the title compound as a tan
solid. [M+H] calc'd for C.sub.31H.sub.41N.sub.7O.sub.5, 592; found,
592.
E.
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1,5-dimethyl-1H-pyrazol-4-yl)-6,7-
-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00135##
[0574] A mixture of tert-butyl
(1S,2R)-2-(6-(2,4-dimethoxybenzyl)-4-(1,5-dimethyl-1H-pyrazol-4-yl)-5-oxo-
-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-2-ylamino)cyclohexylcarbamate
obtained above in TFA (2 mL) was stirred at 70.degree. C. for 2 h.
The mixture was subsequently purified by reverse phase preparative
HPLC. The fractions were collected and concentrated to give a TFA
salt of the title compound as a white solid (0.5 mg). .sup.1H NMR
(500 MHz, CD.sub.3OD) .delta. ppm 1.59 (br s, 2H), 1.67-2.02 (m,
6H), 2.66-2.72 (m, 3H), 3.67 (br s, 1H), 3.85 (s, 3H), 4.29 (s,
2H), 4.50-4.64 (m, 1H), 8.64 (br s, 1H). [M+H] calc'd for
C.sub.17H.sub.23N.sub.7O, 342; found, 342.
Example 47:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1H-indol-2-yl)-6,7-dihydro-5H-pyrro-
lo[3,4-d]pyrimidin-5-one
##STR00136##
[0576] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 46 using
1-(tert-butoxycarbonyl)-1H-indol-2-ylboronic acid in place of
1,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H--
pyrazole. .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 1.46-1.72
(m, 2H), 1.72-2.06 (m, 6H), 3.56-3.89 (m, 1H), 4.36 (s, 2H),
4.52-4.77 (m, 1H), 7.08 (t, J=7.57 Hz, 1H), 7.25 (t, J=7.57 Hz,
1H), 7.47 (d, J=8.30 Hz, 1H), 7.58-7.79 (m, 2H). [M+H] calc'd for
C.sub.20H.sub.22N.sub.6O, 363; found, 363.
Example 48:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1H-pyrazol-5-yl)-6,7-dihydro-5H-pyr-
rolo[3,4-d]pyrimidin-5-one
##STR00137##
[0578] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 46 using tert-butyl
5-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-1H-pyrazole-1-carboxylate
in place of
1,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H--
pyrazole. .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 1.44-1.69
(m, 2H), 1.68-1.94 (m, 6H), 3.64 (br s, 1H), 4.41 (s, 2H), 4.65 (br
s, 1H), 7.11-7.55 (m, 1H), 7.69 (d, J=1.77 Hz, 1H). [M+H] calc'd
for C.sub.15H.sub.19N.sub.7O, 314; found, 314.
Example 49:
2-(3-Aminopropyl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-
-5-one
##STR00138##
[0579] A. Methyl
2-(3-(tert-butoxycarbonylamino)prop-1-ynyl)-4-methyl-6-(m-tolylamino)pyri-
midine-5-carboxylate
##STR00139##
[0581] Methyl
2-chloro-4-methyl-6-(m-tolylamino)pyrimidine-5-carboxylate (0.4 g,
1.371 mmol), tert-butyl prop-2-ynylcarbamate (0.426 g, 2.74 mmol),
tetrakis(triphenylphosphine)palladium (0.032 g, 0.027 mmol), and
copper (I) iodide (0.026 g, 0.137 mmol) was dispersed in DMA (5
mL). Triethylamine (0.382 mL, 2.74 mmol) was added and the mixture
was degassed with nitrogen for 5 min. The reaction mixture was
placed in a sealed tube and heated at 90.degree. C. for 4 h, after
which it was filtered through a pad of Celite, which was rinsed
with MeOH. The filtrate was purified via reverse phase preparative
HPLC and the fractions were concentrated in vacuo to give the title
compound as a brown oil (0.190 g, 34%). [M+H] calc'd for
C.sub.22H.sub.26N.sub.4O.sub.4, 411; found, 411.
B. Methyl
2-(3-(tert-butoxycarbonylamino)propyl)-4-methyl-6-(m-tolylamino)-
pyrimidine-5-carboxylate
##STR00140##
[0583] Methyl
2-(3-(tert-butoxycarbonylamino)prop-1-ynyl)-4-methyl-6-(m-tolylamino)pyri-
midine-5-carboxylate (0.190 g, 0.463 mmol) was dissolved in EtOH (4
mL). To this solution was added palladium on carbon (0.049 g, 0.046
mmol) and the resulting mixture was stirred overnight at RT under
H.sub.2 atmosphere. The mixture was filtered through a pad of
Celite, and the filtrate was evaporated to give the title compound
as a brown oil, which was used in next step without further
purification. [M+H] calc'd for C.sub.22H.sub.30N.sub.4O.sub.4, 415;
found, 415.
C. tert-Butyl
3-(6-(2,4-dimethoxybenzyl)-5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[-
3,4-d]pyrimidin-2-yl)propylcarbamate
##STR00141##
[0585] A mixture methyl
2-(3-(tert-butoxycarbonylamino)propyl)-4-methyl-6-(m-tolylamino)pyrimidin-
e-5-carboxylate (0.124 g, 0.299 mmol) and selenium dioxide (0.033
g, 0.299 mmol) in dioxane (2 mL) was heated at 100.degree. C. for
24 h. The reaction mixture was subsequently cooled and filtered.
The filtrate was concentrated and dried to give a brown foam (0.128
g, 0.299 mmol), which was combined with
(2,4-dimethoxyphenyl)methanamine (0.045 mL, 0.299 mmol), DCM (2 mL)
and MeOH (1 mL). The mixture was stirred at RT for 30 min, after
which sodium cyanoborohydride (0.047 g, 0.747 mmol) was added. The
reaction mixture was stirred at RT for 20 h, and then filtered
through a pad of Celite, which was rinsed with MeOH. The filtrate
was purified via reverse phase preparative HPLC. The fractions were
collected and concentrated in vacuo to yield the title compound as
a tan solid (1.7 mg, 1%). [M+H] calc'd for
C.sub.30H.sub.37N.sub.5O.sub.5, 548; found, 548.
D.
2-(3-Aminopropyl)-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimid-
in-5-one
[0586] A mixture of tert-butyl
3-(6-(2,4-dimethoxybenzyl)-5-oxo-4-(m-tolylamino)-6,7-dihydro-5H-pyrrolo[-
3,4-d]pyrimidin-2-yl)propylcarbamate (1.7 mg, 0.003 mmol) in TFA (2
mL) was stirred at 70.degree. C. for 2 h. The mixture was purified
by reverse phase preparative HPLC. The fractions were collected and
concentrated to give a TFA salt of the title compound as a white
solid (0.6 mg, 65%). .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm
2.11-2.26 (m, 2H), 2.30-2.45 (m, 3H), 2.92-3.09 (m, 4H), 4.39 (s,
2H), 6.98 (d, J=8.34 Hz, 1H), 7.16-7.35 (m, 1H), 7.51 (s, 1H), 7.65
(d, J=8.59 Hz, 1H). [M+H] calc'd for C.sub.16H.sub.19N.sub.5O, 298;
found, 298.
Example 50:
6-((1R,2S)-2-Aminocyclohexylamino)-4-(benzofuran-3-yl)-7-fluoro-1H-pyrrol-
o[3,4-c]pyridin-3(2H)-one
##STR00142##
[0587] A. tert-Butyl
(1S,2R)-2-(4-(benzofuran-3-yl)-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-
-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
##STR00143##
[0589] A mixture of tert-butyl
(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-
-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (65 mg, 0.118
mmol), aqueous sodium carbonate (2 N, 0.237 mL, 0.474 mmol),
2-(benzofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (43 mg,
0.178 mmol) and bis(triphenylphosphine)palladium chloride (17 mg,
0.024 mmol) in DME (2 mL) was placed in a vial. The vial was purged
with nitrogen, sealed, and the reaction mixture heated at
120.degree. C. for 1 h. The mixture was filtered through a pad of
Celite, which was rinsed with MeOH. The solvent was removed in
vacuo and the residue diluted with MeOH, passed through a
microfiltration frit, and purified via preparative HPLC. The
fractions were collected and concentrated in vacuo to give the
title compound as a tan oil (36.3 mg, 48%). [M+H] calc'd for
C.sub.35H.sub.39FN.sub.4O.sub.6, 632; found, 632.
B.
6-((1R,2S)-2-Aminocyclohexylamino)-4-(benzofuran-3-yl)-7-fluoro-1H-pyrr-
olo[3,4-c]pyridin-3(2H)-one
[0590] A mixture of tert-butyl
(1S,2R)-2-(4-(benzofuran-3-yl)-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-
-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (75
mg, 0.119 mmol) and TFA (2 mL) was placed in a vial and heated at
125.degree. C. for 3 h. The solvent was subsequently removed in
vacuo to give a residue which was dispersed in DMSO and MeOH (1/1),
passed through a microfiltration frit, and purified via preparative
HPLC. The fractions were collected and the solvent removed in vacuo
to give a TFA salt of the title compound as a gray solid (9.2 mg,
20%). .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 1.67 (br s,
3H), 1.79-2.05 (m, 5H), 3.98 (br s, 1H), 4.50 (s, 2H), 4.69 (br s,
1H), 7.28-7.47 (m, 2H), 7.56 (d, J=7.81 Hz, 1H), 8.31 (d, J=6.83
Hz, 1H), 9.08 (s, 1H). [M+H] calc'd for
C.sub.21H.sub.21FN.sub.4O.sub.2, 381; found, 381.
Example 51:
6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(imidazo[1,2-a]pyridin-3-yl-
)-1H-pyrrolo[3,4-c]pyridin-3(21)-one
##STR00144##
[0592] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 50 using imidazo[1,2-a]pyridin-3-ylboronic acid
in place of
2-(benzofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.
.sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 1.50-1.75 (m, 3H),
1.74-1.98 (m, 5H), 3.78 (br s, 1H), 4.58 (br s, 3H), 7.57 (t,
J=6.35 Hz, 1H), 7.93-8.21 (m, 2H), 8.78 (br s, 1H), 9.45 (d, J=6.35
Hz, 1H). [M+H] calc'd for C.sub.20H.sub.21FN.sub.6O, 381; found,
381.
Example 52:
6-((1R,2S)-2-aminocyclohexylamino)-4-(benzo[b]thiophen-3-yl)-7-fluoro-1H--
pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00145##
[0594] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 50 using benzo[b]thiophen-3-ylboronic acid in
place of
2-(benzofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.
.sup.1H NMR (500 MHz, CD.sub.3OD) .delta. ppm 1.50-1.93 (m, 8H),
3.80 (br s, 1H), 4.42-4.68 (m, 3H), 7.38 (m, J=4.40 Hz, 2H), 7.94
(br s, 1H), 8.00-8.20 (m, 2H). [M+H] calc'd for
C.sub.21H.sub.21FN.sub.4OS, 397; found, 397.
Example 53:
6-((1S,2R)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00146##
[0595] A. tert-Butyl
(1R,2S)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-
-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
##STR00147##
[0597] To a mixture of
4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(-
2H)-one (200 mg, 0.539 mmol) and tert-butyl
(1R,2S)-2-aminocyclohexylcarbamate (173 mg, 0.808 mmol) in ACN (5
mL) was added N,N-diisopropylethylamine (0.141 mL, 0.808 mmol). The
reaction mixture was heated in a sealed vial at 100.degree. C. for
several hours after which additional amine (0.5 eq) was added. The
mixture was heated overnight and the solvent was subsequently
removed in vacuo. The residue was dispersed in DMSO and MeOH (1/1)
and the resulting mixture was filtered. The filtrate was purified
via preparative HPLC. The fractions were collected and dried in
vacuo to give the title compound as a tan solid (60.7 mg, 21%).
[M+H] calc'd for C.sub.27H.sub.34ClFN.sub.4O.sub.5, 550; found,
550.
B. tert-Butyl
(1R,2S)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)--
3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
##STR00148##
[0599] A mixture of tert-butyl
(1R,2S)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-
-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (60 mg, 0.109
mmol),
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(34 mg, 0.164 mmol) and bis(triphenylphosphine)palladium chloride
(15 mg, 0.022 mmol) in DME (1 mL) was placed in a vial. The vial
was purged with nitrogen and aqueous sodium carbonate (2 N, 0.219
mL, 0.437 mmol) was added. The vial was sealed and the reaction
mixture heated in an oil bath at 85.degree. C. for 3 h. The
reaction mixture was filtered through a pad of Celite, which was
rinsed with MeOH and DCM. The solvent was removed in vacuo and the
residue was diluted with DMSO and MeOH (1/1). The resulting mixture
was filtered to recover a white precipitate (31.3 mg). The mother
liquor was purified via preparative HPLC. The fractions were
collected and dried in vacuo to recover an additional white solid
(10.2 mg). The two crops were combined to give the title compound
as a white solid (41.5 mg, 64%). [M+H] calc'd for
C.sub.31H.sub.39FN.sub.6O.sub.5, 595; found, 595.
C.
6-((1S,2R)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
[0600] A mixture of tert-butyl
(1R,2S)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)--
3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
(41.5 mg, 0.070 mmol) and TFA (2 mL) was heated at 65.degree. C.
for 3 h. Following reaction, the solvent was removed in vacuo. The
residue was diluted with DMSO and MeOH (1/1), passed through a
microfiltration frit, and purified via preparative HPLC. The
fractions were collected and dried in vacuo to give a TFA salt of
the title compound as a white solid (22 mg, 92%). .sup.1H NMR (500
MHz, CD.sub.3OD) .delta. ppm 1.56-2.01 (m, 8H), 3.85 (br s, 1H),
3.94 (br s, 3H), 4.45 (br s, 2H), 4.67 (br s, 1H), 8.31 (br s, 1H),
8.81 (br s, 1H). [M+H] calc'd for C.sub.7H.sub.21FN.sub.6O, 345;
found, 345.
Preparation 16: (R)-tert-Butyl
1-amino-3-ethoxypropan-2-ylcarbamate
##STR00149##
[0601] A. (S)-2-(tert-Butoxycarbonylamino)-3-ethoxypropanoic
acid
##STR00150##
[0603] To a suspension of sodium hydride (17.73 g, 702 mmol) in THF
(600 mL) at 0.degree. C. was added MeOH (18 mL) dropwise. The
mixture was stirred at RT for 1 h to yield a sodium methanolate
solution. Iodoethane (25.5 mL, 316 mmol) and a portion of the
sodium methanolate solution (120 mL) were added to a solution of
(S)-2-(tert-butoxycarbonylamino)-3-hydroxypropanoic acid (18 g, 88
mmol) in THF (600 mL). After stirring at RT for 1 h, the remaining
sodium methanolate solution (480 mL) was added, followed by
additional iodoethane (9.9 mL, 123 mmol). The mixture was stirred
at RT overnight. The mixture was subsequently concentrated and the
residue was dissolved in water. The aqueous layer was washed with
ether (250 mL), acidified to pH 2 using 1N HCl, and extracted with
EtOAc (3.times.300 mL). The combined organic layers were washed
with 1M Na.sub.2S.sub.2O.sub.3 (300 mL), dried, and concentrated.
The resulting crude material was reconstituted in MeOH, DCM and DMF
(total volume: 50 mL) and purified via reverse phase preparative
HPLC. The fractions were collected and the ACN was removed via
rotary evaporation. The resulting aq solution was neutralized with
saturated aq NaHCO.sub.3, washed with EtOAc (2.times.200 mL), dried
over Na.sub.2SO.sub.4, filtered, and the organic phase stripped to
dryness via rotary evaporation to yield the title compound as a
clear oil (1.81 g, 9%). [M+H] calc'd for C.sub.10H.sub.19NO.sub.5,
234; found, 234.
B. (R)-tert-Butyl 1-ethoxy-3-hydroxypropan-2-ylcarbamate
##STR00151##
[0605] To a solution of
(S)-2-(tert-butoxycarbonylamino)-3-ethoxypropanoic acid (1.81 g,
7.76 mmol) in THF (20 mL) at -15.degree. C. was added isobutyl
chloroformate (1.015 mL, 7.76 mmol) in THF (5 mL) and
4-methylmorpholine (0.853 mL, 7.76 mmol) in THF (5 mL). After
stirring for 10 min at -15.degree. C., the mixture was slowly added
to a solution of sodium borohydride (0.881 g, 23.28 mmol) in
H.sub.2O (7 mL). The mixture was stirred at -15.degree. C. for 30
min and was diluted with EtOAc. The organic layer was washed with
saturated aq NaHCO.sub.3 and brine and dried. The residue was
carried to next step without further purification (1.6 g, 94%).
[M+H] calc'd for C.sub.10H.sub.21NO.sub.4, 220; found, 220.
C. (R)-tert-Butyl 1-azido-3-ethoxypropan-2-ylcarbamate
##STR00152##
[0607] Methanesulfonyl chloride (0.851 mL, 10.95 mmol) in DCM (1
mL) was added to a solution of (R)-tert-butyl
1-ethoxy-3-hydroxypropan-2-ylcarbamate (1.6 g, 7.30 mmol) and
Et.sub.3N (1.538 mL, 10.95 mmol) in DCM (10 mL) at 0.degree. C.
After stirring at RT for 1 h, the mixture was diluted with EtOAc.
The organic layer was washed with saturated aq NaHCO.sub.3
solution, dried, and concentrated in vacuo. The residue was
dissolved in DMF (10.00 mL). Sodium azide (2.372 g, 36.5 mmol) and
tetrabutylammonium iodide (0.270 g, 0.730 mmol) were added, and the
reaction mixture was stirred at 75.degree. C. for 4 h. After
cooling to RT, the mixture was diluted with EtOAc. The organic
layer was washed with saturated aq NaHCO.sub.3, dried, and
concentrated in vacuo to give the title compound (1.2 g, 67%).
[M+H] calc'd for C.sub.10H.sub.20N.sub.4O.sub.3, 245; found,
245.
D. (R)-tert-Butyl 1-amino-3-ethoxypropan-2-ylcarbamate
[0608] A mixture of (R)-tert-butyl
1-azido-3-ethoxypropan-2-ylcarbamate (1.2 g, 4.91 mmol) in MeOH (10
mL) was added palladium on carbon (0.523 g, 4.91 mmol). The mixture
was stirred under hydrogen atmosphere overnight at RT. The
resulting crude material was reconstituted in MeOH (1.0 mL) and
purified via reverse phase preparative HPLC. The fractions were
collected and solvent was stripped to dryness via rotary
evaporation to give the title compound as clear oil (722 mg, 67%).
[M+H] calc'd for C.sub.10H.sub.22N.sub.2O.sub.3, 219; found,
219.
Preparation 17: (R)-tert-Butyl
1-ethoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-
-ylamino)propan-2-ylcarbamate
##STR00153##
[0609] A. (R)-Methyl
6-(2-(tert-butoxycarbonylamino)-3-ethoxypropylamino)-4-cyano-2-(m-tolylam-
ino)nicotinate
##STR00154##
[0611] To a solution of methyl
6-chloro-4-cyano-2-(m-tolylamino)nicotinate (200 mg, 0.663 mmol) in
DMF (5 mL) was added DIPEA (0.232 mL, 1.326 mmol) and
(R)-tert-butyl 1-amino-3-ethoxypropan-2-ylcarbamate (174 mg, 0.795
mmol). The reaction mixture was stirred at RT overnight. Additional
(R)-tert-butyl 1-amino-3-ethoxypropan-2-ylcarbamate (231.25 mg,
1.061 mmol) was added and the mixture was heated at 65.degree. C.
for 1 h. After cooling to RT, the reaction mixture was diluted with
EtOAc (30 mL) and washed with water (2.times.20 mL) and brine (20
mL). The combined organic layers were dried over Na.sub.2SO.sub.4
and concentrated to thick yellow oil. The crude product was used in
the next step without further purification (415 mg). [M+H] calc'd
for C.sub.25H.sub.33N.sub.5O.sub.5, 484; found, 484.
B. (R)-tert-Butyl
1-ethoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-
-ylamino)propan-2-ylcarbamate
[0612] In a flask containing (R)-methyl
6-(2-(tert-butoxycarbonylamino)-3-ethoxypropylamino)-4-cyano-2-(m-tolylam-
ino)nicotinate (400 mg, 0.827 mmol) in HOAc (0.25 mL) and DCM (1
mL) was added platinum(IV) oxide (18.78 mg, 0.083 mmol). The flask
was evacuated and filled with H.sub.2 three times, and the reaction
mixture was stirred vigorously at RT under H.sub.2 atmosphere for
3-4 h. The mixture was subsequently filtered through Celite, and
the solvent was removed in vacuo. The residue was kept under vacuum
overnight to remove excess HOAc. The crude residue was dissolved in
anhydrous DCM (20 mL). Potassium carbonate (572 mg, 4.14 mmol) was
added, and the mixture was stirred at RT for 8 h. The mixture was
filtered through Celite and concentrated in vacuo. The residue was
reconstituted in a MeOH/DCM solution (1/1, 5 mL) and purified via
reverse phase preparative HPLC. The collected fractions were
concentrated in vacuo to give the title compound as a TFA salt (109
mg, 28.9%). [M+H] calc'd for C.sub.24H.sub.33N.sub.5O.sub.4, 456;
found, 456.
Example 54:
(R)-6-(2-Amino-3-ethoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]pyr-
idin-3(2H)-one
##STR00155##
[0614] To a solution of (R)-tert-butyl
1-ethoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-
-ylamino)propan-2-ylcarbamate (109 mg, 0.239 mmol) in DCM (1 mL)
was added a TFA/DCM solution (1/1, 10 mL). The mixture was stirred
at RT for 2 h. After removal of the solvent, the resulting crude
material was reconstituted in a solution of MeOH/DCM (1/1, 5 mL)
and was purified via reverse phase preparative HPLC. The fractions
were collected, and ACN was removed via rotary evaporation. The
resulting aq solution was neutralized with saturated aq
NaHCO.sub.3, washed with EtOAc (2.times.200 mL), dried over
Na.sub.2SO.sub.4, and filtered. The organic phase was stripped to
dryness via rotary evaporation to give the title compound (11 mg,
13%). .sup.1H NMR (400 MHz, DMSO-d) 6 ppm 1.08-1.18 (m, 3H),
1.25-1.44 (m, 4H), 2.26-2.32 (m, 3H), 4.07-4.17 (m, 3H), 4.19-4.29
(m, 2H), 6.03 (s, 1H), 6.78 (d, J=7.83 Hz, 1H), 7.06 (br s, 1H),
7.12-7.22 (m, 1H), 7.48 (s, 1H), 7.60 (d, J=7.83 Hz, 1H), 7.66-7.75
(m, 2H), 7.99 (s, 1H), 8.83-8.97 (m, 1H). [M+H] calc'd for
C.sub.19H.sub.25N.sub.5O.sub.2, 356; found, 356.
Preparation 18: (R)-tert-Butyl
1-ethoxy-3-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]-
pyridin-6-ylamino)propan-2-ylcarbamate
##STR00156##
[0616] To a chilled solution of (R)-tert-butyl
1-ethoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-
-ylamino)propan-2-ylcarbamate (94.7 mg, 0.208 mmol) in
CH.sub.2Cl.sub.2 (5 mL) at 0.degree. C. was added SELECTFLUOR.RTM.
(73.6 mg, 0.208 mmol). The mixture was left stirring in an ice bath
and warmed slowly to RT for 6 h. Afterwards, the mixture was
diluted with EtOAc (10 mL) and washed with saturated aq NaHCO.sub.3
(5 mL) followed by water (5 mL) and brine (5 mL). The organic
layers were combined, dried over Na.sub.2SO.sub.4, and concentrated
to a brown residue. The resulting crude material was reconstituted
in MeOH/DCM (5 mL) and purified via preparative HPLC. The collected
fractions were collected and ACN was removed via rotary
evaporation. The resulting aq solution was neutralized with
saturated aq NaHCO.sub.3 and washed with EtOAc (2.times.200 mL),
dried over Na.sub.2SO.sub.4, filtered, and the organic phase
stripped to dryness via rotary evaporation to yield the title
compound. [M+H] calc'd for C.sub.24H.sub.32FN.sub.5O.sub.4, 474;
found, 474.
Example 55:
(R)-6-(2-Amino-3-ethoxypropylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo[-
3,4-c]pyridin-3(2H)-one
##STR00157##
[0618] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 54 using (R)-tert-butyl
1-ethoxy-3-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]-
pyridin-6-ylamino)propan-2-ylcarbamate in place of (R)-tert-butyl
1-ethoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-
-ylamino)propan-2-ylcarbamate. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.08-1.19 (m, 3H), 2.25-2.36 (m, 3H), 3.38-3.77 (m,
7H), 4.40 (s, 2H), 6.80 (d, J=7.58 Hz, 1H), 7.07-7.25 (m, 2H), 7.38
(s, 1H), 7.54 (d, J=7.58 Hz, 1H), 7.92 (br s, 2H), 8.28 (s, 1H),
8.83 (s, 1H). [M+H] calc'd for C.sub.19H.sub.24FN.sub.5O.sub.2,
374; found, 374.
Preparation 19: 3,3,3-Trifluoropropane-1,2-diamine
##STR00158##
[0619] A. 3,3,3-Trifluoro-1-nitroprop-1-ene
##STR00159##
[0621] A mixture of 2,2,2-trifluoroethane-1,1-diol (75% aq
solution, 20 g, 0.13 mol), CH.sub.3NO.sub.2 (24 g, 0.39 mol) and
Na.sub.2CO.sub.3 (0.85 g, 8 mmol) was stirred overnight at RT.
Water (50 mL) was added and the mixture was extracted with diethyl
ether (3.times.30 mL) and dried over Na.sub.2SO.sub.4. After
concentrating the organic extract at low temperature and under
reduced pressure, P.sub.2O.sub.5 (20.0 g, 0.14 mol) was added to
the residue oil, which was distilled at atmospheric pressure to
give a green-yellow oil (4 g, 50% purity, 10% yield). Boiling point
85-90.degree. C.; .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
7.09-7.17 (m, 1H), 7.50 (dd, J=2.0 Hz, 12.0 Hz, 1H).
B. N-Benzyl-1,1,1-trifluoro-3-nitropropan-2-amine
##STR00160##
[0623] A mixture of 3,3,3-trifluoro-1-nitroprop-1-ene (4 g, 28.4
mmol) and benzylamine (3.2 g, 30.0 mmol) in toluene (50 mL) was
stirred for RT or 1 h. The mixture was concentrated and the residue
was purified by column chromatography (EtOAc/PE=1/10) to give the
title compound (5.5 g, 78%). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 3.91-3.95 (m, 1H), 4.06-4.14 (m, 1H), 4.45-4.51 (m,
1H), 4.63-4.67 (m, 1H), 7.30-7.39 (m, 5H).
C. Di-tert-butyl
N,N-(3,3,3-trifluoropropane-1,2-diyl)-biscarbamate
##STR00161##
[0625] A mixture of N-benzyl-1,1,1-trifluoro-3-nitropropan-2-amine
(5.5 g, 22.0 mmol) and Pd/C (3.0 g) in MeOH was stirred at RT
overnight under H.sub.2 atmosphere. The mixture was subsequently
filtered and concentrated to afford an oil, which was combined with
di-tert-butyl pyrocarbonate (11.0 g, 50.0 mmol) and Et.sub.3N (5.0
g, 50.0 mmol) in DCM (100 mL). The mixture was stirred overnight
and then concentrated. The residue was purified by column
chromatography (EtOAc/PE=1/7) to give the title compound as a white
solid (5.5 g).
D. 3,3,3-Trifluoropropane-1,2-diamine
[0626] A mixture of di-tert-butyl
N,N-(3,3,3-trifluoropropane-1,2-diyl)-biscarbamate and 1.0 M
HCl-EtOAc was stirred at RT overnight to give the title compound
(1.5 g, 54%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
3.50-3.55 (m, 1H), 3.61-3.66 (m, 1H), 4.58-4.63 (m, 1H). [M+H]
calc'd for C.sub.3H.sub.7F.sub.3N.sub.2, 129; found, 129.
Example 56:
6-(2-Amino-3,3,3-trifluoropropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]-
pyridin-3(2H)-one
##STR00162##
[0628] The title compound was prepared in a manner similar to
EXAMPLE 54 using 3,3,3-trifluoropropane-1,2-diamine in place of
(R)-tert-butyl 1-amino-3-ethoxypropan-2-ylcarbamate. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 1.12-1.39 (m, 2H), 1.91-2.15
(m, 1H), 2.22-2.40 (m, 3H), 3.47-3.66 (m, 1H), 3.66-3.86 (m, 1H),
4.14-4.27 (m, 1H), 4.33-4.46 (m, 1H), 4.74-4.89 (m, 1H), 5.96-6.13
(m, 1H), 6.71-6.86 (m, 1H), 7.08-7.26 (m, 1H), 7.38-7.70 (m, 2H),
8.79-9.07 (m, 1H). [M+H] calc'd for C.sub.7H.sub.18F.sub.3N.sub.5O,
366; found, 366.
Example 57:
(R)-4-Methyl-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyrid-
in-6-ylamino)pentanamide
##STR00163##
[0630] The title compound was prepared in a manner similar to
EXAMPLE 54 using (R)-2-amino-4-methylpentanamide (64.7 mg, 0.497
mmol) in place of (R)-tert-butyl
1-amino-3-ethoxypropan-2-ylcarbamate. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 0.82-0.88 (m, 3H), 0.91-0.96 (m, 3H),
1.18-1.32 (m, 1H), 1.61 (t, J=7.33 Hz, 2H), 1.69-1.83 (m, 1H),
2.24-2.34 (m, 3H), 4.21 (s, 1H), 4.37 (s, 1H), 6.00-6.17 (m, 1H),
6.69-6.80 (m, 1H), 6.96 (br s, 1H), 7.04 (d, J=7.83 Hz, 1H),
7.10-7.26 (m, 2H), 7.49 (s, 1H), 7.58 (d, J=7.33 Hz, 1H), 7.95 (s,
1H), 8.82-8.97 (m, 1H). [M+H] calc'd for C.sub.20H.sub.25N5O.sub.2,
368; found, 368.
Preparation 20: (3R,4S)-Tetrahydrofuran-3,4-diamine
##STR00164##
[0631] A. (3R,4S)-tetrahydrofuran-3,4-diyl dimethanesulfonate
##STR00165##
[0633] Methanesulfonyl chloride (1.642 mL, 21.13 mmol) in DCM (5
mL) was added to a solution of (3R,4S)-tetrahydrofuran-3,4-diol
(0.787 mL, 9.61 mmol) and Et.sub.3N (4.05 mL, 28.8 mmol) in DCM (10
mL) at 0.degree. C. After stirring at 0.degree. C. for 1 h, the
mixture was diluted with DCM. The organic layer was washed with
saturated aqueous NaHCO.sub.3, dried, and concentrated in vacuo to
give the title compound as a yellowish white solid (2.5 g, 100%).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 3.09-3.20 (m, 6H),
3.90-4.07 (m, 2H), 4.10-4.22 (m, 2H), 5.19 (ddd, J=5.31, 3.54, 1.77
Hz, 2H).
B. (3R,4S)-3,4-Diazidotetrahydrofuran
##STR00166##
[0635] To a solution of (3R,4S)-tetrahydrofuran-3,4-diyl
dimethanesulfonate (2.5 g, 9.60 mmol) in DMF (50 mL) was added
sodium azide (3.75 g, 57.6 mmol) and tetrabutylammonium iodide
(0.355 g, 0.960 mmol). The reaction mixture was heated at
100.degree. C. overnight. After cooling to RT, the mixture was
diluted with EtOAc, and the organic layer was washed with brine,
dried over Na.sub.2SO.sub.4, and concentrated in vacuo. The residue
was dispersed in toluene and the mixture was evaporated in vacuo to
remove excess DMF and to give the title compound as brown oil which
was used in the next step without further purification (2.2 g).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 3.72-3.87 (m, 2H),
3.94-4.46 (m, 4H).
C. (3R,4S)-Tetrahydrofuran-3,4-diamine
[0636] To a mixture of (3R,4S)-3,4-diazidotetrahydrofuran (2.2 g,
14.27 mmol) dispersed in MeOH (10 mL) and DCM (8 mL) was added
palladium on carbon (1.519 g, 14.27 mmol). The reaction mixture was
stirred under H.sub.2 atmosphere overnight. Following
hydrogenation, the mixture was filtered through Celite and the
solvent was removed in vacuo to yield the title compound which was
used without further purification (1.54 g).
Example 58:
6-(cis-4-Aminotetrahydrofuran-3-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4--
c]pyridin-3(2H)-one
##STR00167##
[0637] A. Methyl
6-(cis-4-Aminotetrahydrofuran-3-ylamino)-4-cyano-2-(m-tolylamino)nicotina-
te
##STR00168##
[0639] To a solution of methyl
6-chloro-4-cyano-2-(m-tolylamino)nicotinate (40 mg, 0.133 mmol) in
DMF (1 mL) was added DIPEA (0.046 mL, 0.265 mmol) and
(3R,4S)-tetrahydrofuran-3,4-diamine (13.54 mg, 0.133 mmol). The
mixture was stirred at RT overnight. Additional amine was added and
the reaction mixture was stirred at RT for an additional day. The
reaction mixture was diluted in MeOH (10 mL) and purified by
reverse phase preparative HPLC. The fractions were collected and
ACN was removed via rotary evaporation. The resulting aq solution
was neutralized with saturated aq NaHCO.sub.3 and washed with EtOAc
(2.times.200 mL), dried over Na.sub.2SO.sub.4, and filtered. The
organic phase was stripped to dryness via rotary evaporation to
yield the title compound (35.5 mg, 73%). [M+H] calc'd for
C.sub.19H.sub.21N.sub.5O.sub.3, 368; found, 368.
B.
6-(cis-4-Aminotetrahydrofuran-3-ylamino)-4-(m-tolylamino)-1H-pyrrolo[3,-
4-c]pyridin-3(2H)-one
[0640] To a vessel containing methyl
6-(cis-4-aminotetrahydrofuran-3-ylamino)-4-cyano-2-(m-tolylamino)nicotina-
te (35.5 mg, 0.097 mmol) in MeOH (5 mL) and HOAc (2.5 mL) was added
palladium on carbon (1.028 mg, 9.66 .mu.mol). The vessel was
evacuated and filled with H.sub.2 three times, and the mixture was
then stirred vigorously at RT under H.sub.2 atmosphere overnight.
The mixture was subsequently filtered through Celite, and the
solvent was removed in vacuo. The residue was dissolved in DCM (10
mL) and MeOH (5 mL) and potassium carbonate (26.7 mg, 0.193 mmol)
was added. The mixture was stirred at RT overnight. Additional
potassium carbonate (40.1 mg, 0.290 mmol) was added and the
reaction mixture was stirred for 4 h at RT, and then heated at
50.degree. C. for 30 min. The mixture was filtered to remove solid
K.sub.2CO.sub.3 and the filtrate was diluted with MeOH (10 mL) and
purified by reverse phase preparative HPLC. The fractions were
collected and concentrated in vacuo to give a TFA salt of the title
compound (4.5 mg, 13.7%). .sup.1H NMR (500 MHz, DMSO-d.sub.6)
.delta. ppm 2.30 (s, 3H), 2.52-2.58 (m, 2H), 3.67-3.83 (m, 2H),
3.90 (br s, 1H), 3.98-4.14 (m, 2H), 4.20-4.30 (m, 2H), 4.58 (br s,
1H), 6.16 (s, 1H), 6.81 (d, J=7.32 Hz, 1H), 7.11-7.27 (m, 2H), 7.46
(d, J=7.32 Hz, 1H), 7.59 (br s, 1H), 8.08 (s, 1H), 8.94 (s, 1H).
[M+H] calc'd for C.sub.18H.sub.21N.sub.5O.sub.2, 340; found,
340.
Preparation 21: tert-Butyl
(1S,2R)-2-(4-(1-ethyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c-
]pyridin-6-ylamino)cyclohexylcarbamate
##STR00169##
[0641] A. Methyl 4-cyano-2-(1-ethyl-1H-pyrazol-4-yl)nicotinate
##STR00170##
[0643] A mixture of methyl 2-chloro-4-cyanonicotinate (207 mg,
1.053 mmol),
1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-
e (201 mg, 0.905 mmol) and tetrakis(triphenylphosphine)palladium(0)
(122 mg, 0.105 mmol) in DME (2 mL), and saturated aq
Na.sub.2CO.sub.3 (2 mL) was stirred at 80.degree. C. for 3 h under
N.sub.2 atmosphere. Water and EtOAc were subsequently added. The
organic phase was washed with H.sub.2O and brine, dried over
MgSO.sub.4, and evaporated to yield the title compound (265.3 mg,
98%). [M+H] calc'd for C.sub.13H.sub.12N.sub.4O.sub.2, 257; found,
257.
B. 4-Cyano-2-(1-ethyl-1H-pyrazol-4-yl)-3-(methoxycarbonyl)pyridine
1-oxide
##STR00171##
[0645] To a mixture of methyl
4-cyano-2-(1-ethyl-1H-pyrazol-4-yl)nicotinate (207 mg, 0.808 mmol)
in ACN (2 mL) was added urea hydrogen peroxide (380 mg, 4.04 mmol)
and trifluoroacetic anhydride (0.456 mL, 3.23 mmol) at 0.degree. C.
The resulting mixture was stirred at RT overnight. Next, saturated
aq NaHCO.sub.3 solution and chloroform were added. The aqueous
phase was extracted with chloroform (3.times.200 mL). The organic
layers were combined and washed with brine, dried over MgSO.sub.4,
and evaporated to give the title compound which was used without
further purification (210 mg, 95%). [M+H] calc'd for
C.sub.13H.sub.12N.sub.4O.sub.3, 273.5; found, 273.5.
C. Methyl
6-chloro-4-cyano-2-(1-ethyl-1H-pyrazol-4-yl)nicotinate
##STR00172##
[0647] A solution of
4-cyano-2-(1-ethyl-1H-pyrazol-4-yl)-3-(methoxycarbonyl)pyridine
1-oxide (210 mg, 0.771 mmol) in POCl.sub.3 (2 mL) was heated at
80.degree. C. for 3-4 h. The mixture was concentrated and purified
by flash chromatography (SiO.sub.2, 10-100% EtOAc in Hexane). The
fractions were collected and the solvent was removed in vacuo to
give the title compound (201 mg, 90%).
D. Methyl
6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano--
2-(1-ethyl-1H-pyrazol-4-yl)nicotinate
##STR00173##
[0649] To a solution of methyl
6-chloro-4-cyano-2-(1-ethyl-1H-pyrazol-4-yl)nicotinate (201 mg,
0.691 mmol) in DMF (1 mL) was added DIPEA (0.242 mL, 1.383 mmol)
and tert-butyl (1S,2R)-2-aminocyclohexylcarbamate (237 mg, 1.106
mmol). The reaction mixture was stirred at 100.degree. C.
overnight, after which the solvent was removed, and the resulting
crude material was diluted in MeOH (5.0 mL) and purified via
reverse phase preparative HPLC. The collected fractions were
collected and ACN was removed via rotary evaporation. The resulting
aq solution was neutralized with saturated aq NaHCO.sub.3 and
washed with EtOAc (2.times.200 mL), dried over Na.sub.2SO.sub.4,
and filtered. The organic phase was stripped to dryness via rotary
evaporation to yield the title compound (62 mg, 19%). [M+H] calc'd
for C.sub.24H.sub.32N.sub.6O.sub.4, 469; found, 469.
E. tert-Butyl
(1S,2R)-2-(4-(1-ethyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c-
]pyridin-6-ylamino)cyclohexylcarbamate
[0650] To a flask containing methyl
6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-cyano-2-(1-ethy-
l-1H-pyrazol-4-yl)nicotinate (62 mg, 0.132 mmol) in MeOH (2 mL) was
added HOAc (1 mL) to give a yellow solution. Palladium on carbon
was added (14.08 mg, 0.132 mmol). The flask was evacuated and
filled with H.sub.2 three times, after which the mixture was
stirred vigorously at RT under a H.sub.2 atmosphere overnight. The
mixture was filtered through Celite, and the solvent was removed in
vacuo to give a residue, which was dissolved in DCM (10 mL) and
MeOH (10 mL). Potassium carbonate was added and the mixture was
stirred for 5 h. The solids were filtered out and the filtrate
concentrated to give the title compound (50 mg, 86%). [M+H] calc'd
for C.sub.23H.sub.32N.sub.6O.sub.3, 441; found, 441.
Example 59:
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-1H-pyrrolo-
[3,4-c]pyridin-3(2H)-one
##STR00174##
[0652] To a solution of tert-butyl
(1S,2R)-2-(4-(1-ethyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c-
]pyridin-6-ylamino)cyclohexylcarbamate (50 mg, 0.113 mmol) in DCM
(1 mL) was added DCM/TFA (1/1, 2 mL). The mixture was stirred at RT
for 2 h. After removal of solvent, the resulting crude material was
reconstituted in MeOH (5.0 mL) and was purified by preparative
HPLC. The fractions were collected and the solvent stripped to
dryness via rotary evaporation to yield the title compound as a TFA
salt (10.5 mg, 27%). .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta.
ppm 1.31-1.55 (m, 6H), 1.58-1.86 (m, 8H), 4.20-4.31 (m, 3H), 6.56
(s, 1H), 6.84 (d, J=7.32 Hz, 1H), 7.56-7.76 (m, 2H), 8.10 (s, 1H),
8.38 (s, 1H), 8.96 (s, 1H). [M+H] calc'd for
C.sub.11H.sub.24N.sub.6O, 341; found, 341.
Example 60:
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-7-fluoro-1-
H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00175##
[0653] A. tert-Butyl
(1S,2R)-2-(4-(1-ethyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c-
]pyridin-6-ylamino
##STR00176##
[0655] A solution of tert-Butyl
(1S,2R)-2-(4-(1-ethyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c-
]pyridin-6-ylamino)cyclohexylcarbamate (69.7 mg, 0.158 mmol) in DCM
(5 mL) was cooled to 0.degree. C. SELECTFLUOR.RTM. (84 mg, 0.237
mmol) was added. The mixture was left stirring in an ice bath and
was allowed to warm slowly to RT with stirring overnight.
Additional SELECTFLUOR.RTM. (2 eq) was added and the reaction was
stopped after 2 h. After removal of solvent, the residue was
diluted with EtOAc (10 mL) and washed with saturated aq NaHCO.sub.3
(5 mL), water (5 mL), and brine (5 mL). The organic layers were
combined, dried over Na.sub.2SO.sub.4, and concentrated to a brown
residue. The resulting crude material was reconstituted in MeOH/DCM
(6 mL) and was purified via preparative HPLC. The fractions were
collected and ACN was removed via rotary evaporation. The resulting
aq solution was neutralized with saturated aq NaHCO.sub.3, washed
with EtOAc (2.times.200 mL), dried over Na.sub.2SO.sub.4, and
filtered. The organic phase was stripped to dryness via rotary
evaporation to yield the title compound (20 mg, 28%). [M+H] calc'd
for C.sub.23H.sub.31FN.sub.6O.sub.3, 459; found, 459.
B.
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-ethyl-1H-pyrazol-4-yl)-7-fluoro-
-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
[0656] To a solution of tert-butyl
(1S,2R)-2-(4-(1-ethyl-1H-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrr-
olo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (20 mg, 0.044 mmol)
in DCM (1 mL) was added DCM/TFA (1/1, 2 mL). The mixture was
stirred at RT for 2 h. After removal of solvent, the resulting
crude material was reconstituted in MeOH (5.0 mL) and was purified
by preparative HPLC. The fractions were collected and solvent
stripped to dryness via rotary evaporation to yield the title
compound as a TFA salt (7 mg, 45%). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 1.40 (t, J=7.08 Hz, 4H), 1.54-1.72 (m,
2H), 1.75-1.97 (m, 2H), 3.47-3.60 (m, 2H), 3.69 (br s, 1H), 4.18
(q, J=7.32 Hz, 2H), 4.33-4.52 (m, 3H), 6.74 (d, J=6.83 Hz, 1H),
7.77 (br s, 3H), 8.26-8.44 (m, 2H), 8.88 (s, 1H). [M+H] calc'd for
C.sub.18H.sub.23FN.sub.6O, 359; found, 359.
Preparation 22:
1-Isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
##STR00177##
[0658] In a microwave vial, a solution of
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1 g,
5.15 mmol) in DMF (10 mL) was added cesium carbonate (5.04 g, 15.46
mmol) and 2-iodopropane (2.58 mL, 25.8 mmol). The mixture was
heated at 100.degree. C. overnight. After cooling to RT, H.sub.2O
(300 mL) was added and the aqueous layer was extracted with EtOAC
(2.times.200 mL). The organic extracts were combined, dried over
Na.sub.2SO.sub.4, filtered, and solvent was removed in vacuo. The
resulting crude material was reconstituted in MeOH (1.0 mL) and
purified by HPLC. The fractions were collected and stripped to
dryness via rotary evaporation to yield the title compound. [M+H]
calc'd for C.sub.12H.sub.21BN.sub.2O.sub.2, 237; found 237.
Preparation 23:
1-Cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
##STR00178##
[0660] The title compound was prepared in a manner similar to
PREPARATION 22 using bromocyclopropane in place of iodopropane.
[M+H] calc'd for C.sub.12H.sub.19BN.sub.2O.sub.2, 234; found,
234.
Preparation 24:
1-(Difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyr-
azole
##STR00179##
[0662] The title compound was prepared in a manner similar to
PREPARATION 22 using difluoroiodomethane in place of iodopropane
and carrying out the reaction at 90.degree. C. [M+H] calc'd for
C.sub.10H.sub.15BF.sub.2N.sub.2O.sub.2, 245; found, 245.
Example 61:
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-1H-p-
yrrolo[3,4-c]pyridin-3(2H)-one
##STR00180##
[0664] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 59 using
1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
in place of
1-ethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
H NMR (500 MHz, CD.sub.3OD) .delta. ppm 1.47-1.67 (m, 4H),
1.69-1.95 (m, 8H), 3.63-3.74 (m, 3H), 4.35 (s, 2H), 6.65 (s, 1H),
8.35 (s, 1H), 8.96 (s, 1H). [M+H] calc'd for
C.sub.19H.sub.24N.sub.6O, 353; found, 353.
Example 62:
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-
-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00181##
[0665] A. tert-Butyl
(1S,2R)-2-(4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-2-(2,4-dimethoxybenzyl)-
-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylc-
arbamate
##STR00182##
[0667] A solution of tert-butyl
(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-
-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (35 mg, 0.064
mmol),
1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyr-
azole (18.67 mg, 0.076 mmol) and bis(triphenylphosphine)palladium
chloride (44.7 mg, 0.064 mmol) in dioxane (500 .mu.L) and saturated
aq Na.sub.2CO.sub.3 (500 .mu.L) was heated at 85.degree. C. for 2
h. After filtering out the solids, the solvent was removed and the
residue was dissolved in MeOH and DCM and purified by preparative
HPLC. The fractions were collected and ACN was removed via rotary
evaporation. The resulting aq solution was neutralized with
saturated aq NaHCO.sub.3, washed with EtOAc (2.times.200 mL), dried
over Na.sub.2SO.sub.4, and filtered. The organic phase was stripped
to dryness via rotary evaporation to yield the title compound (36
mg, 90%). [M+H] calc'd for C.sub.31H.sub.37F.sub.3N.sub.6O.sub.5,
631; found, 631.
B.
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(difluoromethyl)-1H-pyrazol-4-y-
l)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
[0668] A solution of tert-butyl
(1S,2R)-2-(4-(1-(difluoromethyl)-1H-pyrazol-4-yl)-2-(2,4-dimethoxybenzyl)-
-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylc-
arbamate (36 mg, 0.057 mmol) in TFA (2 mL) was heated at 60.degree.
C. for 2 h. After removal of the solvent, the residue was diluted
in MeOH (2 mL) and was purified by preparative HPLC. The fractions
were collected and stripped to dryness via rotary evaporation to
yield the title compound as a TFA salt (18.7 mg, 86%). .sup.1H NMR
(500 MHz, DMSO-d.sub.6) .delta. ppm 1.40-1.52 (m, 2H), 1.58-1.76
(m, 3H), 1.75-1.94 (m, 3H), 3.67 (br s, 1H), 4.44 (d, J=4.88 Hz,
2H), 4.53 (br s, 1H), 6.86 (d, J=6.83 Hz, 1H), 7.71 (br s, 2H),
7.79-8.12 (m, 1H), 8.53 (s, 2H), 9.41 (s, 1H). [M+H] calc'd for
C.sub.17H.sub.19F.sub.3N.sub.6O, 381; found, 381.
Example 63:
6-((1R,2S)-2-Aminocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-yl)-7-fl-
uoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00183##
[0670] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 62 using
1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
in place of
1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyr-
azole. .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 0.94-1.11
(m, 4H), 1.47 (d, J=6.35 Hz, 2H), 1.56-1.97 (m, 6H), 3.60-3.85 (m,
2H), 4.28-4.53 (m, 3H), 6.74 (d, J=6.35 Hz, 1H), 7.70 (br s, 2H),
8.25 (s, 1H), 8.38 (s, 1H), 8.94 (s, 1H). [M+H] calc'd for
C.sub.19H.sub.23FN.sub.6O, 371; found, 371.
Example 64:
cis-6-(2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-p-
yrrolo[3,4-c]pyridin-3(2H)-one
##STR00184##
[0671] A. cis-tert-Butyl
2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
##STR00185##
[0673] A mixture of
4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(-
2H)-one (316 mg, 0.851 mmol) and cis-tert-butyl
2-aminocyclohexylcarbamate (365 mg, 1.703 mmol) and DIPEA (0.743
mL, 4.26 mmol) in ACN (2 mL) was stirred at 85.degree. C. for 3 d.
The resulting crude material was reconstituted in MeOH (1 mL) and
purified by preparative HPLC. The fractions were collected and
stripped to dryness via rotary evaporation to yield the title
compound (161 mg, 34%). .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta.
ppm 1.35 (br s, 10H), 1.58 (br s, 2H), 1.76 (br s, 2H), 3.71-3.90
(m, 11H), 4.33 (br s, 2H), 4.51 (br s, 2H), 6.43-6.72 (m, 3H), 6.87
(br s, 1H), 7.07 (br s, 1H). [M+H] calc'd for
C.sub.27H.sub.34ClFN.sub.4O.sub.5, 549; found, 549.
B. cis-tert-Butyl
2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,-
3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
##STR00186##
[0675] A solution of cis-tert-butyl
2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (135.8 mg, 0.247
mmol),
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(154 mg, 0.742 mmol) and bis(triphenylphosphine)palladium chloride
(174 mg, 0.247 mmol) in dioxane (2 mL) and saturated aq
Na.sub.2CO.sub.3 (2 mL) was heated at 120.degree. C. for 30 min.
After filtering out the solids, the solvent was removed and the
residue was dissolved in MeOH and DCM and the mixture was purified
by preparative HPLC. The fractions were collected and the solvent
was stripped to dryness via rotary evaporation to give the title
compound (109 mg, 74%). .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta.
ppm 0.97-1.98 (m, 10H), 2.28-2.44 (m, 3H), 2.56-2.72 (m, 4H),
3.63-3.99 (m, 11H), 4.36 (d, J=18.06 Hz, 2H), 4.56 (br s, 2H), 6.50
(br s, 1H), 6.61 (br s, 1H), 6.65-6.81 (m, 1H), 7.08 (br s, 1H),
7.70 (br s, 1H), 8.30 (br s, 1H), 8.75-9.02 (m, 1H). [M+H] calc'd
for C.sub.31H.sub.39FN.sub.6O.sub.5, 595; found, 595.
C.
cis-6-(2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-
-pyrrolo[3,4-c]pyridin-3(2H)-one
[0676] A solution of cis-tert-butyl
2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,-
3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
(109 mg, 0.183 mmol) in TFA (5 mL) was heated at 60.degree. C. for
2 h. After removal of the solvent, the residue was diluted in MeOH
(2 mL) and was purified by preparative HPLC. The fractions were
collected and stripped to dryness via rotary evaporation to give
the title compound as a TFA salt. .sup.1H NMR (500 MHz, DMSO-d)
.delta. ppm 1.47 (br s, 2H), 1.57-1.75 (m, 3H), 1.84 (br s, 2H),
3.12-3.23 (m, 2H), 3.87-3.94 (m, 3H), 4.35-4.50 (m, 3H), 6.73 (br
s, 1H), 7.71 (br s, 2H), 8.28-8.44 (m, 2H), 8.84 (d, J=3.91 Hz,
1H). [M+H] calc'd for C.sub.17H.sub.21FN.sub.6O, 345; found,
345.
Example 65:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(1-methyl-1H--
pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00187##
[0678] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 64 using (3R,4R)-tetrahydro-2H-pyran-3,4-diamine
dihydrochloride in place of cis-tert-butyl
2-aminocyclohexylcarbamate. The desired stereoisomer was isolated
using preparative HPLC. .sup.1H NMR (500 MHz, CD.sub.3OD) .delta.
ppm 1.29 (br s, 2H), 1.86-1.99 (m, 1H), 3.84-3.99 (m, 4H),
4.03-4.17 (m, 1H), 4.45 (br s, 2H), 8.29 (br s, 1H), 8.79 (br s,
1H). [M+H] calc'd for C.sub.16H.sub.19FN.sub.6O.sub.2O, 347; found,
347.
Preparation 25: cis-4,4-Difluorocyclopentane-1,2-diamine
##STR00188##
[0679] A. Cyclopenta-1,3-diene
##STR00189##
[0681] A flask containing dicyclopentadiene was flushed with
N.sub.2 for 1 min and was then heated by oil bath to approximately
180.degree. C. Cyclopentadiene distilled slowly at 40-45.degree. C.
The title compound (100 g) was collected and kept at -70.degree. C.
under N.sub.2. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 3.02
(t, J=1.4 Hz, 2H), 6.49-6.51 (m, 2H), 6.61-6.62 (m, 2H).
B. Cyclopent-3-enol
##STR00190##
[0683] To cooled alpha-pinene (225.0 g, 1.65 mol) at 0.degree. C.
was added dropwise BH.sub.3-THF (1 M, 750 mL) over a 30 min period
under N.sub.2 atmosphere. The reaction mixture was stirred for 3.5
h at 0.degree. C. Distilled cyclopenta-1,3-diene (99.0 g, 1.50 mol)
was added dropwise at 0.degree. C. over a 40 min period. The
resulting mixture was slowly warmed to RT and stirred for 20 h.
Excess hydride was decomposed by adding water (30 mL) at a
temperature below 10.degree. C. Aqueous NaOH (3N, 300 mL) was added
at a temperature below 5.degree. C., followed by H.sub.2O.sub.2
(30%, 250 mL). The aqueous layer was salted out with NaCl, and the
organic layer was separated and dried over Na.sub.2SO.sub.4. The
product was distilled at 65.degree. C. under a reduced pressure of
20 mm Hg to give the title compound as an oil (30.4 g, 24%). H NMR
(400 MHz, CDCl.sub.3) .delta. ppm 2.29 (d, J=17.6 Hz, 2H), 2.61
(dd, J=6.0, 16.4 Hz, 2H), 4.82 (s, 1H), 5.68 (s, 2H).
C. ((Cyclopent-3-enyloxy)methyl)benzene
##STR00191##
[0685] To a cooled solution of cyclopent-3-enol (30.40 g, 0.36 mol)
in THF (300 mL) at 0.degree. C. was added NaH (18.82 g, 0.47 mol,
60% in mineral oil). After effervescence had ceased, benzyl bromide
(80.45 g, 0.47 mol) was added dropwise at 0.degree. C. over a 45
min period. The reaction mixture was allowed to warm to RT over a 6
h period. Excess NaH was quenched with MeOH (120 mL) at a
temperature below 5.degree. C. The mixture was warmed to RT,
diluted with H.sub.2O, and the two layers were separated. The
aqueous layer was extracted with EtOAc. The organic layers were
combined, concentrated, and purified by column chromatography
eluting with petroleum ether and EtOAc (PE/EA=40/1 to 30/1) to give
the title compound as an oil (45.28 g, 72%). .sup.1H NMR (400 MHz,
CDCl.sub.3) .delta. ppm 2.38-2.41 (m, 2H), 2.49-2.54 (m, 2H),
4.20-4.24 (m, 1H), 4.42 (s, 2H), 5.62 (s, 2H), 7.17-7.28 (m,
5H).
D. (1R,3s,5S)-3-(Benzyloxy)-6-oxabicyclo[3.1.0]hexane and
(1R,3r,5S)-3-(Benzyloxy)-6-oxabicyclo[3.1.0]hexane
##STR00192##
[0687] To a cooled solution of ((cyclopent-3-enyloxy)methyl)benzene
(45.28 g, 260 mmol) in DCM (300 mL) at 0.degree. C. was added
m-chloroperoxybenzoic acid (111.9 g, 520 mmol) in one portion. The
mixture was stirred at a temperature from 0.degree. C. to RT
overnight. The reaction mixture was filtered and excess
m-chloroperoxybenzoic acid was reduced by the addition of saturated
aq Na.sub.2S.sub.2O.sub.3 until a negative starch iodide test was
observed. The mixture was neutralized with saturated NaHCO.sub.3 to
pH 8-9 and filtered. The filtrate was separated with DCM, washed
with brine, dried over Na.sub.2SO.sub.4, and purified by column
chromatography eluting with petroleum ether and EtOAc
(PE/EtOAc=30/1, 20/1 to 10/1) to give the title compounds as oils
((1R,3s,5S): 14.41 g, 76 mmol; ((1R,3r,5S): 21.38 g, 113 mmol).
.sup.1H NMR of (1R,3s,5S) (400 MHz, CDCl.sub.3) .delta. ppm 1.69
(dd, J=6.8, 14.0 Hz, 2H), 2.49 (dd, J=7.2, 14.0 Hz, 2H), 3.49 (s,
2H), 3.85 (quintet J=7.0 Hz, 1H), 4.43 (s, 2H), 7.25-7.34 (m, 5H);
.sup.1H NMR of (1R,3r,5S) (400 MHz, CDCl.sub.3) .delta. ppm 1.99
(dd, J=7.6, 15.6 Hz, 2H), 2.23 (d, J=16.6 Hz, 2H), 3.55 (s, 2H),
4.08 (t, J=7.2 Hz, 1H), 4.49 (s, 2H), 7.27-7.35 (m, 5H).
E. (1S,2S,4R)-2-Azido-4-(benzyloxy)cyclopentanol
##STR00193##
[0689] To a solution of
(1R,3s,5S)-3-(benzyloxy)-6-oxabicyclo[3.1.0]hexane (14.41 g, 76
mmol) in EtOH/H.sub.2O (550 mL/160 mL) was added NH.sub.4Cl (15.06
g, 284 mmol) and sodium azide (18.47 g, 284 mmol), The mixture was
refluxed overnight and then cooled to RT. After removing EtOH,
water was added and the residue was extracted with EtOAc. The
organic layer was washed with brine, dried over Na.sub.2SO.sub.4,
and purified by column chromatography eluting with petroleum ether
and EtOAc (PE/EtOAc=20/1, 10/1 to 6/1) to give the title compound
as an oil (18.24 g, 78.3 mmol). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.65-1.79 (m, 2H), 2.01-2.07 (m, 1H), 2.30-2.37 (m,
1H), 3.49-3.54 (m 1H), 3.97-4.06 (m, 2H), 4.11-4.13 (br, 1H),
4.33-4.40 (m, 2H), 7.18-7.27 (m, 5H).
F. (1R,2R,4R)-2-Azido-4-(benzyloxy)cyclopentyl Methanesulfonate
##STR00194##
[0691] To a cooled mixture of Et.sub.3N (9.49 g, 94.0 mmol) and
(1S,2S,4R)-2-azido-4-(benzyloxy)cyclopentanol (18.25 g, 78.3 mmol)
in DCM (500 mL) was added dropwise methanesulfonyl chloride (9.87
g, 86.2 mmol) in DCM (50 mL) at 0.degree. C. The mixture was
stirred overnight at a temperature of 0.degree. C. to RT. After
complete conversion, aq NaHCO.sub.3 (5%, 300 mL) was added. The
mixture was extracted with DCM, washed with brine, and dried over
Na.sub.2SO.sub.4 to give the title compound as an oil (23.58 g,
75.8 mmol). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.83-1.89
(m, 1H), 2.06-2.13 (m, 1H), 2.34-2.49 (m, 2H), 3.04 (s, 3H),
3.94-3.99 (m, 1H), 4.08-4.13 (m, 1H), 4.64 (s, 2H), 4.93-4.98 (q,
J=5.6/7.0 Hz, 1H), 7.25-7.36 (m, 5H).
G. (((1s,3R,4S)-3,4-Diazidocyclopentyloxy)methyl)benzene
##STR00195##
[0693] To a mixture of (1R,2R,4R)-2-azido-4-(benzyloxy)cyclopentyl
methanesulfonate (23.58 g 75.8 mmol), pyridine (25 mL), water (140
mL), and DMA (350 mL) was added NaN.sub.3 (10.84 g, 166.8 mmol).
The mixture was heated at 130.degree. C. under N.sub.2 atmosphere
overnight. The reaction mixture was cooled to RT and quenched with
cold water (300 mL). The mixture was extracted with EtOAc, washed
with H.sub.2O (several times) and with brine, dried over
Na.sub.2SO.sub.4, and purified by column chromatography eluting
with petroleum ether and EtOAc (PE/EA=40/1 to 30/1) to give the
title compound as an oil (15.35 g, 59.5 mmol). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 1.99-2.08 (m, 2H), 2.23-2.30 (m, 2H),
3.75-3.80 (m, 2H), 3.99-4.04 (m, 1H), 4.49 (s, 2H), 7.26-7.35 (m,
5H).
H. Di-tert-butyl
N,N-((1R,2S,4s)-4-hydroxycyclopentane-1,2-diyl)-biscarbamate
##STR00196##
[0695] To a solution of
(((1s,3R,4S)-3,4-diazidocyclopentyloxy)methyl)benzene (15.35 g,
59.5 mmol) and di-tert-butyl pyrocarbonate (31.69 g, 145.4 mmol) in
MeOH (200 mL) was added Pd/C (50% wet, 8.0 g) in an autoclave. The
autoclave was charged with H.sub.2 to 2.2 MPa. The reaction mixture
was stirred at RT overnight. After conversion, the mixture was
filtered and solvent removed to give the title compound, which was
used without further purification (14.8 g, 46.8 mmol). .sup.1H NMR
(400 MHz, CDCl.sub.3) .delta. ppm 1.45 (s, 18H), 1.72-1.75 (m, 2H),
2.20 (m, 2H), 4.04 (br, 2H), 4.34-4.37 (m, 1H), 4.45 (br, 2H), 5.21
(br, 1H).
I. Di-tert-butyl
N,N-(cis-4-oxocyclopentane-1,2-diyl)-biscarbamate
##STR00197##
[0697] To a cooled solution of di-tert-butyl
N,N-((1R,2S,4s)-4-hydroxycyclopentane-1,2-diyl)-biscarbamate (5.35
g, 16.9 mmol) in DCM 90 (mL) at 0.degree. C. was added Dess-Martin
periodinane reagent (24.4 g, 57.6 mmol). The mixture was stirred
from 0.degree. C. to RT for 1.5 h. After the reaction was
completed, the mixture was filtered and the residue was purified by
column chromatography eluting with petroleum ether and EtOAc
(PE/EtOAc=6/1 to 2/1) to give the title compound as a solid (5.03
g, 15.9 mmol). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 1.38
(s, 18H), 2.30-2.50 (m, 4H), 4.29 (s, 2H).
J. Di-tert-butyl
N,N-(cis-4,4-difluorocyclopentane-1,2-diyl)-biscarbamate
##STR00198##
[0699] To a cooled solution of di-tert-butyl
N,N-(cis-4-oxocyclopentane-1,2-diyl)-biscarbamate (5.00 g, 15.9
mmol) in DCM (100 mL) was added dropwise a mixture of
diethylaminosulfur trifluoride (12.82 g, 79.6 mmol) in DCM (10 mL)
at 0.degree. C. The mixture was stirred at a temperature of from
0.degree. C. to RT overnight. The mixture was subsequently cooled
to 0.degree. C. and its pH adjusted to 9-10 with saturated aq
K.sub.2CO.sub.3, while maintaining the temperature of the mixture
below 5.degree. C. Di-tert-butyl pyrocarbonate (7.60 g, 2.2 eq) was
added and the mixture was stirred at a temperature of from
0.degree. C. to RT for 3 h. After removing DCM, the residue was
purified by column chromatography eluting with petroleum ether and
EtOAc (PE/EtOAc=20/1 to 15/1 to 12/1) to give the title compound as
a solid (2.40 g, 7.10 mmol). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 1.45 (br, 18H), 2.15-2.19 (m, 2H), 2.47-2.52 (m, 2H),
4.22 (br, 2H), 4.87 (br, 2H).
K. cis-4,4-Difluorocyclopentane-1,2-diamine
[0700] To a cooled solution of di-tert-butyl
N,N-(cis-4,4-difluorocyclopentane-1,2-diyl)-biscarbamate (2.40 g,
7.10 mmol) in EtOAc (30 mL) at 0.degree. C. was added 1N HCl-EtOAc
(10 mL) while maintaining the temperature of the mixture below
5.degree. C. The mixture was stirred at RT overnight. The mixture
was subsequently filtered, washed with EtOAc several times, and
dried in vacuo to give a hydrochloride salt of the title compound
as a solid (0.98 g, 4.7 mmol). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. ppm 2.63-2.67 (m, 2H), 2.76-2.86 (m, 2H), 4.15-4.17 (m,
2H). [M+H] calc'd for C.sub.5H.sub.10F.sub.2N.sub.2, 137; found
137.
Example 66:
6-(cis-2-Amino-4,4-difluorocyclopentylamino)-7-fluoro-4-(1-methyl-1H-pyra-
zol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00199##
[0702] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 64 using
cis-4,4-difluorocyclopentane-1,2-diamine in place of cis-tert-butyl
2-aminocyclohexylcarbamate. .sup.1H NMR (500 MHz, DMSO-d.sub.6)
.delta. ppm 2.62-2.69 (m, 2H), 2.87 (td, J=16.84, 8.79 Hz, 2H),
3.89 (s, 3H), 4.14 (br s, 1H), 4.32-4.48 (m, 2H), 4.79 (d, J=9.76
Hz, 1H), 7.28 (d, J=5.37 Hz, 1H), 7.93 (br s, 2H), 8.41 (d, J=7.32
Hz, 2H), 8.87 (s, 1H). [M+H] calc'd for
C.sub.16H.sub.17F.sub.3N.sub.6O, 367; found, 367.
Preparation 26: cis-3,3-Difluorocyclohexane-1,2-diamine
##STR00200##
[0703] A. tert-Butyl(cyclohex-2-enyloxy)dimethylsilane
##STR00201##
[0705] Pyridine (4.74 g, 60 mmol) and tert-butyldimethylsilyl
chloride (4.83 g, 32 mmol) were added to a solution of
cyclohex-2-enol (1.96 g, 20 mmol) in DCM (40 mL). The reaction
mixture was stirred at RT overnight. The mixture was concentrated
and the residue was dispersed in EtOAc and water. The organic phase
was separated and washed with brine, dried over anhydrous
Na.sub.2SO.sub.4, concentrated, and purified by silica flash
chromatography eluting with EtOAc and petroleum ether (5-10% EtOAc)
to give the title compound as an oil (4.1 g, 97%). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 0.06-0.09 (m, 6H), 0.92 (s, 9H),
1.50-1.57 (m, 2H), 1.74-1.89 (m, 2H), 1.93-2.03 (m, 2H), 4.21-4.23
(m, 1H), 5.61-5.64 (m, 1H), 5.72-5.76 (m, 1H).
B. (1S,2S,3S)-3-(tert-Butyldimethylsilyloxy)cyclohexane-1,2-diol
and
(1R,2R,3R)-3-(tert-butyldimethylsilyloxy)cyclohexane-1,2-diol
##STR00202##
[0707] tert-Butyl(cyclohex-2-enyloxy)dimethylsilane (12.72 g, 60
mmol) was dissolved in CH.sub.3CN (100 mL). A solution of
N-methylmorpholine-N-oxide (14 g, 120 mmol) in H.sub.2O (20 mL) and
OsO.sub.4 (0.5 g) in acetone (5 mL) was added, and the mixture was
stirred at RT overnight. The mixture was then diluted with EtOAc
(800 mL), washed with brine and saturated aq NaHCO.sub.3, dried
over anhydrous Na.sub.2SO.sub.4, concentrated, and purified by
silica flash chromatography eluting with EtOAC and petroleum ether
(20-40% EtOAc) to give the title compounds as an oil (12.8 g, 87%).
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 0.06-0.09 (m, 6H),
0.90 (s, 9H), 1.25-1.28 (m, 2H), 1.44-1.62 (m, 2H), 1.80-1.84 (m,
2H), 2.28 (s, 1H), 2.51 (s, 1H), 3.40-3.44 (m, 1H), 3.77-3.82 (m,
1H), 4.08-4.11 (m, 1H).
C. (1S,2R,3S)-3-(tert-Butyldimethylsilyloxy)cyclohexane-1,2-diyl
dimethanesulfinate and
(1R,2S,3R)-3-(tert-Butyldimethylsilyloxy)cyclohexane-1,2-diyl
dimethanesulfinate
##STR00203##
[0709]
(1S,2S,3S)/(1R,2R,3R)-3-(tert-Butyldimethylsilyloxy)cyclohexane-1,2-
-diol (1.9 g, 7.7 mmol) was dissolved in DCM (40 mL). The mixture
was placed in an ice bath. Pyridine (3.1 mL, 38.5 mmol) and
methanesulfonyl chloride (1.44 mL, 18.5 mmol) were added and the
reaction mixture was stirred at RT overnight. Next, the mixture was
diluted with DCM, washed with brine, dried over anhydrous
Na.sub.2SO.sub.4, concentrated, and purified by silica flash
chromatography eluting with EtOAC and petroleum ether (20-30%
EtOAc) to give the title compounds as an oil (2.6 g, 84%). .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. ppm 0.06-0.09 (m, 6H), 0.90 (s,
9H), 1.58-1.64 (m, 2H), 1.70-1.78 (m, 2H), 1.85-1.90 (m, 2H), 3.12
(s, 6H), 4.08-4.12 (m, 1H), 4.51-4.55 (m, 1H), 5.06-5.10 (m,
1H).
D. (1S,2R,6S)-2-Azido-6-(tert-butyldimethylsilyloxy)cyclohexyl
methanesulfonate and
(1R,2S,6R)-2-Azido-6-(tert-butyldimethylsilyloxy)cyclohexyl
methanesulfinate
##STR00204##
[0711]
(1S,2R,3S)/(1R,2S,3R)-3-(tert-Butyldimethylsilyloxy)cyclohexane-1,2-
-diyl dimethanesulfinate (12.0 g, 29.8 mmol) was dissolved in DMF
(80 mL) and hexamethylphosphoramide (20 mL). Sodium azide (10.0 g,
154 mmol) was added and the mixture was stirred at 75.degree. C.
overnight. The mixture was diluted with EtOAc, washed with water
and brine, dried over anhydrous Na.sub.2SO.sub.4, and concentrated.
The solid was washed petroleum ether and dried in vacuo to give the
title compounds (7 g, 68%). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 0.06-0.09 (m, 6H), 0.90 (s, 9H), 1.32-1.47 (m, 3H),
1.76-1.81 (m, 1H), 1.97-2.01 (m, 1H), 2.10-2.14 (m, 1H), 3.14 (s,
3H), 3.33-3.39 (m, 1H), 3.55-3.61 (m, 1H), 4.23-4.28 (m, 1H).
E. tert-Butyl((1S,2R,3R)-2,3-diazidocyclohexyloxy)dimethylsilane
and
tert-Butyl((1R,2S,3S)-2,3-diazidocyclohexyloxy)dimethylsilane
##STR00205##
[0713]
(1S,2R,6S)/(1R,2S,6R)-2-Azido-6-(tert-butyldimethylsilyloxy)cyclohe-
xyl methanesulfonate (7 g, 20 mmol) was dissolved in DMF (80 mL)
and hexamethylphosphoramide (20 mL). Sodium azide (15.0 g, 230
mmol) was added and the mixture was stirred at 120.degree. C. for
24 h. The mixture was diluted with EtOAc, washed with water and
brine, dried over anhydrous Na.sub.2SO.sub.4, concentrated, and
purified by silica flash chromatography eluting with EtOAc and
petroleum ether (3% EtOAc) to give the title compounds as an oil
(3.52 g, 60%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
0.06-0.09 (m, 6H), 0.90 (s, 9H), 1.66-1.70 (m, 2H), 1.72-1.76 (m,
2H), 1.80-1.85 (m, 2H), 3.16-3.21 (m, 1H), 3.71-3.76 (m, 1H),
3.80-3.85 (m, 1H).
F. (1S,2R,3R)-2,3-Diazidocyclohexanol and
(1R,2S,3S)-2,3-Diazidocyclohexanol
##STR00206##
[0715] Tetrabutylammonium fluoride (16.0 g, 61.3 mmol) dissolved in
THF was added to
tert-butyl((1S,2R,3R)/(1R,2S,3S)-2,3-diazidocyclohexyloxy)dimethylsilane
(12.0 g, 40.5 mmol) in THF (300 mL). The reaction mixture was
stirred at RT for 3 h and was then quenched with MeOH. The mixture
was concentrated and the residue was purified by column
chromatography (EtOAc/PE=4/1) to give the title compounds as an oil
(5 g, 68%).
G. (1S,2R,3R)-2,3-Diaminocyclohexanol and
(1R,2S,3S)-2,3-Diaminocyclohexanol
##STR00207##
[0717] A mixture of (1S,2R,3R)/(1R,2S,3S)-2,3-diazidocyclohexanol
(5.0 g, 27.5 mmol) and Pd/C (2.0 g) in MeOH was stirred at RT
overnight under H.sub.2 atmosphere. Following reaction, the mixture
was filtered and concentrated to give the title compounds as an
oil, which was used without further purification (3.18 g).
H. Dibenzyl
N,N-((1R,2R,3S)-3-hydroxycyclohexane-1,2-diyl)-biscarbamate and
Dibenzyl
N,N-((1S,2S,3R)-3-hydroxycyclohexane-1,2-diyl)-biscarbamate
##STR00208##
[0719] To a solution of
(1S,2R,3R)/(1R,2S,3S)-2,3-diaminocyclohexanol (3.1 g, 24.5 mmol)
and Et.sub.3N (7.4 g, 73.5 mmol) in DCM (50 mL) at -10.degree. C.
was added benzyl carbonochloridate (9.6 g, 56.3 mmol). The progress
of the reaction was monitored by TLC and LCMS. Following completion
of the reaction, the mixture was washed with water, dried over
Na.sub.2SO.sub.4, and concentrated. The residue was purified by
column chromatography (EtOAc/PE=2/1) to give the title compounds as
an oil (2.2 g, 22%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm
1.59-1.84 (m, 6H), 3.80 (br, 1H), 4.05-4.16 (m, 2H), 5.12 (s, 4H),
5.4 (s, 1H), 6.4 (s, 1H), 7.33-7.37 (m, 10H).
I. Dibenzyl N,N-(cis-3-oxocyclohexane-1,2-diyl)-biscarbamate
##STR00209##
[0721] To a solution of dibenzyl
N,N-((1R,2R,3S)/(1S,2S,3R)-3-hydroxycyclohexane-1,2-diyl)-biscarbamate
(2.2 g, 5.5 mmol) in DCM (30 mL) at -0.degree. C. was added
Dess-Martin periodinane reagent (5.9 g, 13.8 mmol). The suspension
was stirred at RT for 3 h. The mixture was concentrated and the
residue was purified by column chromatography (EtOAc/PE=2/1) to
give the title compound as a solid (2.0 g, 93%). .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. ppm 1.60-1.70 (m, 3H), 2.00-2.04 (m, 1H),
2.35-2.58 (m, 2H), 4.27-4.31 (m, 1H), 5.12 (s, 4H), 5.82-5.92 (m,
1H), 7.33-7.38 (m, 10H).
J. Dibenzyl
N,N-(cis-3,3-difluorocyclohexane-1,2-diyl)-biscarbamate
##STR00210##
[0723] To a solution of dibenzyl
N,N-(cis-3-oxocyclohexane-1,2-diyl)-biscarbamate (2.0 g, 5.1 mmol)
in DCM (30 mL) at -0.degree. C. was added diethylaminosulfur
trifluoride (4 mL, 1.22 g/cm.sup.3). The reaction mixture was
stirred at -0.degree. C. overnight. The reaction mixture was
neutralized with sodium bicarbonate, concentrated, and the residue
was purified by column chromatography (EtOAc/PE=2/1) to give the
title compound as a solid (1.0 g, 47%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 1.43-2.01 (m, 6H), 3.83-3.84 (m, 1H),
4.23-4.24 (m, 1H), 4.97 (s, 4H), 7.16-7.24 (m, 10H).
K. cis-3,3-Difluorocyclohexane-1,2-diamine
[0724] A mixture of dibenzyl
N,N-(cis-3,3-difluorocyclohexane-1,2-diyl)-biscarbamate (1.0 g, 2.4
mmol) and Pd/C (0.9 g) in MeOH was stirred at RT overnight under
H.sub.2 atmosphere. Following reaction, the mixture was filtered
and concentrated to an oil, which was reacted with EtOAc--HCl to
give a hydrochloride salt of the title compound as a white solid
(280 mg, 77%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm
1.84-2.31 (m, 6H), 4.01 (m, 1H), 4.20-4.26 (m, 1H). [M+H] calc'd
for C.sub.6H.sub.12F.sub.2N.sub.2, 151; found, 151.
Preparation 27:
6-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-chloro-2-(2,4-dimethoxybenz-
yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00211##
[0726] A mixture of
4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(-
2H)-one (100 mg, 0.269 mmol) and
cis-3,3-difluorocyclohexane-1,2-diamine hydrochloride (75 mg, 0.404
mmol) and DIPEA (118 .mu.L, 0.674 mmol) in acetonitrile (449 .mu.L)
was stirred at 100.degree. C. for 3 d. The reaction mixture was
concentrated to a brown oil and reconstituted in DMF (1 mL). The
residue was purified by preparative HPLC, the appropriate fraction
was collected, and excess acetonitrile was evaporated. The residue
was treated with saturated aq sodium carbonate and extracted with
EtOAc (3.times.20 mL). The organic layers were combined, dried over
sodium sulfate, and concentrated to give the title compound as a
colorless residue (13.7 mg, 10%). [M+H] calc'd for
C.sub.22H.sub.24ClF.sub.3N.sub.4O.sub.3, 485; found, 485.
Example 67:
6-(cis-2-Amino-3,3-difluorocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyraz-
ol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00212##
[0727] A.
6-(cis-2-Amino-3,3-difluorocyclohexylamino-2-(2,4-dimethoxybenzy-
l)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-on-
e
##STR00213##
[0729] A microwave vial was charged with
6-(cis-2-amino-3,3-difluorocyclohexylamino)-4-chloro-2-(2,4-dimethoxybenz-
yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one (13.7 mg, 0.028
mmol) and
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(8.82 mg, 0.042 mmol) and bis(triphenylphosphine)palladium chloride
(3.97 mg, 5.65 .mu.mol) and placed under an inert environment. DME
(283 .mu.L) was added to the mixture and the resulting yellow
slurry was degassed for 5 min. Sodium carbonate was added (56.5
.mu.L, 0.113 mmol) and the slurry degassed for an additional 3 min.
The vessel was capped and the mixture was heated at 80.degree. C.
for 4 h, cooled to ambient temperature, diluted with EtOAc (5 mL),
and washed with water (3 mL) and brine (3 mL). The organic layer
was collected, dried over sodium sulfate, and concentrated to give
the title compound as a dark brown residue which was used in the
next step without further purification (21 mg). [M+H] calc'd for
C.sub.26H.sub.29F.sub.3N.sub.6O3, 531; found, 531.
B.
6-(cis-2-Amino-3,3-difluorocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyr-
azol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
[0730] To a solution of
6-(cis-2-amino-3,3-difluorocyclohexylamino)-2-(2,4-dimethoxybenzyl)-7-flu-
oro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
(21 mg, 0.040 mmol) in DCM (300 .mu.L) was added TFA (500 .mu.L,
6.49 mmol). The reaction mixture was stirred at ambient temperature
for 12 h then an additional 3 h at 50.degree. C. The mixture was
subsequently concentrated to a dark oil and diluted with DMF (1 mL)
which was purified via preparative HPLC and lyophilized to give a
TFA salt of the title compound as a fluffy white solid (3.6 mg,
19%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 8.89 (s, 1H),
8.43 (s, 3H), 8.16 (s, 1H), 6.89 (br s, 1H), 6.54 (br s, 1H),
4.65-4.52 (m, 1H), 4.49-4.32 (m, 2H), 4.17 (br s, 1H), 3.89 (s,
3H), 2.37-2.03 (m, 2H), 1.84 (br s, 3H), 1.63 (br s, 1H). [M+H]
calc'd for C.sub.7H.sub.19F.sub.3N.sub.6O, 381; found, 381.
Example 68:
6-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-(1-(difluoromethyl)-1H-pyra-
zol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00214##
[0732] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 67 using
1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyr-
azole in place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.64 (br s, 1H),
1.83 (br s, 3H), 2.00-2.29 (m, 2H), 2.33 (t, J=1.77 Hz, 1H),
2.63-2.72 (m, 1H), 4.11 (br s, 1H), 4.40-4.50 (m, 2H), 4.62 (br s,
1H), 6.93 (d, J=5.31 Hz, 1H), 7.74-8.14 (m, 1H), 8.45 (s, 1H), 8.56
(s, 1H), 9.40 (s, 1H). [M+H] calc'd for
C.sub.7H.sub.7F.sub.5N.sub.6O, 417; found, 417.
Example 69:
6-(cis-2-amino-3,3-difluorocyclohexylamino)-4-(1-cyclopropyl-1H-pyrazol-4-
-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00215##
[0734] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 67 using
1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
in place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.63 (br s, 1H),
1.75-1.92 (m, 3H), 2.00-2.29 (m, 2H), 2.33 (dt, J=3.73, 1.80 Hz,
1H), 2.62-2.74 (m, 1H), 4.34-4.46 (m, 2H), 4.57 (br s, 1H), 4.81
(d, J=5.56 Hz, 2H), 5.08-5.30 (m, 2H), 5.93-6.10 (m, 1H), 6.83 (d,
J=6.06 Hz, 1H), 8.22 (s, 1H), 8.39 (s, 2H), 8.84-9.05 (m, 1H).
[M+H] calc'd for C.sub.19H.sub.21F.sub.3N.sub.6O, 407; found,
407.
Preparation 28:
(R)-2-(4-Chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyr-
rolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide
##STR00216##
[0736] A mixture of
4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(-
2H)-one (200 mg, 0.539 mmol), (R)-2-amino-4-methylpentanamide (140
mg, 1.078 mmol), and N-isopropyl-N-methylpropan-2-amine (310 mg,
2.69 mmol) in acetonitrile (2 mL) was stirred at 85.degree. C. for
3 d. The resulting crude material was reconstituted in MeOH/DCM/DMF
(10.0 mL) and purified via preparative HPLC. The fractions were
collected and stripped to dryness via rotary evaporation to yield
the title compound (83 mg, 33%). [M+H] calc'd for
C.sub.22H.sub.26ClFN.sub.4O.sub.4, 465; found, 465.
Example 70:
(R)-2-(7-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-ylamino)-4-methylpentanamide
##STR00217##
[0737] A.
(R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-
-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentana-
mide
##STR00218##
[0739] A solution of
(R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyr-
rolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide (83 mg, 0.179
mmol),
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(111 mg, 0.536 mmol), and bis(triphenylphosphine)palladium chloride
(12.53 mg, 0.018 mmol) in dioxane (2 mL) and saturated aq
Na.sub.2CO.sub.3 (2 mL) was heated at 120.degree. C. for 30 min.
After filtering off the solid, the solvent was removed, and the
residue was dissolved in MeOH and DCM and was purified by
preparative HPLC. The fractions were collected and the solvent was
stripped to dryness via rotary evaporation to yield the title
compound (40 mg, 44%). [M+H] calc'd for
C.sub.26H.sub.31FN.sub.6O.sub.4, 511; found, 511.
B.
(R)-2-(7-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrro-
lo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide
[0740] A solution of
(R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-ox-
o-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide
(39.8 mg, 0.078 mmol) in TFA (5 mL) was heated at 60.degree. C. for
2 h. After removal of solvent, the residue was diluted in MeOH (2
mL) and was purified by preparative HPLC. The fractions were
collected and the solvent stripped to dryness via rotary
evaporation to yield the title compound (12.8 mg, 46%). .sup.1H NMR
(500 MHz, DMSO-d.sub.6) .delta. ppm 0.82-1.00 (m, 6H), 1.45-1.60
(m, 1H), 1.67-1.83 (m, 2H), 3.87 (s, 3H), 4.36 (s, 2H), 4.50-4.64
(m, 1H), 6.88-7.02 (m, 2H), 7.44 (s, 1H), 8.28 (s, 2H), 8.83 (s,
1H). [M+H] calc'd for C.sub.17H.sub.21FN.sub.6O.sub.2, 361; found,
361.
Example 71:
(R)-2-(4-(1-(Difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro--
1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide
##STR00219##
[0742] The title compound was prepared in a manner similar to
EXAMPLE 70 using
1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)--
1H-pyrazole in place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.63 (br s, 1H),
1.75-1.92 (m, 3H), 2.00-2.29 (m, 2H), 2.33 (dt, J=3.73, 1.80 Hz,
1H), 2.62-2.74 (m, 1H), 4.34-4.46 (m, 2H), 4.57 (br s, 1H), 4.81
(d, J=5.56 Hz, 2H), 5.08-5.30 (m, 2H), 5.93-6.10 (m, 1H), 6.83 (d,
J=6.06 Hz, 1H), 8.22 (s, 1H), 8.39 (s, 2H), 8.84-9.05 (m, 1H).
[M+H] calc'd for C.sub.17H.sub.19F.sub.3N.sub.6O.sub.2, 397; found,
397.
Example 72:
(R)-2-(4-(1-Cyclopropyl-1H-pyrazol-4-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-py-
rrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide
##STR00220##
[0744] The title compound was prepared in a manner similar to
EXAMPLE 70 using
1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-py-
razole in place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 0.70-1.07 (m, 7H),
1.15-1.35 (m, 1H), 1.48-1.64 (m, 1H), 1.67-1.93 (m, 2H), 4.25-4.43
(m, 2H), 4.54 (d, J=9.60 Hz, 1H), 4.79 (d, J=5.81 Hz, 1H),
5.11-5.31 (m, 1H), 5.91-6.16 (m, 1H), 6.80-7.07 (m, 2H), 7.42 (br
s, 1H), 8.25 (s, 1H), 8.34-8.43 (m, 1H), 8.83-8.97 (m, 1H). [M+H]
calc'd for C.sub.19H.sub.23FN.sub.6O.sub.2, 387; found, 387.
Example 73:
(R)-2-(4-(Benzofuran-3-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]py-
ridin-6-ylamino)-4-methylpentanamide
##STR00221##
[0746] The title compound was prepared in a manner similar to
EXAMPLE 70 using
2-(benzofuran-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in
place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyra-
zole. .sup.1H NMR (400 MHz, DMSO-d) .delta. ppm 0.73-0.96 (m, 6H),
1.57-1.91 (m, 3H), 4.42 (s, 2H), 4.63-4.77 (m, 1H), 6.99-7.17 (m,
2H), 7.24-7.42 (m, 3H), 7.62 (d, J=7.83 Hz, 1H), 8.32-8.48 (m, 2H),
9.28 (s, 1H). [M+H] calc'd for C.sub.21H.sub.21FN.sub.4O.sub.3,
397; found, 397.
Example 74:
(R)-2-(7-Fluoro-3-oxo-4-(pyrazolo[1,5-a]pyridin-3-yl)-2,3-dihydro-1H-pyrr-
olo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide
##STR00222##
[0748] The title compound was prepared in a manner similar to
EXAMPLE 70 using
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazolo[1,5-a]pyrid-
ine in place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 0.77-0.99 (m, 6H),
1.57-1.70 (m, 1H), 1.71-1.90 (m, 2H), 4.33-4.45 (m, 2H), 4.56-4.68
(m, 1H), 6.93-7.12 (m, 3H), 7.27-7.42 (m, 2H), 8.27 (s, 1H), 8.47
(d, J=8.84 Hz, 1H), 8.72 (d, J=6.82 Hz, 1H), 9.30 (s, 1H). [M+H]
calc'd for C.sub.20H.sub.21FN.sub.6O.sub.2, 397; found, 397.
Preparation 29: tert-Butyl
(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate
##STR00223##
[0750] A vial was charged with tert-butyl
(1S,2R)-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6--
ylamino)cyclohexylcarbamate (63 mg, 0.140 mmol) and
N-chlorosuccinimide (18.63 mg, 0.140 mmol) in DCM (1.4 mL) to give
a yellow solution. The solution was stirred for 1 h at RT. The
crude reaction mixture was diluted with DCM (20 mL) and washed with
saturated aq NaHCO.sub.3 (2.times.10 mL) followed by water (10 mL)
and brine (10 mL). The organic layers were combined, dried over
sodium sulfate, and concentrated to a residue which was purified by
flash column chromatography. The collected fractions were
concentrated to a brown residue to give the title compound as a
cream colored solid upon drying (38.1 mg, 56%). [M+H] calc'd for
C.sub.25H.sub.32ClN.sub.5O.sub.3, 486; found, 486.
Example 75:
6-((1R,2S)-2-Aminocyclohexylamino)-7-chloro-4-(m-tolylamino)-1H-pyrrolo[3-
,4-c]pyridin-3(2H)-one
##STR00224##
[0752] To a solution of tert-butyl
(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate (20 mg, 0.041 mmol) in DCM
(0.8 mL) was added trifluoroacetic acid (0.31 mL). The reaction
mixture was stirred at RT for 1 h, then concentrated to a brown
residue which was diluted in MeOH (2 mL) and purified via
preparative HPLC to give a TFA salt of the title compound as a
fluffy white solid (12.3 mg, 61.9%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.85 (s, 1H), 8.36 (s, 1H), 7.83 (br s,
3H), 7.39-7.57 (m, 2H), 7.12-7.32 (m, 1H), 6.84 (d, J=7.6 Hz, 1H),
6.22 (d, J=6.8 Hz, 1H), 4.19-4.43 (m, 3H), 3.71 (br s, 1H), 2.32
(s, 3H), 1.37-1.99 (m, 8H). [M+H] calc'd for
C.sub.20H.sub.24ClN.sub.5O, 386; found, 386.
Preparation 30: tert-Butyl
(1S,2R)-2-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyr-
idin-6-ylamino)cyclohexylcarbamate
##STR00225##
[0754] To a screw-top vial was added tert-butyl
(1S,2R)-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6--
ylamino)cyclohexylcarbamate (73 mg, 0.162 mmol) and
1-iodopyrrolidine-2,5-dione (36.4 mg, 0.162 mmol) in DCM (1.6 mL)
to give a yellow solution. The reaction was stirred 0.5 h at RT.
The reaction mixture was diluted with DCM (10 mL) and washed with
saturated aq NaHCO.sub.3 (10 mL), water (10 mL), and brine (10 mL).
The collected organic layers were dried with sodium sulfate and
concentrated to give the title compound as a brown solid, which was
used without further purification (85.7 mg, 92%). [M+H] calc'd for
C.sub.25H.sub.32IN.sub.5O.sub.3, 578; found, 578.
Preparation 31: tert-Butyl
(1S,2R)-2-(7-cyano-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]py-
ridin-6-ylamino)cyclohexylcarbamate
##STR00226##
[0756] To an oven-dried microwave vial was added tert-butyl
(1S,2R)-2-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyr-
idin-6-ylamino)cyclohexylcarbamate (47.0 mg, 0.081 mmol),
dicyanozinc (5.74 mg, 0.049 mmol), zinc powder (0.532 mg, 8.14
.mu.mol), dppf (0.451 mg, 0.814 .mu.mol), and Pd.sub.2(dba).sub.3
(0.745 mg, 0.814 .mu.mol). N,N-Dimethylacetamide (814 .mu.L) was
added and the resulting dark brown solution was degassed with
nitrogen for 3 min. The vial was capped and heated at 80.degree. C.
with stirring for 1 h. The temperature was increased to 110.degree.
C., and the mixture was stirred for an additional 3 h, then cooled
to RT, diluted with EtOAc (10 mL), and washed with water
(2.times.10 mL) and brine (10 mL). The organic phase was dried with
sodium sulfate and concentrated to give the title compound as a
brown residue, which was used without further purification (40 mg,
103%). [M+H] calc'd for C.sub.26H.sub.32N.sub.6O.sub.3, 477; found,
477.
Example 76:
6-((1R,2S)-2-Aminocyclohexylamino)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H--
pyrrolo[3,4-c]pyridine-7-carbonitrile
##STR00227##
[0758] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 75 using tert-butyl
(1S,2R)-2-(7-cyano-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]py-
ridin-6-ylamino)cyclohexylcarbamate in place of tert-butyl
(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.22 (s, 1H), 8.48 (s, 1H), 7.80 (br s,
3H), 7.40-7.59 (m, 2H), 7.26 (t, J=7.7 Hz, 1H), 6.91 (dd, J=13.0,
6.9 Hz, 2H), 4.43 (s, 2H), 4.26-4.38 (m, 1H), 3.68 (br s, 1H), 2.33
(s, 3H), 1.78-1.96 (m, 2H), 1.35-1.79 (m, 6H). [M+H] calc'd for
C.sub.21H.sub.24N.sub.6O, 377; found, 377.
Preparation 32: (R)-tert-Butyl
1-amino-3-methoxypropan-2-ylcarbamate
##STR00228##
[0759] A. (S)-2-(tert-Butoxycarbonylamino)-3-methoxypropanoic
Acid
##STR00229##
[0761] A sodium methanolate (NaOMe) solution was prepared by slowly
adding MeOH (50 mL) to a suspension of sodium hydride (60% in
mineral oil, 28 g, 0.71 mol) in dry THF (1.2 L) at 0.degree. C. The
resulting mixture was stirred at RT for 2 h. A portion of the NaOMe
solution (320 mL) was added to
(S)-2-(tert-butoxycarbonylamino)-3-hydroxypropanoic acid (36 g, 175
mmol) in dry THF (1.6 L), and the mixture was stirred at RT for 1
h. Methyl iodine (16 mL) was then added and the mixture was stirred
at RT for 1 h. Another aliquot of NaOMe solution (540 mL) was added
and the reaction mixture stirred at RT for 1 h. Additional methyl
iodine (38 mL) in THF (200 mL) was added and the reaction mixture
was stirred at RT for 36 h. Following reaction, the mixture was
concentrated and the residue was dissolved in water and washed with
diethyl ether (2.times.100 mL). The aqueous layer was acidified to
pH 2 by the addition of solid citric acid and was extracted with
EtOAc (3.times.200 mL) and dried over Na.sub.2SO.sub.4. The organic
phase was concentrated, and the residue was dissolved in water and
extracted with DCM (4.times.150 mL). The organic layers were
combined and concentrated to give the title compound as an oil,
which was used without further purification (10.9 g, 28%).
B. (R)-tert-Butyl 1-hydroxy-3-methoxypropan-2-ylcarbamate
##STR00230##
[0763] To a mixture of
(S)-2-(tert-butoxycarbonylamino)-3-methoxypropanoic acid (10.9 g)
and N-methylmorpholine (5.6 g, 55 mmol) in THF (50 mL) was added
2-methylpropylchloroformate (7.48 g, 55 mmol) in THF at -15.degree.
C. The reaction mixture was stirred -15.degree. C. for 15 min,
after which NaBH.sub.4 (6.0 g, 159 mmol) in water (10 mL) was
added. The reaction mixture was stirred for 30 min, then diluted
with EtOAc, and neutralized with dilute HCl. The organic layer was
dried over Na.sub.2SO.sub.4 and concentrated. The residue was
purified by column chromatography on silica gel eluting with EtOAc
and petroleum ether (EtOAc/PE=1.5/1) to give the title compound
(6.0 g, 58%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. ppm 5.23
(s, 1H), 3.80 (d, J=8.0 Hz, 2H), 3.72-3.68 (m, 1H), 3.60-3.52 (m,
2H), 3.38 (s, 3H), 2.85 (s, 1H), 1.47 (s, 9H).
C. (R)-tert-Butyl 1-azido-3-methoxypropan-2-ylcarbamate
##STR00231##
[0765] Methanesulfonyl chloride (4.0 g, 35 mmol) in DCM (50 mL) was
slowly added to a solution of (R)-tert-butyl
1-hydroxy-3-methoxypropan-2-ylcarbamate (6.0 g, 29 mmol) and
Et.sub.3N (3.64 g, 36 mmol) in DCM (150 mL) at 0.degree. C. The
reaction mixture was stirred at RT for 2 h. The organic phase was
washed with water and saturated aq NaHCO.sub.3, concentrated, and
dissolved in DMF. Sodium azide (2.34 g, 36.0 mmol) was added, and
the reaction mixture was stirred at 75.degree. C. for 4 h. The
reaction mixture was diluted by EtOAc and washed with water. The
crude product was purified by column chromatography on silica gel
eluting with EtOAc and petroleum ether (EtOAc/PE=2/1) to give the
title compound (4.3 g, 64%). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. ppm 4.92 (s, 1H), 3.91 (m, 1H), 3.53-3.48 (m, 2H),
3.45-3.40 (m, 2H), 3.38 (s, 3H), 1.47 (s, 9H).
D. (R)-tert-Butyl 1-amino-3-methoxypropan-2-ylcarbamate
[0766] A mixture of (R)-tert-butyl
1-azido-3-methoxypropan-2-ylcarbamate (4.3 g, 18.7 mmol) and 10%
Pd/C (1.5 g) in MeOH was stirred at RT under H.sub.2 atmosphere
overnight. After filtration, the crude product was purified by
amino-protected silica gel chromatography eluting with EtOAc and
petroleum ether (EtOAc/PE=1/1) to give the title compound (740 mg,
19.4%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. ppm 5.00 (s, 1H),
3.67-3.66 (m, 1H), 3.51-3.47 (m, 1H), 3.42-3.38 (m, 1H), 3.35 (s,
1H), 2.82-2.78 (m, 2H), 1.46 (s, 9H). [M+H] calc'd for
C.sub.9H.sub.2ON.sub.2O.sub.3, 205; found, 205.
Preparation 33: (R)-Methyl
6-(2-(tert-butoxycarbonylamino)-3-methoxypropylamino)-4-cyano-2-(m-tolyla-
mino)nicotinate
##STR00232##
[0768] To a screw-top vial was added methyl
6-chloro-4-cyano-2-(m-tolylamino)nicotinate (0.28 g, 0.928 mmol),
(R)-tert-Butyl 1-amino-3-methoxypropan-2-ylcarbamate (0.227 g,
1.114 mmol), and DIPEA (0.211 mL, 1.206 mmol) in DMF (3 mL). The
resulting yellow solution was stirred at RT for 12 h, diluted with
EtOAc (30 mL) and washed with water (2.times.20 mL) and brine (20
mL). The organic phase was dried with Na.sub.2SO.sub.4 and
concentrated to give the title compound as thick yellow oil, which
was used without further purification (470 mg). [M+H] calc'd for
C.sub.24H.sub.31N.sub.5O.sub.5, 470; found, 470.
Preparation 34: (R)-tert-Butyl
1-methoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin--
6-ylamino)propan-2-ylcarbamate
##STR00233##
[0770] To a round-bottomed flask was added (R)-methyl
6-(2-(tert-butoxycarbonylamino)-3-methoxypropylamino)-4-cyano-2-(m-tolyla-
mino)nicotinate (84.5 mg, 0.180 mmol) in acetic acid (3 mL) and DCM
(10 mL). To the resulting yellow solution was added platinum(IV)
oxide (4.09 mg, 0.018 mmol). The flask was evacuated and back
filled with hydrogen (3.times.1 atm). The reaction mixture was
stirred vigorously at RT for 16 h, subsequently diluted with DCM
(10 mL), and filtered through Celite. The filtrate was concentrated
to an oil, which was diluted with DCM (10 mL). Potassium carbonate
(24.87 mg, 0.180 mmol) was added and the reaction mixture was
stirred at RT for 12 h. The crude reaction was diluted with DCM (10
mL), filtered through Celite, and concentrated to give the title
compound as a thick yellow oil, which was used without further
purification (26.5 mg, 33.4%). [M+H] calc'd for
C.sub.23H.sub.31N.sub.5O.sub.4, 442; found, 442.
Example 77:
(R)-6-(2-Amino-3-methoxypropylamino)-4-(m-tolylamino)-1H-pyrrolo[3,4-c]py-
ridin-3(2H)-one
##STR00234##
[0772] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 75 using (R)-tert-butyl
1-methoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin--
6-ylamino)propan-2-ylcarbamate in place of tert-butyl
(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 7.57 (d, J=8.3 Hz, 1H), 7.36 (s, 1H), 7.22
(t, J=7.8 Hz, 1H), 6.87 (d, J=7.3 Hz, 1H), 6.07 (s, 1H), 4.30 (s,
2H), 3.70-3.82 (m, 2H), 3.50-3.65 (m, 3H), 3.40 (s, 3H), 2.35 (s,
3H). [M+H] calc'd for C.sub.18H.sub.23N.sub.5O.sub.2, 342; found,
342.
Preparation 35: (R)-tert-Butyl
1-(7-cyano-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6--
ylamino)-3-methoxypropan-2-ylcarbamate
##STR00235##
[0773] A. (R)-tert-Butyl
1-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-y-
lamino)-3-methoxypropan-2-ylcarbamate
##STR00236##
[0775] The title compound was prepared in a manner similar to
PREPARATION 30 using (R)-tert-butyl
1-methoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin--
6-ylamino)propan-2-ylcarbamate in place of tert-butyl
(1S,2R)-2-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6--
ylamino)cyclohexylcarbamate. [M+H] calc'd for
C.sub.23H.sub.30IN.sub.5O.sub.4, 568; found, 568.
B. (R)-tert-Butyl
1-(7-cyano-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6--
ylamino)-3-methoxypropan-2-ylcarbamate
[0776] The title compound was prepared in a manner similar to
PREPARATION 31 using (R)-tert-butyl
1-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-y-
lamino)-3-methoxypropan-2-ylcarbamate in place of tert-butyl
(1S,2R)-2-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyr-
idin-6-ylamino)cyclohexylcarbamate. [M+H] calc'd for
C.sub.24H.sub.30N.sub.6O.sub.4, 467; found, 467.
Example 78:
(R)-6-(2-Amino-3-methoxypropylamino)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1-
H-pyrrolo[3,4-c]pyridine-7-carbonitrile
##STR00237##
[0778] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 75 using (R)-tert-butyl
1-(7-cyano-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6--
ylamino)-3-methoxypropan-2-ylcarbamate in place of tert-butyl
(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 9.25 (s, 1H), 8.47 (s, 1H), 7.93 (br s,
3H), 7.58 (d, J=7.8 Hz, 1H), 7.51 (t, J=5.4 Hz, 1H), 7.42 (s, 1H),
7.27 (t, J=7.8 Hz, 1H), 6.93 (d, J=7.3 Hz, 1H), 4.43 (s, 2H),
3.71-3.80 (m, 1H), 3.60-3.70 (m, 1H), 3.44-3.60 (m, 3H), 3.29 (s,
3H), 2.33 (s, 3H). [M+H] calc'd for C.sub.19H.sub.22N.sub.6O.sub.2,
367; found, 367.
Preparation 36: (R)-tert-Butyl
1-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-
-ylamino)-3-methoxypropan-2-ylcarbamate
##STR00238##
[0780] To a screw-top vial was added (R)-tert-butyl
1-methoxy-3-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin--
6-ylamino)propan-2-ylcarbamate (27 mg, 0.061 mmol) in a mixture of
DCM and MeOH (1/1, 1.2 mL). The resulting colorless solution was
cooled to 0.degree. C. SELECTFLUOR.RTM. (21.66 mg, 0.061 mmol) was
added and the reaction mixture was stirred at 0.degree. C. for 2 h.
Next, the reaction mixture was diluted with EtOAc (10 mL) and
washed with saturated aq sodium bicarbonate (5 mL), water (5 mL),
and brine (5 mL). The organic layer was collected, dried over
Na.sub.2SO.sub.4, and concentrated to give the title compound as a
brown residue, which was used without further purification (32 mg,
114%). [M+H] calc'd for C.sub.23H.sub.30FN.sub.5O.sub.4, 460;
found, 460.
Example 79:
(R)-6-(2-Amino-3-methoxypropylamino)-7-fluoro-4-(m-tolylamino)-1H-pyrrolo-
[3,4-c]pyridin-3(2H)-one
##STR00239##
[0782] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 75 using (R)-tert-butyl
1-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-
-ylamino)-3-methoxypropan-2-ylcarbamate in place of tert-butyl
(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.84 (s, 1H), 8.28 (s, 1H), 7.97 (br s,
3H), 7.47-7.62 (m, 1H), 7.40 (s, 1H), 7.11-7.29 (m, 2H), 6.80 (d,
J=7.6 Hz, 1H), 4.40 (s, 2H), 3.62-3.78 (m, 2H), 3.46-3.61 (m, 3H),
3.31 (s, 3H), 2.31 (s, 3H). [M+H] calc'd for
C.sub.18H.sub.22FN.sub.5O.sub.2, 360; found, 360.
Preparation 37: tert-Butyl
(1S,2R)-2-(7-(3-hydroxyprop-1-ynyl)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-
-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
##STR00240##
[0784] To an oven dried glass pressure vessel was added tert-butyl
(1S,2R)-2-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyr-
idin-6-ylamino)cyclohexylcarbamate (25 mg, 0.043 mmol), copper(I)
iodide (12.37 mg, 0.065 mmol), bis(triphenylphosphine)
palladium(II)chloride (9.12 mg, 0.013 mmol), butylated
hydroxytoluene (one granule), THF (866 .mu.L), and Et.sub.3N (121
.mu.L, 0.866 mmol). The mixture was degassed 3 min with nitrogen.
Propargyl alcohol (31 .mu.L, 0.520 mmol) was added and the vessel
was capped and heated at 80.degree. C. with stirring for 2 h and
then at RT for 12 h. The reaction mixture was diluted with EtOAc
(10 mL) and washed with water (5 mL) and brine (5 mL). The organic
layer was collected, dried with Na.sub.2SO.sub.4, and concentrated
to give the title compound as a brown residue, which was used
without further purification (22 mg, 101%). [M+H] calc'd for
C.sub.28H.sub.35N.sub.5O.sub.4, 506; found, 506.
Example 80:
7-Acryloyl-6-((1R,2S)-2-aminocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo-
[3,4-c]pyridin-3(2H)-one
##STR00241##
[0786] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 75 using tert-butyl
(1S,2R)-2-(7-(3-hydroxyprop-1-ynyl)-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-
-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate in place of
tert-butyl
(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 10.53 (d, J=7.8 Hz, 1H), 9.81 (s, 1H),
8.65 (s, 1H), 7.85 (br s, 3H), 7.60 (s, 1H), 7.51 (s, 1H), 7.27 (t,
J=7.8 Hz, 1H), 7.08 (dd, J=16.5, 10.5 Hz, 1H), 6.93 (d, J=7.6 Hz,
1H), 6.19 (dd, J=16.7, 2.0 Hz, 1H), 5.68-5.90 (m, 1H), 4.50-4.80
(m, 3H), 3.65 (br s, 1H), 2.34 (s, 3H), 1.78-2.01 (m, 2H), 1.75 (s,
3H), 1.43-1.58 (m, 3H). [M+H] calc'd for
C.sub.23H.sub.27N.sub.5O.sub.2, 406; found, 406.
Example 81:
6-((1R,2S)-2-Aminocyclohexylamino)-7-iodo-4-(m-tolylamino)-1H-pyrrolo[3,4-
-c]pyridin-3(2H)-one
##STR00242##
[0788] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 75 using tert-butyl
(1S,2R)-2-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyr-
idin-6-ylamino)cyclohexylcarbamate in place of tert-butyl
(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate. .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. ppm 7.48 (d, J=8.1 Hz, 1H), 7.39 (s, 1H), 7.23
(t, J=7.8 Hz, 1H), 6.90 (d, J=7.6 Hz, 1H), 4.47 (d, J=9.1 Hz, 1H),
4.18 (d, J=3.0 Hz, 2H), 3.80-3.87 (m, 1H), 2.36 (s, 3H), 1.87 (d,
J=5.6 Hz, 4H), 1.66 (br s, 4H). [M+H] calc'd for
C.sub.20H.sub.24IN.sub.5O, 478; found, 478.
Preparation 38: tert-Butyl
4-(6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-3-oxo-4-(m-tol-
ylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-7-yl)-1H-pyrazole-1-carboxyl-
ate
##STR00243##
[0790] To an oven dried vial was added tert-butyl
(1S,2R)-2-(7-iodo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyr-
idin-6-ylamino)cyclohexylcarbamate (40 mg, 0.069 mmol), tert-butyl
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate
(30.6 mg, 0.104 mmol), and sodium carbonate (0.104 mL, 0.208 mmol)
in DMF (1 mL). The resulting tan mixture was degassed 15 min.
Bis(triphenylphosphine) palladium(II)chloride (4.86 mg, 6.93
.mu.mol) was added and the mixture was degassed an additional 5
min. The vial was capped and was heated at 80.degree. C. for 12 h.
The reaction mixture was diluted with EtOAc (10 mL) and washed with
water (5 mL) and brine (5 mL). The organic layer was collected,
dried with Na.sub.2SO.sub.4 and concentrated to give a brown
residue, which was used without further purification (55 mg). LCMS
indicated the desired mass less one of the Boc protecting groups.
[M+H-Boc] calc'd for C.sub.33H.sub.43N.sub.7O.sub.5, 518; found,
518.
Example 82:
6-((1R,2S)-2-Aminocyclohexylamino)-7-(1H-pyrazol-4-yl)-4-(m-tolylamino)-1-
H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00244##
[0792] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 75 using tert-Butyl
4-(6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-3-oxo-4-(m-tol-
ylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-7-yl)-1H-pyrazole-1-carboxyl-
ate in place of tert-butyl
(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 13.13 (br s, 1H), 8.97 (s, 1H), 8.19 (s,
1H), 8.06 (br s, 1H), 7.75 (br s, 4H), 7.42-7.58 (m, 2H), 7.21 (t,
J=8.1 Hz, 1H), 6.81 (d, J=7.3 Hz, 1H), 5.55 (d, J=6.6 Hz, 1H), 4.25
(s, 3H), 3.77 (br s, 1H), 2.32 (s, 3H), 1.63-1.89 (m, 4H),
1.36-1.63 (m, 4H). [M+H] calc'd for C.sub.23H.sub.27N.sub.7O, 418;
found, 418.
Example 83:
6-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo[3-
,4-c]pyridin-3(2H)-one
##STR00245##
[0793] A. Methyl
6-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-cyano-2-(m-tolylamino)nicot-
inate
##STR00246##
[0795] To a screw-cap vial was added methyl
6-chloro-4-cyano-2-(m-tolylamino)nicotinate (200 mg, 0.663 mmol),
cis-3,3-difluorocyclohexane-1,2-diamine hydrochloride (148 mg,
0.795 mmol), and DIPEA (347 .mu.L, 1.989 mmol) in DMF (3.9 mL). The
resulting brownish-yellow mixture was stirred at RT for 2 h and
then at 60.degree. C. for 12 h. The reaction mixture was cooled to
RT, diluted with EtOAc (30 mL) and washed with water (2.times.10
mL) and brine (20 mL). The organic layer was collected, dried over
Na.sub.2SO.sub.4, and concentrated to give a thick brown oil, which
included the title compound and isomers (328 mg, 119%). The crude
product was used without further purification. [M+H] calc'd for
C.sub.21H.sub.23F.sub.2N.sub.5O.sub.2, 416; found, 416.
B.
6-(cis-2-Amino-3,3-difluorocyclohexylamino)-4-(m-tolylamino)-1H-pyrrolo-
[3,4-c]pyridin-3(2H)-one
[0796] A round-bottomed flask was charged with methyl
6-(cis-2-amino-3,3-difluorocyclohexylamino)-4-cyano-2-(m-tolylamino)nicot-
inate (275 mg, 0.662 mmol) in HOAc (2.6 mL) and DCM (10.6 mL). To
the resulting brown solution was added platinum(IV) oxide (15.03
mg, 0.066 mmol). The flask was evacuated and back filled with
hydrogen (3.times.1 atm). The reaction mixture was stirred
vigorously under H.sub.2 atmosphere (1 atm) at RT for 16 h and then
filtered through Celite. The filtrate was washed with DCM (20 mL)
and concentrated to a residue, which was diluted in MeOH (3 mL) and
purified via preparative HPLC to give a TFA salt of the title
compound as a light green solid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.97 (s, 1H), 8.48 (br s, 3H), 8.09 (s,
1H), 7.62 (d, J=8.8 Hz, 1H), 7.32 (s, 1H), 7.14 (t, J=7.8 Hz, 1H),
6.87 (br s, 1H), 6.79 (d, J=7.3 Hz, 1H), 6.15 (s, 1H), 4.45 (br s,
1H), 4.24 (d, 2H), 4.15 (br s, 1H), 2.29 (s, 3H), 2.01-2.25 (m,
2H), 1.74-1.89 (m, 3H), 1.60 (d, J=10 Hz, 1H). [M+H] calc'd for
C.sub.20H.sub.23F.sub.2N.sub.5O, 388; found, 388.
Preparation 39: tert-Butyl
(1S,2R)-2-(7-(1-methyl-1H-pyrazol-5-yl)-3-oxo-4-(m-tolylamino)-2,3-dihydr-
o-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
##STR00247##
[0798] The title compound was prepared in a manner similar to
PREPARATION 36 using
1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyra-
zole in place of tert-butyl
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate-
. [M+H] calc'd for C.sub.29H.sub.37N.sub.7O.sub.3, 532; found,
532.
Example 84:
6-((1R,2S)-2-Aminocyclohexylamino)-7-(1-methyl-1H-pyrazol-5-yl)-4-(m-toly-
lamino)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00248##
[0800] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 75 using tert-butyl
(1S,2R)-2-(7-(1-methyl-1H-pyrazol-5-yl)-3-oxo-4-(m-tolylamino)-2,3-dihydr-
o-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate in place
of tert-butyl
(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 2.33 (d, J=1.26 Hz, 3H), 3.64 (d, J=14.15
Hz, 3H), 3.89-4.00 (m, 1H), 4.02-4.21 (m, 1H), 5.23-5.58 (m, 1H),
6.29-6.47 (m, 1H), 6.85 (d, J=7.58 Hz, 1H), 7.23 (td, J=7.77, 4.93
Hz, 1H), 7.47-7.56 (m, 2H), 7.58 (dd, J=9.35, 1.77 Hz, 1H),
7.64-7.83 (m, 2H), 8.21 (d, J=2.27 Hz, 1H), 9.04 (s, 1H). [M+H]
calc'd for C.sub.24H.sub.29N.sub.7O, 432; found, 432.
Example 85:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(m-tolylamino)-1H-pyrr-
olo[3,4-c]pyridin-3(2H)-one
##STR00249##
[0801] A. Methyl
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-cyano-2-(m-tolylamino)-
nicotinate and Methyl
6-((3R,4R)-4-Aminotetrahydro-2H-pyran-3-ylamino)-4-cyano-2-(m-tolylamino)-
nicotinate
##STR00250##
[0803] To a screw-cap vial was added methyl
6-chloro-4-cyano-2-(m-tolylamino)nicotinate (500 mg, 1.657 mmol),
(3R,4R)-tetrahydro-2H-pyran-3,4-diamine hydrochloride (303.0 mg,
1.989 mmol), and DIPEA (868 .mu.L, 4.97 mmol) in DMF (9748 .mu.L).
The resulting yellow suspension, which became a solution upon
adding base, was stirred at 50.degree. C. for 12 h. The reaction
mixture was cooled to RT, diluted with EtOAc (30 mL), and washed
with water (20 mL) and brine (20 mL). The organic layer was
collected, dried with Na.sub.2SO.sub.4, and concentrated to give a
yellow oil, which included the title compounds (350 mg, 55.4%). The
crude product was used in the next step without further
purification. [M+H] calc'd for C.sub.20H.sub.23N.sub.5O.sub.3, 382;
found, 382.
B.
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(m-tolylamino)-1H-py-
rrolo[3,4-c]pyridin-3(2H)-one
[0804] To a 50 mL round-bottomed flask was added a mixture of
methyl
6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-4-cyano-2-(m-tolylamino)-
nicotinate and methyl
6-((3R,4R)-4-aminotetrahydro-2H-pyran-3-ylamino)-4-cyano-2-(m-tolylamino)-
nicotinate (100 mg, 0.262 mmol) and platinum(IV) oxide (11.91 mg,
0.052 mmol) in DCM (4195 .mu.L) and HOAc (1049 .mu.L). The vessel
was evacuated and back filled with hydrogen (1 atm) and the mixture
was stirred at RT for 12 h. The reaction mixture was diluted with
DCM (10 mL) and MeOH (20 mL), filtered through Celite, and
concentrated to a residue, which was diluted with DCM (50 mL).
Potassium carbonate (217 mg, 1.573 mmol) was added and the mixture
was stirred at RT for 12 h. The mixture was filtered through
Celite, concentrated to a residue, diluted with a mixture of DMF
and MeOH (1/1, 3 mL), and purified via preparative HPLC. The
appropriate isomer peak was collected and lyophilized to give a TFA
salt of the title compound as a light grey solid (20.3 mg, 21.9%).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 8.92 (s, 1H), 8.05
(s, 1H), 7.95 (br s, 3H), 7.50 (d, J=8.1 Hz, 1H), 7.43 (s, 1H),
7.21 (t, J=7.8 Hz, 1H), 7.09 (d, J=4.8 Hz, 1H), 6.80 (d, J=7.6 Hz,
1H), 6.11 (s, 1H), 4.20-4.32 (m, 3H), 3.91-4.06 (m, 2H), 3.76 (br
s, 1H), 3.53-3.72 (m, 2H), 2.31 (s, 3H), 1.99 (qd, J=12.6, 4.7 Hz,
1H), 1.70-1.80 (m, 1H). [M+H] calc'd for C.sub.19H.sub.23NSO.sub.2,
354; found, 354.
Example 86:
6-((3R,4R)-4-Aminotetrahydro-2H-pyran-3-ylamino)-4-(m-tolylamino)-1H-pyrr-
olo[3,4-c]pyridin-3(2H)-one
##STR00251##
[0806] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 85, collecting the fractions corresponding to
6-((3R,4R)-4-aminotetrahydro-2H-pyran-3-ylamino)-4-(m-tolylamino)-1H-pyrr-
olo[3,4-c]pyridin-3(2H)-one in place
6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-4-(m-tolylamino)-1H-pyrr-
olo[3,4-c]pyridin-3(2H)-one. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 8.91 (s, 1H), 7.94-8.15 (m, 4H), 7.52 (s, 1H), 7.43 (d,
J=8.3 Hz, 1H), 7.18 (t, J=7.8 Hz, 1H), 7.03 (d, J=8.3 Hz, 1H), 6.79
(d, J=7.6 Hz, 1H), 6.21 (s, 1H), 4.44 (br s, 1H), 4.20-4.30 (m,
2H), 3.84-3.95 (m, 2H), 3.67-3.81 (m, 1H), 3.62 (dd, J=11.6, 1.8
Hz, 1H), 3.50 (td, J=11.2, 2.4 Hz, 1H), 2.30 (s, 3H), 1.98-2.13 (m,
1H), 1.71-1.82 (m, 1H). [M+H] calc'd for C.sub.19H.sub.23NSO.sub.2,
354; found, 354.
Example 87: tert-Butyl
(1S,2R)-2-(3-oxo-7-phenyl-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate
##STR00252##
[0808] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 82 using phenylboronic acid in place of
tert-butyl
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole-1-carboxylate-
. .sup.1H NMR (400 MHz, DMSO-d) S ppm 9.03 (s, 1H), 8.15 (s, 1H),
7.72 (br s, 3H), 7.51 (d, J=4.5 Hz, 6H), 7.35-7.45 (m, 1H), 7.22
(dd, J=8.7, 7.5 Hz, 1H), 6.83 (d, J=7.6 Hz, 1H), 5.33 (d, J=6.8 Hz,
1H), 4.30 (br s, 1H), 4.17-4.27 (m, 1H), 4.04 (d, J=17.7 Hz, 1H),
3.76 (br s, 1H), 2.33 (s, 3H), 1.59-1.85 (m, 4H), 1.37-1.59 (m,
4H). [M+H] calc'd for C.sub.26H.sub.29NSO, 428; found, 428.
Preparation 40: tert-Butyl
(1S,2R)-2-(7-methyl-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate
##STR00253##
[0810] To an oven dry flask was added tert-butyl
(1S,2R)-2-(7-bromo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]py-
ridin-6-ylamino)cyclohexylcarbamate (40 mg, 0.075 mmol),
2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (20.99 .mu.L, 0.151
mmol), and potassium carbonate (31.3 mg, 0.226 mmol) in dioxane
(1959 .mu.L) and water (196 .mu.L). The resulting tan solution was
degassed with nitrogen for 5 min. Palladium chloride (dppf) (5.52
mg, 7.54 .mu.mol) was added and the mixture was degassed for an
additional 2 min. The vessel was capped and the reaction mixture
was heated at 100.degree. C. with stirring overnight. The reaction
mixture was cooled to RT, diluted with EtOAc (5 mL), and washed
with water (5 mL) and brine (5 mL). The organic layer was
collected, dried over Na.sub.2SO.sub.4 and concentrated to give the
title compound as a brown viscous oil, which was used without
purification (45 mg). [M+H] calc'd for C.sub.26H.sub.35NSO.sub.3,
466; found, 466.
Example 88:
6-((1R,2S)-2-Aminocyclohexylamino)-7-methyl-4-(m-tolylamino)-1H-pyrrolo[3-
,4-c]pyridin-3(2H)-one
##STR00254##
[0812] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 75 using tert-butyl
(1S,2R)-2-(7-methyl-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate in place of tert-butyl
(1S,2R)-2-(7-chloro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)cyclohexylcarbamate. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 8.79 (s, 1H), 8.10 (s, 1H), 7.73 (br s,
3H), 7.48 (d, J=2.0 Hz, 2H), 7.14-7.21 (m, 1H), 6.77 (d, J=7.6 Hz,
1H), 5.69 (d, J=6.6 Hz, 1H), 4.36 (br s, 1H), 4.18-4.29 (m, 2H),
3.72 (br s, 1H), 2.31 (s, 3H), 2.01 (s, 3H), 1.88 (d, J=9.1 Hz,
2H), 1.55-1.79 (m, 4H), 1.39-1.55 (m, 2H). [M+H] calc'd for
C.sub.21H.sub.27NSO, 366; found, 366.
Preparation 41: tert-Butyl
(3R,4R)-4-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate
##STR00255##
[0813] A. tert-Butyl
(3R,4R)-4-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6--
ylamino)tetrahydro-2H-pyran-3-ylcarbamate
##STR00256##
[0815] To a suspension of
6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-4-(m-tolylamino)-1H-pyrr-
olo[3,4-c]pyridin-3(2H)-one (13.0 mg, 0.037 mmol) in DCM (368
.mu.L) was added Et.sub.3N (6.05 .mu.L, 0.043 mmol) and
di-tert-butyl dicarbonate (Boc anhydride) (39.0 .mu.L, 0.039 mmol).
The suspension was sonicated for 5 min and then stirred at RT for
12 h. The solution was diluted with DCM (15 mL) and washed with
water (10 mL) and brine (10 mL). The organic layer was collected,
dried over Na.sub.2SO.sub.4 and concentrated to give the title
compound as a light yellow residue, which was used without further
purification (15.2 mg, 91%). [M+H] calc'd for
C.sub.24H.sub.31N.sub.5O.sub.4, 454; found, 454.
B. tert-Butyl
(3R,4R)-4-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate
[0816] To a screw-cap vial was added tert-butyl
(3R,4R)-4-(3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6--
ylamino)tetrahydro-2H-pyran-3-ylcarbamate (15.2 mg, 0.034 mmol) and
SELECTFLUOR.RTM. (11.87 mg, 0.034 mmol) in DCM (335 .mu.L) and MeOH
(335 .mu.L). The reaction mixture was stirred at RT for 2 h,
diluted with EtOAc (10 mL) and washed with saturated aq NaHCO.sub.3
(5 mL), water (5 mL), and brine (5 mL). The organic layer was
collected, concentrated to a residue, and purified via preparative
HPLC. The appropriate fractions were collected and concentrated to
yield a TFA salt of the title compound as a colorless residue (4.2
mg, 26.6%). [M+H] calc'd for C.sub.24H.sub.30FN.sub.5O.sub.4, 472;
found, 472.
Example 89:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(m-tolylamino-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00257##
[0818] A solution of tert-butyl
(3R,4R)-4-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate (4.5 mg, 9.54
.mu.mol) in 4 M HCl-dioxane (2 mL) was stirred for 0.5 h at RT. The
reaction mixture was concentrated to a residue, which was diluted
in DMF (1 mL) and purified via preparative HPLC. The appropriate
fractions were collected and lyophilized to give a TFA salt of the
title compound as a white solid (2.6 mg, 73%). .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 8.81 (s, 1H), 8.25 (s, 1H), 7.57 (s,
1H), 7.40 (d, J=8.1 Hz, 1H), 7.04-7.28 (m, 2H), 6.79 (d, J=7.3 Hz,
1H), 6.62-6.76 (m, 2H), 4.26-4.46 (m, 3H), 3.85-3.96 (m, 2H), 2.32
(s, 3H), 1.94-2.13 (m, 1H), 1.59-1.70 (m, 1H), 1.07-1.28 (m, 4H).
[M+H] calc'd for C.sub.19H.sub.22FN.sub.5O.sub.2, 372; found,
372.
Preparation 42: tert-Butyl
(1S,2R)-2-(7-bromo-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrr-
olo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
##STR00258##
[0820] To a round bottomed flask was added tert-butyl
(1S,2R)-2-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4--
c]pyridin-6-ylamino)cyclohexylcarbamate (124 mg, 0.291 mmol) in DCM
(30 mL). The resulting white suspension was heated with a heat gun
while stirring until all the starting material was dissolved. The
solution was cooled to 0.degree. C., and while stirring,
1-bromopyrrolidine-2,5-dione (51.7 mg, 0.291 mmol) was added. The
reaction mixture was allowed to warm to RT and was stirred for 30
min. The solution was diluted with DCM (20 mL) and was washed with
saturated aq NaHCO.sub.3 (20 mL), water (20 mL), and brine (20 mL).
The organic layer was collected and concentrated to an orange
solid, which was treated with Et.sub.2O (5 mL). Solids began to
precipitate after the solution was allowed to sit undisturbed for 5
min. The mixture was allowed to sit for 1 h and was then filtered
through paper. The solids were washed with Et.sub.2O (5 mL) and
collected to give the title compound as a tan solid (137.3 mg,
93%). [M+H] calc'd for C.sub.22H.sub.29BrN.sub.6O.sub.3, 505;
found, 505.
Preparation 43: tert-Butyl
(1S,2R)-2-(7-methyl-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyr-
rolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
##STR00259##
[0822] The title compound was prepared in a manner similar to
PREPARATION 40 using tert-butyl
(1S,2R)-2-(7-bromo-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrr-
olo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate in place of
tert-butyl
(1S,2R)-2-(7-bromo-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]py-
ridin-6-ylamino)cyclohexylcarbamate. [M+H] calc'd for
C.sub.23H.sub.32N.sub.6O.sub.3, 441; found, 441.
Example 90:
6-((1R,2S)-2-Aminocyclohexylamino)-7-methyl-4-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00260##
[0824] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 89 using tert-butyl
(1S,2R)-2-(7-methyl-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyr-
rolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate in place of
tert-butyl
(3R,4R)-4-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 8.87 (s, 1H), 8.30 (s, 1H),
8.17 (s, 1H), 7.71 (br s, 3H), 5.71 (d, J=6.3 Hz, 1H), 4.49 (d,
J=2.8 Hz, 1H), 4.24 (s, 2H), 3.91 (br s, 3H), 3.71 (br s, 1H), 2.08
(s, 3H), 1.77-1.93 (m, 3H), 1.69 (d, J=8.6 Hz, 3H), 1.40-1.53 (m,
2H). [M+H] calc'd for C.sub.18H.sub.24N.sub.6O, 341; found,
341.
Preparation 44: (R)-Methyl
6-(2-(tert-butoxycarbonylamino)-3-methoxypropylamino)-4-cyano-2-(1-methyl-
-1H-pyrazol-4-yl)nicotinate
##STR00261##
[0826] To a screw-top vial was added methyl
6-chloro-4-cyano-2-(1-methyl-1H-pyrazol-4-yl)nicotinate (115 mg,
0.416 mmol), (R)-tert-butyl 1-amino-3-methoxypropan-2-ylcarbamate
(93 mg, 0.457 mmol), and DIPEA (87 .mu.L, 0.499 mmol) in DMF (308
.mu.L). The resulting yellow solution was stirred for 12 h at
45.degree. C. and then at 50.degree. C. for 6 h. The reaction
mixture was diluted with EtOAc (20 mL) and was washed with water
(10 mL) and brine (20 mL). The organic layer was collected and
dried over Na.sub.2SO.sub.4 and was concentrated to a yellow oil.
The concentrate was purified via standard phase column
chromatography eluting with EtOAc and hexanes (50-100% EtOAc
gradient) to give the title compound as a light yellow residue
(36.5 mg, 20%). [M+H] calc'd for C.sub.21H.sub.28N.sub.6O.sub.5,
445; found, 445.
Preparation 45: (R)-tert-Butyl
1-methoxy-3-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,-
4-c]pyridin-6-ylamino)propan-2-ylcarbamate
##STR00262##
[0828] The title compound was prepared in a manner similar to
PREPARATION 34 using (R)-methyl
6-(2-(tert-butoxycarbonylamino)-3-methoxypropylamino)-4-cyano-2-(1-methyl-
-1H-pyrazol-4-yl)nicotinate in place of (R)-methyl
6-(2-(tert-butoxycarbonylamino)-3-methoxypropylamino)-4-cyano-2-(m-tolyla-
mino)nicotinate (84.5 mg, 0.180 mmol). [M+H] calc'd for
C.sub.20H.sub.2N.sub.6O.sub.4, 417; found, 417.
Example 91:
(R)-6-(2-Amino-3-methoxypropylamino)-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrr-
olo[3,4-c]pyridin-3(2H)-one
##STR00263##
[0830] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 89 using (R)-tert-butyl
1-methoxy-3-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,-
4-c]pyridin-6-ylamino)propan-2-ylcarbamate in place of tert-butyl
(3R,4R)-4-(7-fluoro-3-oxo-4-(m-tolylamino)-2,3-dihydro-1H-pyrrolo[3,4-c]p-
yridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 8.97 (s, 1H), 8.40 (s, 1H),
8.09 (s, 1H), 8.00 (br s, 3H), 7.17-7.26 (m, 1H), 6.42 (s, 1 H),
4.24 (s, 2H), 3.89 (s, 3H), 3.54-3.60 (m, 5H), 3.33 (s, 3H). [M+H]
calc'd for C.sub.15H.sub.2ON.sub.6O.sub.2, 317; found, 317.
Preparation 46:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-chloro-2-(2,4-dimethox-
ybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00264##
[0832] A mixture of
4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(-
2H)-one (2.5 g, 6.74 mmol), (3R,4R)-tetrahydro-2H-pyran-3,4-diamine
(0.711 g, 6.12 mmol), and DIPEA (5.35 mL, 30.6 mmol) in ACN (30 mL)
was stirred at 85.degree. C. for 3 d in a sealed tube. Additional
(3R,4R)-tetrahydro-2H-pyran-3,4-diamine (0.356 g, 3.06 mmol) and
DIPEA (2.14 mL, 12.2 mmol) were added and the mixture was heated at
100.degree. C. overnight. The mixture was concentrated and purified
via preparative HPLC. The fractions corresponding to the desired
regioisomer were collected to give the title compound (265 mg,
9.60%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.64-1.65
(m, 1H), 1.80-1.82 (s, 1H), 3.40 (td, J=11.47, 2.44 Hz, 1H), 3.53
(dd, J=11.23, 1.95 Hz, 1H), 3.67 (dd, J=11.47, 2.20 Hz, 1H),
3.71-3.73 (m, 1H), 3.75 (s, 3H), 3.77-3.79 (m, 1H), 3.81 (s, 3H),
4.09-4.11 (m, 1H), 4.33 (s, 2H), 4.50 (s, 2H), 6.48 (dd, J=8.30,
2.44 Hz, 1H), 6.58 (d, J=2.44, 1H), 6.90 (br s, 1H), 7.06 (d,
J=8.30 Hz, 1H). [M+H] calc'd for C.sub.21H.sub.24ClFN.sub.4O.sub.4,
451; found, 451.
Example 92:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(pyrazolo[1,5-
-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00265##
[0833] A.
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-2-(2,4-dimethox-
ybenzyl)-7-fluoro-4-(pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-
-3(2H)-one
##STR00266##
[0835] To a 5 mL microwave vial with a stir bar was added
bis(triphenylphosphine)palladium chloride (11.68 mg, 0.017 mmol),
6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-4-chloro-2-(2,4-dimethox-
ybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one (75 mg, 0.166
mmol), pyrazolo[1,5-a]pyridin-3-ylboronic acid (135 mg, 0.832 mmol)
in dioxane (2 mL), and saturated aq NaHCO.sub.3 (2 mL). The mixture
was heated in a Biotage Initiator microwave at 120.degree. C. for
30 min. The mixture was concentrated and purified via preparative
HPLC to give the title compound (89 mg, 100%). .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 1.82-1.84 (m, 1H), 2.10-2.12 (m,
1H), 3.68-3.72 (m, 3H), 3.75 (s, 3H), 3.82 (s, 3H), 3.92-3.95 (m,
1H), 4.01-4.02 (m, 1H), 4.39 (s, 2H), 4.55-4.58 (m, 1H), 4.59 (s,
2H), 6.50 (dd, J=8.30, 1.95 Hz, 1H), 6.60 (d, J=2.44, 1H),
7.04-7.08 (m, 2H), 7.16 (d, J=5.86 Hz, 1H), 7.48-7.51 (m, 1H), 7.93
(br s, 1H), 8.37 (d, J=9.27 Hz, 1H), 8.79 (d, J=6.83 Hz, 1H), 9.36
(s, 1H). [M+H] calc'd for C.sub.2H.sub.29FN.sub.6O.sub.4, 533;
found, 533.
B.
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(pyrazolo[1-
,5-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
[0836] To a 25 mL round bottom flask with a stir bar was added
6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-2-(2,4-dimethoxybenzyl)--
7-fluoro-4-(pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-on-
e (85 mg, 0.160 mmol) in TFA (5 mL). The mixture was heated at
60.degree. C. for 1.5 h and then cooled to RT. The mixture was
concentrated and purified via preparative HPLC to give a TFA salt
of the title compound as a white solid (27 mg, 44.2%). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 1.83-1.85 (m, 1H), 2.12-2.14
(m, 1H), 3.65-3.73 (m, 2H), 3.81-3.82 (m, 1H), 3.93-3.95 (m, 1H),
4.01-4.03 (m, 1H), 4.43 (s, 2H), 4.53-4.55 (m, 1H), 7.04 (t, J=6.83
Hz, 1H), 7.13 (d, J=4.88 Hz, 1H), 7.49 (t, J=8.05 Hz, 1H), 7.94 (br
s, 1H), 8.36-8.42 (m, 2H), 8.78 (d, J=6.83 Hz, 1H), 9.33 (s, 1H).
[M+H] calc'd for C.sub.19H.sub.19FN.sub.6O.sub.2, 383; found,
383.
Example 93:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-(difluoromethyl)-1H-
-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00267##
[0838] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 92 using
1-(difluoromethyl)-1H-pyrazol-4-ylboronic acid in place of
pyrazolo[1,5-a]pyridin-3-ylboronic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.75-1.77 (m, 1H), 2.09-2.12 (m, 1H),
3.60-3.63 (m, 1H), 3.76-3.77 (m, 1H), 3.88-3.98 (m, 3H), 4.44 (d,
J=6.35 Hz, 2H), 4.54-4.55 (m, 1H), 7.17 (d, J=5.86 Hz, 1H), 7.89
(br s, 1H), 8.54 (s, 1H), 8.58 (s, 1H), 9.43 (s, 1H). [M+H] calc'd
for C.sub.16H.sub.17F.sub.3N.sub.6O.sub.2, 383; found, 383.
Example 94:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(benzofuran-3-yl)-7-fl-
uoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00268##
[0840] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 92 using benzofuran-3-ylboronic acid in place of
pyrazolo[1,5-a]pyridin-3-ylboronic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.84-1.88 (m, 2H), 3.68-3.73 (m, 1H),
3.76-4.02 (m, 4H), 4.47 (s, 2H), 4.58-4.59 (m, 1H), 7.25 (d, J=6.35
Hz, 1H), 7.40-7.42 (m, 2H), 7.67-7.69 (m, 1H), 7.93 (br s, 1H),
8.33 (d, J=9.76 Hz, 1H), 8.56 (s, 1H), 9.38 (s, 1H). [M+H] calc'd
for C.sub.20H.sub.19FN.sub.4O.sub.3, 383; found, 383.
Example 95:
(S)-6-(3-Aminopyrrolidin-1-yl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-p-
yrrolo[3,4-c]pyridin-3(2H)-one
##STR00269##
[0841] A. (S)-tert-Butyl
1-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-yl) pyrrolidin-3-ylcarbamate
##STR00270##
[0843] A tube containing
4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(-
2H)-one (300 mg, 0.808 mmol) and (S)-tert-butyl
pyrrolidin-3-ylcarbamate (301 mg, 1.616 mmol) dissolved in ACN (4
mL) was sealed and heated at 100.degree. C. for 2 d. The reaction
mixture was concentrated and dissolved in EtOAc (20 mL) and washed
with saturated aq NaHCO.sub.3 (10 mL) and brine (10 mL). The
organic extracts were dried over Na.sub.2SO.sub.4 and evaporated to
give a crude product, which was purified via preparative HPLC. Pure
fractions were collected and evaporated to give the title compound
(235 mg, 55.8%). [M+H] calc'd for
C.sub.25H.sub.30ClFN.sub.4O.sub.5, 521; found, 521.
B.
(S)-6-(3-Aminopyrrolidin-1-yl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-
-pyrrolo[3,4-c]pyridin-3(2H)-one
[0844] To a 30 mL tube charged with (S)-tert-butyl
1-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-yl)pyrrolidin-3-ylcarbamate (225 mg, 0.43 mmol)
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(145 mg, 0.695 mmol), and PdCl.sub.2(PPh.sub.3) dispersed in
dioxane (5 mL) was added 2 N Na.sub.2CO.sub.3 (0.5 mL). The tube
was sealed and the reaction mixture was heated at 85.degree. C. for
4 h. The mixture was diluted with water (5 mL) and extracted into
EtOAc (2.times.30 mL). The organic layer was dried over
Na.sub.2SO.sub.4 and evaporated to afford a residue, which was
treated with TFA (1 mL) and heated at 85.degree. C. for 1 h to
remove the protecting groups. TFA was evaporated and the mixture
was dissolved in DMSO (8 mL) and purified via preparative HPLC.
Pure fractions were collected, evaporated to a minimal volume, and
lyophilized to give a TFA salt of the title compound as a pale
yellow solid (46 mg, 27.2%). .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 2.05-2.39 (m, 3H), 3.75-4.04 (m, 6H), 3.89 (s, 3H),
4.38 (s, 2H), 8.02 (br s, 2H), 8.26 (d, J=0.51 Hz, 1H), 8.39 (s,
1H), 8.85 (s, 1H);). [M+H] calc'd for C.sub.15H.sub.17FN.sub.6O,
317; found, 317.
Example 96:
(S)-6-(3-Aminopiperidin-1-yl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-py-
rrolo[3,4-c]pyridin-3(2H)-one
##STR00271##
[0846] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 95 using (S)-tert-butyl piperidin-3-ylcarbamate
in place of (S)-tert-butyl pyrrolidin-3-ylcarbamate. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 1.61 (m, 2H), 1.83 (d, J=8.34
Hz, 1H), 2.03 (br s, 1H), 2.53-2.55 (m, 2H), 3.16-3.35 (m, 3H),
3.90 (s, 3H), 3.92 (m, 1H), 4.33 (m, 1H), 4.39 (s, 2H), 8.04 (br s,
3H), 8.36 (s, 1H), 8.51 (s, 1H), 8.90 (s, 1H). [M+H] calc'd for
C.sub.16H.sub.19FN.sub.6O, 331; found, 331.
Example 97:
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-isopropyl-1H-pyrazol-4-y-
l)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00272##
[0848] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 62 using
1-isopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
in place of
1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyr-
azole. .sup.1H NMR (500 MHz, CDCl.sub.3) .delta. ppm 1.14-1.33 (m,
6H), 1.47-1.64 (m, 8H), 1.76 (br. s., 2H), 1.94-2.01 (m, 2H), 3.86
(br. s., 1H), 4.36 (s, 2H), 4.53 (d, J=6.83 Hz, 2H), 8.15 (s, 1H),
8.88 (s, 1H). [M+H] calc'd for C.sub.19H.sub.25FN.sub.6O, 373;
found, 373.
Preparation 47: tert-Butyl
4,6-dichloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
##STR00273##
[0849] A. 2,6-Dichloro-5-fluoronicotinamide
##STR00274##
[0851] A 12-L 3-neck round bottom flask equipped with overhead
stirrer, refluxing condenser, and N.sub.2 inlet/outlet was charged
with 2,6-dichloro-5-fluoronicotinonitrile (2.0 kg, 1.0 eq).
Concentrated sulfuric acid (4.93 L) was added and the mixture was
stirred at RT until most of the brown solids had dissolved. Next,
the reaction mixture was stirred at 65.degree. C. for 1 h. The
dark-brown solution was cooled to a temperature <10.degree. C.
using an ice bath. The reaction mixture was added to a 50-L round
bottom flask, which contained de-ionized water (24.7 L) that had
been cooled to a temperature <10.degree. C., using a peristaltic
pump. The reaction mixture was added to the water quench over a 2.3
h period, which kept the internal temperature of the mixture below
21.degree. C. The resulting slurry was filtered through a Buchner
funnel fitted with a Sharkskin filter paper. The 50-L RBF was
rinsed with water (3.times.4 L) and the rinses were used to wash
the filter cake. The filter cake was conditioned for 50 min,
transferred to a drying tray, and was dried under high vacuum at
40-50.degree. C. for 24 h and then at 20-25.degree. C. for 18 h to
give the title compound as a beige solid (896.4 g, 82%). .sup.1H
NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 7.94 (s, 1H), 8.10 (s, 1H),
8.24 (d, 1H). [M+H] calc'd for C.sub.6H.sub.3Cl.sub.2FN.sub.2O,
209; found, 209.
B.
4,6-Dichloro-7-fluoro-1-hydroxy-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00275##
[0853] A 22-L multi-neck RBF equipped with an overhead stirrer,
temperature probe, and N.sub.2 inlet/outlet was charged with LiHMDS
(10.65 L, 2.5 eq) by N.sub.2 pressure. The orange solution was
cooled to <0.degree. C. using an ice/brine bath. A separate 12-L
RBF was sequentially charged with 2,6-dichloro-5-fluoronicotinamide
(890 g, 1.0 eq), anhydrous THF (6.0 L), and anhydrous DMF (1.0 L,
3.0 eq). The resulting solution was added to the LiHMDS solution
via a peristaltic pump over a 1 h period, which kept the internal
temperature below 5.degree. C. The 12-L flask was rinsed with THF
(1.6 L), and the rinse was transferred to the reaction mixture. The
mixture was stirred at a temperature <5.degree. C. for 1 h, and
the reaction was added to a pre-cooled 2N HCl aq solution via a
peristaltic pump at a rate that kept the temperature of the mixture
below 22.degree. C. Following the quench, IPAc (14 L) was added and
the mixture was stirred for 10 min. The biphasic mixture was
separated and the organic layer was stored in a carboy at RT
overnight. The organic layer was subsequently washed with water
(8.9 L) and was concentrated under reduced pressure to a volume of
about 4.5 L. The distillation was continued the next day. Isopropyl
acetate (16 L) was added to the slurry and the distillation was
continued until about 4.5 L of material remained. The off-white
slurry was transferred into a 50-L multi-neck RBF to which was
charged heptanes (18 L) via a peristaltic pump over a 45 min
period. The resultant slurry was stirred at RT overnight and then
filtered through a Buchner funnel with a Sharkskin filter paper.
The filter cake was washed with heptanes (2.times.4.5 L) and then
dried under high vacuum at RT for 24 h to afford title compound
(913.0 g, 90%). .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. ppm
6.11 (dd, J=9.3 Hz, 1.5 Hz, 1H), 6.95 (d, J=9.3 Hz, 1H), 9.54 (s,
1H). [M+H] calc'd for C.sub.7H.sub.3Cl.sub.2FN.sub.2O.sub.2, 237;
found, 237.
C. 4,6-Dichloro-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00276##
[0855] A 22-L 3-neck RBF equipped with overhead stirrer, refluxing
condenser, and N.sub.2 inlet/outlet, and having all glass or
PTFE-coated parts, was sequentially charged with
4,6-dichloro-7-fluoro-1-hydroxy-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
(908 g), DCM (4.55 L), and TFA (3.46 L, 11.76 eq). Agitation was
started and Et.sub.3SiH (3.05 L, 4.97 eq) was added. The cloudy
mixture was heated to reflux, resulting in a clear solution that
was stirred at refluxing conditions for 24 h. The mixture was
cooled to RT and stirred overnight. The orange solution was cooled
to <10.degree. C. using an ice bath. Methyl tert-butyl ether
(14.0 L) was added via a peristaltic pump within a 1 h period. The
resultant slurry was stirred at <10.degree. C. for 1 h and then
filtered through a coarse fritted glass funnel. The filter cake was
washed with MTBE (2.times.4 L). The solid was dried under high
vacuum at RT for 19 h to afford the title compound (802 g, 94%).
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 4.55 (s, 2H), 9.15
(s, 1H). [M+H] calc'd for C.sub.7H.sub.3Cl.sub.2FN.sub.2O, 221;
found, 221.
D. tert-Butyl
4,6-dichloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
[0856] A 12 L 3-neck RBF was charged with
4,6-dichloro-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one (745.0 g,
1.0 eq), DCM (3.0 L), Et.sub.3N (940 mL, 2.0 eq), and DMAP (20.59
g, 0.05 eq). To a separate 2-L flask containing di-tert-butyl
dicarbonate (882.8 g, 1.2 eq) was added DCM (0.75 L), and the
resulting clear solution was added dropwise to the reaction mixture
over a 20 min period via a peristaltic pump. The 2-L flask was
rinsed with DCM (0.75 L) and the rinse was added to the reaction
mixture, which was stirred at RT for 28 min. Ethanol (7.5 L) was
added and the mixture was concentrated under reduced pressure to a
volume of about 4.5 L. A second volume of EtOH (7.5 L) was added to
the mixture and distillation was continued until about 4.5 L of the
material remained. The resultant slurry was stirred at
15-20.degree. C. for 10 min and was then filtered through a Buchner
funnel. The filter cake was washed with EtOH (3.times.1.5 L) and
dried under high vacuum at RT overnight to give the title compound
as a pink solid (873 g, 81% yield). .sup.1H (300 MHz, CDCl.sub.3)
.delta. ppm 1.61 (s, 9H), 4.82 (d, J=0.9 Hz, 2H), .sup.19F NMR (282
MHz, CDCl.sub.3) .delta. ppm -128.36. [M-H] calc'd for
C.sub.12H.sub.11C.sub.12FN.sub.2O.sub.3, 319; found, 319.
Example 98:
7-Fluoro-4,6-bis(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-
-one
##STR00277##
[0858] A mixture of tert-butyl
4,6-dichloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
(30.0 mg, 0.093 mmol),
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(19.4 mg, 0.093 mmol), tris(dibenzylideneacetone)dipalladium (3.42
mg, 0.003 mmol), tricyclohexylphosphine (3.90 mg, 0.001 mmol) and
potassium phosphate (35.7 mg, 0.168 mmol) in dioxane (1 mL) and
deionized water (0.3 mL) were heated at 120.degree. C. in a
microwave for 20 min. The mixture was concentrated and purified via
preparative HPLC to give a TFA salt of the title compound as a pale
yellow solid (4.1 mg, 14%). .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 3.92 (s, 3H), 3.96 (s, 3H), 4.53 (s, 2H), 8.17 (s, 1H),
8.49 (s, 1H), 8.50 (s, 1H), 8.81 (s, 1H), 8.92 (s, 1H). [M+H]
calc'd for C.sub.1H.sub.13FN.sub.6O, 313; found, 313.
Example 99:
6-((1R,2S)-2-Aminocyclohexylamino)-7-bromo-4-(1-methyl-1H-pyrazol-4-yl)-1-
H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00278##
[0860] A solution of tert-butyl
(1S,2R)-2-(7-bromo-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrr-
olo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (10 mg, 0.020 mmol)
in HCl-dioxane (999 .mu.L, 4.00 mmol) was stirred at RT for 2 h.
The mixture was concentrated to a residue, diluted with Et.sub.2O
(3 mL), and sonicated to yield a white precipitate, which was
filtered and dried overnight in a lyophilizer to give an HCl salt
of the title compound as a white solid (1.8 mg, 21%). [M+H] calc'd
for C.sub.17H.sub.21BrN.sub.6O, 406; found, 406.
Example 100:
2-((1R,2S)-2-Aminocyclohexylamino)-4-(1-(4-fluorophenyl)-1H-pyrazol-4-yl)-
-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-5-one
##STR00279##
[0862] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 14 using
1-(4-fluorophenyl)-1H-pyrazol-4-ylboronic acid in place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyra-
zole. .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 1.43 (br s,
2H), 1.55-1.98 (m, 6H), 4.10-4.35 (m, 2H), 4.34-4.70 (m, 1H), 7.43
(t, J=8.79 Hz, 2H), 7.65 (d, J=7.81 Hz, 1H), 7.68-7.83 (m, 3H),
7.87 (br s, 2H), 8.39 (s, 1H), 8.58-9.00 (m, 1H), 9.62-9.86 (m,
1H). [M+H] calc'd for C.sub.21H.sub.22FN.sub.7O, 408; found,
408.
Example 101:
(R)-6-(2-Amino-3-methoxypropylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00280##
[0864] To a 20 mL round-bottomed flask was added (R)-tert-butyl
1-methoxy-3-(4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,-
4-c]pyridin-6-ylamino)propan-2-ylcarbamate (19.7 mg, 0.047 mmol)
and SELECTFLUOR.RTM. (21.78 mg, 0.061 mmol) in DCM (473 .mu.L) and
MeOH (473 .mu.L). The resulting yellow solution was stirred at RT
for 3 h and concentrated to a residue, which was dissolved in 4 N
HCl-dioxane (2 mL) and stirred at RT for 2 h. The mixture was
concentrated, dissolved in DMF (1 mL) and purified via preparative
HPLC to give a TFA salt of the title compound. [M+H] calc'd for
C.sub.15H.sub.19FN.sub.6O.sub.2, 335; found, 335.
Preparation 48: cis-tert-butyl 2-aminocyclohexylcarbamate
##STR00281##
[0865] A. trans-tert-Butyl 2-hydroxycyclohexylcarbamate
##STR00282##
[0867] To a stirred slurry of trans-2-aminohexanol hydrochloride
(15.0 g, 98.92 mmol) in EtOAc (75 mL) was added a solution of NaOH
(9.1 g, 0.227 mol) in water (150 mL). A solution of di-tert-butyl
dicarbonate (25.9 g, 118.70 mmol) in EtOAc (75 mL) was added in one
portion and the mixture was heated to 45.degree. C. and stirred for
16 h. The phases were separated and the aqueous phase was extracted
with EtOAc (60 mL). The combined organic extracts were washed with
water (45 mL) and phase separated. The organic phase was distilled
at atmospheric pressure until approximately 75 mL of solution
remained. Heptane (90 mL) was added and the solution was distilled
until approximately 75 mL of solution remained. Heptane (150 mL)
was added and the mixture was heated to 98-100.degree. C. The heat
was switched off and the mixture was allowed to cool to RT. Seeds
of pure product were added at 70.degree. C. and crystallization
occurred at about 65.degree. C. Once the slurry reached RT, the
mixture was cooled to about 5.degree. C. and was stirred for 30
min. The solids were filtered, washed with heptane (2.times.45 mL),
and dried to give the title compound as a white crystalline solid
(19.6 g, 92%).
B. cis-tert-Butyl
2-(1,3-dioxoisoindolin-2-yl)cycohexylcarbamate
##STR00283##
[0869] To a stirred slurry of trans-tert-butyl
2-hydroxycyclohexylcarbamate (1.00 g, 4.64 mmol), PPh.sub.3 (1.34
g, 5.10 mmol) and phthalimide (1.50 g, 10.20 mmol) in a 2:1 mixture
of toluene and THF (15 mL) was added diisopropyl azodicarboxylate
(1.0 mL, 5.10 mmol) dropwise over a period of 1 h. Once the
addition was complete, the mixture was stirred at about 0.degree.
C. for 7 h and was then warmed slowly to 7.degree. C. over a period
of 14 h. The mixture was filtered, and the filtrate was
concentrated under reduced pressure to give the title compound as a
yellow oil (3.90 g). The crude product was used in the next step
without further purification.
C. cis-tert-Butyl 2-aminocyclohexylcarbamate
[0870] Crude cis-tert-butyl
2-(1,3-dioxoisoindolin-2-yl)cyclohexylcarbamate (3.90 g) was
dissolved in toluene (20 mL) and charged to a round bottom flask.
Hydrazine hydrate (0.70 mL) was added and the mixture was heated to
80.degree. C. for 2 h whereupon TLC analysis indicated the reaction
was complete. The reaction was cooled to RT and the solids were
filtered and washed with toluene (2.times.5 mL). The filtrates were
washed with 2 N NaOH aq (10 mL) and phase separated. The aqueous
phase was extracted with toluene (2.times.5 mL) and the combined
organic extracts were washed with 10% HOAc aq (2.times.10 mL). The
combined aqueous washes were basified with 2 N NaOH aq (13 mL). The
product was extracted with IPAc (2.times.10 mL) and the combined
organic extracts were washed with water (5 mL). The organic phase
was concentrated to dryness to give 0.78 g of crude product. The
oil was re-dissolved in IPAc (12 mL), heated to about 75.degree.
C., and maleic acid (423 mg) was added. Precipitation of solids
occurred immediately and the thick mixture was diluted with IPAc (5
mL). The slurry was cooled to RT and allowed to stand for 20 min.
The solids were filtered, washed with IPAc (10 mL), and dried to
give a maleic acid salt of the title compound as white crystalline
solid (730 mg, 44%). .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
ppm 1.34-1.42 (m, 2H), 1.50 (s, 9H), 1.50-1.64 (m, 6H), 3.22 (m,
1H), 3.83 (br s, 1H), 6.02 (s, 2H), 6.86 (d, J=7.5 Hz, 1H), 7.68
(br s, 3H).
Preparation 49: tert-Butyl (1S,2R)-2-aminocyclohexylcarbamate,
(S)-mandelic Acid Salt
##STR00284##
[0871] A. cis-N-(2-Aminocyclohexyl)-2,2,2-trifluoroacetamide
##STR00285##
[0873] cis-Cyclohexane-1,2-diamine (5.00 g, 43.9 mmol, 1.00 eq) was
charged to a 250 mL three-neck round bottom flask equipped with an
overhead stirrer and a thermocouple. Ethanol (50 mL) was added and
the solution was cooled to <0.degree. C. using an ice-brine
bath. A solution of ethyl trifluoroacetate (6.23 g, 1.00 eq) in
EtOH (25 mL) was added via a syringe pump over a one hour period.
Once the addition was complete, the cooling bath was removed and
the solution was slowly warmed to RT and stirred for 3.5 hours to
afford the title compound in EtOH. Half (41 mL, about 21.9 mmol) of
the total solution (about 82 mL) was carried into the next
step.
B. cis-tert-Butyl
2-(2,2,2-trifluoroacetamido)cyclohexylcarbamate
##STR00286##
[0875] Triethylamine (3.1 mL, 22.05 mmol, 1.0 eq) was added to a
solution of cis-N-(2-aminocyclohexyl)-2,2,2-trifluoroacetamide in
EtOH (41 mL, 21.9 mmol). Di-tert-butyl dicarbonate (5.74 g, 26.3
mmol, 1.2 eq) was added in one portion at RT. An ice bath was used
to control a modest exotherm and the internal reaction temperature
was maintained at <25.degree. C. Once the exotherm subsided the
ice bath was removed, and the mixture was stirred at RT for 16 h to
give the title compound in EtOH.
C. cis-tert-Butyl 2-aminocyclohexylcarbamate
##STR00287##
[0877] Aqueous sodium hydroxide (50%, 10 g, 0.125 mole, 5.7 eq) was
added to a solution of cis-tert-butyl
2-(2,2,2-trifluoroacetamido)cyclohexylcarbamate in EtOH (about 21.9
mmol). An exotherm from 20 to 37.degree. C. was observed and a fine
white slurry formed. The reaction mixture was stirred overnight,
during which further solids precipitated out of solution. The
solvent volume was concentrated under reduced pressure to about 10
to 15 mL and then IPAc (40 mL) and water (30 mL) were added to form
a clean bi-phasic solution. Following phase separation the aqueous
phase was extracted with IPAc (15 mL) and the organic extracts were
combined and washed with water (15 mL) to give the title compound
as a crude racemic product in IPAc.
D. tert-Butyl (1S,2R)-2-aminocyclohexylcarbamate
[0878] Crude cis-tert-butyl 2-aminocyclohexylcarbamate in IPAc (70
mL, about 21.9 mmol) was charged to a 100 mL three-neck RBF
equipped with a short-path distillation unit, thermocouple, and
stir bar. Vacuum was applied and the solution was heated and the
solvent volume was distilled at 43-44.degree. C. until the volume
reached about 45 mL (10 volumes relative to theoretical crude yield
of racemic product). Karl Fisher analysis indicated a water content
of 4.9%. The vacuum was released and the solution was heated to
60.degree. C. The solution was then slowly cooled to RT and seeds
of tert-butyl (1S,2R)-2-aminocyclohexylcarbamate, (S)-mandelic acid
salt (from small scale resolution experiments) were added at
5.degree. C. intervals. All the seeds dissolved while cooling, but
remained when RT was reached. The solution was cooled in an
ice-brine bath (-15.degree. C.) for 30 min. The solution was
reheated, and following the addition of IPAc (40 mL), was
redistilled under vacuum at 45-46.degree. C. to about 45 mL of
volume. The reaction was cooled to RT and stirred overnight. The
solids were filtered, washed with IPAc (2.times.12.5 mL) and dried
to afford an (S)-mandelic acid salt of the title compound as a
white solid (2.21 g, 28%, 98% ee). .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 1.24-1.30 (m, 2H), 1.35 (s, 9H),
1.35-1.64 (m, 6H), 3.15 (m, 1H), 3.71 (br s, 1H), 4.55 (s, 1H),
6.85-7.11 (br s, 3H), 6.95 (br d, 1H, J=7.5 Hz), 7.15 (m 1H), 7.23
(m, 2H), 7.37 (m, 2H).
Example 102:
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)--
1H-pyrrolo[3,4-c]pyridin-3(21)-one (HCl Salt)
##STR00288##
[0879] A. tert-Butyl
6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-chloro-7-fluoro-
-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
##STR00289##
[0881] To a stirred suspension of tert-butyl
4,6-dichloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
(12.5 g, 38.9 mmol) in 2-propanol (72 mL) was added a solution of
tert-butyl (1S,2R)-2-aminocyclohexylcarbamate (10.01 g, 46.7 mmol)
in DMSO (12.00 mL) and DIPEA (8.84 mL, 50.6 mmol). The reaction
mixture was heated to 90.degree. C. for 16 h at which point it was
cooled to 50.degree. C. and water (50 mL) was added dropwise to
give a precipitate. The suspension was stirred at 50.degree. C. for
1 h then cooled to RT. The suspension was reheated to 50.degree. C.
for 15 min and cooled to RT for two more cycles. The solids were
subsequently filtered and washed with isopropanol (20 mL) and dried
on a filter to give the title compound (9.538 g, 49%). .sup.1H NMR
(400 MHz, DMSO-d) .delta. ppm 1.18-1.76 (br m, 26H), 3.83 (br s,
1H), 4.12 (br s, 1H), 4.72 (s, 2H), 6.71 (d, J=7.58 Hz, 1H), 7.22
(d, J=6.32 Hz, 1H).
B. tert-Butyl
6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-7-fluoro-4-(1-met-
hyl-1H-pyrazol-4-yl)-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
##STR00290##
[0883] A 50 mL, 2-neck round bottom flask was charged with
tert-butyl
6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-4-chloro-7-fluoro-
-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate (520 mg, 1.042
mmol),
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(282 mg, 1.355 mmol), potassium carbonate (504 mg, 3.65 mmol), and
DMA (3 mL). The reaction flask was degassed followed by addition of
1,1-bis (di-tert-butylphosphino)ferrocene palladium chloride (21
mg, 0.032 mmol). Under N.sub.2 atmosphere, the reaction mixture was
heated in an oil bath at 80.degree. C. for 2.5 h and then allowed
to cool to RT. In a separate 50 mL recovery flask was added
de-ionized H.sub.2O (12 mL) and the vessel was cooled in an
ice/water bath. When the internal temperature of the water reached
2.degree. C., the reaction mixture was transferred to the recovery
flask at a rate which kept the internal temperature below
10.degree. C. Following the addition, the reaction vessel was
rinsed with DMA (1 mL). The rinse was added to the recovery flask
and the resulting aqueous slurry was stirred in an ice bath for 10
min and was then allowed to warm to RT with stirring. When the
internal temperature reached 22.degree. C., the mixture was
filtered. The filter cake was rinsed with de-ionized H.sub.2O
(2.times.5 mL) and air-dried under suction. The solids were
re-suspended in glacial acetic acid (3 mL) and stirred at RT for 1
h. Isopropanol (1 mL) was added and the mixture was stirred at RT.
De-ionized water (3.4 mL) was added to induce crystallization.
Precipitation occurred, but some solids were sticky, so the mixture
was heated in a 40.degree. C. oil bath, with stirring, for 20 min.
The mixture was allowed to cool to RT with stirring and then
filtered. The filter cake was rinsed with a 3:3:1 mixture of
HOAc/H.sub.2O/IPA (2.1 mL), briefly air-dried under suction, and
then dried in a vacuum oven at 60.degree. C. to give the title
compound as a tan solid (352 mg, 62%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.35 (s, 9H), 1.53 (s, 9H), 1.65 (m, 3H),
1.76 (m, 3H), 3.94 (s, 3H), 4.03 (br s, 1H), 4.38 (br s, 1H), 4.67
(s, 2H), 5.12 (br s, 1H), 5.77 (br s, 1H), 8.25 (br s, 1H), 8.96
(br s, 1H). [M+H] calc'd for C.sub.27H.sub.37FN.sub.6O.sub.5, 545;
found, 545.
C.
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
[0884] A suspension of tert-butyl
6-((1R,2S)-2-(tert-butoxycarbonylamino)cyclohexylamino)-7-fluoro-4-(1-met-
hyl-1H-pyrazol-4-yl)-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
(2.148 g, 3.94 mmol) in IPA (21 mL) was heated to 70.degree. C. at
which point 2M HCl aq (9.86 mL, 19.72 mmol) was added. The reaction
mixture was heated at 65.degree. C. for approximately 3 h, cooled
in an ice water bath for 1 h, and then filtered. The solids were
rinsed with cold IPA (15 mL) and then dried in a 50.degree. C.
vacuum oven overnight to give an HCL salt of the title compound as
a light yellow solid (1.404 g, 3.37 mmol) having 1.5-2 eq of
associated water (by .sup.1H NMR). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.46 (d, J=7.07 Hz, 2H), 1.57-1.76 (m,
3H), 1.76-2.04 (m, 3H), 3.31 (s, 3H), 3.67 (br s, 1H), 3.90 (s,
3H), 4.39 (d, J=2.53 Hz, 2H), 4.41-4.60 (m, 1 H), 6.75 (d, J=6.57
Hz, 1H), 7.96 (br s, 3H), 8.22-8.31 (m, 1H), 8.34 (s, 1H), 8.84 (s,
1H). [M+H] calc'd for C.sub.17H.sub.21FN.sub.6O, 345; found
345.
Example 103:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiophen-3-y-
l)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00291##
[0886] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 92 using thiophene-3-boronic acid in place of
pyrazolo[1,5-a]pyridin-3-ylboronic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 3.16-3.17 (m, 2H), 3.61-3.63 (m, 1H),
3.77-3.79 (m, 2H), 3.81-3.83 (m, 2H), 4.41-4.43 (m, 2H), 4.49-5.10
(m, 1H), 7.12-7.13 (m, 1H), 7.52-7.54 (m, 1H), 7.90-7.97 (m, 3H),
8.48 (s, 1H), 8.88 (s, 1H). [M+H] calc'd for
C.sub.16H.sub.17FN.sub.4O.sub.2S, 349; found, 349.
Example 104:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(4-methylthio-
phen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00292##
[0888] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 92 using 4-methylthiophene-2-boronic acid in
place of pyrazolo[1,5-a]pyridin-3-ylboronic acid. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. ppm 2.24 (s, 3H), 3.17 (d, J=4.04 Hz,
2H), 3.35-3.39 (m, 1H), 3.62-3.64 (m, 1H), 3.74-3.75 (m, 2H),
4.00-4.03 (m, 2H), 4.42 (d, J=11.62 Hz, 2H), 6.46 (s, 1H),
7.20-7.22 (m, 3H), 8.46 (s, 1H), 8.85 (s, 1H). [M+H] calc'd for
C.sub.17H.sub.19FN.sub.4O.sub.2S, 363; found, 363.
Example 105:
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(4-methylthiophen-2-yl)-1H--
pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00293##
[0890] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 62 using
4,4,5,5-tetramethyl-2-(4-methylthiophen-2-yl)-1,3,2-dioxaborolane
in place of
1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-y-
l)-1H-pyrazole. .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm
1.31-2.04 (m, 8H), 2.24 (s, 3H), 3.83 (br s, 1H), 4.22 (br s, 1H),
4.36-4.49 (m, 2H), 6.98 (d, J=5.37 Hz, 1H), 7.22 (s, 1H), 7.75 (br
s, 2H), 8.47 (s, 1H), 8.85 (s, 1H). [M+H] calc'd for
C.sub.18H.sub.21FN.sub.4OS, 361; found, 361.
Example 106:
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(thiophen-3-yl)-1H-pyrrolo[-
3,4-c]pyridin-3(2H)-one
##STR00294##
[0892] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 62 using
4,4,5,5-tetramethyl-2-(thiophen-3-yl)-1,3,2-dioxaborolane in place
of
1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyr-
azole. .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 1.31-2.05
(m, 8H), 3.84 (br s, 1H), 4.25 (d, J=3.42 Hz, 1H), 4.36-4.50 (m,
2H), 7.01 (d, J=5.86 Hz, 1H), 7.15 (dd, J=5.37, 3.91 Hz, 1H), 7.64
(dd, J=4.88, 0.98 Hz, 1H), 7.75 (br s, 2H), 8.50 (s, 1H), 8.95-9.07
(m, 1H). [M+H] calc'd for C.sub.7H.sub.19FN.sub.4OS, 347; found,
347.
Example 107:
(R)-2-(7-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-ylamino)-N,4-dimethylpentanamide
##STR00295##
[0893] A. (R)-Methyl
2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-ylamino)-4-methylpentanoate
##STR00296##
[0895] A mixture of
4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(-
2H)-one (3 g, 8.08 mmol), (S)-methyl 2-amino-4-methylpentanoate
hydrochloride (2.94 g, 16.16 mmol), and
N-isopropyl-N-methylpropan-2-amine (3.76 mL, 24.25 mmol) in ACN (50
mL) was stirred at 100.degree. C. for 3 d. The solvent was removed
and the resulting residue was used in the next step without further
purification. [M+H] calc'd for C.sub.23H.sub.27ClFN.sub.3O.sub.5,
480; found, 480.
B.
(R)-2-(4-Chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-p-
yrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanoic acid
##STR00297##
[0897] A mixture of (R)-methyl
2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo-
[3,4-c]pyridin-6-ylamino)-4-methylpentanoate (2.9 g, 6.04 mmol) in
MeOH (10 mL) and 1N NaOH (40.0 mL) was stirred at 50.degree. C. for
2 h. UPLC showed 30% starting material remained. Additional
saturated NaOH solution (5 mL) was added and the reaction mixture
was stirred for 3 h at 50.degree. C. The solvent was removed and
the resulting residue was dispersed in H.sub.2O (100 mL) and
acidified to pH 3 using HCl. After stirring at RT for 2 h, the
solid was filtered to give the title compound. [M+H] calc'd for
C.sub.22H.sub.25ClFN.sub.3O.sub.5, 466; found, 466.
C.
(R)-2-(2-(2,4-Dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3--
oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanoic
Acid
##STR00298##
[0899] A solution of
(R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyr-
rolo[3,4-c]pyridin-6-ylamino)-4-methylpentanoic acid (1.1 g, 2.361
mmol),
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(2.456 g, 11.81 mmol) and bis(triphenylphosphine)palladium chloride
(1.657 g, 2.361 mmol) in dioxane (10 mL) and saturated aq
Na.sub.2CO.sub.3 (10.00 mL) was heated to 120.degree. C. for 30
min. After filtering out the solids, the solvent was removed from
the filtrate. The resulting residue was dissolved in MeOH and DCM
and was purified via preparative HPLC eluting with water (0.05%
TFA) and ACN (40-70% gradient, 0.035% TFA). The collected fractions
were combined and the solvent stripped to dryness via rotary
evaporation to yield the title compound. [M+H] calc'd for
C.sub.26H.sub.30FN.sub.5O.sub.5, 512; found, 512.
D.
(R)-2-(2-(2,4-Dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3--
oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-N,4-dimethylpentanamid-
e
##STR00299##
[0901] A solution of
(R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-ox-
o-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanoic
acid (48 mg, 0.094 mmol), methylamine hydrochloride (31.7 mg, 0.469
mmol) and DIPEA (49.2 .mu.L, 0.281 mmol) in DMF (1 mL) was stirred
at RT for 10 min. HATU (71.4 mg, 0.188 mmol) was added and the
mixture was stirred at RT for 1 h, after which UPLC showed about
80% starting material remained. Additional methylamine (58.4 .mu.L,
0.469 mmol, 33% in EtOH) was added, which resulted in little
conversion of the starting material. The solvent was stripped off
and the residue was dissolved in DMF (1 mL). To this solution was
added EDCI hydrochloride (54.0 mg, 0.281 mmol), HOBT monohydrate
(43.1 mg, 0.281 mmol), and methylamine hydrochloride (31.7 mg,
0.469 mmol). The reaction mixture was heated to 60.degree. C. for 4
h. UPLC subsequently showed the reaction mixture contained 95% of
desired product. The reaction mixture was allowed to cool to RT.
Water (50 mL) was added and the mixture was extracted with DCM
(3.times.50 mL). The organic layers were collected, dried over
Na.sub.2SO.sub.4, filtered, and the solvent was stripped to dryness
via rotary evaporation to yield the title compound, which was used
without further purification. [M+H] calc'd for
C.sub.27H.sub.33FN.sub.6O.sub.4, 525; found, 525.
E.
(R)-2-(7-Fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrro-
lo[3,4-c]pyridin-6-ylamino)-N,4-dimethylpentanamide
[0902] A solution of
(R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-3-ox-
o-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-N,4-dimethylpentanamide
(38 mg, 0.072 mmol) in TFA (5 mL) was heated to 65.degree. C. for 4
h. After removal of the solvent, the residue was diluted in MeOH (2
mL) and was purified by preparative HPLC eluting with water (0.05%
TFA) and ACN (25-30%, gradient, 0.035% TFA). The collected
fractions were stripped to dryness to give the title compound.
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 0.84-0.93 (m, 6H),
1.63-1.81 (m, 2H), 2.57 (d, J=4.39 Hz, 3H), 3.88 (s, 3H), 4.04-4.19
(m, 2H), 4.36 (s, 2H), 6.99 (d, J=7.32 Hz, 1H), 7.61-7.76 (m, 1H),
7.93 (d, J=4.39 Hz, 1H), 8.30 (s, 1H), 8.83 (s, 1H). [M+H] calc'd
for C.sub.18H.sub.23FN.sub.6O.sub.2, 375; found, 375.
Example 108:
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(5-methylthiophen-2-yl)-1H--
pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00300##
[0904] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 62 using
4,4,5,5-tetramethyl-2-(5-methylthiophen-2-yl)-1,3,2-dioxaborolane
in place of
1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-y-
l)-1H-pyrazole. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
1.31-2.01 (m, 8H), 2.46 (d, J=0.51 Hz, 3H), 3.80 (br s, 1H), 4.25
(d, J=4.55 Hz, 1H), 4.36-4.50 (m, 2H), 6.83 (dd, J=3.79, 1.01 Hz,
1H), 6.91 (d, J=6.06 Hz, 1H), 7.73 (br s, 2H), 8.43 (s, 1H), 8.82
(d, J=3.54 Hz, 1H). [M+H] calc'd for C.sub.18H.sub.21FN.sub.4OS,
361; found, 361.
Example 109:
(R)-2-(7-Fluoro-4-(4-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,-
4-c]pyridin-6-ylamino)-4-methylpentanamide
##STR00301##
[0906] The title compound was prepared in a manner similar to
EXAMPLE 70 using
4,4,5,5-tetramethyl-2-(4-methylthiophen-2-yl)-1,3,2-dioxaborolane
in place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 0.82-0.95 (m, 6H),
1.20-1.32 (m, 2H), 2.23 (s, 3H), 4.38 (s, 2H), 4.59-4.72 (m, 2H),
6.94-6.99 (m, 1H), 7.02-7.08 (m, 1H), 7.15-7.23 (m, 1H), 7.27-7.34
(m, 1H), 8.35 (s, 1H), 8.78 (d, J=1.26 Hz, 1H). [M+H] calc'd for
C.sub.18H.sub.21FN.sub.4O.sub.2S, 377; found, 377.
Example 110:
(R)-2-(7-Fluoro-3-oxo-4-(thiophen-3-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyri-
din-6-ylamino)-4-methylpentanamide
##STR00302##
[0908] The title compound was prepared in a manner similar to
EXAMPLE 70 using
4,4,5,5-tetramethyl-2-(thiophen-3-yl)-1,3,2-dioxaborolane in place
of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 0.75-1.00 (m, 6H),
1.50-1.63 (m, 1H), 1.69-1.83 (m, 2H), 4.39 (s, 2H), 4.52-4.61 (m,
1H), 6.93 (br s, 1H), 7.01 (d, J=7.58 Hz, 1H), 7.38 (br s, 1H),
7.49 (dd, J=5.05, 3.03 Hz, 1H), 8.04 (dd, J=5.05, 1.26 Hz, 1H),
8.36 (s, 1H), 8.94 (dd, J=3.03, 1.01 Hz, 1H). [M+H] calc'd for
C.sub.17H.sub.19FN.sub.4O.sub.2S, 363; found, 363.
Example 111:
(R)-2-(7-Fluoro-4-(5-methylthiophen-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,-
4-c]pyridin-6-ylamino)-4-methylpentanamide
##STR00303##
[0910] The title compound was prepared in a manner similar to
EXAMPLE 70 using
4,4,5,5-tetramethyl-2-(5-methylthiophen-2-yl)-1,3,2-dioxaborolane
in place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
.sup.1H NMR (400 MHz, DMSO-d) 8 ppm 0.71-0.96 (m, 6H), 1.52-1.85
(m, 3H), 2.45 (s, 3H), 4.38 (s, 2H), 4.56-4.74 (m, 1H), 6.80 (dd,
J=3.66, 1.14 Hz, 1H), 6.93-7.10 (m, 2H), 7.30 (br s, 1H), 8.32 (s,
1H), 8.78 (d, J=3.79 Hz, 1H). [M+H] calc'd for
C.sub.1H.sub.21FN.sub.4O.sub.2S, 377; found, 377.
Example 112:
6-((1R,2S)-2-Aminocyclohexylamino)-4-(2-aminothiazol-5-yl)-7-fluoro-1H-py-
rrolo[3,4-c]pyridin-3(2H)-one
##STR00304##
[0911] A. tert-Butyl
(5-(6-(((1R,2S)-2-((tert-butoxycarbonyl)amino)cyclohexyl)amino)-2-(2,4-di-
methoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)-1-
,3-thiazol-2-yl)carbamate
##STR00305##
[0913] A solution of tert-butyl
(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-
-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (50 mg, 0.091
mmol), tert-butyl 5-(tributylstannyl)thiazol-2-ylcarbamate (53.5
mg, 0.109 mmol), and tetrakis(triphenylphosphine)palladium(0) (105
mg, 0.091 mmol) in toluene (1 mL) was heated to 102.degree. C. for
24 h. After removal of the solvent, the resulting crude material
was reconstituted in MeOH/DMF (6.0 mL) and purified via preparative
HPLC eluting with water (0.05% TFA) and ACN (70-75% gradient,
0.035% TFA). The collected fractions were stripped to dryness via
rotary evaporation to yield the title compound (42 mg, 64%). [M+H]
calc'd for C.sub.35H.sub.45FN.sub.6O.sub.7S, 713; found, 713.
B.
6-((1R,2S)-2-Aminocyclohexylamino)-4-(2-aminothiazol-5-yl)-7-fluoro-1H--
pyrrolo[3,4-c]pyridin-3(2H)-one
[0914] A solution of tert-butyl
(5-(6-(((1R,2S)-2-((tert-butoxycarbonyl)amino)cyclo-hexyl)amino)-2-(2,4-d-
imethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yl)--
1,3-thiazol-2-yl)carbamate (41.5 mg, 0.058 mmol) in TFA (5 mL) was
heated to 65.degree. C. for 3 h. After removal of the solvent, the
resulting crude material was reconstituted in MeOH/DMF (6.0 mL) and
purified via preparative HPLC eluting with water (0.05% TFA) and
ACN (10-20% gradient, 0.035% TFA). The collected fractions were
stripped to dryness via rotary evaporation to yield the title
compound as a TFA salt (6.7 mg, 32%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.12-2.11 (m, 9H), 3.73 (br s, 2H), 4.19
(d, J=3.79 Hz, 1H), 4.41 (d, J=3.03 Hz, 2H), 6.95 (d, J=3.03 Hz,
1H), 7.77 (br s, 2H), 8.44 (s, 1H), 8.93 (s, 1H). [M+H] calc'd for
C.sub.16H.sub.19FN.sub.6OS, 363; found, 363.
Preparation 50.
(R)-2-(4-Chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyr-
rolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide
##STR00306##
[0916] A mixture of
4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(-
2H)-one (7 g, 18.86 mmol), N-isopropyl-N-methylpropan-2-amine
(14.64 mL, 94 mmol), and N-isopropyl-N-methylpropan-2-amine (14.64
ml, 94 mmol) in ACN (100 mL) was stirred at 100.degree. C. for 3 d.
UPLC showed about 10% starting material remained. The reaction was
stopped, the solvent was removed, and the crude product was
reconstituted in MeOH/DCM and dispersed on silica gel (10 g). The
solvent was evaporated and the residue was purified on a silica gel
column eluting with 1-3% MeOH in DCM over a 45 min period. The
collected fractions were combined and stripped to dryness via
rotary evaporation to yield the title compound (5.3 g, 61%). [M+H]
calc'd for C.sub.22H.sub.26ClFN.sub.4O.sub.4, 465; found 465.
Example 113:
(R)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-
-6-ylamino)-4-methylpentanamide
##STR00307##
[0917] A.
(R)-2-(2-(2,4-Dimethoxybenzyl)-7-fluoro-4-(furan-2-yl)-3-oxo-2,3-
-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide
##STR00308##
[0919] A solution of
(R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyr-
rolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide (150 mg, 0.323
mmol), tributyl(furan-2-yl)stannane (138 mg, 0.387 mmol), and
tetrakis(triphenylphosphine)palladium(0) (373 mg, 0.323 mmol) in
toluene (1 mL) was heated to 102.degree. C. overnight. After
removal of the solvent, the residue was diluted in MeOH/DCM (10 mL)
and was purified via preparative HPLC eluting with water (0.05%
TFA) and ACN (45-60% gradient, 0.035% TFA). The collected fractions
were stripped to dryness via rotary evaporation to give the title
compound (93.1 mg, 58%). [M+H] calc'd for
C.sub.26H.sub.29FN.sub.4O.sub.5, 498; found 498.
B.
(R)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyrid-
in-6-ylamino)-4-methylpentanamide
[0920] A solution of
(R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro--
1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide (93.1 mg,
0.188 mmol) in TFA (5 mL) was heated to 65.degree. C. for 3 h. The
solvent was removed and the resulting residue was diluted in
MeOH/DCM (10 mL) and was purified via preparative HPLC eluting with
water (0.05% TFA) and ACN (30%, 0.035% TFA). The collected
fractions were stripped to dryness via rotary evaporation to afford
the title compound. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm
0.79-0.97 (m, 6H), 1.52-1.87 (m, 3H), 4.38 (s, 2H), 4.66-4.85 (m,
1H), 6.61 (dd, J=3.54, 1.77 Hz, 1H), 6.92-7.07 (m, 2H), 7.36 (br s,
1H), 7.79 (dd, J=1.64, 0.63 Hz, 1H), 8.04 (dd, J=3.54, 0.51 Hz,
1H), 8.32 (s, 1H). [M+H] calc'd for
C.sub.17H.sub.19FN.sub.4O.sub.3, 347; found, 347.
Example 114:
(R)-2-(7-Fluoro-4-(furan-3-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-
-6-ylamino)-4-methylpentanamide
##STR00309##
[0922] The title compound was prepared in a manner similar to
EXAMPLE 70 using
2-(furan-3-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane in place of
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole.
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 0.80-0.99 (m, 6H),
1.21-1.33 (m, 1H), 1.50-1.60 (m, 1H), 1.74-1.81 (m, 1H), 4.38 (s,
2H), 4.47-4.61 (m, 1H), 6.89-6.98 (m, 1H), 7.03 (d, J=7.81 Hz, 1H),
7.35 (s, 1H), 7.42 (s, 1H), 7.68 (s, 1H), 8.35 (s, 1H), 8.98 (s,
1H). [M+H] calc'd for C.sub.17H.sub.19FN.sub.4O.sub.3, 347; found,
347.
Example 115:
(R)-2-(7-Fluoro-4-(furan-2-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-
-6-ylamino)-4-methylpentanamide
##STR00310##
[0924] The title compound was prepared in a manner similar to
EXAMPLE 113 using tributyl(5-methylfuran-2-yl)stannane tert-butyl
in place of tributyl(furan-2-yl)stannane. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 0.84-0.97 (m, 6H), 1.51-1.78 (m, 3H),
2.29-2.36 (m, 3H), 4.36 (s, 2H), 4.64-4.86 (m, 1H), 6.22 (dd,
J=3.28, 1.01 Hz, 1H), 6.92 (d, J=8.08 Hz, 1H), 7.01 (br s, 1H),
7.41 (br s, 1H), 7.97 (d, J=3.03 Hz, 1H), 8.26 (s, 1H). [M+H]
calc'd for C.sub.18H.sub.21FN.sub.4O.sub.3, 361; found, 361.
Example 116:
(R)-2-(4-(5-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-
-c]pyridin-6-ylamino)-4-methylpentanamide
##STR00311##
[0925] A.
(R)-2-(4-(5-Cyanothiophen-2-yl)-2-(2,4-dimethoxybenzyl)-7-fluoro-
-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide
##STR00312##
[0927] A solution of
(R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyr-
rolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide (114 mg, 0.245
mmol), 5-cyanothiophen-2-ylboronic acid (113 mg, 0.736 mmol),
tris(dibenzylideneacetone)dipalladium(0) (13.47 mg, 0.015 mmol),
and 2-(dicyclohexylphosphino)biphenyl (5.16 mg, 0.015 mmol) in
dioxane (2 mL) and DMF (0.5 mL) was heated to 160.degree. C. under
microwave irradiation for 45 min. UPLC showed 50% conversion. The
reaction mixture was subsequently heated at 160.degree. C. under
microwave irradiation for 45 min. Additional
5-cyanothiophen-2-ylboronic acid (113 mg, 0.736 mmol) was added and
the reaction mixture was heated at 160.degree. C. under microwave
irradiation for 60 min. After removal of the solvent, the resulting
crude material was reconstituted in MeOH/DMF (6.0 mL) and purified
via preparative HPLC eluting with water (0.05% TFA) and ACN (40-80%
gradient, 0.035% TFA). The collected fractions were stripped to
dryness via rotary evaporation to yield the title compound. [M+H]
calc'd for C.sub.27H.sub.28FN.sub.5O.sub.4S, 538; found, 538.
B.
(R)-2-(4-(5-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3-
,4-c]pyridin-6-ylamino)-4-methylpentanamide
[0928] A solution of
(R)-2-(4-(5-cyanothiophen-2-yl)-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,-
3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)-4-methylpentanamide
(68 mg, 0.126 mmol) in TFA (2 mL) was heated to 65.degree. C. for 3
h. After removal of the solvent, the resulting crude material was
reconstituted in MeOH/DCM (3.0 mL) and purified via preparative
HPLC eluting with water (0.05% TFA) and ACN (40%, 0.035% TFA). The
collected fractions were combined and the solvent was removed via
rotary evaporation to yield the title compound (8.3 mg, 17%).
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 0.86-0.96 (m, 6H),
1.53-1.62 (m, 1H), 1.67-1.88 (m, 2H), 4.45 (s, 2H), 4.50-4.57 (m,
1H), 6.96-7.06 (m, 1H), 7.32-7.54 (m, 2H), 7.86-8.02 (m, 1H), 8.61
(s, 1H), 9.00-9.15 (m, 1H). [M+H] calc'd for
C.sub.18H.sub.18FN.sub.5O.sub.2S, 388; found, 388.
Example 117:
(R)-2-(4-(4-Cyanothiophen-2-yl)-7-fluoro-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-
-c]pyridin-6-ylamino)-4-methylpentanamide
##STR00313##
[0930] The title compound was prepared in a manner similar to
EXAMPLE 116 using 4-cyanothiophen-2-ylboronic acid in place of
5-cyanothiophen-2-ylboronic acid. .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 0.80-0.96 (m, 6H), 1.55-1.66 (m, 1H),
1.65-1.86 (m, 2H), 4.44 (s, 2H), 4.51-4.64 (m, 1H), 6.99 (s, 1H),
7.04-7.20 (m, 1H), 7.32 (d, J=8.30 Hz, 1H), 7.37 (s, 1H), 8.53-8.68
(m, 1H), 9.24 (s, 1H). [M+H] calc'd for
C.sub.18H.sub.18FN.sub.5O.sub.2S, 388; found, 388.
Example 118:
(R)-2-(7-Fluoro-3-oxo-4-(thiazol-5-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyrid-
in-6-ylamino)-4-methylpentanamide
##STR00314##
[0932] The title compound was prepared in a manner similar to
EXAMPLE 113 using 5-(tributylstannyl)thiazole in place of
tributyl(furan-2-yl)stannane. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 0.77-0.98 (m, 6H), 1.53-1.68 (m, 1H), 1.71-1.84 (m,
2H), 4.42 (s, 2H), 4.52-4.66 (m, 1H), 6.95 (br s, 1H), 7.18 (d,
J=8.59 Hz, 1H), 7.34 (br s, 1H), 8.46 (s, 1H), 9.11 (s, 1H), 9.46
(s, 1H). [M+H] calc'd for C.sub.16H.sub.18FN.sub.5O.sub.2S, 364;
found, 364.
Example 119:
(R)-2-(7-Fluoro-4-(isothiazol-5-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]py-
ridin-6-ylamino)-4-methylpentanamide
##STR00315##
[0934] The title compound was prepared in a manner similar to
EXAMPLE 116 using
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isothiazole in place
of 5-cyanothiophen-2-ylboronic acid. .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 0.77-0.97 (m, 6H), 1.56-1.64 (m, 1H),
1.67-1.86 (m, 2H), 4.45 (s, 2H), 4.49-4.62 (m, 1H), 7.00 (s, 1H),
7.33 (d, J=8.30 Hz, 1H), 7.44 (s, 1H), 8.53-8.65 (m, 2H), 8.91 (d,
J=1.46 Hz, 1H). [M+H] calc'd for C.sub.16H.sub.18FN.sub.5O.sub.2S,
364; found, 364.
Example 120:
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-1,1-dimethyl-4-(1-methyl-1H-p-
yrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00316##
[0935] A.
4,6-Dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1,1-dimethyl-1H-py-
rrolo[3,4-c]pyridin-3(2H)-one
##STR00317##
[0937] To a solution of
4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(-
2H)-one (500 mg, 1.347 mmol) in DMF (5 mL) at 0.degree. C. was
added sodium hydride (53.9 mg, 1.347 mmol) and iodomethane (0.084
mL, 1.347 mmol). The mixture was stirred at 0.degree. C. for 1 h,
then diluted to EtOAc (200 mL) and washed with brine (200 mL) and
water (200 mL). The organic phase was dried and concentrated to a
residue, which was purified by reverse phase preparative HPLC to
give the title compound as one of the products (50 mg, 9%,
mono-methylated product was observed). [M+H] calc'd for
C.sub.18H.sub.17C.sub.12FN.sub.2O.sub.3, 400.2; found, 399.4.
B. tert-Butyl
(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1,1-dimethyl-3-oxo-2-
,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
##STR00318##
[0939] In a 10 mL sealed cap glass vial,
4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1,1-dimethyl-1H-pyrrolo[3,4-
-c]pyridin-3(2H)-one (50 mg, 0.125 mmol) and tert-butyl
(1S,2R)-2-aminocyclohexylcarbamate (53.2 mg, 0.250 mmol) were
dissolved in ACN (2 mL). N-ethyldiisopropylamine (0.033 mL, 0.188
mmol) was added, the cap was sealed, and the reaction mixture
heated at 95.degree. C. for 72 h. The reaction mixture was
subsequently purified by preparative HPLC and basified to give the
title compound as a light yellow solid (40 mg, 55%). [M+H] calc'd
for C.sub.29H.sub.38ClFN.sub.4O.sub.5, 578.1; found, 577.4.
C. tert-Butyl
(1S,2R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-1,1-dimethyl-4-(1-methyl-1H-p-
yrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohex-
ylcarbamate
##STR00319##
[0941] In a sealed tube, a mixture of tert-butyl
(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1,1-dimethyl-3-oxo-2-
,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate
(30 mg, 0.052 mmol), Na.sub.2CO.sub.3 aq (2M, 0.065 mL, 0.130
mmol),
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(12.98 mg, 0.062 mmol), bis(triphenylphosphine)palladium chloride
(3.65 mg, 5.20 .mu.mol), and DMF (1 mL) was heated at 160.degree.
C. for 0.5 h in a microwave oven. The reaction mixture was then
heated at 160.degree. C. for an additional 4 h in a microwave oven
and was subsequently purified by preparative HPLC to give the title
compound as a light yellow solid (5 mg, 18%). [M+H] calc'd for
C.sub.28H.sub.35FN.sub.6O.sub.3, 524; found 524.
D.
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-1,1-dimethyl-4-(1-methyl-1H-
-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
[0942] A solution of tert-butyl
(1S,2R)-2-(2-(2,4-dimethoxybenzyl)-7-fluoro-1,1-dimethyl-4-(1-methyl-1H-p-
yrazol-4-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohex-
ylcarbamate (5 mg, 9.57 .mu.mol) in TFA (1 mL) was heated at
60.degree. C. for 0.5 h. The reaction mixture was subsequently
purified by preparative HPLC and the product lyophilized to give
the title compound as a TFA salt (2 mg, 56%). [M+H] calc'd for
C.sub.19H.sub.25FN.sub.6, 374; found, 374.
Example 121:
((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-3-yl)-1H-
-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00320##
[0944] In a 30 mL sealed cap glass vial, tert-butyl
(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-
-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (350 mg, 0.637
mmol),
1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(172 mg, 0.829 mmol) and PdCl.sub.2(PPh.sub.3).sub.2 (44.7 mg,
0.064 mmol) were dissolved in dioxane (5 mL). An aqueous solution
of Na.sub.2CO.sub.3 (2M, 0.5 mL) was added and the cap was sealed.
The reaction mixture was heated at 85.degree. C. for 4 h, then
diluted with water (5 mL), and extracted with EtOAc (2.times.30
mL). The organic phase was dried over Na.sub.2SO.sub.4 and the
solvent evaporated. The resulting residue was treated with TFA (4
mL) and heated at 80.degree. C. for 1.5 h to remove the protecting
groups. Next, TFA was evaporated and the product was dissolved in
DMSO (8 mL) and purified by preparative HPLC. The pure fractions
were combined, concentrated, and lyophilized to give a TFA salt of
the title compound as a white solid (52.3 mg, 24%). .sup.1H NMR
(400 MHz, DMSO-d) .delta. ppm 1.40-1.95 (m, 8H), 3.64 (br s, 1H),
3.92 (s, 2H), 4.28-4.49 (m, 3H), 6.76 (d, J=5.31 Hz, 1H), 7.42 (d,
J=2.27 Hz, 1H), 7.72 (d, J=2.27 Hz, 1H), 7.98 (br s, 3H), 8.39 (s,
1H). [M+H] calc'd for C.sub.17H.sub.21FN.sub.6O, 345; found,
345.
Example 122:
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1H-p-
yrrolo[3,4-c]pyridin-3(2H)-one
##STR00321##
[0945] A.
6-((1R,2S)-2-Aminocyclohexylamino)-4-bromo-7-fluoro-1H-pyrrolo[3-
,4-c]pyridin-3(2H)-one
##STR00322##
[0947] A mixture of tert-butyl
(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-
-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (200 mg, 0.364
mmol) and hydrobromic acid in HOAc (10 mL) was stirred at
90.degree. C. for 6 h. The mixture was concentrated under reduced
pressure, and the resulting crude material was reconstituted in
MeOH (1.0 mL) and was purified via preparative HPLC eluting with
water (0.05% TFA) and ACN (15-30% gradient, 0.035% TFA). The
collected fractions were combined and ACN was removed via rotary
evaporation. The resulting aqueous solution was neutralized with
saturated aqueous NaHCO.sub.3, washed with EtOAc (2.times.200 mL),
dried over Na.sub.2SO.sub.4, and filtered. The organic phase was
stripped to dryness via rotary evaporation to yield the title
compound (38 mg, 30%). [M+H] calc'd for
C.sub.13H.sub.16BrFN.sub.4O, 343; found, 343.
B.
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(2-methylthiazol-5-yl)-1H-
-pyrrolo[3,4-c]pyridin-3(2H)-one
[0948] A solution of
6-((1R,2S)-2-aminocyclohexylamino)-4-bromo-7-fluoro-1H-pyrrolo[3,4-c]pyri-
din-3(2H)-one (38 mg, 0.111 mmol), 2-methylthiazole-5-carboxylic
acid (15.85 mg, 0.111 mmol), silver(I) acetate (18.48 mg, 0.111
mmol), and copper(II) chloride (14.89 mg, 0.111 mmol) in toluene
(1.8 mL) and DMA (0.2 mL) was heated to 135.degree. C. overnight.
The reaction mixture was filtered through a pad of Celite and the
solvent was removed in vacuo. The resulting crude material was
reconstituted in MeOH/DMF (10.0 mL) and purified via preparative
HPLC eluting with water (0.05% TFA) and ACN (50-90% gradient,
0.035% TFA). The collected fractions were combined and the solvent
was stripped to dryness via rotary evaporation to yield the title
compound as a TFA salt (2.3 mg, 6%). .sup.1H NMR (500 MHz,
CDCl.sub.3) .delta. ppm 1.37-1.85 (m, 8H) 2.93 (s, 2H) 2.97-3.08
(m, 3H) 4.22-4.42 (m, 2H) 6.52 (s, 1H) 7.53 (d, J=4.39 Hz, 1H) 7.72
(br s, 1H) 8.08 (br s, 1H) 8.27 (s, 1H) [M+H] calc'd for
C.sub.17H.sub.20FN.sub.5OS, 362; found, 362.
Example 123:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(5-methylthio-
phen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00323##
[0949] A. tert-Butyl
(3R,4R)-4-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-
-pyrrolo[3,4-c]pyridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate
##STR00324##
[0951] A mixture of
4,6-dichloro-2-(2,4-dimethoxybenzyl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(-
2H)-one (320 mg, 0.862 mmol), tert-butyl
(3R,4R)-4-aminotetrahydro-2H-pyran-3-ylcarbamate (280 mg, 1.293
mmol) and DIPEA (0.226 mL, 1.293 mmol) in ACN (5 mL) was stirred at
85.degree. C. overnight. UPLC indicated the presence of starting
material, so the mixture was stirred at 85.degree. C. overnight.
UPLC showed about 50% conversion. Additional stirring at 85.degree.
C. for 3 d and at 100.degree. C. overnight did not appreciably
increase the conversion, so the reaction was stopped and the
solvent was removed. The resulting crude material was reconstituted
in MeOH/DMF (10 mL) and purified via preparative HPLC eluting with
water (0.05% TFA) and ACN (50%, 0.035% TFA). The collected
fractions were combined and the ACN was removed via rotary
evaporation. The resulting aqueous solution was neutralized with
saturated aqueous NaHCO.sub.3, washed with EtOAc (2.times.200 mL),
dried over Na.sub.2SO.sub.4, and filtered. The organic phase was
stripped to dryness via rotary evaporation to give the title
compound (51 mg, 11%). [M+H] calc'd for
C.sub.26H.sub.32ClFN.sub.4O.sub.6, 552; found, 552.
B. tert-Butyl
(3R,4R)-4-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(5-methylthiophen-2-yl)-3-o-
xo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)tetrahydro-2H-pyran-3-yl-
carbamate
##STR00325##
[0953] A solution of tert-butyl
(3R,4R)-4-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-
-pyrrolo[3,4-c]pyridin-6-ylamino)tetrahydro-2H-pyran-3-ylcarbamate
(51 mg, 0.093 mmol),
4,4,5,5-tetramethyl-2-(5-methylthiophen-2-yl)-1,3,2-dioxaborolane
(104 mg, 0.463 mmol), and bis(triphenylphosphine)palladium chloride
(65.0 mg, 0.093 mmol) in dioxane (1 mL) and saturated
Na.sub.2CO.sub.3 aq (1 mL) was heated to 140.degree. C. for 40 min.
After filtering out the solids, the solvent was removed from the
filtrate. The resulting residue was dissolved in MeOH and DCM (10
mL) and was purified via preparative HPLC eluting with water (0.05%
TFA) and ACN (80%, 0.035% TFA). The collected fractions were
combined and solvent was stripped to dryness via rotary evaporation
to give the title compound (31 mg, 55%). [M+H] calc'd for
C.sub.31H.sub.37FN.sub.4O.sub.6S, 613; found, 613.
C.
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(5-methylth-
iophen-2-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
[0954] A solution of tert-butyl
(3R,4R)-4-(2-(2,4-dimethoxybenzyl)-7-fluoro-4-(5-methylthiophen-2-yl)-3-o-
xo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-6-ylamino)tetrahydro-2H-pyran-3-yl-
carbamate (31 mg, 0.051 mmol) in TFA (10 mL) was heated to
80.degree. C. for 1 h. After the solvent was removed, the residue
was dissolved in MeOH and DCM (8 mL) and was purified via
preparative HPLC eluting with water (0.05% TFA) and ACN (15-30%
gradient, 0.035% TFA). The collected fractions were combined and
the solvent was stripped to dryness via rotary evaporation to give
the title compound as a TFA salt (13.5 mg, 74%). .sup.1H NMR (500
MHz, DMSO-d.sub.6) .delta. ppm 1.78 (d, J=13.18 Hz, 1H), 2.03-2.18
(m, 1H), 2.46 (s, 3H), 3.17 (d, J=4.88 Hz, 1H), 3.55-3.65 (m, 1H),
3.75 (d, J=13.18 Hz, 1H), 3.85 (br s, 1H), 3.96-4.06 (m, 2H), 4.41
(d, J=7.81 Hz, 2H), 6.84 (d, J=2.44 Hz, 1H), 7.22 (d, J=4.88 Hz,
1H), 7.92 (br s, 2H), 8.47 (s, 1H), 8.83 (d, J=3.42 Hz, 1H). [M+H]
calc'd for C.sub.17H.sub.19FN.sub.4O.sub.2S, 363; found, 363.
Example 124:
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-1-methyl-4-(1-methyl-1H-pyraz-
ol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00326##
[0955] A.
2,6-Dichloro-4-((3,5-dimethoxybenzylimino)methyl)-5-fluoronicoti-
nic acid
##STR00327##
[0957] A. To a solution of (2,4-dimethoxyphenyl)methanamine (4.4 g,
26.6 mmol) in MeOH (50 mL) was added
4,6-dichloro-7-fluoro-1-hydroxyfuro[3,4-c]pyridin-3(1H)-one (6.0 g,
25.3 mmol). The mixture was stirred for 0.5 h, filtered, and washed
with petroleum ether to give the title compound as a white solid
(5.8 g, 60%). .sup.1H-NMR (CDCl.sub.3, 400 MHz) .delta. 3.75 (s,
3H), 3.79 (s, 3H), 3.93 (s, 2H), 6.30 (s, 1H), 6.40-6.42 (m, 2H),
7.12 (d, J=8.4 Hz, 1H).
B.
4,6-Dichloro-2-(3,5-dimethoxybenzyl)-7-fluoro-1-methyl-1H-pyrrolo[3,4-c-
]pyridin-3(2H)-one
##STR00328##
[0959] To a mixture of
2,6-dichloro-4-((3,5-dimethoxybenzylimino)methyl)-5-fluoronicotinic
acid (5.8 g, 25.3 mmol) in THF (120 mL) was added methyl-lithium
(60.0 mL, 126.6 mmol) drop wise at -78.degree. C. After the
addition was completed, the mixture was stirred for an additional 2
h. The reaction mixture was acidified with 1N HCl to pH 7 and THF
was removed under reduced pressure. The mixture was extracted with
EtOAc, washed with brine, dried over anhydrous Na.sub.2SO.sub.4,
and purified by silica gel chromatography eluting with PE-EtOAc
(5:1) to give the title compound as a white solid (0.93 g, 16%).
.sup.1H-NMR (CDCl.sub.3, 400 MHz) .delta. 1.58 (d, J=6.8 Hz, 3H),
3.79 (s, 3H), 3.84 (s, 3H), 4.35 (d, J=14.4 Hz, 1H), 4.52 (q, J=6.8
Hz, 1H), 5.07 (d, J=14.4 Hz, 1H), 6.43-6.45 (m, 2H), 7.28 (d, J=9.2
Hz, 1H). [M+H] calc'd for C.sub.17H.sub.15Cl.sub.2FN.sub.2O.sub.3,
386; found, 385.
C.
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-1-methyl-4-(1-methyl-1H-pyr-
azol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
[0960] A mixture of
6-((1R,2S)-2-aminocyclohexylamino)-2-(2,4-dimethoxybenzyl)-7-fluoro-1-met-
hyl-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
(20 mg, 0.039 mmol) and TFA (1 mL) was heated at 60.degree. C. for
2 h. Following reaction, the mixture was purified by preparative
HPLC eluting with water (0.05% TFA) and ACN (15-25% gradient,
0.035% TFA) to give the title compound as a TFA salt (10 mg, 71%).
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 1.41 (d, J=6.59 Hz,
3H), 1.46 (d, J=7.02 Hz, 2H), 1.60-1.84 (m, 5H), 3.68 (br s, 1H),
3.89 (s, 2H), 4.44 (br s, 1H), 4.71 (q, J=6.65 Hz, 1H), 6.52 (br s,
1H), 6.73 (d, J=6.53 Hz, 1H), 7.72 (br s, 2H), 8.24-8.32 (m, 1H),
8.46 (s, 1H), 8.82 (s, 1H). [M+H] calc'd for
C.sub.18H.sub.23FN.sub.6O, 359; found, 359.
Example 125:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-(difluoromethyl)-1H-
-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00329##
[0961] A. tert-Butyl
6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-c-
hloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
##STR00330##
[0963] A mixture of tert-butyl
4,6-dichloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
(1.42 g, 4.43 mmol), tert-butyl
(3R,4R)-4-aminotetrahydro-2H-pyran-3-ylcarbamate (1.15 g, 5.52
mmol), diisopropylethylamine (3.87 mL, 22.16 mmol) in DMSO (10 mL)
and 2-propanol (40 mL) were heated to 100.degree. C. in an oil bath
for 20 h. The solution was then concentrated and the resulting oil
was dissolved in water (50 mL) and heated in an oil bath to
50.degree. C. for 1 h then allowed to cool to RT. The solution was
subsequently heated to 50.degree. C. for 15 min, allowed to cool to
RT, again heated to 50.degree. C. for 15 min, and allowed to cool
to RT. The resulting precipitate was filtered and rinsed with water
to give the title compound as a pale pinkish-white solid (1.90 g,
86%, 4:1 mixture with regioisomer) which was used in the next step
without further purification. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.36 (s, 9H), 1.50 (s, 3H), 1.59-1.61 (m, 1H),
1.97-1.99 (m, 1H), 1.97-1.99 (m, 1H), 3.46-3.49 (m, 2H), 3.80-3.83
(m, 3H), 4.31-4.33 (m, 1H), 4.73 (s, 1H), 6.59 (d, J=7.30 Hz, 1H),
7.43 (d, J=7.30 Hz, 1H). [M+H] calc'd for
C.sub.22H.sub.30ClFN.sub.4O.sub.6, 501; found, 501.
B. tert-Butyl
6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-(-
1-(difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridi-
ne-2(3H)-carboxylate
##STR00331##
[0965] A mixture of tert-butyl
6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-c-
hloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
(500 mg, 0.998 mmol), 1-(difluoromethyl)-1H-pyrazol-4-ylboronic
acid (808 mg, 4.99 mmol), bis(triphenylphosphine)palladium chloride
(70.1 mg, 0.100 mmol) in dioxane (15 mL) and 2M saturated sodium
carbonate (2 mL) were heated to 100.degree. C. in a microwave for
30 min. The solution was concentrated and was purified by
preparatory HPLC eluting with water (10 mM NH.sub.4HCO.sub.3) and
ACN/water (80/20 v/v, 15-30% gradient, 10 mM NH.sub.4HCO.sub.3) to
give the title compound as a white solid (132 mg, 23%). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. ppm 1.35 (s, 9H), 1.52 (s, 9H),
1.55-1.56 (m, 1H), 2.46-2.47 (m, 1H), 3.57-3.59 (m, 2H), 3.81-3.84
(m, 3H), 4.61-4.62 (m, 1H), 4.78 (s, 2H), 6.61 (d, J=6.35 Hz, 1H),
7.15 (d, J=6.83 Hz, 1H), 7.97 (s, 1H), 8.54 (s, 1H), 9.24 (s, 1H).
[M+H] calc'd for C.sub.26H.sub.33F.sub.3N.sub.6O.sub.6, 583; found,
583.
C.
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-(difluoromethyl)--
1H-pyrazol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
[0966] tert-Butyl
6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-(-
1-(difluoromethyl)-1H-pyrazol-4-yl)-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridi-
ne-2(3H)-carboxylate (126 mg, 0.998 mmol) was dissolved in
2-propanol (5 mL) and the solution was heated to 75.degree. C. with
a heating block. Then 2M HCl (2.5 mL) was added, the temperature
was lowered to 65.degree. C., and the reaction mixture was stirred
for 3 h. The solution was concentrated and purified by preparatory
HPLC eluting with water (10 mM NH.sub.4HCO.sub.3) and ACN/water
(80/20 v/v, 10-50% gradient, 10 mM NH.sub.4HCO.sub.3) to give the
title compound as a white solid (79 mg, 96%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.75-1.77 (m, 1H), 2.09-2.12 (m, 1H),
3.60-3.63 (m, 1H), 3.76-3.77 (m, 1H), 3.88-3.98 (m, 3H), 4.44 (d,
J=6.35 Hz, 2H), 4.54-4.55 (m, 1H), 7.17 (d, J=5.86 Hz, 1H), 7.89
(br s, 1H), 8.54 (s, 1H), 8.58 (s, 1H), 9.43 (s, 1H). [M+H] calc'd
for C.sub.16H.sub.17F.sub.3N.sub.6O.sub.2, 383; found, 383.
Example 126:
(R)-2-(7-Fluoro-3-oxo-4-(thiophen-2-yl)-2,3-dihydro-1H-pyrrolo[3,4-c]pyri-
din-6-ylamino)-4-methylpentanamide
##STR00332##
[0968] The title compound was prepared in a manner similar to
EXAMPLE 113 using tributyl(thiophen-2-yl)stannane in place of
tributyl(furan-2-yl)stannane. .sup.1H NMR (500 MHz, DMSO-d.sub.6)
.delta. ppm 0.80-0.99 (m, 6H), 1.51-1.84 (m, 3H), 4.40 (s, 2H),
4.59-4.76 (m, 1H), 6.99 (br s, 1H), 7.06-7.17 (m, 2H), 7.34 (br s,
1H), 7.61 (d, J=4.88 Hz, 1H), 8.40 (s, 1H), 8.93-9.05 (m, 1H).
[M+H] calc'd for C.sub.17H.sub.19FN.sub.4O.sub.2S, 363; found,
363.
Preparation 51: tert-Butyl
6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-c-
hloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
##STR00333##
[0970] A mixture of tert-butyl
4,6-dichloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
(1.24 g, 3.85 mmol), tert-butyl
(3R,4R)-4-aminotetrahydro-2H-pyran-3-ylcarbamate (1.00 g, 4.62
mmol), diisopropylethylamine (3.36 mL, 19.27 mmol) in DMSO (10 mL)
and 2-propanol (40 mL) were heated to 100.degree. C. in an oil bath
for 20 h. The reaction was repeated on the same scale and both
reaction solutions were combined and concentrated. The mixture was
purified via silica gel flash chromatography eluting with EtOAc and
hexanes (10-50% EtOAc gradient) to give the title compound as a
pale pinkish-white solid (510 mg, 13%). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. ppm 1.36 (s, 9H), 1.50 (s, 3H), 1.59-1.61 (m,
1H), 1.97-1.99 (m, 1H), 1.97-1.99 (m, 1H), 3.46-3.49 (m, 2H),
3.80-3.83 (m, 3H), 4.31-4.33 (m, 1H), 4.73 (s, 1H), 6.59 (d, J=7.30
Hz, 1H), 7.43 (d, J=7.30 Hz, 1H). [M+H] calc'd for
C.sub.22H.sub.30ClFN.sub.4O.sub.6, 501; found, 501.
Example 127:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiophen-2-y-
l)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00334##
[0971] A. tert-Butyl
6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-7-f-
luoro-3-oxo-4-(thiophen-2-yl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
##STR00335##
[0973] A solution of tert-butyl
6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-c-
hloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
(50 mg, 0.1 mmol), tributyl(thiophen-2-yl)stannane (44.7 mg, 0.12
mmol) and tetrakis(triphenylphosphine)palladium(0) (115 mg, 0.1
mmol) in toluene (3 mL) was heated to 102.degree. C. for 24 h. The
solid was filtered though a pad of Celite, and resulting crude
material was reconstituted in MeOH/DCM (20 mL) and purified via
preparative HPLC. The collected fractions were combined and
stripped to dryness via rotary evaporation to yield the title
compound (30 mg, 55%).
B.
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiophen-2-
-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
[0974] A solution of tert-butyl
6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-7-f-
luoro-3-oxo-4-(thiophen-2-yl)-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
(30 mg, 0.055 mmol) in TFA/DCM (1:1, 10 mL) was stirred at RT for 2
h. The solvent was removed and the resulting crude material was
reconstituted in MeOH/DCM (20 mL) and purified via preparative
HPLC. The collected fractions were combined and stripped to dryness
via rotary evaporation to yield the title compound (16 mg, 85%).
.sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. ppm 1.79 (d, J=9.76 Hz,
1H), 2.12 (qd, J=12.94, 5.13 Hz, 1H), 3.56-3.68 (m, 1H), 3.75 (d,
J=11.72 Hz, 1H), 3.89 (br s, 1H), 4.02 (d, J=11.72 Hz, 2H),
4.28-4.37 (m, 1H), 4.38-4.49 (m, 2H), 7.10-7.20 (m, 1H), 7.28 (d,
J=4.88 Hz, 1H), 7.59-7.70 (m, 1H), 7.93 (br s, 2H), 8.52 (s, 1H),
9.02 (dd, J=3.91, 0.98 Hz, 1H). [M+H] calc'd for
C.sub.16H.sub.17FN.sub.4O.sub.2S, 349; found, 349.
Example 128:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiazol-5-yl-
)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00336##
[0976] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 127 using 5-(tributylstannyl)thiazole in place
of tributyl(thiophen-2-yl)stannane. .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. ppm 1.78 (dd, J=13.67, 4.39 Hz, 1H),
2.04-2.20 (m, 1H), 3.53-3.66 (m, 1H), 3.69-3.85 (m, 2H), 4.01 (d,
J=11.72 Hz, 2H), 4.25-4.38 (m, 1H), 4.41-4.55 (m, 2H), 7.38 (s,
1H), 7.94 (br s, 2H), 8.62 (s, 1H), 9.15 (s, 1H), 9.52 (s, 1H).
[M+H] calc'd for C.sub.15H.sub.16FN.sub.5O.sub.2S, 350; found,
350.
Example 129:
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(thiophen-2-yl)-1H-pyrrolo[-
3,4-c]pyridin-3-one
##STR00337##
[0978] In a 30 mL sealed cap glass vial, tert-butyl
(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-
-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (300 mg, 0.546
mmol), 4,4,5,5-tetramethyl-2-(thiophen-2-yl)-1,3,2-dioxaborolane
(172 mg, 0.820 mmol), and
trans-dichloro-bis(triphenylphosphine)palladium-II (38.4 mg, 0.055
mmol) were dissolved in dioxane (5 mL). An aqueous solution of 2N
Na.sub.2CO.sub.3 (0.5 mL) was added, the cap was sealed, and the
mixture was allowed to react at 85.degree. C. for 3 h. The reaction
mixture was subsequently diluted with water (5 mL) and extracted
into EtOAc (2.times.30 mL). The organic layer was dried over sodium
sulfate and evaporated. The resulting residue was treated with TFA
(4 mL) and heated at 80.degree. C. for 1 h to remove the protecting
groups. Next, TFA was evaporated from the reaction mixture. The
product was reconstituted in DMSO (8 mL) and was then purified via
preparative HPLC eluting with water (0.05% TFA) and ACN (15-45%
gradient, 0.035% TFA). The pure fractions were combined and
evaporated to a minimal volume. Saturated aq NaHCO.sub.3 (10 mL)
was added and the mixture was extracted with EtOAc (3.times.25 mL).
The organic layers were combined, dried over sodium sulfate, and
evaporated to give the title compound as a pale yellow solid (83
mg, 44%). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. ppm 1.16-1.80
(m, 8H), 3.18 (br s, 1H), 3.86-4.11 (m, 1H), 4.39 (s, 2H), 6.60 (d,
J=6.57 Hz, 1H), 7.13 (dd, J=5.05, 3.79 Hz, 1H), 7.60 (dd, J=5.18,
1.14 Hz, 1H), 8.39 (s, 1H), 9.00 (dd, J=3.79, 1.01 Hz, 1H). [M+H]
calc'd for C.sub.17H.sub.19FN.sub.4OS, 347; found, 347.
Example 130:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(4-(trifluoro-
methyl)-1H-imidazol-1-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00338##
[0980] In a 10 mL sealed cap glass vial, tert-butyl
6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-c-
hloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
(60 mg, 0.120 mmol), 4-(trifluoromethyl)-1H-imidazole (48.9 mg,
0.359 mmol) and K.sub.2CO.sub.3 (66.2 mg, 0.479 mmol) were
dissolved in ACN (2 mL). The cap was sealed and the mixture was
reacted at 100.degree. C. for 16 h. The reaction mixture was
subsequently filtered through a Buchner funnel to remove
un-dissolved K.sub.2CO.sub.3. The solids were washed with ACN
(2.times.5 mL) and the filtrate was evaporated to give a residue,
which was treated with TFA (2 mL) at RT for 20 min to remove the
protecting groups. Next, TFA was evaporated from the reaction
mixture. The product was reconstituted in DMSO (5 mL) and was then
purified by preparative HPLC eluting with water (0.05% TFA) and ACN
(15-45% gradient, 0.035% TFA). The pure fractions were combined,
evaporated to a minimal volume, and lyophilized to give a TFA salt
of the title compound as a brown solid (4.2 mg, 8.8%). .sup.1H NMR
(400 MHz, DMSO-d) .delta. ppm 1.67 (m, 1H), 2.05 (td, J=12.88, 7.33
Hz, 1H), 3.30-3.90 (m, 4H), 3.78-3.99 (m, 2H), 4.44 (s, 2H), 6.49
(br s, 2H), 7.54 (d, J=5.56 Hz, 1H), 7.85 (br s, 2H), 8.67-8.80 (m,
2H). [M+H] calc'd for C.sub.16H.sub.16F.sub.4N.sub.6O.sub.2, 401;
found, 401.
Example 131:
6-((1R,2S)-2-Aminocyclohexylamino)-7-fluoro-4-(4-methyl-1H-imidazol-1-yl)-
-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00339##
[0982] In a 10 mL sealed cap glass vial, tert-butyl
(1S,2R)-2-(4-chloro-2-(2,4-dimethoxybenzyl)-7-fluoro-3-oxo-2,3-dihydro-1H-
-pyrrolo[3,4-c]pyridin-6-ylamino)cyclohexylcarbamate (50 mg, 0.091
mmol), 4-methyl-1H-imidazole (22.43 mg, 0.273 mmol) and
K.sub.2CO.sub.3 (50.3 mg, 0.364 mmol) were dissolved in ACN (2 mL).
The cap was sealed and the mixture was reacted at 100.degree. C.
for 16 h. The reaction mixture was subsequently filtered through a
Buchner funnel to remove un-dissolved solids. The solids were
washed with ACN (2.times.5 mL) and the filtrate was evaporated to
give a residue, which was treated with TFA (4 mL) and heated at
80.degree. C. for 1 h to remove the protecting groups. Next, TFA
was evaporated from the reaction mixture. The resulting residue was
reconstituted in DMSO (5 mL) and purified via preparative HPLC
eluting with water (0.05% TFA) and ACN (15-65% gradient, 0.035%
TFA). The pure fractions were combined, evaporated to a minimal
volume, and lyophilized to give a TFA salt of the title compound as
a white solid (7.2 mg, 23%). .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. ppm 1.20-1.65 (m., 8H), 3.65-3.79 (m, 5H), 4.15 (s, 2H),
6.40 (d, 1H), 6.51 (d, 1H), 6.73 (m, 1H), 6.97 (d, 1H), 7.26 (d,
1H), 8.68 (br s, 1H). [M+H] calc'd for C.sub.17H.sub.21FN.sub.6O,
345; found, 345.
Preparation 52: 3-Methyl-5-(tributylstannyl)isothiazole
##STR00340##
[0984] To a cold (-78.degree. C.) solution of 3-methylisothiazole
(100 mg, 1.0 mmol) in anhydrous THF (2.0 mL) was added
n-butyllithium (0.693 mL, 1.1 mmol) dropwise. After stirring for 60
min at -78.degree. C., a solution of tributylchlorostannane (0.326
mL, 1.210 mmol) in anhydrous THF (0.5 mL) was added to the reaction
mixture. The reaction mixture was stirred for 30 min at -78.degree.
C. and then allowed to warm to RT over a 2 to 3 h period. Saturated
aq NaHCO.sub.3 was added and the aqueous phase was extracted with
EtOAc (3.times.50 mL). The combined organic phase was dried over
anhydrous Na.sub.2SO.sub.4, filtered, and evaporated in vacuo. The
residue was purified by silica gel column chromatography (9:1
Hexane/EtOAc, Flash 60 column) to give the title compound. .sup.1H
NMR (500 MHz, CDCl.sub.3) .delta. ppm 0.86-0.94 (m, 9H), 1.05-1.21
(m, 6H), 1.26-1.38 (m, 6H), 1.44-1.65 (m, 6H), 2.56 (s, 3H),
6.97-7.04 (m, 1H).
Example 132:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(3-methylisot-
hiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00341##
[0985] A. tert-Butyl
6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-7-f-
luoro-4-(3-methylisothiazol-5-yl)-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-ca-
rboxylate
##STR00342##
[0987] A solution of tert-butyl
6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-c-
hloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
(10 mg, 0.02 mmol), 3-methyl-5-(tributylstannyl)isothiazole (23.25
mg, 0.06 mmol) and tetrakis(triphenylphosphine)palladium(0) (23.07
mg, 0.02 mmol) in toluene (3 mL) was heated to 120.degree. C. for
45 min under microwave irradiation. The reaction mixture was poured
into water and extracted with EtOAc. The organic extracts were
dried over anhydrous Na.sub.2SO.sub.4, filtered, and evaporated in
vacuo. After removal of solvent, the resulting crude material was
reconstituted in DMF and purified via preparative HPLC eluting with
water (0.05% TFA) and ACN (55-80% gradient, 0.035% TFA). The
collected fractions were combined and ACN was removed via rotary
evaporation. The resulting aq solution was neutralized with
saturated aq NaHCO.sub.3 and washed with EtOAc (2.times.50 mL),
dried over anhydrous Na.sub.2SO.sub.4, filtered, and the organic
phase stripped to dryness via rotary evaporation to give the title
compound. [M+H] calc'd for C.sub.26H.sub.34FN.sub.5O.sub.6S, 564;
found, 564.
B.
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(3-methylis-
othiazol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
[0988] To a solution of tert-butyl
6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-7-f-
luoro-4-(3-methylisothiazol-5-yl)-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-ca-
rboxylate (5.5 mg, 9.76 .mu.mol) in DCM (2.0 mL) was added TFA (2.0
mL, 26.0 mmol). The reaction mixture was stirred at RT for 1 h, and
concentrated in vacuo. The resulting crude material was
reconstituted in DMF and purified via preparative HPLC eluting with
water (0.05% TFA) and ACN (55-80% gradient, 0.035% TFA). The
collected fractions were combined and the ACN was removed via
rotary evaporation. The resulting aq solution was neutralized with
saturated aq NaHCO.sub.3, washed with EtOAc (2.times.50 mL), dried
over anhydrous Na.sub.2SO.sub.4, filtered, and the organic phase
stripped to dryness via rotary evaporation. The residue was
recrystallized from THF/hexane to give a TFA salt of the title
compound. [M+H] calc'd for C.sub.16H.sub.18FN.sub.5O.sub.2S, 364;
found, 364.
Preparation 53: 1: 2-Methyl-5-(tributylstannyl)thiazole
##STR00343##
[0990] To a cold (-78.degree. C.) solution of 2-methylthiazole
(2.80 g, 28.2 mmol) in anhydrous THF (100 mL) was added
butyllithium (19.41 mL, 31.1 mmol) dropwise. After stirring for 60
min at -78.degree. C., a solution of tributylchlorostannane (9.14
mL, 33.9 mmol) in anhydrous THF was added to the reaction mixture.
The reaction mixture was stirred for 30 min at -78.degree. C. and
then allowed to warm to RT over a 2 to 3 h period. Saturated aq
NaHCO.sub.3 was added and the aqueous phase was extracted with
ether (3.times.200 mL). The combined organic phase was dried over
anhydrous Na.sub.2SO.sub.4, filtered, and evaporated in vacuo. The
crude product was purified on a silica gel column eluting with
10-50% EtOAc in Hexane over a 60 min period. The fractions were
collected and solvent was removed in vacuo to give the title
compound as a yellow oil (72%). .sup.1H NMR (500 MHz, DMSO-d) S ppm
0.71-0.92 (m, 9H), 0.96-1.18 (m, 6H), 1.23-1.38 (m, 6H), 1.40-1.64
(m, 6H), 2.69 (s, 3H), 7.56 (d, J=12.69 Hz, 1H).
Example 133:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(2-methylthia-
zol-5-yl)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00344##
[0992] A TFA salt of the title compound was prepared in a manner
similar to EXAMPLE 132 using 2-methyl-5-(tributylstannyl)thiazole
in place of 3-methyl-5-(tributylstannyl)isothiazole. .sup.1H NMR
(500 MHz, DMSO-d.sub.6) .delta. ppm 1.24 (s, 1H), 1.73 (d, J=12.69
Hz, 1H), 1.93-2.03 (m, 1H), 2.57-2.71 (m, 4H), 3.38-3.44 (m, 1H),
3.48-3.55 (m, 1H), 3.67 (d, J=11.72 Hz, 1H), 3.82-3.97 (m, 2H),
4.22 (br s, 1H), 4.43 (s, 2H), 7.06 (br s, 1H), 8.52 (s, 1H),
9.21-9.34 (m, 1H). [M+H] calc'd for
C.sub.16H.sub.18FN.sub.5O.sub.2S, 364; found, 364.
Example 134:
(R)-2-(7-Fluoro-4-(2-methylthiazol-5-yl)-3-oxo-2,3-dihydro-1H-pyrrolo[3,4-
-c]pyridin-6-ylamino)-4-methylpentanamide
##STR00345##
[0994] The title compound was prepared in a manner similar to
EXAMPLE 113 using 2-methyl-5-(tributylstannyl)thiazole in place of
tributyl(furan-2-yl)stannane. .sup.1H NMR (500 MHz, DMSO-d.sub.6)
.delta. ppm 0.74-0.98 (m, 6H), 1.54-1.63 (m, 1H), 1.64-1.83 (m,
2H), 2.61-2.68 (m, 3H), 4.41 (s, 2H), 4.56 (ddd, J=10.50, 8.30,
4.15 Hz, 1H), 6.97 (s, 1H), 7.19 (d, J=7.81 Hz, 1H), 7.35 (s, 1H),
8.45 (s, 1H), 9.22 (s, 1H). [M+H] calc'd for
C.sub.17H.sub.20FN.sub.5O.sub.2S, 378; found, 378.
Example 135:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(5-chlorothiophen-2-yl-
)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00346##
[0996] To a solution of
6-((3R,4R)-3-aminotetrahydro-2H-pyran-4-ylamino)-7-fluoro-4-(thiophen-2-y-
l)-1H-pyrrolo[3,4-c]pyridin-3(2H)-one (12 mg, 0.034 mmol) in DCM (3
mL) was added pyridine (8.17 mg, 0.103 mmol) and
1-chloropyrrolidine-2,5-dione (4.60 mg, 0.034 mmol). The reaction
mixture was stirred at RT for 3 h. The reaction mixture was
subsequently diluted with MeOH (3 mL) and was purified via
preparative HPLC eluting with water (0.05% TFA) and ACN (45-70%
gradient, 0.035% TFA). The collected fractions were combined and
the solvent was removed via rotary evaporation. The resulting
product was purified a second time using a gradient eluent of
15-45% ACN in 0.035% TFA (aq). The collected fractions were
combined and the solvent was removed via rotary evaporation to
yield a TFA salt of the title compound (2 mg, 15%). .sup.1H NMR
(500 MHz, CD.sub.3OD) .delta. ppm 1.92 (d, J=13.18 Hz, 1H), 2.14
(dd, J=12.69, 4.88 Hz, 1H), 3.56-3.66 (m, 2H), 3.65-3.78 (m, 1H),
3.90 (d, J=12.20 Hz, 1H), 4.04-4.19 (m, 3H), 4.37-4.47 (m, 1H),
6.99 (d, J=3.91 Hz, 1H), 8.80 (d, J=3.91 Hz, 1H). [M+H] calc'd for
C.sub.16H.sub.16ClFN.sub.4O.sub.2S, 383; found, 383.
Example 136:
6-((3R,4R)-3-Aminotetrahydro-2H-pyran-4-ylamino)-4-(1-cyclopropyl-1H-pyra-
zol-4-yl)-7-fluoro-1H-pyrrolo[3,4-c]pyridin-3(2H)-one
##STR00347##
[0998] A 2 mL microwave vial was charged with tert-butyl
6-((3R,4R)-3-(tert-butoxycarbonylamino)tetrahydro-2H-pyran-4-ylamino)-4-c-
hloro-7-fluoro-3-oxo-1H-pyrrolo[3,4-c]pyridine-2(3H)-carboxylate
(55 mg, 0.11 mmol),
1-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
(77 mg, 0.329 mmol), and bis(triphenylphosphine)palladium chloride
(15.41 mg, 0.022 mmol) and placed under an inert environment.
Dioxane (1.1 mL) was added and the yellow slurry was degassed for 5
min. To the slurry was then added Na.sub.2CO.sub.3 (220 .mu.L,
0.439 mmol) which caused the reaction slurry to turn orange. The
mixture was degassed an additional 3 min. The vessel was capped and
the reaction mixture was heated to 80.degree. C. for 4 h. The
reaction mixture was subsequently diluted with EtOAc (10 mL) and
washed with water (8 mL) followed by brine (8 mL). The organic
phase was collected, dried over Na.sub.2SO.sub.4, and concentrated
to an oil, which was diluted with DCM (2 mL) and treated with HCl
(4 M in dioxane, 1 mL). The mixture was stirred for 1 h at RT, and
then concentrated. The residue was diluted with MeOH (2 mL) and was
purified via preparative HPLC to give a TFA salt of the title
compound as a white solid. .sup.1H NMR (DMSO-d.sub.6) .delta. ppm
1.75 (t, 1H), 2.03-2.17 (m, 1H), 3.57-3.67 (m, 1H), 3.78 (br s,
1H), 3.82-3.88 (m, 1H), 3.93-4.02 (m, 2H), 4.39 (d, J=5.3 Hz, 2H),
4.45-4.54 (m, 1H), 4.82 (d, J=5.8 Hz, 2H), 5.15 (dd, J=17.2, 1.5
Hz, 1H), 5.22 (dd, J=10.2, 1.4 Hz, 1H), 6.04 (dddd, J=16.8, 10.6,
5.8, 5.7 Hz, 1H), 7.09 (d, J=5.3 Hz, 1H), 7.93 (d, J=4.3 Hz, 3H),
8.32 (s, 1H), 8.40 (s, 1H), 8.85-9.03 (m, 1H). [M+H] calc'd for
C.sub.18H.sub.21FN.sub.6O.sub.2, 373; found, 373.
[0999] TABLE 1, below, lists SYK inhibition data for many of the
compounds described in the examples, where larger pIC.sub.50 values
represent higher potency. The compounds were tested in accordance
with the assay described on page 60 of the specification.
TABLE-US-00001 TABLE 1 SYK Inhibition (pIC.sub.50) for Example (Ex)
Compounds Ex pIC.sub.50 1 8.1 2 6.9 3 7.6 4 7.8 5 6.2 6 6.3 7 6.0 8
8.1 9 5.1 10 <4.7 11 5.9 12 5.7 13 8.7 14 6.9 15 6.0 16 5.5 17
7.4 18 7.1 19 6.6 20 6.7 21 6.3 22 5.7 23 8.7 24 7.6 25 9.0 26 7.5
27 7.4 28 8.6 29 8.5 30 8.4 31 8.6 32 5.4 33 7.3 34 6.5 35 7.3 36
7.6 37 6.0 38 6.2 39 5.5 40 6.6 41 5.9 42 6.8 43 5.3 44 6.2 45 6.1
46 5.8 47 8.6 48 6.1 49 <4.7 50 8.6 51 7.2 52 7.2 53 5.8 54 6.6
55 7.8 56 5.6 57 7.8 58 5.8 59 7.1 60 7.8 61 7.2 62 8.0 63 8.1 64
8.0 65 8.0 66 6.3 67 7.4 68 7.0 69 6.8 70 8.8 71 8.1 72 7.5 73 8.1
74 8.3 75 9.1 76 9.3 77 7.5 78 8.4 79 7.7 80 5.5 81 8.5 82 9.2 83
6.6 84 7.7 85 8.4 86 5.6 87 7.2 88 8.5 89 8.4 90 8.0 91 6.6 92 7.9
93 8.0 94 8.5 95 5.4 96 6.7 97 6.8 98 5.7 99 8.5 100 6.8 101 7.2
102 8.4 103 6.9 104 8.7 105 9.0 106 8.6 107 6.3 108 8.6 109 8.5 110
7.3 111 8.1 112 8.7 113 6.7 114 6.6 115 6.5 116 8.1 117 7.9 118 7.9
119 7.8 120 6.6 121 5.4 122 6.2 123 8.1 124 7.6 125 8.0 126 8.1 127
8.2 128 7.7 129 8.4 130 5.0 131 <4.7 132 8.4 133 7.6 134 135 136
7.5
[1000] As used in this specification and the appended claims,
singular articles such as "a," "an," and "the," may refer to a
single object or to a plurality of objects unless the context
clearly indicates otherwise. Thus, for example, reference to a
composition containing "a compound" may include a single compound
or two or more compounds. It is to be understood that the above
description is intended to be illustrative and not restrictive.
Many embodiments will be apparent to those of skill in the art upon
reading the above description. Therefore, the scope of the
invention should be determined with reference to the appended
claims and includes the full scope of equivalents to which such
claims are entitled. The disclosures of all articles and
references, including patents, patent applications and
publications, are herein incorporated by reference in their
entirety and for all purposes.
* * * * *